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Abbreviations 
AAS  anabolic-androgenic steroid. 
API  atmospheric pressure ionization. 
BHA  British Horseracing Authority. 
C18 steroid  a steroid based on the estrane nucleus. 
C19 steroid  a steroid based on the androstane nucleus. 
C21 steroid  a steroid based on the pregnane nucleus. 
C24 steroid  a steroid based on the cholane nucleus. 
C27 steroid  a steroid based on the cholestane nucleus. 
CAD  collision activated dissociation. 
CCα  decision limit. 
CCβ  detection capability.  
CRL  European Community Reference Laboratory.  
CYP  cytochrome P450. 
DHEA  dehydroepiandrosterone.  
DMF  dimethylformamide. 
DNA  deoxyribonucleic acid.  
EI  electron ionisation.  
EIA  enzyme immunoassay. 
ELISA  enzyme linked immunosorbent assay 
EPI  enhanced product ion scan. 
ERC  endogenous reference compound.  
EU  European Union. 
FDA  Food and Drug Administration. 
FEI  Federation Equestre Internationale. 
FWHM full width at half maximum height. 
GC-C-IRMS  gas chromatography combustion isotope ratio mass spectrometry. 
GC-MS gas chromatography-mass spectrometry. 
GC-MS/MS gas chromatography-tandem mass spectrometry. 
GBGB  Greyhound Board of Great Britain. 
HCD  higher-energy collision decomposition. 
HCl hydrochloric acid. 
HPLC high performance liquid chromatography. 
HR-LC-MS  high resolution-liquid chromatography-mass spectrometry. 
IA  Immunoassay. 
ICRAV International Conference of Racing Analysts and Veterinarians.  
IFHA  International Federation of Horseracing Authorities.  
ILAC  International Laboratory Accreditation Cooperation. 
IM  intramuscular.  
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IUPAC  International Union of Pure and Applied Chemistry. 
IV  intravenous.  
LC-MS  liquid chromatography-mass spectrometry. 
LC-MS/MS  liquid chromatography-tandem mass spectrometry. 
LLOQ  lower limit of quantification.  
LOD  limit of detection.  
LOQ  limit of quantification.  
LTQ  linear trap quadrupole.  
MeOH  methanol.  
MO  methoxyamine. 
MO-TMS methoxyamine-trimethylsilyl. 
MRPL  minimum required performance limit. 
MSTFA – N-Methyl-n (trimethylsilyl)-trifluoroacetamide. 
MTBSTFA – N (t-butyldimethylsilyl)-N-methyltrifluoroacetamide. 
m/z  mass to charge ratio 
NAD+  nicotinamide adenine dinucleotide. 
NADPH  nicotinamide adenine dinucleotide phosphate. 
NaOH  sodium hydroxide.  
NMR  nuclear magnetic resonance.  
ND  not detected. 
NMP  national monitoring programme.  
PTV  programmable temperature vaporiser. 
QC  quality control.  
qRT-PCR  quantitative real time reverse transcriptase polymerases 
chain reaction technology  
RIA  radio-immunoassay 
RSD  relative standard deviation (also known as coefficient of 
variation). 
SCVPH Scientific Committee on Veterinary Measures relating to 
Public Health. 
SRM  selected reaction monitoring. 
SPR  surface plasmon resonance.  
THG  tetrahydrogestrinone. 
TLC-FL  thin layer chromatography-fluorescence. 
TBDMS  tertiary-butyl,dimethyl-silyl 
TMS trimethylsilyl.  
TOF time of flight.  
u  atomic mass unit 
ULOQ  upper limit of quantification.  
UV  ultraviolet.  
WADA  World Anti-Doping Agency. 
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INTRODUCTION 
Steroid structure and pharmacology 
 
If one were to ask a member of the public what images the word ‘steroid’ conjured into 
their imagination, the use of anabolic-androgenic steroids (AASs) in athletics or 
bodybuilding would no doubt rank near the top of the list. However, steroids have a 
range of structures and pharmacological actions that reach far beyond the anabolic 
effects of AASs. The term ‘steroid’ itself refers to any compound possessing the basic 
perhydrocyclopentanophenanthrene nucleus (Figure 1) (Makin, 1995). 
 
A) 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 1 – A) the perhydrocyclopentanophenanthrene nucleus, on which all steroids are 
based and B) cholesterol as an example. Each carbon is assigned a number and the 
four hydrocarbon rings are numbered A-D, as shown.  
 
The nomenclature of this class of compounds is complex and large arrays of different 
systems are used. These include; the official International Union of Pure and Applied 
Chemistry (IUPAC) recommended systematic nomenclature (IUPAC, 2010), a range of 
‘trivial’ or ‘common’ names and those of some proprietary preparations. Additionally, 
many organisations use their own nomenclature (for example the company Steraloids). 
However, these often deviate from the IUPAC recommendations. The choice of how to 
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best name a steroid in a particular situation is, therefore, dependent on a number of 
factors. If one were to always use only the IUPAC systematic name, then this could 
make the text difficult to read for a non-expert. However, inappropriate over-use of trivial 
names does not always give enough information in order to inform the reader. Therefore, 
a combination of systematic and trivial names is often employed as a pragmatic 
compromise (such as described by Makin et al. 1995) and this will be used in the current 
text. As an example of the different ways of naming a steroid, some options for 
testosterone are given below: 
 
Trivial name: testosterone. 
IUPAC systematic name: 17β-hydroxy-androst-4-en-3-one. 
Proprietary example (containing testosterone esters): Sustanon. 
 
When depicted in the orientation shown in Figure 1, substituents on the steroid backbone 
may protrude below or above the plane of the paper and are drawn as such using either 
a dashed or solid wedge respectively (indicating the stereochemistry α and β 
respectively).  Hydrogens in positions 8, 9, 10, 13 and 14 (when present) take β, α, β, β, 
and α orientation respectively in all steroids discussed in this manuscript so their 
stereochemistry will not be shown in any of the subsequent diagrams. A substituent in 
position 5 may take either the α or β form, so hydrogens in this position will always be 
labelled. A wavy line indicates that stereochemistry is unspecified. 
 
In order to aid in the systematic naming of steroids, a number of different hydrocarbon 
backbones are specified for use by IUPAC. These differ in the number and orientation of 
carbons, which range from the 17-carbon (C17) gonane nucleus to the 27-carbon (C27) 
cholestane nucleus (on which cholesterol is based). The range of steroid backbones 
used in systematic nomenclature is shown in Figure 2. In this text, when describing the 
trivial name for the oestrogens, the English version will be used (as opposed to the USA 
use of estrogens). However, when systematically naming steroids that are based on the 
estrane nucleus, the ‘o’ will not be used (in accordance with IUPAC guidelines). 
 
No endogenous and very few exogenous steroids are based on the gonane nucleus. The 
oestrogens and nandrolone (17β-hydroxy-estr-4-en-3-one) are based on the estrane 
nucleus. The majority of androgens are based on the androstane nucleus and the 
majority of progestagens and corticosteroids are based on the pregnane nucleus. Most 
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of the bile acids are based on the cholane nucleus and sterols such as cholesterol are 
based on the cholestane nucleus.  
 
Gonane (C17)    Estrane (C18) 
 
Androstane (C19)    Pregnane (C21) 
Cholane (C24)          Cholestane (C27) 
 
Figure 2 – the range of hydrocarbon backbones used in steroid nomenclature.  
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While many steroids are known to be endogenous (discussed further in chapter 1), a 
wide range of exogenous steroid structures have been synthesized by chemists over the 
years in order to optimise their biological properties. Pharmacologically, steroids possess 
a range of activities far more diverse than their seemingly similar structures may 
suggest. The following discussion considers the major effects of different steroid classes 
in mammals. There are some subtle differences between various species, but these will 
not be considered here since it is only a general overview. 
 
Cholesterol (cholest-5-en-3β-ol – Figure 1) is derived from dietary intake, but is also 
synthesized in the body. Cholesterol acts to regulate the fluidity of cell membranes and is 
the precursor to the endogenous androgens, oestrogens, progestagens, corticosteroids, 
vitamin D, the bile acids and, in certain species, to pheromones such as the 16-
androstenes (Hadley and Levine, 2006). 
 
Bile acids such as cholic acid (3α,7α,12α-trihydroxy-5β-cholan-24-oic acid – Figure 3) 
are secreted by the gall bladder into the intestine where they aid the absorption of lipids 
into the body by reducing their surface tension (Hadley and Levine, 2006).  
 
Figure 3 – cholic acid (a bile acid). 
 
Progestagens such as progesterone (pregn-4-ene-3,20-dione – Figure 4) are produced 
by both males and females in the adrenal glands and gonads. However, they are 
secreted in much higher concentrations by females during certain stages of the ovulatory 
cycle (including by the corpus luteum) and during pregnancy (Hadley and Levine, 2006). 
Progestagens produce the majority of their effects through agonism of the progesterone 
receptor. This leads to an increased metabolic rate, changes in breast morphology and 
development/maintenance of the uterus/oviduct before and during pregnancy (Hadley 
and Levine, 2006). Progestagens (and synthetic progestins) may also be used as 
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contraceptives in females, which act by suppressing endogenous gonadotrophin release 
and by inhibiting sperm penetration due to a change in viscosity of the cervical mucous 
(Westhoff et al. 2010). 
 
 
Figure 4 – progesterone (a progestagen). 
 
Corticosteroids are produced by the adrenal cortex and fall into one of two broad 
classes, depending on their predominant mechanism of action. However, there is some 
overlap in the effects of the two classes. Glucocorticoids such as cortisol (11β,17α,21-
trihydroxy-pregn-4-en-3,20-dione – Figure 5a) agonise the glucocorticoid receptor and 
act to regulate inflammation and immunity as well as fat, protein and carbohydrate 
metabolism (Hadley and Levine, 2006). Mineralocorticoids such as aldosterone (11β,21-
dihydroxy-3,20-dioxo-pregn-4-en-18-al – Figure 5b) agonise the mineralocorticoid 
receptor and act to maintain sodium and potassium balance (Hadley and Levine, 2006).   
       
A      B 
Figure 5 – A) cortisol (a glucocorticoid), B) aldosterone (a mineralocorticoid). 
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Androgens are produced by both males and females in the adrenal glands and gonads. 
However, they are secreted in much higher concentrations by male gonads. 
Testosterone (17β-hydroxy-androst-4-en-3-one – Figure 6) is the most abundant 
circulating androgen in males, but requires reduction in position 5 to produce the fully 
active androgen, 5α-dihydrotestosterone (17β-hydroxy-5α-androstan-3-one – Figure 6). 
The androgenic effects of these steroids are produced by agonising the androgen 
receptor (AR) (Hadley and Levine, 2006). Androgens produce both androgenic 
(masculinising) and anabolic (growth promoting) effects to varying degrees. This leads to 
their more correct classification as anabolic-androgenic steroids (AASs). The androgenic 
effects are the characteristic male secondary sexual features such as facial/body hair 
growth and deepening of the voice, while the anabolic effects are predominantly muscle 
and bone growth (Hadley and Levine, 2006). Whether or not all the anabolic effects of 
AASs are mediated through the AR is currently unknown. Another possible mechanism 
of action is antagonism of the glucocorticoid receptor (subject discussed further in 
Kicman, 2008). 
 
Figure 6 – testosterone and its conversion to the more  
active androgen 5α-dihydrotestosterone. 
 
Oestrogens such as oestradiol (estra-1,3,5(10)-triene-3,17β-diol – Figure 7) are 
produced by both males and females in the adrenal glands, gonads and adipose tissue. 
However, they are secreted in much higher concentrations by females during certain 
stages of the ovulatory cycle (including by the corpus luteum) and during pregnancy 
(Hadley and Levine, 2006). Oestrogens produce the majority of their effects through 
agonism of the oestrogen receptor. This leads to breast growth and redistribution of fat 
within the body, development/maintenance of the uterus before and during pregnancy, 
changes to skin morphology and they are also important for bone growth (Hadley and 
Levine, 2006). Oestrogens are also used as female contraceptives, which act primarily 
by suppressing endogenous gonadotrophin release (Westhoff et al. 2010). 
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Figure 7 – oestradiol (an oestrogen). 
 
A wide range of synthetic AASs, oestrogens, progestagens and corticosteroids have 
been produced over the years with the aim of enhancing their pharmaceutical qualities. 
Modifications that have been applied to the majority of the steroid classes include 
alkylation (in order to produce more orally active versions), esterification (to prolong 
duration of action), acetylation (to enhance absorption) and halogenation (to enhance 
potency) (Kicman, 2008). Specifically relating to AASs, the addition of a double bond at 
position 1, the attachment of a pyrazole group to the A-ring or the removal of the 19 
methyl group have been employed in order to increase the anabolic to androgenic ratio 
and/or to inhibit their conversion to oestrogens (Kicman, 2008). Similar modifications to 
glucocorticoids have been engineered in order to try and maximise the glucocorticoid to 
mineralocorticoid effect ratio. Figure 8 shows a range of different synthetic AASs. 
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Methyltestosterone     Methandienone 
Mesterolone         Stanozolol  
 
Figure 8 – structures of the synthetic AASs methyltestosterone (17β-hydroxy,17α-
methyl-androst-4-en-3-one), methandienone (17β-hydroxy,17α-methyl-androsta-1,4-
dien-3-one), mesterolone (17β-hydroxy,1α-methyl,5α-androstan-3-one), stanozolol (17β-
hydroxy,17α-methyl-5α-androstano[3,2-c]pyrazole). 
 
Steroid use in food production and competitive sports 
 
The above discussion highlighted the potential anabolic effects of AASs in mammals. In 
some species, however, oestrogens and progestagens may also produce anabolic 
effects. In addition to effects on muscle and bone, steroids may also affect the pattern of 
fat deposition within the body, leading to differential partitioning of muscle and fat; 
although this depends on the steroid, species and sex of animal in question (Heitzman, 
1975, Lone, 1997). Corticosteroids may produce some positive metabolic effects 
following initial administration, but long-term use of high doses produces a general state 
of catabolism within the body (Hadley and Levine, 2006).  
 
Because of their potential anabolic effects, some steroids have been used to boost the 
mass and quality of animal carcasses in food production for economic reasons 
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(Heitzman, 1975, Lone, 1997, Kay, 2010).  Although there are a number of steroid 
preparations authorised for this purpose in countries such as the USA, the use of growth 
promoters (also including non-steroidal products such as the oestrogenic compound 
zeranol, growth hormone and the β2-agonist class of drugs) is banned within the EU (EU 
Council Directive 96/22/EC). The reasons for this ban were highlighted in two reports 
from the European Commission in 1999 and 2002, which concluded that the presence of 
hormones in meat products may potentially be harmful to human health through 
endocrine disrupting or carcinogenic mechanisms (SCVPH, 1999, SCVPH, 2002). 
However, two subsequent opinions published by the UK Veterinary Products Committee 
failed to agree with the findings of the earlier European Commission’s studies (VPC, 
1999, VPC, 2006). For example, the latter of these two UK reports estimated that, as a 
worst case scenario, a postmenopausal woman eating a kilogram of meat (kidney) 
containing the highest concentration of oestradiol detected (56 ng/kg) following 
administration of the steroid would experience an increased oestrogen level of only 
0.01% of average endogenous production. Indeed, it has also been speculated that the 
ban may have more to do with regulating trade, leading to official disputes between the 
EU and USA (Charlier and Rainelli, 2002). Nonetheless, the hormone ban remains and 
non-EU countries are, therefore, required to provide sufficient animal segregation and 
residue testing schemes to ensure that treated animals are not sold in the EU. 
 
In addition to their use in food production, steroids may also be used in competitive 
human and animal sports in order to improve performance. The range of steroids used 
for this purpose is generally limited to the AASs. These may enhance performance 
through a number of mechanisms including increased muscle mass, enhanced recovery 
from training, raised red blood cell count and heightened aggression (Kicman, 2008). 
Because of their potential to affect performance, the use of AASs in the majority of 
horseracing, greyhound racing and human sports is prohibited (IFHA, 2008, GBGB, 
2009, FEI, 2010, WADA, 2009a). Protection of the welfare of individual competitors is 
another reason for prohibiting these substances; an aspect that takes increased 
importance in animal sports where trainers decide on the animal’s behalf what 
substances are administered.  
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The detection of steroid abuse in food production and animal sports 
 
In order to enforce the ban on hormone use in food production, EU Council Directive 
96/23/EC (and EU Commission Decision 2002/657/EC) lay down the requirements for 
residue testing. Enforcement of the ban on steroid use in competitive sports is not 
regulated in law in the same way as in food production, but guidelines regarding the 
analytical methods that must be followed by individual laboratories when confirming 
cases of steroid abuse have been produced by both the animal (AORC, 2003, ILAC-G7, 
2009) and human authorities (WADA, 2009b). A comparison of the regulations used in 
the food residue and sports doping control arenas can be found in Van Eenoo and 
Delbeke, 2004.   
 
The type of matrix used for steroid residue analysis in food and sports drug surveillance 
differs by a number of variables including the country, the individual authority concerned, 
whether samples are taken from live animals, at slaughter or from a food import 
programme and whether the analyses for a particular analyte are suited to a specific 
tissue. Other than food import programmes, where analysis of meat and organs are 
typically required, urine and blood are the most common matrices for testing in both the 
food and sports residue arenas (Wynne, 2004, Stolker et al. 2005). However, faeces and 
hair are also important matrices in some countries. When dealing with blood or hair, 
detection of unchanged ‘parent’ drug is often considered suitable for determination of 
drug abuse. However, when dealing with urine or faeces, a large proportion of the 
excreted dose can take the form of metabolites. This is a particularly important 
consideration in the case of steroids, which are typically heavily metabolised (Scarth et 
al. 2009). It is, therefore, often necessary to conduct metabolism studies in order to 
determine the appropriate target metabolites for the detection of steroid abuse. The 
metabolism of the steroid can be broadly categorised into phases 1 and 2. Phase 1 
typically involves the modification of existing functional groups within the steroid 
molecule (namely oxidation, reduction, hydrolysis etc.), whereas phase 2 involves 
conjugation with, typically, polar moieties such as glucuronic or sulphuric acid in order to 
increase water solubility and, therefore, aid excretion (see example in Figure 9). 
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Figure 9 – examples of theoretical phase 1 and 2 metabolic pathways for the boldenone 
‘pro-drug’ boldione (androsta-1,4-diene-3,17-dione - top). A possible pathway of phase 1 
metabolism is reduction of the 17-keto group to form boldenone (17β-hydroxy-androsta-
1,4-dien-3-one - middle). This may be followed by phase 2 conjugation with sulphate to 
form boldenone-17-sulphate (17β-hydroxy-androsta-1,4-dien-3-one-17-sulphate - 
bottom).  
 
Because of the common aims of food residue and sport drug surveillance laboratories, 
the development and application of analytical techniques for detecting steroid abuse has 
been broadly similar between the two fields over the years. Indeed, many individual 
laboratories across the world are involved in residue analysis within both of these fields. 
Review articles concerning the analytical methods used specifically for veterinary steroid 
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analysis can be found in Stolker et al. 2005 and De Brabander et al. 2009 (food residue 
analysis) and McKinney, 2009 (equine sports). Figure 10 and the following discussion 
serves as a brief overview of the scientific evolution within these two fields. 
 
 
Figure 10 – summary of the evolution of steroid screening techniques used in residue 
analysis. 
 
Initially, thin layer chromatography-fluorescence detection (TLC-FL) was widely used 
(Moss and Rylance, 1967, De Brabander and Verbeke, 1975). Immunoassay techniques 
such as enzyme-linked immunosorbent assays (ELISA) became popular during the 
1980s and 1990s, but were largely replaced in the late 1990s and early 2000s by more 
definitive mass spectrometric-based techniques such as gas- and liquid-chromatography 
mass spectrometry (GC- and LC-MS respectively) (McKinney, 2009). The ability of many 
modern GC- and LC-MS instruments to carry out MSn experiments makes them 
particularly useful for identifying compounds due to their high selectivity. Also, the recent 
emergence of higher resolution LC equipment allowing the use of sub-2 m particle 
sizes and high flow rates (ultra-pressure liquid chromatography or UPLC) means that 
metabolites with similar molecular masses and retention times can now be more easily 
resolved and that analytical run times are shorter (Plumb et al. 2009). 
 
Although there has been a general shift from GC-MS to LC-MS for drug residue analysis 
during the past decade, GC-MS has remained an important tool for analysing saturated 
steroid metabolites. This is because saturated steroids generally suffer from poor 
ionisation properties under the atmospheric pressure ionisation conditions of LC-MS 
(McKinney et al. 2009, Teale and Houghton, 2010). Although the majority of current 
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urinary screening procedures are based on detection of the ‘free’ steroid (liberated from 
its phase conjugates), it may be possible in the future to design assays based on the 
analysis of intact conjugates. At present, progress in this area has been limited by a lack 
of availability of the relevant analytical reference standards for animal specific 
metabolites. However, the potential of this approach has already been demonstrated in 
human sports, where the availability of reference material has allowed the development 
of LC-MS/MS assays for intact steroid conjugates (Kuuranne et al. 2002, Hintikka et al. 
2008, Pozo et al. 2008).  
 
Most recently, robust high-resolution-accurate-mass LC-MS (HR-LC-MS) systems 
operating at an increased level of resolution, typically ranging between 7,500 and 
100,000 full width at half maximum height (FWHM) depending on the type of mass 
analyser employed, have become commercially available and have started gaining 
popularity for sports drug surveillance screening and research (Virus et al. 2008, Scarth 
et al. 2010). Because the data acquired are full scan analyses of intact [M+H]+ or [M-H]- 
species at very high resolution, a very large number of analytes can be simultaneously 
monitored. Another advantage of using HR-LC-MS includes the ability to retrospectively 
analyse data once new drug information comes to light.  
 
The powerful technique of gas chromatography combustion isotope ratio mass 
spectrometry studies (GC-C-IRMS) has been applied to the confirmation of endogenous 
steroid abuse (discussed further in chapter 1) in both food and sports drug residue 
analysis. However, it is not currently suitable as a screening technique due to its low 
throughput nature (Piper et al. 2010).  
 
In addition to the classical analytical chemistry techniques that are targeted toward the 
detection of ‘parent’ steroids or their metabolites, a number of indirect techniques have 
recently gained attention (discussed further in chapter 1). These include immunoassay 
and receptor based biosensor assays as well as a range of ‘omics’ biomarker 
approaches such as metabolomics, proteomics and transcriptomics (Scarth et al. 2006). 
Because these techniques are targeted toward pharmacological activity rather than 
individual drug structure, they produce complementary screening data that can be used 
to indicate whether steroid abuse may have occurred. However, these techniques have 
yet to find widespread application in the confirmation of steroid abuse, which is typically 
still achieved by the direct measurement of a steroid or its metabolite.  
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While the above discussion served to summarise the range of instrumental techniques 
that may be used to detect steroid abuse, the ability to detect the abuse of each 
individual steroid is determined by a number of factors. Firstly, the sample needs to be 
taken from the animal at a time close enough to the point of steroid administration for the 
concentrations to be above the limits of instrumental sensitivity. If the sample is taken too 
long after steroid administration, then traces of the drug may be too low to be detected. 
Also, each individual steroid can be classified into one of three broad categories, which 
impacts on the ability to detect the abuse of each: 
 
‘Exogenous’ steroids are known marketed ‘classical’ steroids, such as stanozolol. 
These contain synthetic structures that are thought not to occur naturally. Detection of 
this class of steroid is relatively straightforward since a purely qualitative demonstration 
of the presence of these synthetic steroids is all that is required in order to determine 
abuse 
 
‘Endogenous’ steroids are also known marketed steroids, such as testosterone, but 
contain structures that are known to exist naturally. Detection of the abuse of 
‘endogenous’ steroids is more complicated because they are, by definition, ‘natural’ to 
some extent and so a simple qualitative demonstration of their presence is insufficient to 
indicate abuse (discussed further in chapter 1). Some endogenous steroids such as 
testosterone, progesterone and oestradiol are known to be ubiquitous amongst 
mammals. However, the classification of a steroid as ‘endogenous’ is a grey area and 
there are some steroids that may be considered ‘semi’-endogenous. This term signifies 
that the steroid in question has been suspected to be endogenous, but only in certain 
situations i.e. in a specific species or at particular time. Analytical sensitivities for 
detecting steroids have increased significantly over the years, which has resulted in 
more and more compounds being suspected as ‘endogenous’ or ‘semi-endogenous’ at 
low concentrations.  
 
‘Designer’ steroids are previously unmarketed steroids that contain synthetic structures 
that are thought not to occur naturally. The use of a designer steroid first came to the 
public attention in 2003 when a syringe containing the novel steroid tetrahydrogestrinone 
(THG) was handed to doping officials. This resulted in the disqualification of several 
athletes after they were subsequently found to have used the steroid (Catlin et al. 2004). 
Designer steroids have chemical structures based on previously marketed products, but 
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with minor modifications which make them undetectable by the majority of current 
targeted mass spectrometric procedures. In the case of THG for example, the drug’s 
structure is based upon gestrinone, but with the 17-alkyl side chain fully saturated such 
that the relative molecular mass of THG is 4 atomic mass units (u) higher than 
gestrinone. Designer steroids are synthesized either to deliberately evade detection, or 
as appears more common, to enable them to be marketed freely on the Internet to 
customers in some countries because their structures do not fall within the scope of legal 
regulations that prevent the sale of defined steroidal products. 
 
Detection of the abuse of the latter two classes of steroids in food production and animal 
sports is very challenging. The development of analytical approaches to tackle these 
associated issues forms the basis of the current thesis. 
 
Aims and objectives of the current work 
 
Within the author’s laboratory, analytical methods are already available to detect the 
abuse of the majority of endogenous AASs in horseracing. However, the same is not true 
for the majority of endogenous steroids in other food producing animals. ‘Designer’ 
steroids could in theory be abused in both horseracing and food production, but at 
present the majority of work on designer steroids has been commissioned by the sports 
regulatory authorities. One reason that this class of compounds has received more 
attention in sports doping control is because of the proven use of designer steroids such 
as THG by a number of athletes. Another factor may relate to the fact that human and 
animal sports typically involve single individuals looking to gain marginal advantages for 
significant financial and/or sociological gain, whereas food production involves large 
herds of animals with smaller financial return relative to the risk. These differences in 
return relative to risk could, therefore, be considered to make the abuse of relatively 
expensive ‘exotic’ treatments such as designer steroids more likely in competitive sports 
compared to food production. In light of the aforementioned discussion, the following 
were determined as the overall aims and objectives of the research reported herein: 
 
Overall aims: To develop novel analytical approaches for the detection of ‘endogenous’ 
steroid abuse in food-production (part 1) and of ‘designer’ steroid abuse in animal sports 
(part 2). The primary focus of this thesis will relate to AASs such as nandrolone, 
boldenone, testosterone and their synthetic ‘designer’ analogues. However, chapter 3 
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will also consider the important natural steroids oestradiol and progesterone in relation to 
the detection of their abuse in the bovine. 
 
Part 1 objectives:  
 
- To review the literature regarding endogenous steroids and their detection 
in food production, focussing mainly on endogenous AASs (chapter 1). 
- To develop approaches for the detection of nandrolone abuse in the 
porcine (chapter 2). 
-  To develop approaches for the detection of androgen, oestrogen and 
progestagen abuse in the bovine (chapter 3). 
 
Part 2 objectives:  
 
- To review the literature regarding steroid metabolism and detection in the 
equine (especially in relation to designer steroids) and to compare the 
trends with those observed in other species (chapter 4). 
- To develop and assess the suitability of in vitro techniques for conducting 
equine drug metabolism studies (chapter 5). 
- To use the newly developed in vitro methods to study the metabolism of a 
novel ‘designer’ steroid in the equine (chapter 6). 
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1.1 Introduction 
 
As discussed in the introductory chapter, EU Council Directive 96/22/EC of 1996 states 
that “substances having a hormonal action” are prohibited for use in animals intended for 
meat production. As well as purely novel steroids not existing in nature, the directive also 
covers synthetically produced versions of steroids that are known to occur naturally in 
certain species under particular circumstances. However, in some countries, including 
the USA, Canada and Australia, some (combinations of) steroids and a related synthetic 
compound Zeranol are officially registered for use as hormonal growth promoting 
compounds. Due to their anabolic and/or partitioning effect they increase the profit per 
unit head for the farmer. EU Council Directive 96/23/EC (and EU Commission Decision 
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2002/657/EC) lays down the requirements for residue testing in order to ensure 
compliance with the EU prohibition.  
 
The steroid hormones considered in this review chapter are the androgenic-anabolic 
steroids (AASs) that potentially derive from precursors within the body such as 
cholesterol and pregnenolone (see figure 1). These include testosterone, 
androstenedione, nandrolone, boldenone and dehydroepiandrosterone (DHEA), as well 
as their numerous catabolic products and any precursor compounds that might 
potentially lead to conversion to these steroids within the body. The major focus of this 
chapter will relate to phase 1 steroid metabolites because there is much less information 
relating to phase 2 metabolism. However, details of the phase 2 metabolism of some 
steroids will be given where they have been shown to usefully distinguish situations of 
abuse (for example boldenone). The task of detecting the abuse of synthetically 
produced hormones that are also known to be endogenous under certain conditions, 
dubbed ‘pseudo-endogenous’ or ‘grey zone substances’ due to their dual 
synthetic/endogenous nature (Van Thuyne Wim 2006), is problematic for many reasons. 
The most significant challenge arises due to the fact that when they are shown to occur 
naturally within a particular type of animal, a simple qualitative demonstration of their 
presence does not necessarily prove abuse. Most, but not all, steroid preparations are 
ester versions of these potentially endogenous steroids. However, a simple 
demonstration of the presence of the steroid ester as proof of abuse is not always 
possible (with the exception of hair and injection/implant sites in some cases) due to a 
large proportion of the steroid ester being cleaved by the time it reaches the test matrix 
i.e. plasma or urine. Some type of quantitative uni- or multi-variate threshold approach is 
therefore usually required in order to confirm abuse. Furthermore, as analytical limits of 
detection decrease, the list of compounds that are suspected to be endogenous at low 
concentrations increases. These and some further analytical and physiological 
considerations are taken up again later in this review. 
 
Analytical methods of various kinds have in the past been employed to identify and 
quantify endogenous steroids, their metabolites and precursors, but their effectiveness 
and the harmonisation of their application in different countries and situations is 
questionable. For example, Van Ginkel et al. 1993 highlight the wide range of different 
analytical methods and thresholds that have been applied in different EU countries in the 
past. Since the author was aware of no comprehensive published review on the 
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concentrations and metabolism of such steroids in food producing animals, the overall 
aim of the work reported herein was therefore to carry out a survey of the existing 
literature. This then guided further practical work in order to increase knowledge and to 
develop more effective testing methods (Chapters 2 and 3).  
 
  
Figure 1 – schematic of the biosynthetic pathways for endogenous steroids in mammalian species. Many of the reactions that involve 
oxidation or reduction of hydroxyl and ketone groups respectively are reversible. Wavy arrows indicate a putative pathway only. 
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1.2 Literature survey methods 
 
The overall aim was to collect as much published and unpublished data as possible in 
order to provide for the most comprehensive evaluation of the field. This review was 
originally published in the journal Food Additives and Contaminants in June 2009. 
However, studies reported after this date (up to October 2010) have now also been 
reviewed and are discussed in the text. Literature searches were conducted using the 
Pubmed facility of the USA National Centre for Biotechnology Information (NCBI) 
(www.ncbi.nlm.nih.gov/), Scopus (www.scopus.com), the Web of Science 
(www.scientific.thomson.com/products/wos/) and various ‘grey’ literature sources. Many 
researchers were also contacted so that as much data as possible from individual 
animals and particularly for values below the reported LODs, decision limit (CCα) or 
detection capability (CCβ) could be obtained. This had the advantage that some 
appreciation of concentrations could be obtained where analyte concentrations were 
currently too challenging for fully rigorous quantitative analysis.   
 
In the following sections, the occurrence of precursors and metabolites of testosterone, 
nandrolone and boldenone in bovine, porcine and ovine matrices is reviewed in narrative 
fashion. Also reviewed are precursors and metabolites of nandrolone and boldenone in 
equine, cervine and caprine matrices. Ideally, a statistical analysis of results using a 
meta-analysis (defined here as “the statistical analysis of a large collection of analysis 
results for the purpose of integrating the findings” – from Glass, 1976) would be a 
desirable outcome. However, due to a lack of sufficient data this approach could not be 
used. Where differences between results in this review are stated to be “statistically 
significant,” this refers to comparisons of controlled populations within a single study and 
not between results of different studies. Unless otherwise stated, the results reviewed 
derive from controlled studies where the use of banned steroids can be ruled out. 
   
As many relevant matrices as possible have been considered in this review. However, 
due to the magnitude of the literature and the overall scope of this review being 
predominantly targeted at control of abuse rather than the safety implications, there is an 
inevitable bias in the output toward plasma, urine, bile, faeces and hair over tissues such 
as muscle and fat. Also, longitudinal studies using solid tissues are not often possible 
because this usually means slaughter of the animal (hence only one sample can be 
taken). In addition to the individual studies reviewed herein, several reviews dealing with 
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the concentrations of steroid hormones in different food products are also available 
(Velle 1976, Henricks et al. 1976, Hartmann et al. 1998, Arnold 2000, Daxenberger et al. 
2001, Stephany et al. 2004, Fritsche et al. 1999 and Mouw et al. 2006). 
 
1.3 Physiological and analytical considerations regarding comparisons of 
steroid concentrations within and between different species 
 
A basic understanding of the analytical and physiological context of natural steroids is 
assumed in this review. Nevertheless, some information of specific relevance is given 
below and the biosynthetic and catabolic pathways of some representative natural 
steroids are summarised in Figures 1 and 2 and Table 4. Further background information 
on general analytical aspects can be found in Makin et al. 1995 and Stolker et al. 2005 
while further physiological information can be found in Mason et al. 2002 and Hadley and 
Levine 2006.  
 
Although the background given here is separated into analytical and physiological 
factors, there are areas of overlap between the two. A critical theme that will become 
apparent is that the lack of reporting of sufficient method details (at least in a standard 
format) often means that rigorous quantitative comparisons between different studies are 
not possible. It was also necessary to limit the number of parameters chosen for study. 
The remaining analytical parameters subject to full analysis were chosen by 
consideration of a combination of their impact on any results as well as the frequency 
and reliability of their reporting.  
 
1.3.1 Analytical factors 
 
Although most published methods rely on direct identification and/or quantification of 
analytes, indirect approaches utilising biosensors, biomarkers, gas chromatography-
combustion-isotope ratio-mass spectrometry (GC-C-IRMS) or the detection of intact 
steroid esters have also been investigated (discussed further in later sections). For the 
purposes of the main body of this review chapter however, studies were limited to direct 
detection/quantification using such techniques as immunoassay (IA), high performance-
liquid chromatography with ultraviolet detection (HPLC-UV) and liquid or gas 
chromatography coupled to mass spectrometry (LC- and GC-MS respectively).  
  
 
 
Figure 2 – schematic representation of the phase 1 metabolism of nandrolone in the three species for which most information is 
available (bovine, porcine and equine). Sites of possible metabolic epimerisation are highlighted (*). For space purposes, and due to 
the number of potential isomers, it is only possible to depict the major metabolites of nandrolone. For the same reasons it is also not 
possible to give schematic metabolic pathway representations for all the individual steroids covered in this review. However, it is 
worth noting that the same functional groups that are subject to metabolism in nandrolone are also liable to metabolism in other 
androgenic-anabolic steroids.  
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When comparing data between studies, it becomes apparent that while ‘true’ differences 
between data points and populations do exist, that variation can also be caused by 
biases in sampling designs or the type of analysis used. In many cases, comparison of 
data is further complicated by the reporting of different types of information i.e. LOD or 
CCα/β are often not reported. Some examples of analytical aspects that can lead to 
variation within the data are given below: 
 
● Qualitative, semi-quantitative and fully quantitative data – While the ultimate aim of this 
review was to consider concentrations of natural steroids in a quantitative fashion, it was 
also recognised that a number of useful studies only reported data in a qualitative or 
semi-quantitative fashion. While the results of these analyses were not subject to any 
statistical analysis, they were considered useful in answering certain qualitatively 
focussed questions e.g. does boldenone occur naturally at any concentration in species 
X? Where qualitative or semi-quantitative data are analysed, this will be highlighted and 
any assumptions stated. Even with studies that are reported to be ‘quantitative’ it is 
important to understand that all data has a degree of uncertainty attached. However, tor 
the majority of studies reviewed herein, insufficient validation data were available to fully 
assess the degree of uncertainty of the results. 
 
● Method of calibration line construction – When dealing with endogenous substances, 
quantification can sometimes be complicated by the difficulty of finding a true blank 
matrix. In cases where a blank matrix of the same type as the study samples is not 
available then one can either use standard addition; where known amounts of steroids 
are added ‘on top’ of the existing concentrations present, or alternatively a surrogate 
matrix can be used. If using a surrogate matrix devoid of endogenous steroid, then 
appropriate measures need to be taken to ensure the chosen matrix behaves in a similar 
way to the actual sample matrix in order to control for any variation in the analytical 
procedure. Neither of the two aforementioned measures is perfect and each can lead to 
different reported concentrations for the same data set due to differential matrix effects 
or recovery of analyte. In many published reports, the actual calibration range applied 
was not explicitly given. This made it difficult to evaluate whether individual results fell 
within a linear range. Due to the need to limit the number of factors that were being taken 
into account in this review, adjustment of analytical data for recovery and matrix effects 
was not attempted. In any case, many of the aforementioned parameters were not 
always reported by authors. 
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● Limit of Detection (LOD) or CCα/β – For some steroids in certain physiological 
situations, a large number of reported concentrations are ‘not detectable’ (ND). This 
causes problems for two main reasons, one statistical and the other regulatory. From a 
statistical angle, the existence of large numbers of concentrations below the LOD are 
problematic because these values have to be effectively treated as zero, making it more 
difficult to define the population distribution and hence set threshold levels. If the LOD is 
not reported at all then this further complicates meta-analyses. From a regulatory point of 
view, because sensitivities generally increase as technologies improve, this sometimes 
means that steroids once thought to be purely synthetic appear to exist naturally at very 
low levels. However, it is difficult to assess whether new clusters of positive findings at 
such low levels are due to an increased abuse of steroids or natural occurrence. The 
issue in this context is therefore not the LOD per se, but the LOD in the physiological, 
analytical and regulatory context. Where possible, authors of published works were 
contacted and information on LODs or CCα/βs was requested. Also requested (where 
relevant) were any results that were quantified, but which were below the LOD or CCα. 
In these cases, an estimation of the reliability of the additional trace concentration data 
was also requested.  
 
● Sample collection and subsequent preparation technique – Prior to analysis, most 
techniques require some degree of sample preparation, which typically involves 
extraction of the analytes of interest from unwanted or interfering matrix components. 
The treatment of the sample once taken from the animal can influence the analytical 
results in several ways, all of which highlight the need to stabilise samples appropriately 
and to take into account any artefactual processes occurring prior to analysis. For 
example, it is known that a number of meat producing species, e.g. bovine, ovine and 
equine, but not porcine, have a propensity to convert 17β-hydroxy or ketone functions 
into 17α-hydroxy compounds. (Gaiani et al. 1984). Bovine plasma in particular is known 
to be especially active at catalysing this reaction and the addition of methanol to the 
matrix has been shown to inhibit the activity (Gaiani et al. 1984).  
 
It has also been shown that the new-born of the ovine, caprine and bovine display very 
high rates of 20α-hydroxysteroid dehydrogenase activity (acting on progestagens and 
corticosteroids) and that this activity diminishes rapidly with age; possibly due to the 
replacement of fetal with adult erythrocytes (Nancarrow et al. 1983). Due to a general 
dearth of knowledge on the metabolism of steroids in caprine, and ovine species, the 
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significance of this finding for surveillance of steroid abuse is currently difficult to assess. 
However, for all the species concerned, the data suggests that it is important to choose 
the correct age of the animals from a reference population that is used for establishing 
thresholds. This is so that the ages reflect those of the animals likely to be encountered 
in routine surveillance programmes. 
 
Bovine faeces are known to be capable of producing boldenone and other 1-dehydro 
steroids as metabolites from some steroidal precursors ex-vivo (Pompa et al. 2006). It is 
therefore recommended that sampling of bovine urine be devoid of faecal contamination 
in order to avoid boldenone false positives (De Brabander et al. 2004).  
 
It has also been shown that nandrolone related compounds can be formed from 
testosterone derivatives in human urine. The authors of this work showed that this 
reaction can be partially stabilised by adding EDTA to the samples (Grosse et al. 2005).  
 
Many steroids can also be conjugated with polar moieties such as sulphuric and/or 
glucuronic acid. Samples are often hydrolysed prior to analysis in order to produce the 
‘free’ steroid. Hydrolysis can be performed before or after preliminary extraction or group 
separation and even then can be performed by a variety of methods. Helix pomatia 
digestive juice is the most often applied enzymatic form of deconjugation and this 
method affords hydrolysis of glucuronic acid conjugates and aryl sulphates at optimum 
pH. However, it is also known to contain hydroxylase and oxidoreductase enzyme 
activity that can artefactally oxidise or reduce some steroids (Houghton et al. 1992). 
Another preparation that is frequently used is the β-glucuronidase enzyme from E. coli, 
which as its name suggests cleaves glucuronic acid conjugates but not sulphate 
conjugates (Houghton et al. 1992). In a ‘two fraction’ extraction, glucuronic acid 
conjugates may be cleaved by enzymes from extracts of Helix pomatia, while sulphate 
conjugates can be cleaved using acidified ethyl acetate:methanol (termed solvolysis; as 
reported in Teale and Houghton, 1991). An alternative is to cleave both types of 
conjugates simultaneously using acidified methanol (termed methanolysis; as reported in 
Tang and Crone, 1989), but this can lead to more complex mixture of components 
retained within extracts (James Scarth, personal observation). The use of a number of 
different hydrolysis (or no hydrolysis at all) steps in the literature, all with varying 
capacities to deconjugate steroids, is another factor that potentially leads to variation in 
the reported concentrations.  
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A mixture of purification/concentration approaches were identified in the literature 
including solid phase extraction, liquid-liquid extraction, protein precipitation, 
immunoaffinity column chromatography, supercritical fluid extraction, accelerated solvent 
extraction (ASE) and some very elaborate, but often effective, multi-step HPLC 
fractionation processes. Results using these methods are generally not compared in this 
review, unless there was specific relevance to a result. 
 
● Type of analytical method used – A major factor leading to variation between reported 
values lies in the type of end-point detection method used. These included (in 
approximate descending order of reported use), immunoassay (IA), gas-
chromatography-mass spectrometry (GC-MS), liquid-chromatography-mass 
spectrometry (LC-MS), high-performance-liquid chromatography-ultra-violet detection 
(HPLC-UV) and thin-layer-chromatography-fluorescence detection (TLC-FL). 
Immunoassay and mass spectrometry techniques generally afford higher sensitivity over 
HPLC-UV or and TLC-FL and are also generally more selective. Mass spectrometry is 
considered to offer more selectivity than IA, predominantly due to variable extents of 
cross-reactivity of steroids against the IA antibody, although the impact of any cross-
reactivity can be reduced by performing HPLC separation of sample extracts prior to 
analysis. Although generally considered very selective, mass spectrometry is still subject 
to matrix effects such as ion suppression or enhancement (LC-MS generally more so 
than GC-MS). However, these can usually be overcome through the use of matrix 
matched standards (where available). As a general rule, it has been observed that IA 
tends to overestimate oestrogen levels at low concentrations while underestimating them 
at high concentrations (Stephany et al. 2004).  
 
● Statistical analyses used within the studies reviewed –. Depending on a number of 
factors, including the steroid, species, matrix and analytical LOD, a Gaussian distribution 
of steroid concentration population data may or may not be determined. In this respect, a 
large number of parametric and non-parametric approaches were reported by authors, 
reflecting the different findings under varying conditions. With such major differences in 
statistical reporting, such as mean vs median or standard deviation vs inter-quartile 
range, it is very difficult to make quantitative comparisons between data sets. It is also 
important to highlight a major difference between a statistical method being able to 
discriminate a control from a steroid treated population (i.e. a T-test result) and a 
statistical method that allows a workable threshold to be calculated (i.e. allowing a 
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degree of certainty that at a particular threshold a false positive will not  occur). There 
can be a significant amount of overlap in individual steroid concentrations from control 
and treated steroid populations that can be discerned using a T-test, but this does not 
necessarily mean they are significant enough differences to allow a realistic threshold to 
be fixed. 
 
It is also important to add that the uncertainty of measurement was very rarely reported 
in the studies reviewed and was not easily calculated from the data available, further 
adding to the difficulty in making quantitative comparisons between data sets.  
 
1.3.2 Physiological factors 
 
Some of the physiological considerations regarding steroid concentrations were given in 
the analytical section above. In addition to inter-individual differences, there are many 
further factors that lead to variation in the observed concentrations. For example, 
Challenger (2004) has reviewed the peak ovarian cycle plasma/serum oestradiol and 
progesterone concentrations in mammalian species. It was found that oestradiol 
concentrations spanned around four orders of magnitude while those for progesterone 
spanned three orders of magnitude. Oestradiol concentrations were on average two 
orders of magnitude lower than progesterone concentrations and there were significant 
differences between different animal orders. Maximum oestradiol concentrations were 
more variable in artiodactyls and primates than in carnivores. Absolute oestradiol 
concentrations were not correlated with dietary niche, but the progesterone to oestradiol 
ratio was lower in artiodactyls and primates compared with carnivores. Although this 
study refers to oestrogens and progestagens rather than androgens (a comparable study 
for androgens could not be found by the author), it highlights the significant differences in 
steroid concentrations between species and identifies the need to obtain endogenous 
population data for hormones in each species before detection strategies for regulatory 
surveillance are devised. As many references in this review will demonstrate, intra- and 
inter-species genetic variation may be responsible for a large proportion of the observed 
variation between animals.  
 
● 4- vs 5-ene pathways – As well as the absolute differences in oestradiol and 
progesterone described above, species are also known to vary in their utilisation of the 
4- and 5-ene pathways for the production of steroids; which can be traced back to 
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differences in the substrate requirements of the CYP17 enzyme (Mason et al. 2002). 
This means that some species produce more steroid precursors with a 4-ene group (e.g. 
androstenedione) whereas others produce more with a 5-ene group (e.g. DHEA 
[dehydroepiandrosterone]). Of relevance to meat producing animals,  5-ene precursors 
are relatively high in bovine, porcine, ovine and equine species, while the cervine is 
lower in 5-ene and higher in 4-ene steroids (Wichman et al. 1984). 
 
● Pregnancy and pseudopregnancy – It is well known that pregnancy can lead to 
extremely high concentrations of certain relevant steroids. Pregnant animals are 
therefore usually excluded from threshold value calculations. However, a phenomenon 
termed pseudo-pregnancy (also known as phantom pregnancy or pseudocyesis) also 
exists. In some species this condition leads to the physiological appearance of a state of 
pregnancy (including raised steroid concentrations), but without an actual fetus being 
conceived (Johnson and Everitt 2000). The effect is certainly frequent in rodent and 
canine species, but some references to its occurrence in the porcine (Pusateri et al. 
1996), caprine (Lopes Junior et al. 2002) and ovine-caprine hybrids (Maclaren et al. 
1993) were also obtained. While the condition does seem to occur naturally at a high 
incidence in some caprine species, the porcine reports were of artificially induced 
pseudo pregnancy by administering oestradiol. No reports of pseudopregnancy in bovine 
species could be found in the published literature.  
 
● Oestrous synchronisation – The effects of oestrous synchronisation devices are not 
covered in this survey, but the subject has received comprehensive review in Rathbone 
et al.1998. 
 
● Route of excretion – Endogenous and artificially administered steroids are 
predominantly excreted from the body via the urine and faeces. The excretion of steroids 
is species and compound dependent, with some species preferentially excreting in 
faeces and some in urine. Consideration of whether urine, bile or faeces are the most 
suitable choices for a particular steroid/species combination depends on a number of 
factors (taken up later in this review), but their relative excretion in the form of recovered 
radioactivity in urine versus faeces is one consideration. Although an important factor for 
consideration, a predominance of radioactivity in one or other matrices does not always 
imply greater suitability for that matrix since a smaller proportion of radioactivity present 
as one analyte may be more useful than a larger proportion of radioactivity present as 
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many metabolites. Differences in the total volume of excreted material can influence 
resulting concentrations. On the whole, urine generally suffers less analytical matrix 
effects and residual ex-vivo metabolism than faeces. Figure 3 exemplifies the range of 
different excretion patterns that have been observed for some steroids. 
 
 
Figure 3 – Percentage excretion of radioactivity in different waste products after 
intravenous infusion of testosterone into different species (adapted from Martin 1966, 
Calvert et al. 1975, Velle 1976 and Palme et al. 1996).  
 
● Hydration status– The concentrations of steroids in some matrices, especially urine, 
can be affected by the hydration status of the animal (Wolfgang Korth – personal 
observation). One could predict that this might be a particularly important factor in 
countries that have experienced frequent droughts in recent years, for example Australia. 
The adjustment of urinary steroid concentrations for the hydration status of the animal 
(often measured as the specific gravity or the creatinine concentration of the urine) 
therefore has potential to reduce the variation in steroid values among the population. 
Like many physiological variables, it is also possible that dehydration may be a stressor 
that affects minor metabolic pathways such as the rate of biosynthesis/catabolism of 
steroids. However, the author is not aware of any studies that have assessed this 
particular variable.  
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● Other variables – Many other physiological variables can affect the concentrations of 
steroids in different animals. Previously proposed regulatory thresholds for natural 
steroids in meat producing species (i.e Scippo et al. 1993, Arts et al. 1991) have taken 
into account at least the age and sex of the animal when constructing thresholds. In the 
current review, some of the factors that were analysed include the steroid in question, 
matrix, age, sex, herd demographics, gestation and castration status, geographical 
factors, housing conditions, season and time of day, disease, stress, medication, 
housing conditions, diet and breed.  
 
1.4 Natural androgenic-anabolic steroid concentrations in the bovine 
 
1.4.1 General trends in the data 
 
Figures 4 and 5 summarise the different analyte/matrix and analytical technique/analyte 
combinations found for the bovine studies reviewed (as of June 2009 when the original 
literature review on which this chapter is based was published in Food Additives and 
Contaminants. Studies published after this date are reviewed in a narrative fashion in the 
text, but do not appear in figures 4 and 5). This analysis was not repeated for other 
species as it was apparent that a similar analysis of other species would not provide 
sufficient data for a meaningful comparison. 
Figure 4 – Summary of the use of different analytical techniques used in the bovine 
studies reviewed in this report. 
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As Figure 4 shows, testosterone has most often been analysed using IA, whilst 
nandrolone and boldenone by GC or LC-MS. The predominant use of IA (most often 
radioimmunoassay [RIA], followed by enzyme immunoassay [EIA]) is mainly due to its 
ease of application, its cost effectiveness, the fact that many studies were carried out in 
research laboratories that do not have mass spectrometry facilities or only use them for 
confirmatory analysis and because of its high sensitivity in determining analytes present 
at low concentrations. Nandrolone and boldenone on the other hand are most often 
analysed by GC-MS or LC-MS. This can be partially explained by the fact that 
proportionally more research on these analytes is reported by residue screening 
laboratories; which are more likely to use mass spectrometry than research departments 
focussing on physiology. However, it may also be because of the ambiguous status of 
these analytes and their metabolites i.e. are they endogenous or not?  
 
Figure 5 – Summary of the matrices used in the bovine studies reviewed in this report 
(all methods of analysis included). 
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As Figure 5 shows, testosterone has most often been analysed in plasma or serum, 
whereas nandrolone and boldenone have most often been analysed from urine/bile or 
urine/faeces respectively. As in the case of the explanation for the use of different 
analytical techniques for different analytes, these differences can be in part explained by 
quantitative biases in the type of research being carried out: either 1) physiology 
research looking at matrices indicating relevant circulating concentrations (i.e. plasma) 
for testosterone and 2) research for residue control in matrices more relevant to the 
detection of abuse (i.e. concentrated amounts in urine, bile or faeces for nandrolone and 
boldenone).  
 
Data on the endogenous presence of androgenic-anabolic steroids in the bovine are 
summarised in Table 3 while details of the major phase 1 metabolic products following 
exogenous administration are given in Table 4.  
 
1.4.2 Testosterone and related androgens in the bovine 
 
1.4.2.1 Endogenous occurrence 
 
As a general rule for all steroids, circulating plasma and tissues from non-excretory 
organs contain relatively high concentrations of unchanged ‘parent’ steroid while 
excretory products such as urine, bile or faeces contain relatively higher concentrations 
of metabolites. As well as a relative difference in the proportion of each 
steroid/metabolite present, excretory products generally contained higher absolute 
concentrations of total analyte/metabolite due to a concentrating effect. 
 
Testosterone and related steroids such as epitestosterone, androstenedione and DHEA 
are ubiquitous among male and female animals of all mammalian species, so differences 
among various groups and times are purely quantitative. When surveying the ranges of 
mean, minimum and maximum values among the published studies (over 1,000 papers 
for all species concerned), an approximate overall rank order of absolute concentrations 
can be constructed. It must be stressed that some positions within this rank may be 
caused by biases in the amount of information reported for each steroid in different 
matrices. An approximate rank order for testosterone concentrations in the bovine is hair 
> urine ~ fat ~ faeces ~ kidney > plasma > liver ~ muscle. An approximate rank order for 
the significant testosterone metabolite epitestosterone is urine > faeces > plasma > 
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muscle > hair (no data in fat, liver or kidney). In terms of absolute values, testosterone 
and epitestosterone were present at similar concentrations in muscle and plasma, 
testosterone was at least a factor of 10 higher in hair and epitestosterone was around a 
factor of 10 higher in urine and faeces (no data for fat, liver or kidney). There was more 
variation among epitestosterone values relative to those for testosterone. As mentioned 
elsewhere in this review, the majority of plasma results that contributed to the 
aforementioned results do not use sample hydrolysis. However, Scippo et al. 1993 
showed that while the maximum testosterone concentration found in bull plasma were 
5.8 and 0.97 ng ml-1 for unconjugated and conjugated, respectively; the reverse was 
seen for epitestosterone with values of 0.97 and 1.8 ng ml-1 for unconjugated and 
conjugated, respectively. This could lead to artificially low reported concentrations of 
epitestosterone in plasma relative to testosterone.  
 
Several other precursors including DHEA, androstenediol isomers and androstenedione 
were also occasionally quantified and there may be value in monitoring perturbations of 
endogenous steroid feedback loops after exogenous steroid administration.  
 
Existing EU guidelines for positive decision limits (as proposed by Heitzman 1994) in the 
bovine already rely on separation of sex, age and gestation status as summarised in 
Table 1 below. 
 
Table 1 – EEC decision limits for testosterone in plasma (as proposed by Heitzmann 
1994). 
 
 
Age/sex of animal 
EEC decision limit in plasma (ng ml-1) 
Testosterone  
Female (non-pregnant) 0.5 
Male (< 6-months) 10 
Male (> 6-months) 30 
 
From the current review, ranges of mean plasma/serum concentrations of testosterone 
and epitestosterone were found to be approximately 10-fold higher in intact mature 
males relative to females (no data for steers). One significant finding was of a study that 
stated that plasma testosterone was exceptionally high for a very brief time during the 
late luteal phase of the normal female oestrous cycle exceeding 1.8 ng ml-1 (Dobson et 
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al. 1977). All other ranges of testosterone reported by this author were in-line with those 
of other studies, so if real, this phenomenon could have a serious, negative impact on 
the validity of the existing EU decision limit for females.  
 
From the current review, ranges of mean urinary concentrations of testosterone and 
epitestosterone were found to be approximately three-fold higher in mature males 
relative to females (no data for steers). Ranges of mean muscle concentrations of 
testosterone were found to be approximately 10-fold higher in mature males relative to 
females or steers, although epitestosterone was similar between steers and bulls (no 
data for females). Ranges of mean liver and kidney concentrations of testosterone were 
found to be approximately 10-fold higher in mature males relative to females (no data for 
androgens in steers or epitestosterone in any sex). Ranges of mean hair concentrations 
of testosterone were found to be approximately three-fold higher in mature males relative 
to females and steers (no data for epitestosterone). There were insufficient data to 
compare testosterone concentrations by sex in faeces, fat or bile. 
 
Several studies have assessed the effect of age on the plasma/serum concentrations of 
testosterone in males, although the different ages, matrices and conditions under which 
the animals were studied and a lack of standardisation in reporting the uncertainty of 
measurement makes meaningful comparisons difficult. The results from three of the 
most informative studies are summarised below: 
 
1) Bagu et al. 2006 showed that mean male serum testosterone concentrations at 4-
weeks of age were around 0.1 ng ml-1. Concentrations then rose to 1.0 ng ml-1 at 20-
weeks, then dropped back to 0.4 ng ml-1 at 28-weeks and rose again to 1.1 ng ml-1 at 
32-weeks. The authors of this study also referenced other studies that have shown a 
trough in testosterone concentrations between 20 and 32 weeks of age. 
 
2) Looking at older animals, Moura et al. 2001 reported that mean male serum 
testosterone concentrations were 1.8 ng ml-1 at 26-weeks of age, rose to 8 ng ml-1 at 
43 weeks and then dropped to 6.5 ng ml-1 at 52-weeks. In the same study, 
androstenedione was 0.45 ng ml-1 at 17-weeks and dropped to 0.25 ng ml-1 at 52-
weeks.  
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3) The most informative single study on the effect of age was published by Arts et al. 
1990. Median male plasma testosterone concentrations at 15-weeks of age were 0.8 
ng ml-1 and then rose to 1.3 ng ml-1 at 28-weeks. Concentrations of epitestosterone, 
however, dropped from 7.1 ng ml-1 at 15-weeks to 0.8 ng ml-1 at 28-weeks. In the 
same study, median male urinary testosterone concentrations were 1.0 ng ml-1 at 15-
weeks and rose to 3.7 ng ml-1 at 28-weeks. Epitestosterone concentrations did not 
change with age and values 15- and 28-weeks were 40 and 41 ng ml-1 respectively. 
As a result of the aforementioned testosterone and epitestosterone concentration 
changes with age, the epitestosterone:testosterone ratio fell significantly from 15- to 
28-weeks of age. On this note, the testosterone:epitestosterone ratio has been found 
to be a good indicator of testosterone abuse in humans and horses (due to selective 
elevation of testosterone after testosterone doping), but Angeletti et al. 2006 showed 
it to be of less use in the bovine, probably due to the relatively high 17α-hydroxylase 
enzyme activity.  
 
Relatively fewer studies have analysed the effect of age on female testosterone 
concentrations. Nakada et al. 2000 reported that mean female plasma testosterone 
concentration immediately after birth was 0.075 ng ml-1 but then fell, ranging between 
means of 0.015 and 0.021 ng ml-1 between birth and puberty. Mean (and standard error 
of the mean) age to puberty was 43.3 (1.3) weeks, with a range of 38-55 weeks. The 
same study by Arts et al. 1990 that reported male testosterone data by age also reported 
female data. Median female plasma testosterone concentration was less than the LOD at 
both 15- and 28-weeks, while median plasma epitestosterone was less than the LOD at 
15-weeks and then rose to 0.2 ng ml-1 at 28-weeks. Median female urinary testosterone 
concentration at 15-weeks was less than the LOD and then rose to 1.1 ng ml-1 at 28-
weeks. Median female urinary epitestosterone at 15- and 28-weeks were 6 and 17 ng ml-
1 respectively.  There were insufficient data to compare the effect of age on testosterone 
or related metabolites/precursors in faeces, liver, kidney, bile, muscle, hair or fat.  
 
Data on the concentration of testosterone in any matrix from pregnant females was not 
available, but it would be expected to be elevated relative to non-pregnant females in line 
with other steroids (see later sections). However, mean plasma concentrations of DHEA 
and androst-5-ene-3β,17β-diol were found to be approximately three-fold higher in 
pregnant females (Gabai et al. 2004). 
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In a 2001 study, Plusquellec et al. showed that lactating cows of the Herens breed 
(artificially selected for fighting ability) had significantly higher (P<0.05) median plasma 
testosterone concentrations compared to Brune des Alpes animals, with values of 0.21 
and 0.11 ng ml-1 respectively. This conforms to the observation that aggression 
correlates with increasing testosterone levels. The biochemical observations were also 
borne out by secondary sexual characteristics, which were more prominent in the Herens 
breed.  
 
A study by Moura et al. 2001 showed that bulls suffering spermatic arrest had only 
slightly lower serum testosterone concentrations than healthy controls. However, serum 
androstenedione in one diseased animal was > 0.8 ng ml-1 at 12-months, relative to a 
mean of 0.25 ng ml-1 in healthy controls. No reports on the effect of other factors known 
to increase the androgen output in other species were found i.e. stress or congenital 
adrenal hyperplasia.  
 
No studies were found that directly compared concentrations of testosterone or related 
precursors/metabolites in similar breeds under different housing conditions or in different 
countries, nor of diet, time of day or season on testosterone or related 
precursor/metabolite concentrations.  
 
In most species long-term treatment with gonadotrophin-releasing hormone (GnRH) 
agonists such as deslorelin decrease luteinzing hormone (LH) output (and therefore 
testosterone secretion) due to desensitization of the pituitary gland. However, Aspden et 
al. 1997a reported that testosterone concentrations in mature bulls are increased 
following deslorelin administration, although another effect of this drug is that LH 
pulsatility is lost, leading to a flat LH secretion profile. On the other hand, Renaville et al. 
1996 showed that administration of GnRH to immature bulls between 70- and-150 days 
of age delayed puberty relative to controls with mean pubarche ages of 180- and 120-
days respectively. No reports of the effects of other non-steroidal medications on 
androgen concentrations were found, but several types of medication in other species 
are known to affect increase or decrease in concentrations e.g. cytochrome P450 
enzyme inducing inhibiting drugs. 
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1.4.2.2 Metabolism following administration  
 
Many studies have reported the changes in natural steroid profiles after exogenous 
steroid administration and some general trends as well as the results of one particularly 
informative study, whose results are in line with other reports, are summarised below. 
Testosterone itself was most often reported as being given in esterified form as an 
implant in the ear or as an intramuscular (IM) injection, either alone or in combination 
with oestradiol esters. A general trend in the bovine is for animals of both sexes to 
epimerise 17β-hydroxyl groups to the corresponding 17α isomer. While this 
epimerisation results in significant amounts of 17α-hydroxy steroids in urine, the 
enzyme/s responsible for the activity are also present in plasma/serum. This highlights 
the need to consider steroid stability studies in all matrices in order to ensure that 
appropriate action to maintain stability is taken. 
 
Biddle et al. 2003 reported the effect of component-EH administration (a testosterone 
plus oestradiol preparation) to heifers and steers on the concentrations of urinary, serum 
and bilary androgens and compared the results to ‘natural’ populations (sampled from 
the field so not considered a fully ‘controlled’ population with respect to ruling out steroid 
abuse). For heifers and steer serum, basal androgen levels were very low (all most all 
results below the LOD) and no significant changes were noted after administration of 
component-EH. In heifer and steer urine, epietiocholanolone, 5β-androstane-3α,17β-diol 
and 5β-androstane-3β,17α-diol were present at similar levels and were around 10 times 
the concentration of testosterone. No data for epitestosterone were reported. After 
component-EH administration, the most significantly increased urinary metabolites 
relative to baseline values were 5β-androstane-3β,17α-diol and 5β-androstane-3α,17β-
diol. Testosterone was not detectable in the majority of steer and heifer bile samples 
collected at slaughter.  Epietiocholanolone and 5β-androstane-3α,17β-diol were 
detectable somewhat more frequently, with 5β-androstane-3β,17α-diol being present at 
higher concentrations and therefore detectable in the majority of samples. However, no 
significant differences were observed in any of these analytes in animals administered 
Component-EH. Overall, concentrations of testosterone metabolites were present in the 
following rank order of concentration: bile > urine > serum. It is important to add that the 
conclusions reached in the above study may be partially dependent on the analytical 
detection capabilities i.e. if significantly reduced LODs were applied then it might be 
possible to discern steroid abuse from the natural population. 
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1.4.3 Nandrolone and related 19-nor androgens in the bovine 
 
1.4.3.1 Endogenous occurrence 
 
Nandrolone was once thought to be a solely synthetic steroid, but in the 1980s it was 
isolated as a natural hormone in the stallion (Houghton et al. 1984) and boar (Maghuin-
Rogister et al. 1988). Since then, nandrolone related compounds have also been 
detected in matrices originating in the bovine (Vandenbroeck et al. 1991), ovine (Clouet 
et al. 1997), caprine (Sterk et al. 1998), human (Dehennin et al. 1984) and cervine (Van 
Hende 1995). Non-phenolic C18 steroids (19-nor androgens) such as nandrolone are 
likely to be produced predominantly as minor pathways of the normal aromatisation 
process of androgens that gives rise to the phenolic oestrogens. C18 androgens are 
therefore most often encountered in situations of high oestrogen out-put (Van Eenoo et 
al. 2001) such as pregnancy, although other contributory causes such as consumption of 
contaminated dietary products (Le Bizec et al. 2000), increased physiological stress (De 
Geus 2004) and in-situ formation in stored urine samples (Grosse et al. 2005) (including 
whilst stored in the bladder prior to sampling), have also been implicated. As the later 
section on the equine describes, the possibility that 19-nor androgens may arise as 
artefactual products of 19-carboxy compounds also has to be considered because most 
methods to date have not taken this possibility into account (Houghton et al. 2007). It is 
also possible, however, that the production of these 19-carboxy compounds is limited to 
certain animals such as the equine due to unique genetic sequences in these species. A 
representative selection of studies reporting endogenous bovine nandrolone are 
summarised below: 
 
In 1993, Daeseleire et al. reported that traces of 5α-estrane-3β,17α-diol could be 
detected in urine from a pregnant control cow and that 19-noretiocholanolone was 
detected in two control steers by GC-MS (the breed not reported). Nandrolone and 
epinandrolone could not be detected in the cow or steer urine (method not quantitative 
so no LOD reported). No C18 androgens were present in calf urine.  
 
In 1994, De Brabander et al. reported the results of a multi-laboratory study on the 
natural occurrence of C18 androgens in the bovine. Although no nandrolone could be 
detected at an LOD of 0.5 ng ml-1, all four laboratories involved found that urine from 
pregnant cows (the breed was not reported) contained epinandrolone for up to four-
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month pre-partum and two-days post-partum when analysed by GC-MS. Although most 
laboratories agreed when epinandrolone was or wasn’t present in a sample (with some 
exceptions probably due to concentrations close to LODs), there was significant variation 
in the quantified concentrations when the compound was found (i.e. between 0.7 and 4.3 
ng ml-1 for one sample). This study is seminal in that it highlights the huge uncertainty of 
measurement that can surround the determination of steroid concentrations. It highlights 
the need to standardise as many experimental factors as possible and then cross-
validate methods before the results of such studies can be compared with confidence. It 
also serves as caution when trying to make too detailed a comparisons between data 
already in the published literature.  
 
In 1998, McEvoy et al. studied the natural occurrence of nandrolone and epinandrolone 
in the bile of pregnant Friesian cows using GC-MS. Nandrolone itself was not detectable 
in all samples from all stages of pregnancy (LOD not reported), but epinandrolone was 
detected from days-120 pre-partum onwards. Concentrations at 120-days pre-partum 
were around 1 ng ml-1, rising to 37 ng ml-1 at parturition and then dropping to not 
detectable within 1-week post-partum. Cows carrying male fetuses had higher (P<0.001) 
epinandrolone concentrations than those carrying female fetuses. Cows had lower 
(P<0.001) epinandrolone concentrations during their second pregnancy compared to 
during their first pregnancy. In 1999, McEvoy subsequently showed that the bile of steers 
and bulls derived from an untreated population did not contain nandrolone or 
epinandrolone above a GC-MS LOD of 0.4 ng ml-1. However, some bile samples from 
steers (but not from bulls) suspected of nandrolone abuse did contain epinandrolone.  
 
In 2009, Kennedy et al. reported the detection of epinandrolone and, on occasion, 
nandrolone in the urine of male cattle (bulls and steers) slaughtered on farm because of 
trauma. Similar results were also found in animals that were found to be injured on anti-
mortem inspection. Significant circumstantial evidence was presented that strongly 
suggested that the occurrence of these steroids was causally linked to the trauma. The 
authors therefore proposed that the production of these steroids may be related to 
increased adrenal steroid output during times of extreme stress. This theory was 
supported by the observation that urinary nandrolone could be detected in the urine of 
male animals that were administered the adrenal androgen DHEA sulphate. 
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1.4.3.2 Metabolism following administration 
 
Van Ginkel et al. (1989a) reported that in calves administered nandrolone (animal and 
administration details not available), that concentrations of epinandrolone were always 
greater than nandrolone, while concentrations of each were greater in bile than urine.  
 
Samuels et al. 1998 used GC-MS to study plasma, urine and bile steroid levels after IM 
administration of a 1:1 mixture of nandrolone and a deuterated labelled analogue to cull 
cows, steers and heifers, with only urinary results being reported in this paper. Between 
zero and 12-hour after administration, urinary epinandrolone and 5β-estran-3α,17β-diol 
peaked at around 200 ng ml-1 while 5β-estran-3α,17α-diol and 5α-estran-3β,17α-diol 
were lower at around 160 and 80 ng ml-1 respectively. However, between 12 and 24-
hours 5β-estran-3α,17α-diol and 5α-estran-3β,17α-diol were predominant with 
concentrations of around 120 and 90 ng ml-1 respectively, followed by epinandrolone and 
5β-estran-3α,17β-diol at concentrations of 30 and 40 ng ml-1 respectively. The 
aforementioned compounds were detected for both the deuterium labelled and non-
labelled mass transitions, suggesting that they were direct metabolites of the 
administered nandrolone laurate rather than through latent natural metabolic pathways 
being activated. 
 
Biddle et al. 2003 reported the effect of nandrolone laurate administration to heifers and 
steers on the concentrations of urinary, serum and bilary C18 androgens and compared 
the results to ‘natural’ populations (sampled from the field so not considered a fully 
‘controlled’ population with respect to ruling out steroid abuse). The majority of steer and 
heifer plasma samples contained natural concentrations of nandrolone, epinandrolone, 
5α-estrane-3β,17α-diol and 5β-estrane-3α,17α-diol that were below the LOQ and there 
was no significant increase in C18 androgens after administration relative to the ‘natural’ 
population. The majority of steer and heifer urine samples contained concentrations of 
nandrolone, epinandrolone, 5α-estrane-3β,17α-diol, 5β-estrane-3α,17α-diol, 5β-estrane-
3α,17β-diol and 19-noretiocholanolone that were below the LOQ. Laurabolin (nandrolone 
laurate) administered to females produced significant increases in epinandrolone, 5α-
estrane-3β,17α-diol, 5β-estrane-3α,17α-diol and 19-noretiocholanolone concentration. 
5-Estrane-3,17-diol was also elevated but to a much less marked extent. However, 
administration of Laurabolin to males only produced a slight rise in epinandrolone and 
5-estrane-3,17-diol concentrations. In bile, the majority of steer, heifer and bull 
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samples contained concentrations of nandrolone, epinandrolone, 5β-estrane-3α,17β-diol, 
5α-estrane-3β,17α-diol and 5β-estrane-3α,17α-diol that were below the LOQ. In post-
administration samples taken at slaughter from both heifers and steers (no samples for 
bulls), concentrations of 5β-estrane-3α,17α-diol were the most obviously increased of the 
steroids relative to samples from the ‘natural’ population. Nandrolone itself was not 
detectable in post-administration heifer bile samples, while interpretation of nandrolone 
data in steers and epinandrolone data in heifers and steers was complicated by the co-
elution of a large interfering peak in the relevant mass transition windows.  
 
In 2008, Pinel et al. reported the effect of nandrolone laurate administration to male and 
female calves (concomitant with oestradiol benzoate administration) on the resulting 
urinary metabolite profiles. Of the nandrolone metabolites identified following steroid 
administration, epinandrolone was highest in concentration. Nandrolone, 19-
noretiocholanolone and 19-norandrostenedione were identified as secondary 
metabolites. Overall, nandrolone metabolite profiles were similar between males and 
females, with the exception that epinandrolone concentrations in females were 
approximately twice those in males.  
 
Most recently (2010), Pinel et al. have extended the above study protocol to assess the 
effects of nandrolone laurate administration to male and female calves (concomitant with 
oestradiol benzoate administration) on the profile of estranediol nandrolone metabolite 
isomers. Of the isomers identified, 5α-estrane-3β,17α-diol was the most abundant, with 
less abundant isomers corresponding to 5β-estrane-3α,17α-diol, 5β-estrane-3α,17β-diol 
and 5α-estrane-3β,17β-diol. Concentrations of 5α-estrane-3β,17α-diol, 5β-estrane-
3α,17α-diol and 5α-estrane-3β,17β-diol were found to be an average of 2, 1.5 and 1.5 
times greater in females relative to males. Recent evidence (Gaud Pinel, personal 
communication) has suggested that while the isomer 5α-estrane-3β,17α-diol can occur 
naturally in the urine of pregnant and injured cattle, the 17β-isomers 5β-estrane-3α,17β-
diol and 5α-estrane-3β,17β-diol are only found following nandrolone administration. The 
17β-isomers may therefore be appropriate marker metabolites of nandrolone abuse.  
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1.4.4 Boldenone and related 1-dehydro androgens in the bovine 
 
1.4.4.1 Endogenous occurrence 
 
As in the case of nandrolone, 1-dehydro steroids such as boldenone were once thought 
to be purely synthetic in origin. Since the 1990s however, boldenone related compounds 
have been detected in different matrices from several species including microbes 
(Mahato et al. 1997), maggots (Verheyden et al. 2007), crustaceans (Verslycke et al. 
2002), rats (Song et al. 2000), pigs (Poelmans et al. 2005a), horses (Ho et al. 2004) and 
cattle (veal calves) (Arts et al. 1996). A comprehensive review of the presence and 
metabolism of boldenone in various animal species was published by De Brabander et 
al. in 2004. Extra-enteral production of 1-dehydro steroids within the body (i.e. testes) 
has not been demonstrated in the bovine (De Brabander et al. 2004), but boldenone has 
been identified in porcine testes (Poelmans et al. 2005a). One of the most likely origins 
of 1-dehydro compounds in the bovine is currently considered to be through conversion 
of precursors such as phytosterols or other steroids, possibly by gut microbes (Pompa et 
al. 2006, Draisci et al. 2007, Verheyden et al. 2007, Verheyden et al. 2010a). The 
endogenous occurrence of 1-dehydro steroids in the bovine has been the subject of 
some debate. 1-dehydro compounds appear to be present in some animal populations 
but not others. The extent to which this is due to real physiological variation versus 
experimental design is hard to establish, but the general consensus (various personal 
communications) is that it is likely a mix of both. The following selection of studies 
highlights many of the issues relating to the possible ‘endogenous’ nature of boldenone 
in the bovine: 
 
Draisci et al. (2003) analysed urine samples for boldenone, epiboldenone and androsta-
1,4-diene-3,17-dione by LC-MS from 25 untreated animals. Boldenone (LOQ = 0.2 ng 
ml-1), epiboldenone (LOQ = 0.5 ng ml-1) and androsta-1,4-diene-3,17-dione (LOQ 0.2 ng 
ml-1) were not detected above the LOQ in any of the urine samples from the untreated 
animals.  
 
Pompa et al. (2006) studied the concentrations of boldenone, epiboldenone,  androsta-
1,4-diene-3,17-dione, testosterone and epitestosterone in the urine, skin swabs and 
faeces of Friesian calves and also assessed the effect of drying the faeces on the 
resulting faecal steroid concentrations. In urine, LODs for all steroids were 0.1 ng ml-1 
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and in faeces LODs for all steroids were 0.5 ng g-1 (based on S:N>3:1). Boldenone, 
epiboldenone and androsta-1,4-diene-3,17-dione in urine were not detected in any of the 
samples from 10 calves. Boldenone was detected in faeces sampled directly from the 
rectum (rectal faeces) in all the calves at concentrations ranging from 28 to 89 ng g-1. 
Epiboldenone in rectal faeces was not detectable in six calves and between 2.6 and 5.9 
ng g-1 in the other four animals. Androsta-1,4-diene-3,17-one was not detected in the 
rectal faeces from 9 calves while one calf had 21 ng g-1. Results from faeces scraped 
from the skin, faeces taken from the stall floor and faeces stored for up to 13 days at 
room temperature in a cowshed showed that the concentrations of all steroids increased 
significantly (but variably) over time. This is especially true of epiboldenone and 
androsta-1,4-diene-3,17-dione, which by day-13 of storage are present in high 
concentrations, while boldenone was reduced to not detectable by day-13. This study 
exemplifies the need for avoiding faecal contamination of urine during sampling and to 
ensure swift storage and analysis of any samples taken. 
 
In 2007, Draisci et al. reported the effect of feeding two different types of milk replacers, 
containing different concentrations of phytosterols, on the urinary excretion of boldenone, 
epiboldenone and androsta-1,4-diene-3,17-dione in male calves. Boldenone and 
androsta-1,4-diene-3,17-dione were not detected in any animal during either treatment, 
but epiboldenone conjugates were present in samples from animals receiving both types 
of milk replacer. Although concentrations of conjugated epiboldenone were always below 
2 ng ml-1, concentrations in urine samples from the animals receiving the milk replacer 
with the higher phytosterol content were significantly higher. These results support the 
suggestion that epiboldenone may be formed through conversion of phytosterols and 
that it may also be present ‘naturally’ as a conjugate.  
 
In a publication assessing the ability of several invertebrate species to metabolise a 
number of different steroids, Verheyden et al. 2010a reported that feed-borne fungi were 
capable of converting phytosterols into 1-dehydro-steroids. Specifically, several 
unidentified fungal species growing on corn were found to be capable of converting the 
phytosterol β-sitosterol into androstenedione. On further incubation with 
androstenedione at higher concentrations, androsta-1,4-diene-3,17-dione was detected. 
Furthermore, following subsequent incubation with androsta-1,4-diene-3,17-dione at 
higher concentrations, boldenone was detected. This study demonstrates the usefulness 
in using in vitro models to study the possible pathways of steroid formation in cattle and 
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also further supports the proposal that phytosterols may be precursors to boldenone 
related compounds.  
 
Most recently, Verheyden et al. 2010b have demonstrated that some types of wooden 
crate in which veal calves are housed may contain precursors to boldenone. Specifically, 
the related compound androsta-1,4-diene-3,17-dione was detected at concentrations 
ranging from 20 to 34 ng g-1 in the wood from calves housing. The wood was also found 
to contain progesterone, androstenedione and epitestosterone. This raises the possibility 
that 1-dehydro steroids may be consumed inadvertently by calves due to environmental 
contamination. In light of these results, some kind of threshold concentration approach 
might therefore be more appropriate for detecting boldenone abuse compared to a 
qualitative marker metabolite based method. 
 
1.4.4.2 Metabolism following administration 
 
In a 1998 study, Van Puymbroeck et al. studied the metabolism of boldenone in the 
bovine using semi-quantitative GC-MS analysis of urine and faecal samples. In urine 
from animals given various boldenone ester administrations, epiboldenone was the 
major metabolite in urine, followed by significant amounts of two 5-reduced metabolites 
with unidentified stereochemistry at positions 3, 5 and 17 with molecular masses two 
units higher than boldenone. Other urinary metabolites identified were, 6z-
hydroxyboldenone, androsta-1,4-diene-3,17-dione and 5β-androst-1-ene-3,17-dione (‘z’ 
indicates that the isomer configuration has not been established). In faeces, boldenone, 
androsta-1,4-diene-3,17-dione and 6z-hydroxyboldenone were absent, while only small 
amounts of epiboldenone, 5β-androst-1-ene-3,17-dione and some unidentified reduced 
metabolites were found. 
 
In a 2004 study, Sterk et al. used GC-MS to study the effect on urinary and faecal 
metabolites after IM boldenone ester administration to veal calves.  Not all experimental 
details or results were reported, but the authors stated that “..both 17α and 17β-
boldenone were almost 100% present in urine as glucuronic acid conjugates. The 6z-
hydroxy-boldenone metabolite was present as a sulphate conjugate. In faeces 
boldenone was present in the non-conjugated form.”  
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Biddle et al. reported a quantitative metabolism study of boldenone in the bovine in 2005. 
Two steers were sequentially treated with A) bolus 400mg boldenone IM injection, B) 
followed 14-days after the bolus injection by an oral 500 mg androsta-1,4-diene-3,17-
dione administration, C) followed 10-days after the oral administration by a 700 mg 
boldenone undecylenate IM injection. Samples of plasma and urine were analysed as 
‘free’ and ‘glucuronic acid conjugated’ fractions using differential extraction and E. coli 
hydrolysis. Analysis was by GC-MS and was qualitative/semi-quantitative only. Where an 
analyte is preceded by a question mark (?) in the remainder of this section, it signifies 
that the structure is putative (although with strong evidence to suggest its structure) as 
no reference standard was available. After oral androsta-1,4-diene-3,17-dione 
administration, the free plasma metabolites were of the order of epiboldenone > ?6β-
hydroxyepiboldenone > boldenone ~ 6β-hydroxyboldenone. The plasma glucuronic acid 
conjugate fraction metabolites were also of the order of epiboldenone > ?6β-
hydroxyepiboldenone > boldenone ~ 6β-hydroxyboldenone, but absolute concentrations 
were approximately 10-times those of the free fraction. Of these, boldenone and 6β-
hydroxyboldenone were only transiently visible at low concentrations. The free urinary 
metabolites were of the order of epiboldenone > ?5β-androst-1-ene-17α-ol-3-one > 6β-
hydroxyboldenone ~ 5β-androst-1-ene-17β-ol-3-one. The urinary glucuronic acid 
conjugate fraction metabolites were of the order of epiboldenone > ?5β-androst-1-ene-
17α-ol-3-one > 5β-androst-1-ene-17β-ol-3-one > ?6β-hydroxyepiboldenone > 6β-
hydroxyboldenone. After IM boldenone undecylenate administration, the only free 
plasma analyte present was boldenone, which was detected for the whole 56-days after 
administration. The glucuronic acid conjugate plasma metabolites were of the order of 
epiboldenone > ?6β-hydroxyepiboldenone > boldenone. Of the glucuronic acid 
conjugated metabolites, ?6β-hydroxyepiboldenone had the longest detection time after 
administration. Boldenone itself was present in greater quantities in the free than 
glucuronic acid conjugate fraction in plasma. The free urinary metabolites were of the 
order of epiboldenone > boldenone. The glucuronic acid conjugated urinary metabolites 
were of the order of ?6β-hydroxyepiboldenone ~ ?5β-androst-1-ene-17α-ol-3-one ~ 5z-
androst-1-ene-3z-ol-17-one ~ epiboldenone > 5β-androst-1-ene-17β-ol-3-one. 
Boldenone and epiboldenone were present at higher concentrations as glucuronic acid 
conjugates than free steroids.  
 
In a 2006 study, Le Bizec et al. used GC-MS to analyse the urinary metabolite profile 
after various boldenone administrations in cattle. Treated animals received either a 
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single oral boldenone + androsta-1,4-diene-3,17-dione dose, a daily oral boldenone 
ester dose for three-days, a daily oral androsta-1,4-diene-3,17-dione dose for six-days, a 
daily oral boldenone ester dose for five-days or a single IM injection of boldenone esters. 
In all treated animal’s hydrolysed urine, epiboldenone was by far the most predominant 
metabolite, while 17α-hydroxy-5β-androst-1-en-3-one, 17β-hydroxy-5β-androst-1-en-3-
one and 3α-hydroxy-5β-androst-1-en-17-one were the only other metabolites always 
present. Analysis with and without hydrolysis suggested that the majority of metabolites 
were glucuronic acid conjugated; with boldenone having a variable degree of sulphate 
conjugation. Analysis using LC-MS was also carried out and it was found that urine from 
treated animals contained boldenone sulphate conjugate whereas urine from untreated 
animals did not. In a subsequent study from the same laboratory in 2009, Destrez et al. 
measured intact boldenone sulphate from urine in a larger number of treated and 
untreated animals using a number of different analytical techniques. This study 
supported the findings from Le Bizec et al. 2006 and provided further evidence of the 
suitability of boldenone sulphate as a marker metabolite of boldenone administration. In 
2008, Van Poucke et al. presented an alternative method for the analysis of boldenone 
conjugates based on the separation of free, glucuronide and sulphate fractions prior to 
hydrolysis of the conjugate fraction and analysis of the resulting ‘free’ steroids. One of 
the stated advantages of this method was the lack of requirements for conjugate 
reference standards.  
 
A recent study by Piper et al. (2010) highlighted the potential use of gas chromatography 
combustion isotope ratio mass spectrometry (GC-C-IRMS) to differentiate endogenous 
and exogenous boldenone and its main metabolite in human urine. The potential 
applications of GC-C-IRMS are taken up further in section 1.11.2. 
 
1.4.4.3 EU recommendations regarding boldenone testing 
 
The outcome of an experts meeting on the control of Boldenone in veal calves in 
September 2003 (European Commission 2003) recommended the following: 
 
“On the basis of the scientific information available, the experts of the Member States 
agreed that the presence of boldenone conjugates at any levels in urine from veal calves 
is proof of illegal treatment. In order for positive results for boldenone to be used as 
evidence of illegal treatment, the following must be fulfilled: 
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● Sampling of urine must be done without faecal contamination of the samples. The 
samples should be frozen as soon as possible after collection in order to avoid hydrolysis 
of the conjugates. 
● Analytical results related to boldenone residues (boldenone or epiboldenone) must 
always be specified as free or conjugated forms, with the explicit identification of the 
animal species, including breed, gender and age of the animal. 
 
There is sufficient scientific knowledge to conclude that the presence of epiboldenone in 
urine and faeces of bovine animals can come from other sources than illegal treatment. 
A number of explanations are currently being investigated by the scientific community. If 
only epiboldenone is found and if the levels are above 2 ng g-1 in urine of veal calves, 
additional investigations would need to be carried out before concluding on illegal use of 
boldenone.  
 
An MRPL for the analytical methods for the detection of boldenone and epiboldenone in 
urine of veal calves should be set at 1 ng g-1. Further studies of appropriate marker 
metabolites of boldenone are encouraged. The member states should transmit existing 
and future data to the CRL in Bilthoven. This position could be amended in the light of 
additional data from ongoing and future research.” 
 
1.5.1 Testosterone and related androgens in the ovine 
 
Data on the endogenous presence of androgenic-anabolic steroids in the ovine are 
summarised in Table 3 while details of the major phase 1 metabolic products following 
exogenous administration are given in Table 4.  
 
1.5.1.1 Endogenous occurrence 
 
In this review, ranges of mean plasma/serum testosterone concentrations were found to 
be between three- and 100-fold higher in rams relative to ewes (depending on the 
season), while concentrations in wethers were similar to those of ewes. Concentrations 
of androstenedione in the only report of concentrations in wethers were similar to the 
lowest mean concentrations reported in rams, but approximately 60-fold lower than the 
highest mean concentrations reported in rams. 
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Plasma/serum concentration levels of testosterone in late pregnant ewes were similar to 
those of non-pregnant animals, while pregnant ewe DHEA concentrations were similar to 
concentrations in rams. Androstenedione concentrations in pregnant ewes were similar 
to the maximum mean concentrations reported in rams and approximately 60-fold higher 
than the only report of concentrations in wethers.  
 
Several studies have assessed the effect of age on plasma/serum testosterone 
concentrations in rams. Fahmy et al. 1997 studied the serum concentrations of 
testosterone from the ages of 10 to 34-weeks in rams of the Romanov breed as well as 
the Booroola Merina x DLS breed. Testosterone concentrations increased in a linear 
fashion with age in both breeds (P<0.01). Mean concentrations in the Romanov breed at 
10-weeks were 3.8 ng ml-1, rising to 13 ng ml-1 at 34 weeks. Mean concentrations in the 
Booroola Merina x DLS breed were 0.8 ng ml-1 at 10-weeks, rising to 8.0 ng ml-1 at 34-
weeks. Concentrations were significantly higher (P<0.05) in the Romanov breed at all 
ages other than 14-weeks, which corresponded to a temporary reduction in 
concentrations in the Romanov breed. 
 
Langford et al. 1998 reported the serum concentrations of testosterone in each of the 
Canadian Arcott, Outaouais Arcott, Rideau Arcott and Finnish Landrace breeds at six-, 
eight- and 12-months then at three years.  Mean concentrations in the Canadian Arcott, 
Outaouais Arcott, Rideau Arcott and Finnish Landrace at six-months were 3.3, 4.0, 3.5 
and 3.9 ng ml-1 respectively, at 8-months were 3.1, 5.0, 5.5 and 8.2 ng ml-1 respectively, 
at 12-months were 3.5, 5.3, 5.4 and 7.8 ng ml-1 respectively. Mean concentrations at 
three-years were 8.0, 7.0, 5.7 and 7.0 ng ml-1 respectively. Concentrations were 
significantly higher (P<0.05) in Finnish relative to Canadian Arcott male lambs at eight 
and 12-months, but none of the other differences were significant (P<0.05). 
 
There was insufficient data to compare concentrations of testosterone or related 
precursors/metabolites between sexes, ages, gestation and castration statuses in any 
other matrix. 
 
No reports on the effect of time of day or geographical factors were found, but two 
reports on the effect of diet and several reports on the effect of season and housing 
conditions were retrieved. Schanbacher et al. 1979 reported the effect of transferring 
animals from a 12-hour light, 12-hour dark photoperiod to either short day photoperiod 
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(eight hour light, 16 hour dark) or long day photoperiod (16 hour light, eight hour dark) on 
serum testosterone concentrations in Suffolk-Hampshire rams. The animals exposed to 
short days had increased testosterone concentrations, heavier testes, larger 
seminiferous tubules and produced more sperm relative to the long-day rams. This effect 
of photoperiod has obvious implication for resulting testosterone concentrations, 
dependent upon the type of artificial light conditions and the hemisphere inhabited.  
Borque et al. 1999 studied the effect of season on the concentration of plasma 
testosterone in Manchego rams living in the northern hemisphere (Spain). 
Concentrations varied with the season, such that mean peak values were in the second 
week of September at 7.2 ng ml-1, while trough concentrations were 0.40 ng ml-1 in the 
second week of February. The authors also commented that increasing testosterone 
concentrations were correlated with a decreasing photoperiod. 
 
Rosa et al. 2000 studied the effect of housing males with females on plasma 
testosterone concentrations in Texel and Suffolk rams. Testosterone concentrations 
were increased on introduction to ewes (P<0.05), but the effect did not depend on 
whether ewes were in oestrous or not. Mean basal concentrations in different groups 
varied from 5 to 10 ng ml-1, while after introduction to ewes, concentrations increased by 
between 3 to 5 ng ml-1 to between eight and 15 ng ml-1. 
 
Parkinson et al. 2001 studied the effect of intersex relative to concentrations in ‘normal’ 
rams and ewes during the breeding season. Freemartin ewes (XX/XY chimaeras) were 
classified as either ‘male (MF)’ type or ‘undifferentiated (UF)’ depending upon the 
masculinisation of their genitalia. In one of the experiments (1b) mean basal testosterone 
concentrations in MF, UF, ewes and rams were 0.79, 0.29, 0.14 and 2.4 ng ml-1 
respectively. The testosterone concentrations in Freemartins were significantly higher 
(P<0.05) than in ewes, but lower than in rams. 
 
Stellflug et al. 2004 studied the effect of administering the opioid antagonist naloxone on 
plasma testosterone concentrations in rams with different sexual orientations. Mean 
basal testosterone concentrations in the first experiment were 2 ng ml-1 for all animals. 
After naloxone administration, mean testosterone concentrations rose significantly 
(P<0.01) after 60-minutes in both sexually active and male oriented rams to 8.0 and 8.2 
ng ml-1 respectively, but a rise in testosterone concentrations in sexually inactive rams to 
3.5 ng ml-1 at 60-minutes was not reported as significant. Although this example on it’s 
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own may have little relevance to the regulation of steroid abuse, it highlights the fact that 
concomitant medication can sometimes have effects on natural steroids and may 
therefore need to be considered. 
 
1.5.1.2 Metabolism following administration  
 
Only one study analysing androgen profiles after testosterone administration to sheep 
was found. Yamamoto et al. 1978 reported the effect of infusing a ram with radiolabelled 
testosterone and androstenedione and a second ram with radiolabelled epitestosterone 
and testosterone on resulting androgen profiles in bile and urine. Between 80-90% of the 
doses were excreted as either glucuronic acid or sulphate conjugates. Urine contained 
mainly glucuronic acid conjugates, while bile mainly sulphate conjugates. 
Epitestosterone, along with some unidentified polar compounds, was the major 
metabolite in urine and bile, with androsterone, etiocholanolone, 5β-androstane-3α,17β-
diol and 2 other androstanediols also identified. The study was not quantitative and 
metabolites were identified on the basis of their co-crystallisation with standards using 
TLC-FL. 
 
1.5.2 19-nor and 1-dehydro steroids in the ovine 
 
Very few reports on the occurrence of 19-nor and 1-dehydro-androgens in the ovine 
were found. 
 
In a 1991 study by Vandenbroeck et al, the authors reported that the urine of 11 
rams/lambs and 10 pregnant/non-pregnant ewes were positive for nandrolone at around 
2.5 ng ml-1 when analysed by RIA. However, the samples were not confirmed positive by 
GC-MS (the LOD was not reported). 
 
In 1995, Van Hende analysed the urine of four ewes at different stages of pregnancy and 
the amniotic fluid of one ewe for the presence of epinandrolone. Animals were sampled 
between 43 and zero-days prior to parturition, some at multiple times and others only at 
one time-point. Using semi-quantitative GC-MS analysis, the amniotic fluid did not 
contain epinandrolone above the LOD of 1 ng ml-1. The urine of the four pregnant 
animals was found to contain epinandrolone at concentrations ranging from below the 
LOD to above 2 ng ml-1. There was no clear correlation between the stage of gestation 
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and the concentration of epinandrolone determined. The ages, parity and fetal number of 
the animals were not reported.  
 
Clouet et al. 1997 reported the analysis of urine from 30 pregnant and non-pregnant 
French Vendenne four-year-old ewes for the presence of nandrolone and epinandrolone 
using GC-MS with an LOD of 0.2 ng ml-1. Nandrolone was not detected in the pregnant 
ewe’s urine and neither analyte was detected in the non-pregnant ewe’s urine. However, 
epinandrolone was detected at somewhere between the LOD and 0.5 ng ml-1 
(insufficient experimental details available to allow the quantitative significance of this 
statement to be determined) in pregnant animals at 120 to 39-days before parturition, 
with concentrations then increasing to 3.4 ng ml-1 at seven days before parturition. There 
was no correlation between the sex or number of fetuses with the epinandrolone 
concentrations found.  
 
The above results contrast with those of Sterk et al. 1998, who could not detect 
nandrolone or epinandrolone in the urine of five Flevolander ewes during early or late 
stages of pregnancy using a GC-MS method with an LOD of 0.5 ng ml-1. The ages, parity 
and fetal number of the animals were not reported.  
 
Casson et al. 2006 reported on the use of LC-MS to assess whether nandrolone and 
epinandrolone were natural in a population of 130 male and female sheep in the UK. 
Although the population could not be guaranteed ‘clean’, the authors report that no 
evidence of steroids abuse was found on any of the farms tested. The background to this 
research was an observation that the incidence of nandrolone positives rose once an 
LC-MS screening method with an LOD of 0.5 ng ml-1 replaced an ELISA method with an 
LOD of 2 ng ml-1 in 2004. The authors commented the following: 
 
“Nortestosterone seems endemic in British sheep; primarily as the 17α-isomer, but also 
with some 17β- present. There does not seem to be much correlation with age or sex of 
the animal, although the majority of the population tested was 6-12 months and some of 
the other categories contained very few samples (e.g. all 5 males of over 12-months 
contained the 17α-isomer at 0.4ng ml-1 or greater). In light of this, it seems unwise to 
extrapolate the “17α- in male animals indicates abuse” rules from cattle to sheep. An 
exercise to test the urine of a controlled population will validate these conclusions, and 
demonstrate any link to other physiological factors such as breed or feedings regime.” 
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Most recently (2009), Rosegger et al. have reported the plasma, urinary and faecal 
concentrations of nandrolone, epinandrolone and 19-norandrostenedione in pregnant 
ewes and male/female lambs in Austria before and after nandrolone laurate IM 
administration. Following extraction of the analytes from the samples, analysis was 
carried out using both HPLC-EIA and LC-MS. None of the three analytes were detected 
in the plasma of pregnant ewes. However, epinandrolone and 19-norandrostenedione 
(but not nandrolone) were detected in urine (concentrations up to 15 and 2.8 ng ml-1 
respectively) and faeces (concentrations up to 15 and 18 ng g-1 respectively) during 
pregnancy. None of the three nandrolone related analytes were detected in the plasma 
or faeces of untreated male or female lambs. However, epinandrolone (but not 
nandrolone or 19-norandrostenedione) was sporadically detectable in the urine from 
untreated male and female lambs at concentrations up to 3.0 ng ml-1 in females and 1.6 
in males. Following administration of nandrolone laurate to male and female lambs, 
nandrolone (but not epinandrolone or 19-norandrostenedione) could be detected in 
plasma up to 0.9 ng ml-1. In the urine of treated lambs, maximum mean nandrolone 
concentrations were 17 and 20 ng ml-1 for males and females respectively, while the 
corresponding figures for epinandrolone were 242 and 254 ng ml-1 respectively and for 
19-norandrostenedione were 12 and 11 ng ml-1 respectively. In the faeces of treated 
lambs, epinandrolone and 19-norandrostenedione were only detected sporadically at 
concentrations around the LOD. Following the statistical treatment of the endogenous 
population data, the authors proposed a screening threshold of 2.06 ng ml-1 of urinary 
epinandrolone in sheep (using the 95th percentile from a normal distribution of the 
population) and then also recommended that confirmation of nandrolone abuse be based 
on the qualitative detection of nandrolone itself in urine or plasma. The latter suggestion 
conflicts with the report of Cason et al. 2006, in which the possible endogenous 
occurrence of nandrolone was raised. However, the population animal population studied 
by Cason et al. was uncontrolled for steroid use, so further studies are warranted before 
a strategy for prosecution can be fully ratified.  
 
No reports on the endogenous or post-administration levels of boldenone or related 
compounds in the ovine were found, but 2 of 961 ovine urine samples tested in an 
Australian national monitoring programme (not therefore a controlled population with 
respect to ruling out steroid abuse) were above the 1 ng ml-1 LOD for epiboldenone with 
concentrations of 5.9 and 17 ng ml-1 respectively (Wolfgang Korth, personal 
communication). No samples were above the LOD for boldenone. Clearly, more work is 
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required to establish the endogenous versus exogenous nature of boldenone in the 
ovine. 
 
1.6.1 Testosterone and related androgens in the porcine 
 
Data on the endogenous presence of androgenic-anabolic steroids in the porcine are 
summarised in Table 3 while details of the major phase 1 metabolic products following 
exogenous administration are given in Table 4.  
 
1.6.1.1 Endogenous occurrence 
 
From the current review, ranges of mean plasma/serum concentrations of testosterone in 
boars were found to be between seven and 500-fold greater than those observed in 
barrows (castrated males), while those in gilts/sows were around five-fold lower than 
those in barrows. There were insufficient data to compare the concentrations of any 
other steroids by sex as there were few reports of steroid concentrations in barrows and 
gilts/sows. 
 
The most extensive study of steroid concentrations with age in boar plasma (Yorkshire 
breed) was carried out by Schwarzenberger et al. in 1993. Before detailing the results, it 
is important to point out that the concentrations reported seem to be much higher than 
those reported by other authors. The authors commented that steroids were almost 
exclusively present in plasma as sulphate conjugates, so unless indicated, the results 
below are for sulphated steroids. Androstenedione and DHEA-sulphate were measured 
directly, whereas other steroids were measured after extraction and solvolysis of 
separated fractions (solvolysis carried out by heating samples in 5 mL of acidified ethyl 
acetate [6 drops of 6 M sulphuric acid in 100 mL ethyl acetate] overnight at 45oC), thus 
inferring, but not proving, the status of most conjugates. For testosterone, concentrations 
after birth were around 1 ng ml-1 for both free and sulphate conjugates, rising to around 3 
ng ml-1 for each at one month. Concentrations of each then dropped back to around 1 ng 
ml-1 at five months where they then increased again, in the case of free testosterone to 
around 3 ng ml-1 at six months and in the case of testosterone-sulphate to around 6 ng 
ml-1 at seven months. Concentrations of free and sulphated testosterone seemed to dip 
slightly after seven months. For free androstenedione, the pattern was similar to 
testosterone such that concentrations after birth were around 6 ng ml-1, increasing to 
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around 24 ng ml-1 at one month, then dropping to around 6ng ml-1 until five months. 
Concentrations then increased again to around 18ng ml-1 at six months and then dipped 
to around 9 ng ml-1 at eight months. For DHEA-sulphate (authors reported that <10% of 
the total concentration of this steroid of was present in the unconjugated form), the 
pattern was again similar to testosterone such that concentrations after birth were 
around 3 ng ml-1, increasing to around 80 ng ml-1 at one month, then dropping to around 
15 ng ml-1 at five months. Concentrations then increased to around 80 ng ml-1 at six 
months and then dropped to around 60 ng ml-1 at eight months. For 5α-androstane-
3β,17β-diol-sulphate (authors reported that <10% of the total concentration of this steroid 
of was present in the unconjugated form), the pattern was again similar to testosterone 
such that concentrations after birth were around 3 ng ml-1, increasing to around 12 ng ml-
1 at one month, then dropping to around 3-6 ng ml-1 at five months. Concentrations then 
increased to around 35 ng ml-1 at seven months. There was then only a very slight drop 
between seven and eight months. In summary, sulphate conjugates were (or were 
inferred to be) the most predominant steroids measured in plasma; with the exception of 
androstenedione, which was measured in the free fraction only. Concentrations of most 
steroids peaked first at one month after birth and then dropped until around five months, 
before increasing again at six-eight months (with some dropping slightly after seven 
months). The rank order of absolute determined concentrations in plasma was DHEA 
sulphate > 5α-androstane-3β,17β-diol-sulphate > androstenedione > testosterone 
sulphate.  
 
McCoard et al. 2003 studied the concentrations of plasma testosterone in Meishan and 
White Composite fetal and neonatal boars. Fetal testosterone concentrations were not 
significantly different (P<0.05) in Meishan and White Composite boars, with values 
ranging from around 1 to 2 ng ml-1. However, testosterone concentrations in both breeds 
increased neonatally, peaking at 14-days post-partum with concentrations of around 5.5 
and 7 ng ml-1 in Meishan and White Composites respectively (significantly higher in 
White Composites at P<0.05). Concentrations then dropped to around 4 ng ml-1 in both 
breeds by 25-days post-partum. Park et al. 2002 reported serum testosterone 
concentrations in Duroc versus Yorkshire boars living in the northern hemisphere country 
South Korea during spring, summer, autumn and winter. Mean testosterone 
concentrations in Duroc boars during spring, summer, autumn and winter were 3.1, 0.73, 
1.3 and 1.4 ng ml-1 respectively, while in Yorkshire boars were 5.1, 2.6, 2.5 and 2.6 ng 
ml-1 respectively. The higher testosterone concentrations in Spring occur at a time when 
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photoperiod is increasing in this country, but peak photoperiod (during the summer) does 
not correlate with peak testosterone concentrations. The testosterone concentrations in 
Yorkshire boars were significantly higher (P<0.05) than for Duroc boars at all stages of 
the year. Testosterone concentrations were higher in all breeds in spring compared with 
the rest of year (P<0.05). Walker et al. 2004 measured plasma testosterone 
concentrations in Duroc boars that had or had not been subject to selection for high 
testosterone concentrations over 10 generations. Mean testosterone concentrations in 
boars selected over 10 generations were 49 ng ml-1, which were significantly higher 
(P<0.01) than controls with a mean testosterone concentration of 28 ng ml-1. 
 
No reports of the effect of pregnancy, diet, housing conditions or geographical factors on 
testosterone concentrations were found.  
 
1.6.1.2 Metabolism following administration 
 
No studies assessing the metabolism of testosterone following administration to porcine 
animals were found. 
 
1.6.2 Nandrolone and related androgens in the porcine 
 
1.6.2.1 Endogenous occurrence  
 
As discussed in the earlier bovine section, nandrolone has been shown to be produced 
naturally in the porcine (Maghuin-Rogister et al. 1988). The following discussion reviews 
a selection of studies assessing the concentrations of nandrolone related compounds in 
different porcine matrices. 
 
Van Ginkel et al. 1989b (article in Dutch but abstract in English) studied the natural 
concentrations of nandrolone in 25 young boars using RIA for bile and urine and GC-MS 
for muscle and liver. The mean and maximum urinary nandrolone concentrations were 
55 and 130 ng ml-1 respectively, biliary concentrations were 88 and 210 ng ml-1 
respectively, muscle concentrations were 1.1 and 13 ng g-1 respectively and liver 
concentrations were 23 and 200 ng g-1 respectively. 
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Vandenbroeck et al. 1991 studied the concentrations of nandrolone in the urine of a 
population of boars, cryptorchids, castrated males and pregnant/non-pregnant sows. The 
limit of detection was not reported. Screening was by RIA and confirmation by GC-MS. A 
cut-off for reporting positives by RIA was set at 2 ng ml-1. Samples above 3 ng ml-1 (or 
more precisely, the result of a ‘blank’ cattle urine with 2 ng ml-1 nandrolone added 
externally) were subsequently analysed by GC-MS. For 10 boars, the mean nandrolone 
concentrations determined by RIA was around 300 ng ml-1 and for six cryptorchids was 
around 120 ng ml-1. The presence of nandrolone in these animals was then confirmed by 
GC-MS. No nandrolone was detected at the RIA cut-off level for pregnant and non-
pregnant sows (n=10). In 12 castrated males (barrows), nandrolone was around 2 ng ml-
1 by RIA, but the samples were negative when analysed by GC-MS. 
 
In 1993, Rizzo et al. reported the plasma and urinary concentrations of nandrolone in 
boars, cryptorchids and barrows of the Landrace x Large White breed. Concentrations in 
the boars and cryptorchids were determined by ELISA and GC-ECD, while those in the 
barrows were determined by ELISA.  LODs of 7 and 5 ng ml-1 for plasma and urine 
respectively were reported for GC-ECD, but the LODs for the ELISA were not reported. 
Using ELISA, mean (range) urinary nandrolone concentrations in boars (n=20), 
cryptorchids (n=10) and barrows (n=23) were 25 ng ml-1 (10-55 ng ml-1), 25 ng ml-1 (10-
47 ng ml-1) and 1.0 ng ml-1 (0.3-2.1 ng ml-1) respectively, while in plasma concentrations 
were 4.8 ng ml-1 (0.6-17.5 ng ml-1), 5.0 ng ml-1 (1.1-15 ng ml-1) and 0.5 ng ml-1 (0.1-1.2 
ng ml-1) respectively. With GC-ECD, mean (range) urinary nandrolone concentrations in 
boars (n=10 above LOD and 1 not detected) and cryptorchids (n=6 above the LOD and 1 
not detected) were 83 ng ml-1 (1-280 ng ml-1) and 93 ng ml-1 (10-150 ng ml-1). With GC-
ECD, mean (range) plasma nandrolone concentrations in boars (n= six above LOD and 
one not detected) and cryptorchids (n=3 above LOD and 2 not detected) were 4 ng ml-1 
(2-8 ng ml-1) and 6 ng ml-1 (2-13 ng ml-1) respectively (not including the not detectable 
samples). The authors recognised the fact that the ELISA and GC-ECD results 
correlated well, but that urinary results by GC-ECD were much higher than ELISA. The 
authors suggested that this was due to the increased linear range of GC-ECD relative to 
the ELISA method. 
 
In 1993, Raeside et al. presented HPLC evidence for the presence of 19-
hydroxyandrostenedione and 19-hydroxytestosterone in leydig cell incubates in-vitro and 
testicular venous plasma in-vivo from boars of the Yorkshire breed in a semi-qualitative 
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fashion. 19-hydroxytestosterone was present at apparently higher concentration in 
plasma than 19-hydroxyandrostenedione. Miyashita et al. 1990 (article in Japanese, but 
abstract in English) were able to detect 19-hydroxyandrostenedione (a putative precursor 
to 19-nor-androgens) and 19-norandrostenedione after in-vitro incubations of porcine 
adrenal tissue with androstenedione.  
 
Van Cruchten et al. (2002) reported the presence of 19-nor-androgens in what initially 
appeared to be a female pig. However, close inspection determined that the animal was 
in fact a hermaphrodite (intersex animal) due to the presence of both a left ovary and a 
right un-descended testicle (with functioning leydig cells, but no spermatozoa). Samples 
of urine, fat, faeces, liver, kidney, muscle and testes were analysed for nandrolone and 
19-norandrostenedione using GC-MS for fat, urine and faeces and LC-MS for the 
remaining matrices. Concentrations of nandrolone in fat, urine, faeces, liver, kidney, 
muscle and testes were 0.3 ng g-1, 27 ng ml-1, not detectable, not detectable, 1.6 ng g-1, 
not detectable and 5.3 ng g-1 respectively, while concentrations of 19-
norandrostenedione in these matrices were not detectable, 0.5 ng ml-1, not detectable, 
not detectable, 1.1 ng g-1, not detectable and 0.9 ng g-1 respectively. The authors 
proposed visual inspection of pig external sexual organs in female pigs suspected of 
nandrolone abuse at slaughter in order to discern false positives due to intersex. 
 
Poelmans et al. 2005b reported the results of the most comprehensive analysis of 
nandrolone and boldenone related compounds in the porcine to date. Samples of 
muscle, liver, kidney, testicles and urine from boars, cryptorchids, barrows, gilts and 
sows derived from France, the Netherlands, Belgium and the USA were analysed for 
boldenone, nandrolone and 19-norandrostenedione using GC-MS and LC-MS (with n = 
between 5 and 14 for the different sexes). The results from an inter-sex animal were also 
reported, but the 19-norandrogen results for this animal appear to be the same as those 
given in Van Cruchten et al. 2002, so will not be reproduced again here. The results of 
this study are summarised in Table 2. Limits of detection were not reported. Since 
barrows are castrated males, the major source of steroid production in this animal is 
likely to be the adrenal gland. While it is theoretically possible that androgens produced 
by the adrenal gland in the barrow may be converted into 19-nor-androgens and/or their 
precursors in the systemic circulation, i.e. in adipose tissue, a study by Miyashita et al. 
1990 suggests that these compounds may be directly secreted from the adrenal gland. 
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1.6.2.2 Metabolism following administration 
 
Debruyckere et al. (1991) presented the results of a metabolism study of nandrolone in 
Gottinger x Vietnamese mini-pigs before and after injection of nandrolone laurate. One 
boar, one barrow and one sow (all two years old) were used and GC-MS was employed 
in a qualitative fashion to identify the compound present in urine.  Nandrolone was 
detected in boar urine, but not barrow or sow urine, prior to nandrolone administration 
and in all animals after administration. No 17-keto, A-ring reduced compounds were 
detected in any of the animals before nandrolone administration, but after administration 
19-noretiocholanolone and 19-norepiandrosterone were detected in all animals. 19-
norandrosterone was detected in barrows after nandrolone administration, but not in the 
boar or sow. 19-Norepietiocholanolone was not detected after nandrolone administration 
in any animal. No estranediols were detected before nandrolone administration in any 
animal.  Neither 5α-estrane-3α,17β-diol or 5α-estrane-3β,17α-diol were detected after 
nandrolone administration, but two other estranediols, proposed to be 5β-estrane-
3α,17β-diol and 5α-estrane-3β,17β-diol, were found in some of the animals. 
 
McEvoy et al. 1998 studied the bioavailability of nandrolone phenylpropionate in 
prepubertal Landrace gilts given the drug as either an IV or parenteral dose (in either 
arachis oil or aqueous solution). The same animals were used for each of the different 
formulations with suitable washout periods in-between doses and resulting plasma 
nandrolone levels were analysed by EIA. The bioavailability (and range) was 0.35% 
(0.25-0.41%) for the aqueous oral dose and 2.25% (0.86-2.85%) for the arachis oil oral 
dose. Peak plasma concentrations after the IV, arachis oil PO and aqueous PO doses 
were approximately 200, 36 and 3.2 ng ml-1 respectively. The plasma concentrations 24 
hours after the IV dose were orders or magnitude lower than those resulting from oral 
dosing. 
 
In 2007, Claus et al. studied the effect of sublingual nandrolone administration to five 
groups of five German Landrace barrows. two groups were controls, while the other 
three groups received either 1 mg testosterone, 1 mg, estradiol or 1mg nandrolone 
sublingually (under anaesthesia). Mean plasma nandrolone concentrations in pre-
treatment animals, as measured by EIA, were 0.45 ng ml-1, whilst mean maximum 
concentrations 10-minutes after nandrolone application were 4.3 ng ml-1. Concentrations 
were still significantly higher (P<0.01) after 1-3 hours relative to controls.  
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Roig et al. 2007 reported the results of a quantitative GC-MS metabolism study following 
IM nandrolone laurate injection to a ten week old boar. Only post-administration urine 
results were reported. Following the administration, the boar urine contained nandrolone 
in predominantly the sulphate fraction (the most abundant analyte in this fraction) with 
peak concentrations of around 80 ng ml-1 at day one dropping to around 10 ng ml-1 by 
day four. Peak concentrations of different analytes in the glucuronic acid conjugate 
fraction were generally around 20 ng ml-1 or lower while in the free fraction, 
norepiandrosterone, noretiocholanolone and 5β-estrane-3α,17β-diol were most abundant 
with peak concentrations of  around 40, 60 and 100 ng ml-1 respectively. 
 
More recently, Ventura et al. 2008 extended the urinary methodology used in Roig et al. 
2007 to look at the effect of administering 2 nandrolone laurate IM injections to a larger 
number of boars. The authors also assessed the endogenous concentrations from 60 
boars taken during a routine monitoring programme. The post administration metabolite 
profiles were similar to those reported in Roig et al. 2008, but nandrolone and 19-
norandrostenedione were also found to be present in the urine of untreated animals in 
the free, sulphate and glucuronide fractions. However, none of the A-ring reduced 
metabolites were detected in the untreated animals. The authors therefore proposed that 
noretiocholanolone and norepiandrosterone might be suitable qualitative markers for 
detecting nandrolone abuse in boars since they were detectable for the longest time 
period following nandrolone administration. 
 
A major consideration regarding 19-nor-androgens in the porcine is whether or not these 
compounds are excreted as 19-nor compounds or whether they are, in fact, artefacts of 
sample preparation produced from an initial 19-carboxy metabolite; analogous to what is 
experienced in the male horse (Houghton et al. 2007). Several lines of evidence support 
this hypothesis, including the above detailed observation that no A-ring reduced 
metabolites are found in untreated boar urine (Debruyckere et al. 1991). These A-ring 
reduced metabolites would be expected to occur as metabolic products if free 
nandrolone and/or 19-norandrostenedione were present in-vivo. Their absence suggests 
that nandrolone and/or 19-norandrostenedione are naturally present as carboxylic acid 
precursors since these compounds would be unlikely to undergo A-ring metabolism 
directly. However, they may be cleaved to form nandrolone and 19-norandrostenedione 
during any sample preparation procedures that involve a derivatisation step or even a 
minor downward pH change. The 19-carboxylic metabolite of androstenedione has also 
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previously been identified in porcine granulosa cells (Garrett et al. 1991). Lastly, an 
unusually high ratio of 19-nor-androgens in boar urine, relative to faeces, has been 
observed (H. De Brabander, unpublished observation). This adds further weight to the 
theory of 19-nor-androgens in the porcine actually being the 19-carboxylic acid, as these 
acidic compounds could be substrates for organic anion transport proteins in the liver/gut 
that actively transport compounds from one area to another and maintain large 
concentration gradients (something that is less likely to occur for neutral steroids). If the 
compounds in porcine tissues that are currently thought to be 19-nor-androgens are 
proven to be predominantly 19-carboxylic acids (similar to the situation in the equine) 
then this could have major implications for nandrolone residue screening methods in the 
porcine. For example, Debruyckere et al. 1991 and Ventura et al. 2008 have shown that 
A-ring reduced metabolites are only detectable after nandrolone administration. It may 
therefore be feasible to use a threshold of nandrolone sulphate or an A-ring reduced 
metabolite as an indicator of nandrolone abuse in this species. 
 
 
1.6.3 Boldenone and related androgens in the porcine 
 
Only one published study relating to the occurrence of boldenone in the porcine was 
found. In a study on boars, barrows, gilts and sows, Poelmans et al. 2005b reported the 
concentrations of endogenous boldenone and 19-nor-androgens in muscle, liver, kidney, 
testicles and urine using GC-MS and LC-MS methods. Calibration ranges and LODs 
were not reported, but the resulting concentration ranges in the different tissues were 
reported. The results from this study are presented in Table 2 along with the nandrolone 
data discussed above. In addition to the data in Table 2, the authors looked at levels of 
boldenone in an intersex animal, with muscle, liver, kidney, urine and testicles found to 
contain no boldenone above the LOD. More studies to determine the endogenous 
occurrence of boldenone in the porcine are clearly warranted. 
  
Table 2 – concentrations of nandrolone, 19-norandrostenedione and boldenone quantified by Poelmans et al. 2005b in different 
matrices from different sex porcine animals (the number of animals are given in brackets. < refers to concentrations below the 
LOD). 
 
Nandrolone (ng g-1) Gilt Sow Boar Barrow Cryptorchid
Meat < (11) 0.4-0.5 (11) 0.7-13.4 (11) 0.7-11.8 (11) 0.1-2.4 (11) 
Liver 0.1-0.9 (11) < (11) 1-63 (11) < (11) 0.2-12.3 (14) 
Kidney 0.2-0.5 (11) 0.2-1.5 (11) 2.5-232 (11) 0.1 (10) 1.3-78 (14) 
Urine (ng ml-1) 1.3-2.8 (11) 1.3-1.9 (9) 51-344 (11) 0.5-16.3 (11) 8.6-343 (14) 
Testes - - 24-144 (5) - 2.2-101 (11) 
19-norandrostenedione  
(ng g-1) 
Gilt Sow Boar Barrow Cryptorchid
Meat < (11) 0.04-0.07 (11) 0.1-5.5 (11) 0.05-0.8 (11) 0.04-0.4 (11) 
Liver 0.3-1.3 (11) 3.1-8.3 (11) 0.1-24 (11) 1.9-16 (11) 0.4-3.5 (14) 
Kidney 8.3-25 (11) 2.7-18 (11) 2.3-535 (11) 0.1-15 (10) 0.2-159 (14) 
Urine (ng ml-1) 1.8-17 (11) 0.9-18 (8) 5-109 (11) 1.1-16 (11) 9.9-103 (14) 
Testes - - 6.2-110 (5) - 1.3-25 (11) 
Boldenone (ng g-1) Gilt Sow Boar Barrow Cryptorchid
Meat < (11) < (11) 0.5-2.5 (11) < (11) 0.7 (11) 
Liver < (11) < (11) 1.3-4.9 (11) < (11) 0.5-2.3 (11) 
Kidney < (11) < (11) 0.8-9.2 (11) < (10) 0.3-8.1 (14) 
Urine (ng ml-1) 0.5-0.6 (11) < (11) 5.1-120.5 (11) 1.1 (11) 0.9-57.6 (14) 
Testes - - 2.1-16 (5) - 0.6-15.1 (11) 
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1.7 Natural androgenic-anabolic steroid concentrations in the equine 
 
Data on the endogenous presence of androgenic-anabolic steroids in the equine are 
summarised in Table 3 while details of the major phase 1 metabolic products following 
exogenous administration are given in Table 4.  
 
While the majority of data reported for androgenic-anabolic steroids in the equine relate 
to urine (discussed below), interest is beginning to grow regarding their endogenous 
presence in blood. This is especially true in the US, where a large proportion of testing 
focuses on this matrix. While it has long been known that testosterone is endogenous in 
the blood of equine animals of all sexes, recent studies have also shown that nandrolone 
can be detected in intact males (Soma et al. 2007 and 2008). To date, nandrolone and 
boldenone related compounds have not been shown to occur naturally in the blood of 
non-pregnant females or castrated males and boldenone has not been shown to occur in 
the blood of intact males (McKinney, 2009). In the future, it may be possible to establish 
thresholds for endogenous steroids in blood, but all the currently internationally 
thresholds related to this matrix (IFHA, 2008). The following discussion therefore focuses 
on urine. 
 
1.7.1 Testosterone 
 
Concentrations of testosterone in equine matrices were not fully reviewed as part of the 
current survey, but testosterone and its precursors/metabolites are known to be 
endogenous in males and females of this species at varying concentrations. A large 
amount of data is available on the detection of steroid abuse in horseracing, the results 
of which are relevant to residue testing in meat production because the strategies for 
detection apply equally. The approach to controlling testosterone abuse in horseracing 
varies depending upon the sex and gestation status of the animal (James Scarth, 
personal experience with the application of these assays). There is no threshold in the 
intact male due to the high and variable concentrations produced in this animal. In the 
gelding and filly/mare, population studies have allowed urinary threshold concentrations 
for testosterone confirmation to be set at 20 and 55 ng ml-1 respectively in order to 
control the abuse of this steroid. A maximum urinary ratio threshold of 
testosterone:epitestosterone of 12:1 was in the past adopted in the filly/mare (analogous 
to the 4:1 ratio for either sex in human urine), but an absolute threshold of 55 ng ml-1 is 
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now used (IFHA, 2008). The major phase 1 urinary metabolites of testosterone after 
exogenous administration have been reported as 5α-androstane-3β,17β-diol, 5α-
androstane-3β,17α-diol and 3β-hydroxy-5α-androstan-17-one (Dumasia and Houghton 
1981). 
 
1.7.2 Nandrolone 
 
Early nandrolone administration studies on castrated males (geldings) in the 1970s and 
early 1980s suggested that 19-nor-androgens did not occur naturally in the horse 
(Houghton 1977, Houghton et al. 1978, Houghton and Dumasia 1980, Houghton and 
Teale 1981 and Dumasia and Houghton 1984). Indeed, since 19-nor-androgens have 
not been shown to be endogenous in the gelding or filly/mare, their presence at any 
concentration is considered evidence of abuse in horseracing (at least with current 
detection capabilities). Roig et al. 2007 have recently confirmed the findings of some of 
the earlier studies on nandrolone metabolism following its administration to geldings. 
While pre-administration samples contained no 19-nor-androgens, the major post-
administration metabolites were 5α-estrane-3β,17α-diol in the glucuronic acid conjugate 
fraction followed by nandrolone in the sulphate fraction. In contrast to the situation in 
geldings and filly/mare, in 1984 Houghton et al. showed that the urine of untreated intact 
male horses appeared to contain nandrolone and a range of other 19-norandrogens. A 
threshold approach utilising a ratio of 5α-estrane-3β,17α-diol:estr-5(10)-ene-3β,17α-diol 
of greater than 1:1 as indicative of abuse was subsequently introduced for detecting 
nandrolone abuse in intact male horses (Houghton et al. 1984). However, this has now 
been replaced with a threshold for the nandrolone metabolite 5α-estrane-3β,17α-diol of 
45 ng ml-1 in urine (IFHA, 2008).  
 
Despite the lack of data to suggest that 19-norandrogens are endogenous in non-
pregnant filly/mares, Sterk et al. 1998 have shown that pregnant mares may excrete the 
epinandrolone naturally in urine at concentrations ranging from less than their LOD of 1 
ng ml-1 up to 26 ng ml-1. Nandrolone was not detected at any concentration above the 
LOD of 1 ng ml-1. This study highlights the need to consider the gestation status in 
mares.  
 
Although intact male horse urine has for many years been considered to contain 19-nor-
androgen sulphates, Houghton et al. 2007 have recently shown that these compounds 
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are predominantly artefactual in origin. The authors suggested that it is in fact 19-
carboxy-nandrolone and 19-carboxyandrostenedione that occur naturally in intact male 
horse urine and that their decarboxylation under acidic sample preparation procedures 
leads, respectively, to the artefactual production of nandrolone and 19-
norandrostenedione. The finding that nandrolone and 19-norandostenedione may be 
predominantly de-carboxylation artefacts during sample preparation is significant since 
nandrolone administration studies in horses have confirmed that, exogenously, 
nandrolone is excreted as a sulphate (Teale et al. 2000). This study also raises the 
possibility that 19-nor androgens found in other species, i.e. the porcine, may also be 
artefactual in origin.  
 
In 2008, Grace et al. used LC-MS/MS analysis of intact nandrolone sulphate to 
demonstrate that while the majority of nandrolone detected in intact male urine may be 
artefactual in nature, low concentrations of nandrolone sulphate are present. In a post-
race samples population of 77 intact males, nandrolone sulphate was present at 
concentrations ranging from less than the LOQ (1 ng ml-1) up to 21 ng ml-1. Because 
these concentrations are significantly lower than those typically produced following 
nandrolone administration, the authors proposed that a threshold of nandrolone sulphate 
in urine may be suitable alternative to the current ‘free and glucoconjugated’ 5α-estrane-
3β,17α-diol threshold currently in use.  
 
1.7.3 Boldenone 
 
Boldenone has recently been shown to be naturally occurring as a sulphate conjugate in 
the urine of intact males (Ho et al. 2004). However, to date it has not been reported to be 
endogenous in geldings or fillies/mares. The major phase 1 urinary metabolite of 
boldenone after exogenous administration is epiboldenone in the glucuronide fraction, 
but significant quantities of parent boldenone are excreted as a sulphate conjugate 
(Houghton and Dumasia 1979). 1-Dehydro-androgens are prohibited at any 
concentration in the urine of non-pregnant females or castrated males, but a urinary 
threshold of 15 ng ml-1 has been validated internationally for controlling abuse in males 
(IFHA, 2008). 
 
In 2008, Grace et al. applied LC-MS/MS analysis of intact boldenone sulphate to a post-
race urine sample population of 77 intact males, and found that boldenone sulphate was 
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present at concentrations ranging from less than the LOQ (0.5 ng ml-1) up to 3 ng ml-1. 
Because these concentrations are significantly lower than those typically produced 
following boldenone administration, the authors proposed that an intact boldenone 
sulphate urinary threshold may be a useful alternative to the 15 ng ml-1 ‘free and 
conjugated boldenone’ threshold currently in use. 
 
1.8 Natural androgenic-anabolic steroid concentrations in the cervine 
 
Data on the endogenous presence of androgenic-anabolic steroids in the cervine are 
summarised in Table 3. Data on the major phase 1 metabolic products following 
exogenous administration was not available.   
 
Concentrations of testosterone in cervine matrices were not reviewed as part of the 
current survey, but testosterone and its precursors/metabolites are known to be 
endogenous in males and females of this species at varying concentrations (Hamasaki 
et al. 2000). Only one report on the natural occurrence of 19-nor-androgens in the 
cervine was found. Van Hende (1995) analysed the urine of pregnant red deer for the 
presence of epinandrolone. Using semi-quantitative GC-MS analysis, epinandrolone was 
not detected at an LOD of 1 ng ml-1 in two of the animals and was somewhere between 1 
and 2 ng ml-1 in the third animal. The ages, parity, fetal number and gestation status of 
the animals was unknown. No reports on the endogenous or post-administration levels of 
boldenone or related compounds in the cervine were found, but one of 35 cervine urine 
samples analysed for nandrolone and epinandrolone in an Australian national monitoring 
programme (not therefore a controlled population with respect to ruling out steroid 
abuse) was above the 1 ng ml-1 LOD for epinandrolone with a concentration of 4.5 ng ml-
1. No samples were above the 1 ng ml-1 LOD for nandrolone. Clearly, more work is 
required to establish the endogenous versus exogenous nature of 19-nor and 1-dehydro-
androgens in deer of different ages, sexes, gestation/castration status and breeds etc. 
 
1.9 Natural androgenic-anabolic steroid concentrations in the caprine 
 
Data on the endogenous presence of androgenic-anabolic steroids in the caprine are 
summarised in Table 3. Data on the major phase 1 metabolic products following 
exogenous administration was not available.   
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Concentrations of testosterone in caprine matrices were not reviewed as part of the 
current survey, but testosterone and its precursors/metabolites are known to be 
endogenous in males and females of this species at varying concentrations (Ahmad et 
al. 1996, Flint and Burrow 1979). Only two reports on the occurrence of 19-nor-
androgens in the caprine were found and both relate to female urine. Van Hende (1995) 
analysed the urine from two pregnant animals and a pool of urine from a number of 
pregnant animals for the presence of epinandrolone. Using semi-quantitative GC-MS 
analysis, the two individual samples were found to contain epinandrolone at a 
concentration above 2 ng ml-1, while the pooled urine contained concentrations 
somewhere between 1 and 2 ng ml-1. The ages, parity, fetal number and gestation status 
of the animals was unknown. In 1998, Sterk et al. analysed the urine from two pregnant 
animals throughout gestation and four non-pregnant animals for the presence of both 
nandrolone and epinandrolone using GC-MS (LOD of 1g ml-1 for each). Nandrolone was 
not detected in any of the samples while epinandrolone was only detected in one sample 
from one animal at 16-weeks into pregnancy with a concentration of 2 ng ml-1. The ages 
and parity of the animals was not reported. No reports on the endogenous or post-
administration concentrations of boldenone or related compounds in the caprine were 
found. Clearly, more work is required in order to establish the endogenous versus 
exogenous nature of 19-nor and 1-dehydro-androgens in goats of different ages, sexes, 
gestation/castration status and breeds etc. 
 
1.10 Summary tables of the occurrence and metabolism of endogenous 
steroids in meat-producing animals 
 
Data on the endogenous presence of androgenic-anabolic steroids in the species 
currently reviewed are summarised in Table 3 while details of the major phase 1 
metabolic products following the exogenous administration of testosterone, nandrolone 
and boldenone are given in Table 4.  
 
 
 
 
 
 
 
  
Table 3 – summary of the endogenous occurrence of androgenic-anabolic steroids in mammalian meat-producing animal species. NMP 
= National Monitoring Programme, therefore not controlled with respect to steroid abuse. 
 
 
Steroid  
Details of endogenous presence in different species
 
Bovine 
 
Ovine Porcine Equine Cervine Caprine 
 
Testosterone  
 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in males 
and females at varying 
concentrations 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in 
males and 
females at 
varying 
concentrations 
 
Nandrolone and 
related 19-nor 
androgens 
 
 
Epinandrolone detectable 
during pregnancy. Most 
other studies find no 
nandrolone or related 
metabolites in males, but 
some find trace amounts in 
male and female urine i.e. 
following casualty 
(Kennedy et al. 2009) 
 
Epinandrolone 
detectable during 
pregnancy. Two reports 
published on the 
endogenous presence of 
urinary nandrolone, 
epinandrolone and 19-
norandrostenedione in 
male + female UK and 
Austrian populations 
 
 
Nandrolone and 19-
norandrostenedione 
detected in urine and 
some other matrices 
of animals of all sexes 
(including intersex 
animals) at different 
concentrations 
 
Detected in urine of 
pregnant mares and at 
high concentrations in 
stallions (probably as a 
byproduct of the high 
concentration of 
aromatisation in the 
testes) but not in 
geldings or fillies 
 
Urinary epinandrolone 
detected in a pregnant 
red deer, but no other 
animals studied.  One of 
35 urines from an 
Australian NMP contained 
epinandrolone but not 
nandrolone  
 
Epinandrolone, but 
not nandrolone, 
detected in urine 
during pregnancy, 
while neither analyte 
detected in non-
pregnant females. 
Studies on 
endogenous 
concentrations in 
males is lacking  
 
Boldenone and 
related 1-
dehydro 
androgens 
 
 
Boldenone and related 
compounds have been 
detected in urine and 
faeces, possibly secondary 
to their formation by gut 
bacteria. Some phase 1 + 2 
metabolites only detected 
after boldenone admin. 
Boldenone precursors also 
detected in wood crates 
from calves housing 
 
Insufficient data to draw 
any conclusions, 
although 2 of 961 urines 
from an Australian NMP 
contained low 
concentrations of 
epiboldenone 
 
 
Boldenone detected in 
urine and some other 
matrices of boars, 
cryptorchids, gilts and 
barrows at different 
concentrations, but not 
above the LOD in 
sows or an intersex 
animal 
 
Boldenone detected at 
low concentrations in the 
urine of stallions, but not 
geldings or fillies 
 
Insufficient data to draw 
any conclusions, although 
zero of 35 urines from an 
Australian NMP contained 
boldenone or 
epiboldenone 
 
 
Insufficient data to 
draw any conclusions 
  
Table 4 – summary of the major catabolic pathways of endogenous androgenic-anabolic steroids in mammalian meat-producing animal 
species. * More definitive quantitative studies required in order to confirm results 
 
 
 
Steroid  
 
Details of major phase 1 urinary metabolic products after administration to different species 
 
 
Bovine 
 
 
Ovine 
 
Porcine 
 
Equine 
 
Cervine 
 
Caprine 
 
Testosterone  
 
 
Epitestosterone, 
epietiocholanolone,        
5β-androstane-3α,17β-
diol + 5β-androstane-
3β,17α-diol 
 
 
Epitestosterone, 
androsterone, 
etiocholanolone + 
5β-androstane-
3α,17β-diol * 
 
 
Insufficient data to 
draw any conclusions 
 
5α-androstane-
3β,17β-diol, 5α-
androstane-
3β,17α-diol + 
 3β-hydroxy-5α-
androstan-17-
one 
 
 
 
Insufficient 
data to draw 
any 
conclusions 
 
 
Insufficient data 
to draw any 
conclusions 
 
Nandrolone  
 
 
Epinandrolone, 
5α-estrane-3β,17α-diol, 
5β-estrane-3α,17β-diol, 
5β-estrane-3α,17α-diol, 
5α-estrane-3β,17β-diol, 
19-noretiocholanolone, 
19-norandrostenedione 
 
 
 
Epinandrolone 
(more data 
required to confirm 
whether other 
metabolites also 
present) 
 
 
 
19-
norepiandrosterone, 
19-noretiocholanolone 
+     5β-estrane-
3α,17β-diol 
 
 
 
 
5α-estrane-
3β,17α-diol 
 
 
 
 
Insufficient 
data to draw 
any 
conclusions 
 
 
 
 
Insufficient data 
to draw any 
conclusions 
 
Boldenone  
 
 
Epiboldenone, 17α-
hydroxy-5β-androst-1-en-
3-one,                  
6β-hydroxyepiboldenone,   
17β-hydroxy-5β-androst-
1-en-3-one + 3α-hydroxy-
5β-androst-1-en-17-one. 
 
 
 
 
Insufficient data to 
draw any 
conclusions 
 
 
 
Insufficient data to 
draw any conclusions 
 
 
 
Epiboldenone  
 
 
 
Insufficient 
data to draw 
any 
conclusions 
 
 
 
Insufficient data 
to draw any 
conclusions 
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1.11 Alternative methods for detecting endogenous steroid abuse 
 
The discussions in this chapter up to now have focussed mainly on direct, univariate 
steroid measurements. This is because the majority of published methods for detecting 
their abuse have to date been based on identifying suitable ‘qualitative marker 
metabolite’ or ‘quantitative threshold’ approaches. However, there is increasing interest 
in the use of alternative approaches to detect endogenous steroid abuse. These include 
the use of biosensors, biomarkers, gas chromatography-combustion-isotope ratio-mass 
spectrometry (GC-C-IR-MS) or the detection of intact steroid esters. While none of these 
techniques form the basis of the experimental side of this thesis, the following discussion 
serves to provide an overview of this emerging field.   
 
1.11.1  Biosensors and biomarkers 
 
As an alternative to the direct univariate measurement of endogenous steroids in 
biological matrices, a range of assays based on detecting the biological effects of the 
steroids have been developed. These assays can be broadly split into the areas of 
‘biosensors’ and ‘biomarkers’. Biosensors utilise biological techniques to detect the 
presence of steroidal activity in a sample ex vivo (outside of the body), whereas 
biomarker techniques aim to monitor activity through perturbation of ‘normal’ in vivo 
physiological parameters. The following discussion introduces some of different 
approaches that have been investigated according to these two definitions.  
 
1.11.1.1  Biosensors 
 
Biosensors show a great deal of promise for detecting steroid abuse; especially where 
designer steroids are concerned (discussed further in chapter 4). However, their use is 
likely to be restricted to screening rather than confirmation of abuse since the structure of 
the steroid in typically not identified unequivocally. Also, they are less useful for 
discerning the abuse of endogenous steroids since, by definition, these compounds are 
natural and some level of biological activity is therefore always present. Given these 
possible limitations, the following discussion briefly highlights some of the different 
biosensor approaches available. 
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In certain respects, biosensors have been applied to residue surveillance for years in the 
form of immunoassays (Mooney et al. 2009a). Whilst many of the traditional 
immunoassays have now been replaced with more selective mass spectrometric based 
methods of detection, an interesting ELISA based assay has recently been reported by 
Hungerford et al. (2005). This approach utilises an antibody that recognises steroids 
containing a 17α-methyl,16β,17β-dihydroxy epitope. It therefore produces a suspicious 
result for any 17α-methyl steroid that undergoes 16β-hydroxylation as part of it’s 
metabolism. Since 16β-hydroxylation is a major pathway of metabolism of such steroids, 
especially in equine animals (Houghton, 1992), this highlights a suspicious sample for 
further work to identify the unknown molecules present.  
 
Beyond the established field of immunoassay, several biologically based measurement 
technologies have recently been developed and are commonly classified as ‘biosensor’ 
technologies. Two such techniques are surface plasmon resonance (SPR) and 
potentiometric detection, where antibody-antigen binding can be measured quickly and 
assay times therefore reduced. For example, an SPR based immunobiosensor has 
recently been developed to detect abuse of steroids through a reduced sex hormone-
binding globulin binding capacity in bovine plasma (Mooney et al. 2009b). A further 
application in the biosensor field utilises knowledge of the endogenous biological 
receptor responsible for the pharmacological effect of the drug. The principle of this 
approach is that all drugs sharing a common method of action should be detectable 
through measuring the response of a recombinantly produced version of the relevant 
receptor. One particularly attractive class of compounds for application of this technology 
are AASs, since most of these bind to the androgen receptor. However, alternative 
approaches are also possible for oestrogens, progestagens and glucocorticoids through 
use of their respective endogenous receptor proteins. A number of radioreceptor assays 
have been developed, but have the disadvantage of requiring the use of radioactivity 
(Mooney el al. 2009a). More attractive assays based on reporter gene detection have 
since been developed. As an example, Peters et al. 2010 have reported the liquid 
chromatographic separation of extracted urinary steroids prior to analysis using both an 
androgen receptor reporter gene bioassay and a time-of-flight mass spectrometry (TOF). 
In addition to identifying steroids such as testosterone with known structures, this 
approach is also able to identify novel anabolic steroids such as the ‘designer’ steroid 
tetrahydrogestrinone (see chapter 4). An extension of the aforementioned method 
utilises liver S9 bioactivation to convert biologically inactive versions of steroids 
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(prohormones or metabolites) into active versions that can be detected by the androgen 
receptor (Rijk et al. 2008). 
 
1.11.1.2  Biomarkers 
 
The rapidly advancing applications of ‘omics’ related technologies, which allow the 
simultaneous analysis of a large number of components within a biological system, have 
huge potential to transform the way drug residue surveillance detection is performed. 
The idea behind applying the ‘omics’ approaches are not to detect the presence of a 
drug directly, but instead to be able to detect its cumulative biological effect (biomarker) 
within the animal through either targeted (pre-defined profiling) or untargeted (global 
profiling) approaches. One of the key advantages of the biomarker approach is that no 
matter what method of doping is used, then a change in the mRNA (transcriptomics), 
protein (proteomics) or metabolite (metabolomics) profile should be detectable for drugs 
with common pharmacology. The definition of a ‘normal’ versus ‘suspect’ biomarker 
profile depends on whether ‘latitudinal’ or longitudinal’ comparisons are applied – both of 
which are currently being investigated. Latitudinal comparisons rely on analysing large 
populations of individual subjects and defining a ‘normal’ range, a value outside of which 
is considered suspect. Longitudinal measurements on the other hand could use a 
change in an animal’s own unique biomarker profile over time to indicate whether 
external perturbation had occurred.  
 
The following discussion introduces a representative sample of the different ‘omics’ and 
other biomarker approaches that have been reported in the veterinary drug residue 
surveillance area. A full discussion of this topic is beyond the scope of this thesis. For 
more detailed account the reader is directed to a recent review by Mooney et al. (2009a).  
 
As an example of a recent transcriptomics approach, Riedmaier et al. (2009) have 
reported the effect of trenbolone acetate plus oestradiol administration on the profile of 
38 pre-defined candidate genes in bovine calf blood. The authors determined gene 
expression in blood cells by quantifying concentrations of mRNA using quantitative real 
time reverse transcriptase polymerases chain reaction technology (qRT-PCR) and found 
that 11 of the 38 candidate genes were influenced by treatment. These included the 
oestrogen receptor-α, the glucocorticoid receptor-α, the apoptosis regulator Fas, the 
proinflammatory interleukins IL-1α, IL-1β and IL-6 as well as the major histocompatibility 
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complex II, creatine kinase, myotropin, RNA binding protein 5 and actin-β. Principal 
component analysis was then applied and was able to discern untreated animals from 
those treated at days 2 and 16 post-administration. 
 
As an example of a recent proteomic approach, Cacciatore et al. (2009) have reported 
the effect of concomitant oestradiol and nandrolone on the plasma concentrations of a 
range of pre-defined candidate proteins using a number of different detection techniques 
for the various analytes. Concentrations of immunoreactive inhibin were found to be 
decreased following administration of the steroids to male calves for up to 38 days, but 
not in females. Concentrations of the remainder of the targeted proteins including insulin-
like growth factor-1, insulin-like growth factor-binding proteins-2 and 3, luteinising 
hormone, follicle-stimulating hormone and prolactin were not affected by steroid 
treatment.  
 
As an example of a recent metabolomics approach, Di Nardo et al. (2010) have reported 
the effect of androstenedione administration on the profile of phase 2 steroid conjugate 
metabolites in bovine urine. The authors used a combination of targeted (selected 
reaction monitoring) and semi-targeted (precursor ion scanning) LC-MS/MS approaches 
to identify altered metabolite profiles. Using the targeted approach, concentrations of 
epiandrosterone-3-sulphate were found to be unregulated in treated animals, while some 
unidentified metabolites were found to be unregulated when applying the semi-targeted 
approach.  
 
As an example of an alternative type of biomarker approach, the 1992 PhD thesis of 
Maria Groot describes and interesting study based on ‘Histological Screening for illegal 
administration of growth promoting agents in veal calves.’ This technique showed some 
potential for using the effects of androgens and oestrogens on male prostate or female 
clitoris/Bartholin gland as biomarkers of abuse and has recently been followed up by 
looking at the range of ‘normal’ histological findings in large numbers of untreated calves 
(Groot et al. 2007). However, the technique can only be applied post-mortem and, to 
date, has only been adopted for routine screening in a small number of countries (Maria 
Groot, personal communication). 
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Whether biomarker approaches are suitable as confirmatory techniques or just as 
screening tools remains to be determined. However, further studies are clearly warranted 
in order to investigate their great potential. 
 
1.11.2  Combustion isotope ratio mass spectrometry studies 
 
Results of gas chromatography combustion isotope ratio mass spectrometry studies 
(GC-C-IRMS) are considered separately from those quantifying concentrations in bovine 
tissues because GC-C-IRMS measures the relative composition of 12C and 13C atoms of 
steroids rather than their absolute concentrations. However, since the aim of using GC-
C-IRMS is to be able to distinguish natural from exogenous steroids, a consideration of 
the results of studies using this technique is relevant to the current review.  
 
The majority of published studies relate to the bovine, but one study looked at porcine 
tissues. The following overview of the potential use of this technique was based on 
results of published studies as well as an executive summary from the EU supported 
ISOSTER project GRD1-2001-40085 (which coordinated several of the published 
studies). 
 
The technique of GC-C-IRMS relies on detecting differences in the relative 12C and 13C 
composition of steroids between the natural and synthetic states. Synthetic steroids are 
typically synthesized from a single C3 plant (often soy), while the natural diet of the 
bovine is usually a mixture of both C3 and C4 plants (Balizs et al. 2005). The terms C3 
and C4 refer to the type of metabolic pathway used by the plant in synthesising organic 
compounds during photosynthesis, utilising either 3 or 4 carbon-chain metabolites 
respectively. The significance of this lies in the fact that the two types of pathway display 
differing degrees of discrimination against 13C and thus result in different 13C to 12C 
ratios. C4 plants have lower discrimination against 13C than C3 plants, resulting in higher 
13C to 12C ratios in C4 plant material (Balizs et al. 2005). Since steroids produced within 
the body will derive carbon from both C3 and C4 plant material of dietary sources, the 
resulting 13C to 12C ratio will be lower after exogenous steroid administration (mainly C3 
plant material derived) relative to the endogenous state.  
 
The method itself requires substantial sample preparation prior to analysis including 
hydrolysis, solid phase extraction, liquid-liquid extraction and HPLC fractionation steps, 
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as the influence of matrix interferences need to be minimised. Suitable derivatisation of 
the extracts followed by separation using gas chromatography further purifies the extract 
before introduction into a furnace. The furnace then combusts the introduced sample, 
which is then analysed alongside a reference gas by mass spectrometry in order to 
determine the relative levels of 13C and 12C (Prevost et al. 2004).  
 
The resulting 13C to 12C ratio determined by GC-C-IRMS is usually expressed as a δ13C 
value, calculated as follows: 
 
 
 
The range of δ13C values for C3 plants (hence also abused steroids) is around -25 to    -
35o/oo, whereas for C4 plants is around -11.9 to -15.2o/oo (Mason et al. 1998). With diets 
usually containing both C3 and C4 plants, the range of δ13C values for endogenous 
steroids is usually somewhere between these two ranges. However, as will become 
apparent later in this section, the exact location on this continuum will depend on the 
type of diet fed to the animal (Buisson et al. 2005). The δ13C values of the steroid or 
metabolite being measured is usually referenced to an endogenous reference compound 
(ERC) such as DHEA that is not affected by exogenous steroid administration (Ferchaud 
et al. 1998). This is to ensure that the endogenous make up of the animal has not been 
affected in some way (i.e. diet) so as to give low δ13C values for all steroids. A high 
relative difference between the δ13C values of the steroid or metabolite and the ERC can 
therefore be used as an indicator of abuse. The absolute sensitivity of the method 
depends to some extent on the analyte and matrix in question, but 10 ng ml-1 is typically 
required, meaning that only some analyte matrix combinations are currently suitable 
(ISOSTER project [GRD1-2001-40085], publishable executive summary 2006 and 
personal observation of Bruno Le Bizec).  
 
As mentioned elsewhere in this review, diet is a major factor influencing the δ13C value 
of endogenous steroids. In the UK for example, animals are typically fed a much higher 
base of C3 plants than in Europe, leading to a lower difference in the δ13C values 
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between administered steroids and the ERC (Mason et al. 1998). However, as studies by 
Buisson et al. 2005 and Hebestreit et al. 2006 have shown, the difference after steroid 
administration to animals consuming a predominantly C3 diet is still usually sufficient to 
discern testosterone abuse. The Hebestreit et al. 2006 study showed that after 
testosterone administration, the difference in δ13C between the testosterone metabolite 
etiocholanolone and the ERC DHEA for C4 plant fed animals (maize) was typically 
around 10o/oo, whereas the difference for C3 fed animals (grasses) was typically around 
4o/oo. In the endogenous state, the difference in δ13C between the testosterone 
metabolite etiocholanolone and the ERC DHEA was a mean of 0.9o/oo with a standard 
deviation of 0.7o/oo. Applying a confidence interval of three standard deviations to either 
side of the mean, endogenous δ13C difference between etiocholanolone and the ERC 
DHEA allowed a 100% discrimination of samples as either positive or negative.  
 
The ISOSTER project successfully validated the use of this technique for detecting 
testosterone abuse in urine via monitoring of etiocholanolone values in relation to DHEA 
as the ERC. The method was also applied to steroids in other tissues, but in most cases 
the steroid or ERC contents were too low to be of use in the technique. In addition to 
testosterone, Buisson et al. 2005 showed that detection of oestradiol abuse in the bovine 
was possible via monitoring the δ13C value of the urinary oestradiol metabolite 
epioestradiol (17α-oestradiol) relative to DHEA. GC-C-IRMS has also been used to 
analyse porcine nandrolone and 19-norandrostenedione concentrations in testicles, liver 
and kidney, although post administration samples were not included (Prevost et al. 
2004).  
 
One question that still remains to be answered (several researchers, personal 
communications) is what the final statistical approach to determining the threshold for 
δ13C value differences between target steroids and the ERC will be. If the use of an ERC 
is adopted as standard, then it is theoretically possible that some positive samples would 
be called negative due to a high proportion of C3 plant in their diet, but the converse 
situation of calling false positives is less likely than using the technique without an ERC.  
 
The laborious nature of the sample preparation technique currently makes the technique 
unsuitable for use as a screening tool (various researchers, personal communications), 
but it has already found use as a confirmatory technique for determining testosterone 
abuse in human sports (Saudan et al. 2006). The executive summary of the ISOSTER 
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project GRD1-2001-40085 in 2006 showed that the GC-C-IRMS method for detecting 
testosterone abuse in bovine urine was successfully validated in several European 
laboratories. It is therefore recommended that the use of this technique be further 
explored in order to act as a confirmatory method following screening using a uni- or 
multi-variate threshold of some kind.  
 
1.11.13 The detection of intact steroid esters in hair and plasma 
 
The majority of injectable steroid preparations contain steroids in esterified forms. The 
direct detection of steroid esters in matrices from an animal may therefore be indicative 
of steroid abuse. The only exception to this would be if the ester is also known to occur 
naturally. For example, oestradiol and testosterone have been shown to be present in 
enzymatically hydrolysed fractions, but not unhydrolysed fractions, of human high 
density lipoprotein and rat adipose tissue respectively (Hockerstedt et al. 2006 and Borg 
et al. 1995). While the exact nature of steroid esters were not unequivocally identified in 
either of these studies, the oestradiol related compound identified by Hockerstedt et al. 
2006 co-crystallised with an oestradiol stearate reference standard. However, in all 
studies that have looked at the detection of steroid esters in animal tissues following 
administration of commercially available steroid ester preparations, no endogenous 
concentrations of the esters were detected in the pre-dose or untreated samples. 
Depending on the matrix in question, contamination issues also need to be considered 
carefully in order to eliminate environmental contamination as a possible cause of false 
non-compliant results.  
 
The detection of intact steroid esters in hair has attracted the most attention in the 
literature for this purpose and has already found use in some European labs as a 
confirmatory technique for detecting natural steroid abuse (see for example Marcos et al. 
2004, Nielen et al. 2006, Boyer et al. 2007, Anielski, 2008, Stolker et al. 2009 and Duffy 
et al. 2010). Until recently, the detection of intact steroid esters in plasma was hampered 
by their typically low concentrations in this matrix relative to analytical limits of detection 
(Kim et al. 2000, Hooijerink et al. 1994). However, analytical methods based on the 
detection of intact testosterone, nandrolone and boldenone esters below 0.01 ng ml-1 in 
equine plasma have recently been developed (Gray et al. 2010). When a testosterone 
ester is administered as a depot injection, these sensitive assays allow detection of 
testosterone abuse in female and castrated male equine animals for several weeks 
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longer than the existing (2010) international urinary testosterone concentration 
thresholds (IFHA, 2008). They also allow the detection of testosterone abuse in intact 
males for the first time. However, these assays are not suitable for detecting the abuse 
of steroids that are administered in a non-esterified form. Also, it is likely that the 
detection time for the administration of an oral preparation of steroid esters would be 
reduced compared to that of a depot injection due to the lack of sustained release. 
Despite these potential limitations, the detection of steroid esters shows great promise 
for detecting the abuse of endogenous steroids (at least when they are administered as 
esters), more studies in other species and matrices are clearly warranted.  
 
1.12 Summary and consideration of areas for future research 
 
In this chapter, the occurrence of steroids related to testosterone, nandrolone and 
boldenone in bovine, ovine and porcine matrices, as well as the occurrence of steroids 
related to nandrolone and boldenone in equine, caprine and cervine matrices have been 
reviewed.    
 
Several specific questions have been raised during this review, including some unusually 
high steroid concentrations under specific physiological conditions and a relevant dearth 
of information regarding some steroids in different species (i.e. boldenone/ nandrolone). 
Furthermore, continuously improving standards of analytical detection, as well as 
artificial selection within certain animal populations suggests that constant re-evaluation 
of detection approaches is necessary. An ideal situation might therefore be analogous to 
human sports: the use of a uni/multivariate concentration threshold or biomarker 
approach as a screening strategy (as are currently in use for some steroid/matrix/species 
combinations already) and the use of more laborious but definitive techniques such as 
carbon isotope ratio mass spectrometry, intact steroid ester analysis or more 
conservative concentration thresholds for confirmation. 
 
A major deficiency in much of the existing published literature is the lack of 
standardisation and formal validation of experimental approach. Key articles are cited 
that highlight the huge variation in reported steroid concentrations that can result when 
samples are analysed by different laboratories under different conditions. These 
deficiencies are in most cases so fundamental that it is difficult to make reliable 
comparisons between data sets and hence it is currently impossible to recommend 
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definitive detection strategies. Standardisation of experimental approach would need, 
most importantly, to involve communication among researchers before experiments are 
conducted and methods cross-validated. As far as cross-validation is concerned, it is 
also important to ensure access to the relevant reference standards and/or incurred 
sample material. 
 
In order to standardize data amongst researchers aiming to producing thresholds for 
controlling steroid abuse, the following specific recommendations are made: 
 
Physiologically based recommendations: 
 
1) Adequate consideration should be given to the demographic of the animal population 
used for the study. Specifically, the population needs to be representative of that 
which control of abuse is aimed at i.e. it must take into account sex, age, gestation 
and castration status, breed (genetic history), housing conditions, geographical region 
of origin, disease, medication, hydration and stress status, diet, housing, time of 
sampling (clock hour and sun hour) and season (and particularly the terminology 
surrounding season i.e. the word ‘September’ may relate to a different photoperiod in 
one hemisphere compared to the other hemisphere so could lead to confusion when 
considering seasonal effects). When delineating the resulting data for the control of 
endogenous steroid abuse, it would seem necessary to separate animals based upon, 
at the very least, their age, sex, castration, gestation, disease (particularly casualty 
animals) and medication status otherwise the variation under these different 
conditions may lead to irrelevantly high thresholds for the control of steroid abuse. 
However, there would appear to be balance between a physiological need to separate 
animals and a statistical requirement for a large enough population on which to base 
threshold calculations.  
 
2) When considering sample collection strategies, it is very difficult to produce unilateral 
recommendations because different matrices are likely to be suitable in different 
locations i.e. many labs will have access to urine or plasma, but export testing 
programmes may need to analyse meat. Factors that apply to all situations include the 
need to avoid contamination of one matrix with that from another e.g. no faecal 
contamination of urine and the need for samples to be frozen as quickly as possible 
after collection in order to reduce degradation or the artefactual production of certain 
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steroids. It may be necessary to consider data derived from live animals differently to 
dead animals, not necessarily because the physiology of a live animal would be 
different to a dead animal, but because ‘on-farm’ testing of live animals compared to 
‘slaughter-house’ testing of dead animals may have implications for type of matrix 
used, the age of the animal, stress levels etc. When sampling from dead animals, the 
time from slaughter to sample collection should be minimised. 
 
3) Care should be taken to distinguish between the usefulness of longitudinal and 
latitudinal studies. Latitudinal studies may be of most use when applying unilateral 
thresholds to whole populations, while longitudinal studies may be of more use in 
probing the individual variables that may need to be taken into account when 
designing the demographic of animal populations used in latitudinal studies.   
 
Analytically based recommendations: 
 
1) All methods should be subject to a full quantitative validation prior to use. As a 
minimum, the following factors should be covered and reported: 
 
 - Intra- and inter-batch precision and accuracy. 
 - The ability to dilute samples from outside the calibration range. 
 - Method selectivity. 
- Method sensitivity (defined here using the common [non-IUPAC] usage of this 
term to describe the ability of the method to determine low concentrations of 
sample). The LOD or CCα/β and LOQ should be reported where appropriate. 
 - Recovery. 
 - Linearity. 
 - Stability (of analyte solutions, extracted samples and samples stored in matrix 
 under the appropriate conditions). 
 
2) Following validation of any new method, the laboratory should attempt, where 
possible, to cross-validate their method with those from other laboratories and 
participate in the inter-laboratory exchange of QC samples. 
 
3) Data should only be considered fully quantitative if a certified reference standard is 
available. 
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4) Mass spectrometry (preferably MS/MS) following chromatographic separation should 
be the method of choice for definitive quantitative studies.  
 
5) Measures should be taken to ensure suitable chromatographic reproducibility and 
resolution; especially where isomers of the target analyte are suspected to be 
present. 
 
6) Sample preparation procedures should be designed such that it can be stated whether 
data are derived from an analysis of the ‘total’ concentration of steroid, or the 
concentration from a particular fraction i.e. glucuronic acid conjugates. When 
hydrolysing glucuronide steroid conjugates, recombinant versions of the 
glucuronidase enzymes should be used. This is because heterogeneous preparations 
such as that from Helix pomatia are known to produce artefacts of certain steroids.  
 
7) Given the above quantitative validation requirements, consideration needs to be given 
as to whether calibration lines and QCs are best prepared in matrix i.e. standard 
addition, or through alternative means i.e. using isotope dilution or surrogate 
matrices. The most suitable option will depend on the steroid, matrix and species in 
question.  
 
8) Where possible, attempts should be made to monitor various precursors, metabolites 
and other compounds related to the steroids in question so that multi-variate 
approaches based on the perturbation of ‘normal’ profiles can be investigated.  
 
9) Once published, the raw data from all studies should be made available to the EU 
Community Reference Laboratory (CRL) so that independent statisticians are able to 
combine data from a number of studies and produce more workable unilateral 
thresholds. The current approach of reporting certain statistical parameters, but not 
others, makes the amalgamation of data-sets difficult. 
 
General recommendations: 
 
When publishing the results of studies, as many details as possible regarding the 
aforementioned factors (including, critically, the analytical method validation results) 
should be reported so that comparisons can be made between different studies.  
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Further work: 
 
The results of this literature review (originally completed in February 2007 but since 
updated for publication in Food Additives and Contaminants in June 2009 and then again 
for the current thesis in October 2010) were discussed with Sponsors at the UK 
Government Department of Food, Environment and Rural Affairs (DEFRA) in 2007 and 
used to inform an appropriate strategy for the remainder of part 1 of this thesis. As 
discussed in the introduction, this involved developing approaches for the detection of 
nandrolone abuse in the porcine (chapter 2) and for the detection of androgen, 
oestrogen and progestagen abuse in the bovine (chapter 3). 
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2.1 Introduction 
 
As discussed in the introductory chapter, the use of anabolic steroids as growth 
promoting agents in food production is prohibited under European Union legislation 
(European Union, 1996). However, some androgenic-anabolic steroids, such as 
testosterone (17β-hydroxy-androst-4-en-3-one), nandrolone (17β-hydroxy-estr-4-en-3-
one), and boldenone (17β-hydroxy-androsta-1,4-dien-3-one), are known to be 
endogenous in certain species (Scarth et al. 2009), making a simple qualitative 
determination of their presence insufficient for proving abuse (see chapter 1 for further 
details). The detection of intact steroid esters or the use of combustion isotope ratio 
mass spectrometry can be useful for the confirmation of certain endogenous steroids 
(Scarth et al. 2009), but these methods are not suitable for all steroids or are too 
laborious to be used as screening approaches. Therefore, a quantitative threshold or 
biomarker approach is usually required to regulate the use of endogenous steroids.  
 
For many years, nandrolone was considered to be a purely synthetic steroid, but in the 
1980s it was isolated as a natural hormone in the stallion (Houghton et al. 1984) and 
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boar (Maghuin-Rogister et al. 1988). Since then, nandrolone related compounds have 
also been detected in the bovine (Vandenbroecke et al. 1991), ovine (Clouet et al. 1997), 
caprine (Sterk et al. 1998), human (Dehenin et al. 1984) and cervine (Van Hende, 1995). 
The presence of nandrolone in boar meat also has potential consequences for 
consumers, since it has been shown that following consumption of boar meat, human 
urine contains increased concentrations of nandrolone metabolites (Le Bizec et al. 
2000). 
 
Studies on the metabolism of nandrolone following administration to the pig (Roig et al. 
2007, Ventura et al. 2008) have shown that nandrolone itself is excreted in urine 
predominantly as a sulphate, while a number of A-ring reduced metabolite isomers are 
present in the free, glucuronide and sulphate fractions. Although nandrolone has been 
found to be present in the urine and several other matrices of untreated porcine animals 
(Debruyckere et al. 1990, De Brabander et al. 1994, Poelmans et al. 2005), these 
studies have reported that the A-ring reduced metabolites were not detected in porcine 
urine.  
 
The absence of A-ring reduced metabolite in the ‘natural’ state is hard to rationalise if 
nandrolone is truly produced by the porcine, since nandrolone administration studies 
have clearly demonstrated them to be major metabolites. A clue to the real source of 
nandrolone in porcine urine may lie in studies carried out in the equine, where similarly to 
the porcine, nandrolone is detected in the urine of intact males, but the A-ring reduced 
metabolites are much less abundant than would be expected if nandrolone itself were 
present (Houghton et al. 2007). Nandrolone in the equine is now known to be 
predominantly an analytical artefact of the breakdown of a 19-carboxylic acid precursor 
that is endogenous in this species (Houghton et al. 2007). It has therefore recently been 
suggested (Scarth et al. 2009) that such 19-carboxylic acids may also be the precursors 
to urinary nandrolone in the porcine (Fig. 1). This theory is supported by studies in 
porcine granulosa cells, where the existence of a 19-carboxylic acid derivative of 
androstenedione has been demonstrated (Garrett et al. 1991). 
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Figure 1 – diagram depicting some of the possible metabolic pathways leading to the 
presence of 19-noretiocholanolone in porcine urine. A similar pathway could also operate 
starting with androstenedione carboxylic acid in place of nandrolone carboxylic acid, 
leading to either 19-noretiocholanolone or 19-norandrostenedione as metabolites. 
 
Since the A-ring reduced nandrolone metabolites are present in large quantities in the 
urine of treated, but not untreated porcine animals, a quantitative method for 19-
noretiocholanolone (3α-hydroxy-5β-androstan-17-one) (Fig. 1) in the urinary free fraction 
was therefore validated and applied to real samples. The ultimate aim of this work was to 
use this data to produce thresholds for screening and/or confirmation of nandrolone 
abuse in the porcine. The reason for choosing 19-noretiocholanolone in particular is 
because it has been shown to be one of the most abundant urinary metabolites following 
nandrolone administration and was therefore predicted to be a good biomarker of 
nandrolone abuse (Roig et al. 2007). Analysis of the free fraction was preferred over the 
glucuronic or sulphate fractions because the free fraction contains the highest 
concentrations of 19-noretiocholanolone (Roig et al. 2007) and also because the other 
fractions contain significant quantities of other materials that interfere in GC-MS based 
analytical assays (James Scarth, personal observation). 
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2.2 Experimental 
 
2.2.1 Chemicals and Reagents 
 
Deionized water was prepared using an SG Ultrachem TWF UV system (Barsbuttel, 
Germany). All organic solvents, buffers and bases were analytical grade and were 
purchased from Fisher Scientific (Loughborough, UK). Ammonium iodide, N-(t-
butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA), dimethylformamide (DMF) 
and ethane thiol were obtained from Sigma-Aldrich (Dorset, UK). C18, 6 cc, 500 mg and 
silica, 6 cc, 500 mg solid phase extraction cartridges were supplied by Waters (Wexford, 
Ireland). 19-noretiocholanolone was supplied by Steraloids (Rhode Island, USA) and D4-
19-noretiocholanolone was provided by LGC Promochem (Teddington, UK). 
 
2.2.2 Collection of Samples from Untreated Animals 
 
Urine samples were obtained in the UK from both live animals (various university and 
research institute owned herds; from animals housed in metabolic cages and collecting 
urine using a floor-based drainage system) and from animals going for slaughter 
(organically farmed animals slaughtered for food production; collecting urine directly from 
the bladder post-mortem). A total of 205 gilt urine samples (none from pregnant animals) 
were obtained from animals ranging from 10 to 39 weeks of age and a total of 263 boar 
urine samples were obtained from animals ranging from 10 to 28 weeks of age.  Whilst 
future European legislation may lead to a more widespread banning of porcine 
castration, many countries in Europe currently prefer to rear castrated males because of 
the potentially unsavoury ‘boar taint’ odour of meat from intact males (Font i Furnols et 
al. 2008). Boar taint is believed to result from the increased concentrations of skatole 
and androstenone produced by intact boars (Font i Furnols et al. 2008). However, the 
rearing of intact males is currently preferred in the UK because these animals are 
generally slaughtered earlier than in Europe, with the result that the animals are less 
likely to reach sexual maturity and hence produce lower concentrations of skatole and 
androstenone. Also, reducing profit margins in the UK pork industry have meant that the 
economic benefits to rearing intact males are also factors in refraining from castration 
(various researchers and organic farming consultants – personal communications 2008 
and 2009). Because of the current UK practice to rear intact males, no urine samples 
from castrated males were available for study. 
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Samples were collected and stored chilled on ice within 1-hour. Samples on ice were 
then delivered by courier within 48-hours before being frozen at -80oC until the time of 
analysis.  
 
2.2.3 Preparation of Calibration Lines and QCs 
 
Calibration lines were constructed using pooled urine from castrated male bovine 
animals as a surrogate matrix. Bovine calibrant urine was augmented with 19-
noretiocholanolone at concentrations of 0, 25 (the lower limit of quantification or LLOQ), 
50, 100, 250, 500, 1,000, 1,500, 2,000 and 3,000 (the upper limit of quantification or 
ULOQ) pg ml-1. This calibration range was chosen in order to provide maximal sensitivity 
at the low concentrations (instrumental responses saturated at concentrations above the 
upper limit of the calibration range due to the high sensitivity of the method). The reason 
for not using pooled porcine urine for constructing calibration lines was two-fold; firstly 
because it contained measurable endogenous concentrations of 19-noretiocholanolone 
(bovine urine did not) and secondly because the volumes needed to produce enough of 
the pool for both the validation and sample analysis studies were not available.  
 
In order to validate the use of bovine urine as a surrogate calibration line matrix, pooled 
porcine boar urine was used as the QC matrix. Porcine QC concentrations were; the 
endogenous concentration only (E), endogenous augmented with 25 pg ml-1 (E+25), 100 
pg ml-1 (E+100), 1,000 pg ml-1 (E+1,000) and 2,000 pg ml-1 (E+2,000). 
  
2.2.4 Extraction Method 
 
Samples were prepared and extracted according to the scheme shown in Fig. 2. The D4-
19-noretiocholanolone internal standard was added at a concentration of 800 pg ml-1 to 
all samples (other than an extracted blank bovine urine control sample). 
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Sample preparation: 
Sample (3 ml) + internal marker (10 μl) + pH 6.8 phosphate buffer (1 M, 1.5 ml)  
 
C18 extraction (6 cc, 500 mg): 
Condition with MeOH (5 ml) then Water (5 ml) 
Load the sample  
Wash with water (5 ml) than hexane (5 ml) 
Dry cartridge under Vacuum for 20 minutes 
Elute the cartridge with diethyl ether (5 ml)  
 
Sodium hydroxide clean-up: 
Rotary mix diethyl ether with 2 M NaOH (2 ml) for 10 mins 
Discard aqueous layer  
Dry ether over sodium sulphate 
Transfer the diethyl ether to a separate tube  
Extract the sodium sulphate with diethyl ether (2 x 1ml) 
Evaporate to dryness under nitrogen 
 
Silica extraction (6 cc, 500mg): 
Reconstitute the extract in diethyl ether (0.5 ml) and then hexane (0.5 ml)  
Condition with chloroform (5 ml) and then diethyl ether/hexane (1:1; 5 ml) 
Load the sample  
Elute the cartridge with chloroform/ethyl acetate (1:1; 3 ml) 
Dry over sodium sulphate 
Transfer the chloroform/ethyl acetate to a new tube 
Extract the sodium sulphate with chloroform/ethyl acetate (1:1, 2 x 1ml) 
Evaporate to dryness under nitrogen 
 
Enol-TBDMS (tertiary-butyl,dimethyl-silyl) derivatisation: 
Add enol-TBDMS derivatisation reagent (100 l - prepared by mixing 3 ml MTBSTFA, 
1.5 ml DMF, 18 mg ammonium iodide and 30 μl ethane thiol) 
Heat for 1 hour (1,000 C) 
Add methanol (0.5 ml) and water (0.5 ml) 
Extract with hexane (2 x 2ml) 
Evaporate to dryness under nitrogen 
Add 30ul dried ethyl acetate and vortex  
 
GC-MS/MS Analysis 
 
Figure 2 – schematic of the extraction method. 
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2.2.5 Method Validation Protocol 
 
The validation protocol was based on the USA Food and Drug Administration (FDA) 
Centre for Drug Evaluation and Research guidelines for bioanalytical method validation 
(FDA, 2001), with accuracy defined as the degree of bias (% bias) and precision as the 
relative standard deviation (% RSD). In terms of % bias and % RSD acceptance limits, 
the FDA recommended +/- 20% limit for the lower limit of quantification (LLOQ) and +/- 
15% limit for all other concentrations were relaxed to 25 and 20 % respectively. This was 
because the assay was considerably more complex than the majority of small molecule 
applications that the FDA guidelines are designed for. These somewhat relaxed limits 
were considered ‘fit-for-purpose’ according to the recommendations for biomarkers of 
Lee et al. (2006), the results of which are taken into account through the application of 
uncertainty of measurement (see later section on statistical analysis). Three separate 
precision and accuracy batches were extracted and analyzed in order to determine the 
inter-batch precision and accuracy, chromatographic separation, selectivity, linearity, 
lower and upper limits of quantification (LLOQ and ULOQ respectively) and the limit of 
detection (LOD). Each precision and accuracy batch contained a blank sample 
(extracted bovine urine with no internal standard or analyte added), a bovine urine 
calibration line (as described in the above section) and 5 replicates of each of the 
porcine urine QC concentrations (E, E+25, E+100, E+1,000 and E+2,000 pg ml-1).  
 
Stability of the analytes in the porcine E+100 and E+1,000 QCs was assessed by 
measuring 19-noretiocholanolone concentrations at 3-, 6-, 9-, 12 and 13.5-months (the 
longest period for which ‘real’ samples were stored) and comparing the results to those 
determined at time-zero. 
 
Recovery was assessed by comparing porcine urine spiked with 19-noretiocholanolone 
at 1,000 pg ml-1 before (matrix fortified) and after (matrix matched) extraction (n=5).  
 
The ability to dilute from outside the calibration range was assessed by spiking pooled 
porcine urine with 16,667 pg ml-1 19-noretiocholanolone and then performing a 1 in 10 
dilution with pooled porcine urine in order to bring the resulting concentration of analyte 
into the workable calibration range.  
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2.2.6 Analysis of Samples from Untreated Animals 
 
Following validation of the method, samples from untreated animals were analyzed 
alongside a bovine urine spiked calibration line (25 to 3,000 pg ml-1, made up of 9 
separate calibrant concentrations) and 6 porcine urine spiked QCs (2 at each of the 
E+100, E+1,000 and E+2,000 pg ml-1 concentrations) interspersed with the samples 
throughout the batch.  
 
2.2.7 GC-MS/MS Method 
 
Nine microlitres of sample was introduced into a Varian 1079 programmable temperature 
vaporiser (PTV) injector held at 125oC for 1 min and then ramped to 280oC at a rate of 
150oC min-1 before being held at 280oC for 13 mins. The injector split/column flow ratio 
was 20:1 until 1 min, before being reduced to 0:1 until 3 mins, before being increased to 
50:1 for the remainder of the run-time. Chromatography was carried out using an Varian 
CP-3800 gas chromatograph with helium as the carrier gas (1.0 mlmin-1) and a 30m x 
250 um x 0.25 um Varian VF-17MS column initially held at 120oC for 2.00 mins and then 
ramped by 50oC min-1 to 220oC at 4.00 mins, ramped by a further 4.5oC min-1 to 291oC at 
19.78 mins, held for 2.00 mins, ramped by a further 4.5oC min-1 to 300oC at 23.78 and 
then ramped at 50oC min-1 to 320oC at 28.18 mins.  
 
Mass spectrometry was carried out using a Varian 320-MS triple quadrupole mass 
spectrometer operated in the electron ionization (EI) mode. Transfer line temperature 
was 280oC, ion source temperature was 220oC, electron energy was 20 eV and electron 
multiplier voltage was typically around 1,800 V.  Positive ion MS/MS data was acquired 
in the selected reaction monitoring (SRM) mode using argon as the collision gas at a 
pressure of 1.5 m Torr. Precursor and parent m/z transitions monitored were 451.3 to 
375.2 for D4-19noretiocholanolone (collision energy 7 V), 447.3 to 371.2 for 19-
noretiocholanolone transition 1 (used for quantification) (collision energy 7 V) and 447.3 
to 239.1 for 19-noretiocholanolone transition 2 (used to provide additional support for the 
peak of interest relating to 19-noretiocholanolone) (collision energy 10 V) (Figs. 3 and 4). 
Dwell times were 0.167 seconds for each transition. Data were acquired and processed 
using the Varian Workstation version 6.9 software. 
 
 
Chapter 2 
116 of 331 
Figure 3 – full scan EI-MS spectrum of 19-noretiocholanolone-bis-TBDMS (tertiary-
butyl,dimethyl-silyl) at 20 eV, highlighting the molecular ion and the fragment chosen as 
the MS/MS precursor ion.  
Figure 4 – full scan EI-MS/MS spectrum of 19-noretiocholanolone-bis-TBDMS at a 
collision energy of 7 eV, highlighting the MS/MS product ions. 
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2.2.8 Statistical Analysis of the Untreated Animal Population Data 
 
In order to control the abuse of nandrolone in the porcine, the statistical analysis set out 
to suggest 19-noretiocholanolone thresholds with various probabilities (1 in 20, 1 in 100, 
1 in 1,000 and 1 in 10,000) of finding a larger value by chance in a natural population. 
The one-tailed version of the Chebyshev inequality was used. This method, described by 
Estler (1997), is based on probability theory and makes minimal assumptions about the 
distribution of the data. Chebyshev confidence intervals are as far as possible from a 
mean for a given standard deviation; they are distribution-independent confidence 
intervals and are ideally suited to dealing with non-normally distributed data such as 
those resulting from the current study.  A one-tailed Chebyshev confidence interval is 
given by 
 
Vt1
1p 2  
Hence 
V
p
Vt   
Where: 
 
  t is the difference between the mean and concentration at the upper 
 confidence interval 
 V is the variance (square of the standard deviation), 
p is the probability that difference between the mean concentration and the 
concentration of a sample taken at random is greater than t. 
 
To assess the extent to which concentration differed between gilts and boars, a Monte 
Carlo permutation test was implemented (Manly, 2007). Here, gender was permuted 
amongst individuals and the mean difference in concentration of 19-noretiocholanolone 
between gilts and boar was calculated for each permutation. The observed difference 
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was then compared to the distribution of mean differences for 1,000 permutation and 
significance assessed on the basis of the position of the observed mean in the 
distribution.  
 
Uncertainty of measurement was calculated using a Monte Carlo sample (Manly, 2007) 
from the distribution consistent with the observed result along with the analytical 
performance observed at validation. 1,000 samples were taken from these distributions 
and 1,000 Chebyshev threshold estimates were generated. The different probabilities of 
finding a value by chance in a ‘natural’ population are then reported at the upper 95% 
quantile results after factoring in the determined method uncertainty. Values for CCα and 
CCβ (Decision limit and detection capability respectively) on each Chebyshev threshold 
associated with these probabilities (European Union, 2002), again at the 95% confidence 
interval, were also calculated for each analytical method used. 
 
2.3 Results  
 
In the following section all raw data and calculated threshold concentrations are 
uncensored and are given to one decimal place. All other summary statistics are 
presented to three significant figures. 
 
2.3.1 Chromatography 
 
Complete chromatographic separation for 19-noretiocholanolone in bovine urine was 
achieved (Fig. 5). In some porcine urine samples there was a small peak close after 19-
noretiocholanolone (Fig. 5), but this did not reach significant enough a size to interfere 
with the integration of 19-noretiocholanolone.  
 
2.3.2 Selectivity 
 
In addition to the chromatographic separation, selectivity was assessed through 
monitoring the ratio of two separate MS/MS transitions for 19-noretiocholanolone, which 
support the suggestion that the peaks found in the porcine samples relate to 19-
noretiocholanolone (Figs. 4 and 5).  
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2.3.3 Linearity  
 
The calibration curves (weighted 1/x) were linear over the range studied (25 to 3,000 pg 
ml-1 – see chromatograms in Fig. 5). The mean r2, slope, intercept and response factor 
% RSD values were 0.995, 0.00143, 0.0150 and 14.8 respectively (n=15 over the 
validation and sample analysis phases).   
 
  
   
               a                                                                              b                                                                              c 
 
Figure 5 – chromatograms obtained for samples at a) the lower limit of quantification (a 25 pg ml-1 spiked calibration line sample. Note: this 
peak was absent in unspiked bovine urine), b) the upper limit of quantification (a 3,000 pg ml-1 spiked calibration line sample) and c) a porcine 
urine from the sampled population with a determined concentration of 896.5 pg ml-1. The top trace refers to the D4-19-noretiocholanolone 
internal standard (m/z 451 to 375), the middle trace refers to 19-noretiocholanolone transition 1 (used for quantification) (m/z 447 to 371) and 
the bottom trace refers to 19-noretiocholanolone transition 2 (used to provide additional support for the peak of interest relating to 19-
noretiocholanolone) (m/z 447 to 239). 
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2.3.4 Lower Limits of Quantification (LLOQ) and Detection (LOD) 
 
The limit of quantification (25 pg ml-1) was defined by the lowest point on the bovine 
urine calibration curve that could be quantified with a % bias and % RSD of less than 
25% (based on the FDA guidelines, as discussed earlier). The LOD was calculated using 
the endogenous porcine QCs analyzed during the validation. The mean S:N of the 19-
noretiocholanolone peaks in these samples was 8.15 at a mean calculated concentration 
of 35.9 pg ml-1. When defining the LOD as the concentration that leads to a S:N of 3:1, 
extrapolation of the endogenous porcine QC data leads to a predicted LOD of 13.2 pg 
ml-1. 
 
2.3.4 Precision and Accuracy 
 
Inter-batch precision and accuracy during both the validation and sample analysis stages 
were good, with % bias and % RSD within 15.0% throughout (Tables 1 and 2). 
  
2.3.6 Linearity of Dilution 
 
Results of QC samples diluted 1 in 10 from above the calibration range were acceptable, 
with the % bias and % RSD being less than 2% in each case (Table 3). 
 
2.3.7 Recovery 
 
The mean recovery of 19-noretiocholanolone spiked at 1,000 pg ml-1 (n=5 for each of the 
matrix fortified and matrix matched spikes) was 87.4%. 
 
2.3.8 Matrix Stability 
 
19-noretiocholanolone was found to be stable in urine at -80oC during the 13.5-months 
period studied (within +/- 20.0% of time-zero values at all subsequent time-points 
studied). 
 
 
  
Table 1 – inter-batch precision and accuracy results for 19-noretiocholanolone concentrations in porcine QCs during the validation (n=15 
at each concentration). * The theoretical concentration for the endogenous QCs was the mean of the determined concentrations in the 
endogenous QCs in the first of the three precision and accuracy validation batches. The theoretical concentration for the remainder of 
the QCs was this endogenous concentration plus the known spiked amount on top of this number i.e. endogenous + 100 pg ml-1 for 
LOW QCs. 
 
  
Endogenous QCs 
pg ml-1 (E) 
Endogenous +  
25 pg ml-1 QCs  
(E+25) 
 
Endogenous +  
100 pg ml-1 QCs 
(E+100) 
 
Endogenous +  
1,000 pg ml-1 QCs 
(E+1,000) 
Endogenous +  
2,000 pg ml-1 QCs 
(E+2,000) 
 
Theoretical 
conc.* 
 
36.1 
 
61.1 
 
136.1 
 
1,036.1 
 
2,036.1 
 
Measured mean 
conc. 
 
35.9 
 
68.6 
 
136.4 
 
1,049.8 
 
1,945.9 
 
SD 
 
5.22 
 
10.1 
 
16.1 
 
56.6 
 
147 
 
% RSD 
 
14.5 
 
14.7 
 
11.8 
 
5.39 
 
7.55 
 
% Bias 
 
-0.391 
 
12.3 
 
0.237 
 
1.32 
 
-4.43 
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Table 2 – inter-batch precision and accuracy results for 19-noretiocholanolone 
concentrations in porcine QCs during the sample analysis phase of the study (n=24 at 
each concentration). * See footnote to Table 1. 
 
 
Endogenous +  
100 pg ml-1 QCs 
(E+100) 
 
Endogenous +  
1,000 pg ml-1 QCs 
(E+1,000) 
 
Endogenous +  
2,000 pg ml-1 QCs 
(E+2,000) 
 
Theoretical 
conc.* 
 
136.1 
 
1,036.1 
 
2,036.1 
Measured mean 
conc. 
141.0 1,036.3 2,021.0 
SD 15.0 134 320 
% RSD 10.6 12.9 15.8 
% Bias 3.61 0.0186 -0.743 
 
 
 
 
Table 3 – results of the 1 in 10 dilution QCs (note: no samples needed to be diluted 
during the population sample analysis phase). * Because of the endogenous contribution 
in the porcine urine used for dilution, in order to compare the % bias of the measured 
concentrations in the diluted samples compared to the theoretically spiked concentration, 
it was necessary to adjust the measured values for the endogenous contribution. This 
was achieved by subtracting the endogenous concentration of the diluting matrix (as 
measured by the mean of five endogenous QCs run in this batch) from the dilution QC 
measured value and then multiplying the result by the dilution factor of 10. 
 
 
 
Measured concentration 
(pg ml-1) after 1 in 10 
dilution 
 
Adjusted concentration (relative 
to the theoretically spiked 
concentration of 16,667 pg ml-1)* 
 
Measured mean 
conc. 
 
1,679.4 
 
16,399.4 
SD 28.9 289 
% RSD 1.72 1.76 
% Bias N/A -1.61 
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2.3.9 Application of the Method to a Population of Samples from Untreated Animals 
 
The descriptive statistics of the population data from untreated animals are shown in 
Table 4. 19-noretiocholanolone distributions in boars and gilt were bimodal, with a small 
number of concentrations in each sex at around the 1,000 pg ml-1 region and the majority 
of concentrations closer to the lower end of the calibration range. The ratio of the two 
MS/MS transitions in these samples is consistent with them relating to 19-
noretiocholanolone (Fig. 5). 
 
Table 4 – summary statistics for determined 19-noretiocholanolone concentrations in the 
free fraction of porcine urine. 
 
 
 Boars 
 
Gilts 
Mean concentration (pg ml-1) 
 
12.2 
 
40.5 
SD 69.7 183 
% RSD 572 452 
Minimum determined concentration (pg ml-1) < LOD < LOD 
Maximum determined concentration (pg ml-1) 937.2 1,181.8 
n 263 205 
 
 
2.3.10 Statistical Analyses of the Population Data 
 
19-noretiocholanolone concentrations in gilt and boar urines were determined to be 
statistically significantly different from each other (Monte Carlo permutation test p<0.025, 
1,000 permutations) and hence threshold calculations were performed separately for 
each sex. The estimated thresholds of finding a value by chance in a ‘natural’ population 
at different probabilities are given in Table 5 and are reported as the ‘95% confidence 
interval,’ signifying that they are the upper estimates for the thresholds after factoring in 
the method’s uncertainty of measurement. Table 5 also lists the CCα and CCβ values 
relating to these thresholds when using the analytical methodology presented herein. 
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The application of the resulting thresholds for screening and confirmation of nandrolone 
abuse will be discussed in the following section.  
 
Table 5 – the 95% quantile thresholds (the upper threshold estimate after factoring in 
uncertainty of measurement) and associated CCα/β concentrations (p=0.05) for free 
fraction 19-noretiocholanolone in porcine urine at different false non-compliance 
probability rates. 
 
    
Chebyshev thresholds (pg ml-1) at different  
false non-compliance probability rates 
 
 
  1 in 20
 
1 in 100
 
1 in 1,000
 
1 in 10,000 
 
 
Boar 95% quantile 345.4 763.8 2,384.3 7,501.6 
 CCα 396.4 876.4 2,735.8 8,607.5 
 CCβ
 
464.9 
 
1,027.9 
 
3,208.9 
 
10,096.0 
 
 
Gilt 95% quantile 885.1 1,955.8 6,103.4 19,200.4 
 CCα 1,015.6 2,244.2 7,003.2 22,031.1 
  CCβ
 
1,191.2 
 
2,632.2 
 
8,214.2 
 
25,840.8 
 
 
2.4 Discussion 
 
Previous studies have suggested the existence of endogenous nandrolone in porcine 
urine and at the same time the absence of the A-ring reduced metabolites in untreated 
animals (Roig et al. 2007, Ventura et al. 2008, Debruyckere et al. 1990, De Brabander et 
al. 1994, Poelmans et al. 2005). Several authors have therefore suggested that 19-
noretiocholanolone could be used as a biomarker for nandrolone abuse (Scarth et al. 
2009, Roig et al. 2007, Ventura et al. 2008). The results of the current study have shown 
that while concentrations of 19-noretiocholanolone are relatively low (maximum of 0.937 
and 1.182 ng ml-1 in boars and gilts respectively), it has been demonstrated for the first 
time that 19-noretiocholanolone is endogenous in this species. Since the limit of 
detection (13.2 pg ml-1) was much lower than previously (Roig et al. 2007, Ventura et al. 
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2008) reported methods (due to the analysis of the urinary ‘free’ fraction, the use of a 
PTV injector and analysis by GC-MS/MS), it is not surprising that a small amount of 19-
noretiocholanolone can be detected in porcine urine, since it might be expected that a 
small proportion of the suggested nandrolone carboxylic acid precursors might be 
converted into nandrolone metabolites in vivo.  
 
The endogenous nature of 19-noretiocholanolone, albeit at low concentrations, means 
that a threshold approach rather than a simple qualitative demonstration of it’s presence 
is required in order to be able to use this compound as a biomarker of nandrolone abuse. 
The principle of adopting thresholds to control the abuse of endogenous compounds has 
long been an accepted approach in both food production (Heitzman, 1994) and animal 
sports (Houghton and Crone, 2000). If used to formally confirm the abuse of an 
endogenous substance, the standard approach is to set the threshold at a statistical 
probability of finding a false non-compliance at a rate of 1 in 10,000 in a natural 
population (Houghton and Crone, 2000), since this is considered to offer a sufficiently 
large safety margin to prevent the occurrence of false non-compliances.  
 
Thresholds for screening may be set at a lower probability, but there then needs to be a 
secondary mechanism for confirmation if the confirmatory threshold is not also breeched. 
Typically, this may include follow-up analyses using gas chromatography carbon isotope 
mass spectrometry (GC-C-IRMS) (Prévost et al. 2004), detection of an intact steroid 
ester (Boyer et al. 2007) or an on-farm inspection (Jack Kay, personal communication). 
In an ideal world, a confirmatory threshold would also be suitable as a screening 
threshold, but this requires that the threshold is able to produce both low rates of false 
compliance and non-compliance; an ideal that is seldom achieved. 
 
The analytical method presented herein was validated to a high standard and therefore 
considered suitable for application to a population of animals for use in establishing 
urinary 19-noretiocholanolone confirmatory thresholds. Because of the non-normal 
distribution of the data, it was necessary to use a non-parametric method of statistical 
analysis and the Chebyshev was considered the most suitable as it makes minimal 
assumptions about the population distribution and produces conservative thresholds 
relative to methods based on normally distributed data (Roy Macarthur, personal 
communication).  
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As shown in Table 5, the suggested confirmatory thresholds for free fraction 19-
noretiocholanolone concentrations at a false non-compliance probability rate of 1 in 
10,000 are 7.502 and 19.200 ng ml-1 for boars and gilts respectively. To put these 
thresholds into context, in a recent study administering 2 mg/kg nandrolone laurate via 
intra-muscular injection to six boars aged 8-10 weeks, the mean free fraction 19-
noretiocholanolone concentration at the last time-point of the study (15 days following 
administration) was 28.4 ng ml-1, with a range of 9.6 to 53.6 ng ml-1 (Ventura et al. 2008). 
The suggested threshold of 7.502 ng ml-1 in boar urine should therefore be able to detect 
the abuse of nandrolone for a significant time period in most treated animals and lead to 
rates of both low false compliance and non-compliance. 
 
Quantitative data on 19-noretiochlanolone concentrations following nandrolone 
administration to gilts are lacking, but if the results are similar to boars, then the 
suggested threshold of 19.200 ng ml-1 in gilt urine should still be able to detect abuse in 
a significant number of cases in this sex also. Since no castrated males were available 
within the current study, it was not possible to suggest thresholds for these animals, but 
if the current (2009) UK trend to leave animals intact continues, then a threshold for 
castrated animals would not be required.  
 
Although the current study has focussed on male and female porcine animals, recent 
studies have also suggested that inter-sex porcine animals may occasionally be 
encountered (Van Cruchten et al. 2002, Cornillie et al. 2009). Therefore, it is important 
that these animals be identified during regulatory surveillance procedures in order that 
they can either be excluded from measurement against threshold concentrations or be 
subject to further investigations to rule out nandrolone abuse should a breech of one of 
the threshold concentrations be observed. 
 
Threshold concentrations at false non-compliance probabilities of lower than 1 in 10,000 
are given in Table 5 in order that these concentrations could also be used in screening 
programmes prior to confirmatory analysis using one or more of the alternative follow-up 
techniques described earlier, should this be required. For example, should screening 
thresholds be set at a false non-compliance probability of 1 in 1,000 instead of the 1 in 
10,000 used for confirmation, then the resulting threshold concentrations for boars and 
gilts are reduced by a factor of approximately three-fold to 2.384 and 6.103 ng ml-1 
respectively. With reference to the 19-noretiocholanolone concentrations reported in the 
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Ventura et al. 2008 nandrolone administration study, these threshold concentrations 
would be able to detect 100% of the instances of nandrolone use in boars at the last time 
point studied (15 days), while also leading to a low rate of follow-up work (1 in 1,000 
samples tested). Ultimately, the decision to establish a particular screening threshold is 
at the discretion of the individual regulatory authority and will no doubt reflect the striking 
of a balance between the amount of unnecessary follow-up work generate and the ability 
to minimise false non-compliances at the different probabilities. Although the CCα and 
CCβ values for the thresholds using the method above are also given in Table 5, these 
are unique to this laboratory. If other laboratories adopt these thresholds, then CCα and 
CCβ values must be independently determined in these laboratories before applying the 
method to ‘real-life’ samples. 
 
In conclusion, the analytical method presented above has been validated and applied to 
a population of boars and gilts in order to suggest urinary 19-noretiocholanolone 
screening and confirmatory biomarker thresholds for the detection of nandrolone abuse. 
The establishment of these thresholds is significant since there is currently no 
internationally accepted method for detecting nandrolone abuse in this species.  
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Chapter 3: Validation of analytical biomarker 
approaches for the detection of androgen, oestrogen 
and progestagen abuse in the bovine 
 
______________________________________________________________________ 
After: 
 
Scarth, J., Clarke, A., Hands, J., Teale, P., Macarthur, R. and Kay, J. Validation 
of a quantitative multi-residue urinary assay for the detection of androgen, 
oestrogen and progestagen abuse in the bovine. (2010). Chromatographia. 71, 
241-252. 
 
______________________________________________________________________ 
 
 
3.1 Introduction 
 
As discussed in the introductory chapter, the use of steroids as growth promoting agents 
in food production is prohibited under European Union legislation (European Union, 
1996). However, some steroids are known to be endogenous in certain species (Scarth 
et al. 2009), making a simple qualitative determination of their presence insufficient for 
proving abuse (see chapter 1 for further details). The detection of intact steroids esters 
or the use of combustion isotope ratio mass spectrometry can be useful for the 
confirmation of certain endogenous steroids (Scarth et al. 2009), but these methods are 
not suitable for all steroids or are too laborious to be used as screening approaches. As 
discussed in chapter 2 in relation to the porcine, some sort of quantitative threshold or 
biomarker approach is therefore usually required to regulate the use of endogenous 
steroids  
 
In the work reported in the current chapter, a multi-residue analytical method was 
developed and validated in order to quantify urinary target analytes indicative of the 
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abuse of testosterone, nandrolone, boldenone, progesterone and oestradiol in the 
bovine. Once validated, the aim was then to apply this method to a large number of 
samples from natural populations of animals in order to determine baseline steroid 
concentrations and establish thresholds for detecting steroid abuse. Urine was the matrix 
of choice as it is available at both slaughter and from live animals and is known to 
contain higher concentrations of most steroids relative to blood (Scarth et al. 2009).  
 
In human sports, an increased ratio of testosterone to epitestosterone is used as a 
marker of testosterone abuse, but since epitestosterone is a major metabolite of 
testosterone in the bovine (Angeletti et al. 2006), the ratio has little use in this species. 
However, testosterone is also metabolised to a number of androstanediol isomers in the 
bovine (Scarth et al. 2009). 5β-androstane-3α,17β-diol (BAB-androstanediol - Fig. 1) was 
chosen as the testosterone target analyte for the current study as this analyte has been 
shown to be increased in the urine of testosterone treated animals (Scarth et al. 2009) 
and a deuterated version of this analogue is commercially available.  
 
Analogous to testosterone metabolism, nandrolone is converted to epinandrolone, 19-
noretiocholanolone and a mixture of estranediol isomers in the bovine. Since it is 
currently unknown which of these analytes will produce the most useful threshold for 
detection of nandrolone abuse, epinandrolone, 19-noretiocholanolone and 5α-estrane-
3β,17α-diol (ABA-estranediol) were all targeted with the current method (Fig. 1).  
 
Boldenone is metabolized by the bovine to epiboldenone and a number of isomers 
reduced in the A- and/or D-ring of the steroid molecule (Scarth et al. 2009). Current EU 
guidelines for detecting boldenone abuse in the bovine (European Commission, 2003) 
target boldenone conjugates as indicative of abuse, but these guidelines also 
recommend that further work to identify more appropriate metabolites be encouraged. 
Therefore, the current study focused on the A-ring reduced boldenone metabolite 17β-
hydroxy-5β-androst-1-ene-3-one (Fig. 1), as this compound has been detected in the 
urine of animals administered boldenone, but not unequivocally in untreated animals 
(Scarth et al. 2009). It has also been observed that boldenone related compounds are 
present in some animal sub-populations and absent in others (De Brabander et al. 
2004). Therefore, in order to assess whether any absence of detectable 17β-hydroxy-5β-
androst-1-ene-3-one in bovine urine was due to it’s true absence (even in the presence 
of endogenous epiboldenone) or instead only absent because there was no endogenous 
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epiboldenone that could be metabolized through to 17β-hydroxy-5β-androst-1-ene-3-
one, epiboldenone was also included in the assay.  
 
In contrast to the aforementioned androgenic-anabolic steroids, data on the metabolism 
of progesterone following exogenous administration is lacking. Therefore, the target 
analyte that was chosen for the current study, 5α-pregnane-3β,20α-diol (ABA-
pregnanediol – Fig. 1), was one that was shown by preliminary analyses to be detected 
in the urine of bovine steers at a concentration within the same calibration range used for 
the other androgenic-anabolic steroids.  
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BAB-Androstanediol       ABA-Estranediol 
 
Epinandrolone          Epiboldenone 
 
17β-Hydroxy-5β-androst-1-en-3-one  19-Noretiocholanolone 
 
ABA-Pregnanediol           Epioestradiol 
Fig. 1 – structures of the analytes studied. 
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Lastly, the target analyte chosen for detecting the abuse of oestradiol was epioestradiol 
(Fig. 1) because concentrations of this steroid in urine are much higher than oestradiol 
(Biddle et al. 2007) and hence are more readily quantified. Additionally, there is an 
overlap in the concentrations of epioestradiol between treated and untreated animals, so 
it is anticipated that the control of oestradiol abuse will necessitate a provisional urine 
screen using epioestradiol followed by confirmation using an auxiliary techniques such 
as gas-combustion-isotope-ratio-mass-spectrometry (GC-C-IRMS). The higher 
concentrations of epioestradiol are more amenable to confirmatory analysis using GC-C-
IRMS compared to oestradiol.  
 
Due to the high sensitivity and selectivity obtained with GC- or LC-MS/MS, these 
techniques are the most frequently applied in steroid residue analysis (Stolker et al. 
2005). The chemically reduced nature of many of the androgen and progestagen urinary 
metabolites means that these compounds do not ionize well under atmospheric pressure 
ionization (API), hence GC-MS/MS was chosen for these compounds. For oestradiol 
however, its fractionation from the androgens and progestagens using an extractive 
derivatisation procedure allowed LC-MS/MS analysis to be used. This was desirable 
since the LC-MS/MS analysis of the dansyl derivative of ethinyloestradiol has been 
demonstrated to provide high sensitivity by virtue of introducing a functional group with 
high proton affinity into the molecule (Anari et al. 2002). 
 
3.2 Experimental Data 
 
3.2.1 Chemicals and Reagents 
 
Deionized water was prepared using an SG Ultrachem TWF UV system (Barsbuttel, 
Germany). All organic solvents, buffers and bases were analytical grade and were 
purchased from Fisher Scientific (Loughborough, UK). Ammonium iodide, N-(t-
butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA), di-methyl-formamide (DMF), 
D3-testosterone, oestradiol, dansyl chloride, β-glucuronidase from e. coli and ethane thiol 
were obtained from Sigma-Aldrich (Dorset, UK). C18, 6 cc, 500 mg and silica, 6 cc, 500 
mg solid phase extraction cartridges were supplied by Waters (Wexford, Ireland). 19-
noretiocholanolone, 5α-pregnane-3β,20α-diol, 5α-estrane-3β,17α-diol and epinandrolone 
were supplied by Steraloids (Rhode Island, USA). D4-19-noretiocholanolone, D3-
boldenone, epiboldenone, 5β-androstane-3α,17β-diol, D5-5β-androstane-3α,17β-diol and 
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17β-hydroxy-5β-androst-1-ene-3-one were provided by LGC Promochem (Teddington, 
UK). D2-epioestradiol was obtained from CDN Isotopes (Quebec, Canada). D3-
androstanediol (isomer nature unknown) and D4-5α-pregnane-3β,20α-diol were 
synthesized in our laboratories. Urine samples from castrated male bovine animals not 
treated with steroids were obtained in the UK from both live animals (various university 
and research institute owned herds) and from animals going for slaughter (organically 
farmed animals slaughtered for food production). 
 
3.2.2 Preparation of Calibration Lines and QCs 
 
Calibration lines were constructed using pooled urine from castrated male bovine 
animals using a ‘standard addition’ approach. By spiking known quantities of analyte 
onto existing endogenous concentrations, the slope and intercept of the calibration line 
was used to calculate the endogenous concentrations of analyte present. The resulting 
calibrant concentrations were then adjusted to account for the endogenous plus known 
spiked amount at each point. Bovine calibrant urine was augmented with steroid at 
concentrations of 0, 25, 50, 100, 250, 500, 1,000, 1,500, 2,000 and 3,000 pg ml-1 for 
androgens/progestagens and at 0, 20, 40, 80, 200, 400, 800, 1,200, 1,600 and 2,400 pg 
ml-1 for oestrogens. These calibration ranges were chosen in order to provide maximal 
sensitivity at the low concentrations (instrumental responses saturated at concentrations 
above the upper limit of the calibration range due to the high sensitivity of the method). 
QCs were also prepared in pooled urine from castrated males. QC concentrations for 
androgens/progestagens were: the endogenous concentration only (E), endogenous 
augmented with 25 pg ml-1 (E+25), endogenous augmented 100 pg ml-1 (E+100), 
endogenous augmented with 1,000 pg ml-1 (E+1,000) and endogenous augmented with 
2,000 pg ml-1 (E+2,000). QC concentrations for oestrogens were: the endogenous 
concentration only (E), endogenous augmented with 20 pg ml-1 (E+20), endogenous 
augmented with 80 pg ml-1  (E+80), endogenous augmented with 800 pg ml-1 (E+800) 
and endogenous augmented with 1,600 pg ml-1 (E+1,600). 
  
3.2.3 Extraction Method 
 
Samples were prepared and extracted according to the scheme shown in Fig. 2a 
(androgens and progestagens) and 2b (oestrogens). The internal standards were added 
to all samples (other than an extracted blank bovine urine control sample) at 
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concentrations of 800 pg ml-1 (androgens) and 400 pg ml-1 (oestrogens). A 
chromatogram for the related internal standard is shown for comparison in Fig. 3 to 10.  
 
Sample preparation: 
Sample (3 ml) + internal marker (10 μl) + pH 6.8 1 M phosphate buffer (1.5 ml)  
 
C18 extraction (6 cc, 500 mg): 
Condition with MeOH (5 ml) then Water (5 ml) 
Load the sample  
Wash with water (5 ml) than hexane (5 ml) 
Dry cartridge under Vacuum for 20 minutes 
Elute the cartridge with diethyl ether (1 ml), followed by methanol (4 ml)  
Evaporate to dryness under nitrogen 
 
Hydrolysis 
Reconstitute the extract in 3.25 ml pH 6.8 1M phosphate buffer 
Add 60 ul -Glucuronidase from E Coli (type 1X-A, 10,000 units ml-1) 
Hydrolyse overnight at 37oC 
Extract free steroids with 5ml diethyl ether by rotary mixing for 15 minutes 
Discard aqueous layer 
 
Sodium hydroxide extraction: 
Rotary mix diethyl ether with 2 M NaOH (2 ml) for 10 mins 
Remove NaOH. Discard 1.6ml, but retain 0.4 ml for the oestrogen fraction* 
Dry ether over sodium sulphate and transfer the diethyl ether to a separate tube  
Extract the sodium sulphate with diethyl ether (2 x 1ml) 
Combine extracts and evaporate to dryness under nitrogen 
 
Silica extraction (6 cc, 500mg): 
Reconstitute the extract in diethyl ether (0.5 ml) and then hexane (0.5 ml)  
Condition with chloroform (5 ml) and then diethyl ether/hexane (1:1; 5 ml) 
Load the sample  
Elute the cartridge with chloroform/ethyl acetate (1:1; 3 ml) 
Dry over sodium sulphate and transfer the chloroform/ethyl acetate to a new tube 
Extract the sodium sulphate with chloroform/ethyl acetate (1:1, 2 x1 ml) 
Combine extracts and evaporate to dryness under nitrogen 
 
Enol-TBDMS Derivatisation: 
Add enol-TBDMS derivatisation reagent (100 l - prepared by mixing 3 ml MTBSTFA, 
1.5 ml DMF, 18 mg ammonium iodide and 30 μl ethane thiol) 
Heat for 1 hour (1,000 C) 
Add methanol (0.5 ml) and water (0.5 ml) 
Extract with hexane (2 x 2ml) 
Combine extracts and evaporate to dryness under nitrogen 
Add 30 ul dried ethyl acetate and vortex  
 
GC-MS/MS Analysis for androgens and progestagens 
 
Fig. 2a – schematic of the androgen/progestagen extraction method. 
* See Fig. 2b for the details of the oestrogen extraction from this point. 
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Extractive derivatisation: 
To the 0.4 ml of 2 M NaOH derived from the androgen/progestagen extraction, add a 
further  1.6 ml of 2 M NaOH 
Rotary mix for 30 mins with 4 ml of 0.175 mg ml-1 dansyl chloride in hexane  
(in darkness) 
Remove the hexane layer and evaporate it to dryness under nitrogen 
Reconstitute in 45 ul of 75:25 acetonitrile:0.1% formic acid (aq) 
 
LC-MS/MS Analysis for oestrogens 
 
Fig. 2b – schematic of the oestrogen extraction method that follows from the 
androgen/progestagen method in Fig. 2a. 
 
 
3.2.4 Method Validation Protocol 
 
The ultimate application of the validated method presented herein will be for analysis of 
steroid concentrations in a large population of animals in order to produce quantitative 
thresholds for detecting steroid abuse. The establishment of each threshold will be 
based on the probability of finding a value above a specified concentration by chance in 
the ‘natural’ population. The statistical model that will be used to produce these threshold 
concentrations is known as the Chebyshev inequality and has been described by Estler 
(1997). Further details of the Chebyshev inequality and its application will be published 
once the population data have been generated.  
 
For the purposes of the current validation in the context of the Chebyshev inequality, the 
most critical aspect is to ensure that the analytical methods are validated to a high level 
of precision and accuracy across a wide range of concentrations, not just at the lower 
limits of detection. Based on previous experience with the use of the Chebyshev 
inequality, it has been observed that the population concentrations toward the upper end 
of the calibration range are the most important parameters affecting the resulting 
thresholds (Roy Macarthur, personal communication). Concentrations around the lower-
limits of detection or quantification have little or no effect on these thresholds (Roy 
Macarthur, personal observation). Therefore, the current method validation protocol was 
designed to fully characterise the performance of the analytical method over a wide 
range of concentrations, rather than focussing on the CCα and CCß at the lower limits of 
detection. However, it will be necessary to calculate the CCα and CCß values at the 
thresholds produced by the Chebyshev method. Because these calculations can only be 
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carried out once these threshold concentrations have been determined, they will be 
published separately once the population studies are complete.  
 
The calculated thresholds are likely to be in significant excess of the upper calibration 
ranges used in the current study. Therefore, although individual laboratories are 
welcome to use the current analytical method to regulate each threshold, they will most 
likely not need to use methods as sensitive or time-consuming as these (which were 
required here in order to define the population values over the whole range of observed 
concentrations). However, it will be essential for them validate their own CCα and CCß 
values around the defined thresholds using whatever analytical methods they choose to 
adopt.   
 
The validation protocol was based on the USA Food and Drug Administration (FDA) 
Centre for Drug Evaluation and Research guidelines for bioanalytical method validation 
(FDA, 2001), with accuracy defined as the degree of bias (% bias) and precision as the 
relative standard deviation (% RSD). In terms of % bias and % RSD acceptance limits, 
the FDA recommended +/- 20% limit for the lower limit of quantification (LLOQ) and +/- 
15% limit for all other concentrations were relaxed to 20 and 25% respectively. This was 
because the assay was considerably more complex than the majority of small molecule 
applications that the FDA guidelines are designed for. These somewhat relaxed limits 
were considered ‘fit-for-purpose’ according to the recommendations for biomarkers of 
Lee et al. (2006), the results of which are taken into account through the application of 
uncertainty of measurement (see later section on statistical analysis). Three separate 
precision and accuracy batches were extracted and analyzed for oestrogens and four 
batches for androgens/progestagens (an additional batch relative to the oestrogens due 
to the increased complexity of the androgen multi-residue GC-MS/MS method) in order 
to determine the inter-batch precision and accuracy, chromatographic separation, 
selectivity, linearity, lower and upper limits of quantification (LLOQ and ULOQ 
respectively) and the limit of detection. Each precision and accuracy batch contained a 
blank sample (extracted bovine urine with no internal standard or analyte added), a 
bovine urine calibration line (as described in the above section) and 5 replicates of each 
of the bovine urine QC concentrations (E, E+25, E+100, E+1,000 and E+2,000 pg ml-1 
for androgens/progestagens and E, E+20, E+80, E+800 and E+1,600 pg ml-1 for 
oestrogens).  
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Stability of the analytes in bovine urine at the E + 1,000 QC (androgens and 
progestagens) and E + 1,600 QC (oestrogens) points was assessed by measuring 
concentrations at 3- and 6-months and comparing the results to those determined at 
time-zero. The ability to dilute samples was assessed by spiking pooled bovine urine 
with concentrations of each steroid at approximately 10 times the middle of the 
calibration range and then performing a 1 in 10 dilution with pooled bovine urine in order 
to bring the resulting concentration of analyte into the workable range.  
 
3.2.5 GC-MS/MS Androgen/Progestagen Method 
 
Nine microlitres of sample was introduced into a Varian 1079 programmable temperature 
vaporiser (PTV) injector held at 125oC for 1.00 min and then ramped to 280oC at a rate 
of 150oC min-1 before being held at 280oC for 13.00 min. The injector split/column flow 
ratio was 20:1 until 1.00 min, when it was immediately reduced to 0:1 and held at this 
ratio until 3.00 min. It was then immediately increased to 50:1 for the remainder of the 
run-time. Chromatography was carried out using a Varian CP-3800 gas chromatograph 
with helium as the carrier gas (1.0 ml min-1) and a 30m x 250 um x 0.25 um Varian VF-
17MS column initially held at 120oC for 2.00 min and then ramped by 50oC min-1 to 
220oC at 4.00 min, a further 4.5oC min-1 to 291oC at 19.78 min, held for 2.00 min, 
ramped by a further 4.5oC min-1 to 300oC at 23.78 and then by 50oC min-1 to 320oC at 
28.18 min. Mass spectrometry was carried out using a Varian 320-MS triple quadrupole 
mass spectrometer operated in the electron ionization (EI) mode. Transfer line 
temperature was 280oC, ion source temperature was 220oC, electron energy was 20 eV 
and electron multiplier voltage was typically 1800 V.  Positive ion MS/MS data was 
acquired in the selected reaction monitoring (SRM) mode using argon as the collision 
gas at a pressure of 1.5 m Torr. The SRM conditions for each compound are given in 
Table 1. 
 
3.2.6 LC-MS/MS Oestrogen Method 
 
15 μl of sample was introduced into an Applied Biosystems Sciex 5000 instrument using 
a Waters Acquity autosampler/HPLC. Chromatography was carried out using a Waters 
100 mm x 2.1 ID 1.8 µm HSS T3 column held at 37OC. Flow rate was 650 μl min-1 and 
mobile phase A was acetonitrile and mobile phase B was 0.1% formic acid in water. 
Mobile phase A was at 76.5% from 0 to 2.90 min, rising to 99% at 2.95 min, held at 99% 
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until 4.60 min, before being reduced back to 76.5% at 4.65 min and then being held at 
76.5% until 5.10 min. 
 
Sample ionisation was carried out in the positive mode using the Turbo Ionspray source 
at a source temperature of 750oC. Ion spray voltage was 4000 V, gas one had a flow of 
30 units, gas two a flow of 70 units, the curtain gas had a flow of 10 units, the CAD gas 
setting was 7 units, declustering potential was 175 V, collision cell exit potential was 22 V 
and entrance potential 10 V. The MS/MS transitions and collision energies are given in 
Table 1. Data was processed using the Analyst version 1.4.2 software. 
 
LC-MS/MS matrix effects were studied by spiking 5 individual bovine urine samples 
(from different animals with varying endogenous epioestradiol concentrations) with 1200 
pg ml-1 epioestradiol and measuring the determined concentration of the analyte after 
subtracting the known endogenous concentration for each sample (determined by 
analysing the urines unspiked alongside the spiked samples). Since the method uses a 
standard addition approach with a deuterated epioestradiol internal standard, the key 
parameter to measure the matrix effect was considered to be a sufficiently low relative 
standard deviation between the individual replicates to ensure that there were no 
differential matrix effects that were not corrected for by the deuterated internal standard.  
 
 
  
Table 1 – GC/LC-MS/MS conditions for the compounds studied. N.B. qualifier transitions were not required for internal standards 
* No qualifier ions could be monitored for epioestradiol as no alternative diagnostic fragments were formed during collision induced dissociation of this 
compound. 
 
 
Steroid (and derivative) 
 
 
Typical 
retention time 
(min) 
 
MS/MS quantifier 
precursor ion m/z 
 
MS/MS quantifier 
product ion m/z 
(collision energy in 
brackets) 
 
MS/MS  
qualifier precursor 
ion m/z 
MS/MS qualifier 
product ion m/z 
(collision energy in 
brackets) 
 
Androgens and progestagens by GC-MS/MS:      
5β-Androstane-3α,17β-diol (bis-TBDMS) 16.8 463.3 (M – 57) 255.1 (10) 463.3 (M – 57) 387.2 (10) 
5α-Estrane-3β,17α-diol (bis-TBDMS) 16.0 449.4 (M - 57) 241.1 (10) 241.2 (M – 265) 145.0 (10) 
Epinandrolone (bis-TBDMS) 18.6 502.4 (M) 445.2 (10) 502.4 (M) 369.2 (13) 
19-Noretiocholanolone (bis-TBDMS) 16.4 447.3 (M – 57) 371.2 (7) 447.3 (M – 57) 239.1 (10) 
17β-Hydroxy-5β-androst-1-ene-3-one  
(bis-TBDMS) 
16.3 516.5 (M) 501.3 (10) 501.5 (M – 15) 369.2 (10) 
Epiboldenone (bis-TBDMS) 16.7 514.5 (M) 248.1 (10) 367.1 (M – 147) 271.0 (10) 
5α-Pregnane-3β,20α-diol (bis-TBDMS) 22.0 491.5 (M – 57) 159.0 (10) 491.5 (M – 57) 283.2 (10) 
D3-Testosterone (bis-TBDMS)  20.0 519.3 (M) 462.4 (10) N/A N/A 
D3-Boldenone (bis-TBDMS) 20.0 517.5 (M) 248.1 (10) N/A N/A 
D3-Androstanediol (bis-TBDMS) 16.5 466.3 (M – 57) 258.2 (10) N/A N/A 
D5-5β-Androstane-3α,17β-diol (bis-TBDMS) 16.7 468.3 (M – 57) 260.2 (10) N/A N/A 
D4-19-Noretiocholanolone (bis-TBDMS) 16.3 451.3 (M – 57) 243.2 (10) N/A N/A 
D4-5α-Pregnane-3β,20α-diol (bis-TBDMS) 21.5 495.4 (M – 57) 162.1 (10) N/A N/A 
 
Epioestradiol by LC-MS/MS:      
*Epioestradiol (dansyl) 2.7 506.2 (M+H) 427.3 (45) *N/A *N/A 
D2-Epioestradiol (dansyl) 2.7 510.2 (M+H of S34 
isotope) 
431.3 (45) N/A N/A 
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3.2.7 Recovery 
 
Since the current method quantifies total ‘free and glucuronide conjugated’ steroid in 
bovine urine and since glucuronide derivatives of the majority of steroids were not 
available as reference standards at the time the work was conducted, it was not possible 
to determine meaningful absolute recoveries for the different steroids. However, 
increasing the amount of β-glucuronidase enzyme above that used in the final extraction 
scheme (Fig. 2) did not increase the yield of metabolites (data not shown), so the 
extraction was considered optimised with respect to glucuronide conjugate hydrolysis.  
 
3.3 Results  
 
All raw data in the following section are uncensored and hence calculated concentrations 
are given to one decimal place. All summary statistics are presented to three significant 
figures. 
 
3.3.1 Chromatography 
 
Complete chromatographic separation was achieved for ABA-estranediol, 19-
noretiocholanolone, epinandrolone, epiboldenone, 17β-hydroxy-androst-1-en-3-one, 
ABA-pregnanediol and epioestradiol in bovine urine (Fig. 4 to 10). In the chromatogram 
for BAB-androstanediol in bovine urine samples, there were a series of three peaks 
close before BAB-androstanediol (Fig. 3). However, these peaks did not reach significant 
enough a size to interfere with the integration of BAB-androstanediol and in all cases the 
‘cleaner’ qualifier ion transition assured the identity of BAB-androstanediol. Interestingly, 
these three earlier running peaks increased and decreased in proportion with the 
endogenous BAB-androstanediol peaks in different urines (but did not increase when 
BAB-androstanediol was artificially spiked into samples), suggesting that these peaks 
are related androstane-metabolite isomers that are produced in synchrony with BAB-
androstanediol.  
 
 
 
 
 
  
   
                                     a                                                                       b                                                                              c 
 
Fig. 3 – chromatograms obtained for BAB-androstanediol at a) the bovine urine pool endogenous concentration (measured at 449.3 pg 
ml-1) b) the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D5-BAB-androstanediol internal 
standard used for this analyte (m/z 468.3 to 260.2). The top BAB-androstanediol trace refers to the quantifier ion (m/z 463.3 to 255.1) 
and the bottom trace refers to the qualifier ion (m/z 463.3 to 387.2).  
  
   
                                     a                                                                           b                                                                             c 
Fig. 4 – chromatograms obtained for ABA-estranediol at a) the bovine urine pool endogenous concentration (measured at 178.7 pg ml-1) 
b) the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D3-androstanediol internal standard 
used for this analyte (m/z 466.3 to 258.2). The top ABA-estranediol trace refers to the quantifier ion (m/z 449.4 to 241.1) and the bottom 
trace refers to the qualifier ion (m/z 241.2 to 145.0).  
 
  
 
                    a                                                                               b                                                                            c 
Fig. 5 – chromatograms obtained for epinandrolone at a) the bovine urine pool endogenous concentration (measured at 81.7 pg ml-1) b) 
the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D3-testosterone internal standard used 
for this analyte (m/z 519.3 to 462.4). The top epinandrolone trace refers to the quantifier ion (m/z 502.4 to 445.2) and the bottom trace 
refers to the qualifier ion (m/z 502.4 to 369.2).  
  
          
                                       a                                                                          b                                                                             c 
 
Fig. 6 – chromatograms obtained for 19-noretiocholanolone at a) the bovine urine pool endogenous concentration (measured at 82.7 pg 
ml-1) b) the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D4-19-noretiocholanolone internal 
standard used for this analyte (m/z 451.3 to 243.2). The top 19-noretiocholanolone trace refers to the quantifier ion (m/z 447.3 to 371.2) 
and the bottom trace refers to the qualifier ion (m/z 447.3 to 239.1).  
  
 
                                  a                                                                                 b                                                                             c 
Fig. 7 – chromatograms obtained for 17β-hydroxy-5β-androst-1-en-3-one at a) the bovine urine pool endogenous concentration (no 
peak) b) the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D3-androstanediol internal 
standard used for this analyte (m/z 466.3 to 258.2). The top 17β-hydroxy-5β-androst-1-ene-3-one trace refers to the quantifier ion (m/z 
516.5 to 501.3) and the bottom trace refers to the qualifier ion (m/z 501.5 to 369.2).  
 
  
   
         a                                                                    b                                                                     c 
Fig. 8 – chromatograms obtained for epiboldenone at a) the bovine urine pool endogenous concentration (measured at 55.9 pg ml-1) b) 
the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D3-boldenone internal standard used for 
this analyte (m/z 517.5 to 248.1). The top epiboldenone trace refers to the quantifier ion (m/z 514.5 to 248.1) and the bottom trace refers 
to the qualifier ion (m/z 367.1 to 271.0).  
 
  
   
          a                                                                               b                                                                             c 
Fig. 9 – chromatograms obtained for ABA-pregnanediol at a) the bovine urine pool endogenous concentration (measured at 1168.5 pg 
ml-1) b) the upper limit of quantification (an E + 3,000 pg ml-1 spiked calibration line sample) and c) the D4-ABA-pregnanediol internal 
standard used for this analyte (m/z 495.4 to 162.1). The top ABA-pregnanediol trace refers to the quantifier ion (m/z 491.5 to 159.0) and 
the bottom trace refers to the qualifier ion (m/z 491.5 to 283.2).  
 
  
   
 
  a                                                                               b                                                                             c 
 
 
Fig. 10 – chromatograms obtained for epioestradiol (m/z 506.2 to 427.3) at a) the bovine urine pool endogenous concentration 
(measured at 475.1 pg ml-1) b) the upper limit of quantification (an E + 2,000 pg ml-1 spiked calibration line sample) and c) the D2-
epioestradiol internal standard used for this analyte (m/z 510.2 to 431.3 – monitoring the S34 isotope in order to avoid the interference 
caused by the S34 isotope of epioestradiol-dansyl). No qualifier ions could be monitored for epioestradiol as no alternative diagnostic 
fragments were formed during collision induced dissociation of this compound.  
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3.3.2 Selectivity  
 
In addition to the chromatographic separation, selectivity was assessed through 
monitoring the ratio of two separate MS/MS transitions for each steroid (with the 
exception of epioestradiol, for which a second selective transition could not be found). 
The matching transition ratios for these steroids support the suggestion that the 
endogenous peaks found in the bovine samples relate to the analytes in question (Fig. 3 
to 10). The only exception was for 17β-hydroxy-androst-1-en-3-one, where no 
endogenous peaks were detected.  
 
3.3.3 LC-MS/MS Matrix Effects 
 
After correcting for the known endogenous concentration for each of the 5 individual 
bovine urines spiked with epioestradiol at 1200 pg ml-1, the % bias and % relative 
standard deviations were 0.948 and 10.3% respectively, indicating that there were no 
significant matrix effects that the deuterated internal standard did not correct for. 
 
3.3.4 Calibration Line Linearity  
 
The calibration curves (weighted 1/x) were linear over the range studied (from E to E + 
3,000 pg ml-1 for all steroids other than 17β-hydroxy-androst-1-en-3-one, which was 
linear from 250 to 3,000 pg ml-1). R2 values were greater than 0.99, intercepts were 
minimal relative to the y axes scale and all back-calculated concentrations were within 
+/- 20.0% of the nominally spiked concentrations  (+/- 25.0% at the LLOQ; based on the 
FDA guidelines, as discussed earlier) (Table 2) . 
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Table 2 –calibration line results (mean values of n=4 for androgens/progestagens and 
n=3 for oestrogens). 
 
 
Analyte  
(all weighted 1/x) 
 
R2 
 
 
Slope 
 
Intercept 
 
Response factor 
RSD (%) 
 
BAB-Androstanediol 0.994 1.97 x 10-3 -8.00 x 10-4 5.98 
ABA-Estranediol  0.998 3.67 x 10-3 6.27 x 10-3 5.78 
Epinandrolone  0.997 1.20 x 10-3 -8.03 x 10-3 6.84 
19-Noretiocholanolone  0.994 2.93 x 10-3 1.04 x 10-2 8.31 
 
17β-Hydroxy-5β-
androst-1-ene-3-one  
 
0.994 
 
1.61 x 10-4 
 
1.23 x 10-3 
 
11.9 
Epiboldenone  0.998 1.50 x 10-3 5.60 x 10-3 7.41 
ABA-Pregnanediol  0.994 2.70 x 10-3 0.125 5.53 
     
Epioestradiol 0.996 3.82 x 10-2 1.50 5.92 
 
 
3.3.5 Precision and Accuracy 
 
Inter-batch precision and accuracy were good, with bias (% bias) and relative standard 
deviations (% RSD) generally within 20% (Table 3). The only instances where values fell 
outside of +/- 20% were for 19-noretiocholanolone, where the % bias of the endogenous 
(E) QCs was  -20.9% and the RSD of the E+25 QCs was 20.5%, and for epiboldenone 
where the RSD of the E QCs was 27.4%. In each of these cases, the reason that these 
values were outside the desired 20.0% (based on the FDA guidelines, as discussed 
earlier) was because of the limiting sensitivity at these low concentrations. Since 
uncertainty of measurement will be factored into any real-life utilization of the methods 
presented, the only practical significance of these low-concentration deviations from the 
desired 20.0% bracket will be an increase in the uncertainty associated with any results 
generated. Since the difference between the concentrations of 19-noretiocholanolone 
and epiboldenone in the urine from untreated and steroid treated animals is expected to 
be several orders of magnitude, the slight increase in uncertainty of measurement that 
will result for these analytes is not expected to have a significant impact on any resulting 
concentration thresholds for detecting steroid abuse once these methods are applied.  
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3.3.6 Linearity of Dilution 
 
Results of QC samples diluted 1 in 10 from above the calibration range were acceptable, 
with % bias being less than 15.0% in each case (Table 4). 
 
3.3.7 Limits of Quantification (LOQ) and Detection (LOD) 
 
The limit of quantification was defined by the lowest point on the bovine urine calibration 
curve that could be quantified with a % bias and % RSD of less than 25.0% (based on 
the FDA guidelines, as discussed earlier) (Table 5). The limits of detection were 
calculated using the endogenous bovine QCs analyzed during the validation. The mean 
S:N of the peaks in these samples were used to extrapolate to the limits of detection at a 
S:N of 3:1 (Table 5). 
 
3.3.8 Matrix Stability 
 
All analytes were found to be stable in urine at -80oC during the 6-months period studied 
(within +/- 20.0% of time-zero values at all subsequent time-points studied). 
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Table 3 – inter-batch precision and accuracy QC results (n=20 at each level for 
androgens/progestagens and n=15 at each level for epioestradiol).  
* The nominal value for the endogenous QCs was the mean of the determined 
concentrations in the endogenous QCs in the first of the precision and accuracy 
validation batches. The nominal value for the remainder of the QCs was this endogenous 
concentration plus the known spiked amount on top of this number i.e. endogenous + 
100 pg ml-1  for LOW QCs. 
 
 
All concentrations  
are in pg ml-1 
Endogenous 
QCs 
(E) 
Endogenous 
+  
25 pg ml-1 
QCs (E+25) 
Endogenous 
+  
+ 100 pg ml-1 
QCs (E+100) 
Endogenous +  
1,000 pg ml-1 
QCs (E+1,000) 
Endogenous +  
2,000 pg ml-1 
QCs (E+2,000) 
BAB-Androstanediol      
Nominal conc.* 449.3 474.3 549.3 1,449.3 2,449.3 
Measured mean 461.2 505.7 559.7 1,433.9 2,340.6 
% RSD 9.56 12.6 9.85 6.22 6.17 
% Bias 2.66 6.63 1.90 -1.06 -4.44 
ABA-Estranediol      
Nominal conc.* 178.7 203.7 278.7 1,178.7 2,178.7 
Measured mean 176.4 202.3 275.0 1,245.3 2,179.2 
% RSD 9.06 8.34 6.41 3.15 5.63 
% Bias -1.26 -0.651 -1.32 5.65 0.026 
Epinandrolone      
Nominal conc.* 81.7 106.7 181.7 1,081.7 2,081.7 
Measured mean 87.6 109.3 186.6 1,154.0 2,118.5 
% RSD 15.3 19.0 15.3 6.11 6.25 
% Bias 7.21 2.47 2.68 6.68 1.77 
19-
Noretiocholanolone 
     
Nominal conc.* 82.7 107.7 182.7 1,082.7 2,082.7 
Measured mean 65.4 92.2 163.1 1,109.7 2,042.2 
% RSD 19.1 20.5 11.5 8.76 11.3 
% Bias -20.9 -14.4 -10.7 2.49 -1.95 
17β-Hydroxy-5β-
androst-1-en-3-one 
     
Nominal conc.* < LOD < LOD < LOD 1,000 2,000 
Measured mean < LOD < LOD < LOD 1,042.9 1,994.6 
% RSD < LOD < LOD < LOD 10.1 8.84 
% Bias < LOD < LOD < LOD 4.29 -0.268 
Epiboldenone      
Nominal conc.* 55.9 80.9 155.9 1,055.9 2,055.9 
Measured mean 65.0 93.8 166.3 1,142.2 2,087.8 
% RSD 27.4 13.9 17.1 8.19 5.34 
% Bias 16.4 16.0 6.71 8.17 1.55 
ABA-Pregnanediol      
Nominal conc.* 1,168.5 1,193.5 1,268.5 2,168.5 3,168.5 
Measured mean 991.2 1,011.7 1,022.9 1,935.1 2,830.6 
% RSD 16.1 18.8 11.0 10.1 8.54 
% Bias -15.2 -15.2 -19.4 -10.8 -10.7 
Epioestradiol (E) (E+20) (E+80) (E+800) (E+1,600) 
Nominal conc.* 475.1 495.1 555.1 1,275.1 2,075.1 
Measured mean 444.1 469.8 528.2 1,274.0 2,108.0 
% RSD 7.06 8.17 6.62 7.03 7.55 
% Bias -6.54 -5.11 -4.85 -0.088 1.58 
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Table 4 – results of the 1 in 10 dilution QCs.  
 
* Because of the endogenous contribution in the urine used for dilution, in order to 
compare the % bias of the measured concentrations in the diluted samples compared to 
the nominally spiked concentration, it was necessary to adjust the measured values for 
the endogenous contribution. This was achieved by subtracting the endogenous 
concentration of the diluting matrix (as measured by the mean of five endogenous QCs 
run in this batch) from the dilution QC measured value and then multiplying the result by 
the dilution factor of 10.   
 
 
All concentrations  
are in pg ml-1 
 
 
Measured concentration  
after 1 in 10 dilution  
 
*Adjusted concentration 
relative to the nominally 
spiked concentration of 
16667 pg ml-1  (12,000 for 
epioestradiol) 
BAB-Androstanediol   
Measured mean 1,828.4 14,185.0 
% RSD 5.07 6.54 
% Bias N/A -14.9 
ABA-Estranediol   
Measured mean 1,902.4 17,258.7 
% RSD 4.23 4.67 
% Bias N/A 3.55 
Epinandrolone   
Measured mean 1,769.0 17,145.5 
% RSD 4.84 5.00 
% Bias N/A 2.87 
19-Noretiocholanolone   
Measured mean 1,652.4 15,949.7 
% RSD 10.1 10.4 
% Bias N/A -4.30 
17β-Hydroxy-5β-androst- 
     1-ene-3-one 
  
Measured mean 1,418.4 14,184.0 
% RSD 11.5 11.5 
% Bias N/A -14.9 
Epiboldenone   
Measured mean 1,811.6 17,388.5 
% RSD 7.50 7.82 
% Bias N/A 4.33 
ABA-Pregnanediol   
Measured mean 2,227.2 14,691.7 
% RSD 3.62 5.49 
% Bias N/A -11.9 
Epioestradiol   
Measured mean 1,824.0 13,400.0 
% RSD 7.85 10.7 
% Bias N/A 11.7 
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Table 5 – calculated limits of detection and limits of quantification for the different 
analytes. 
 
* The limit of detection was calculated by taking the mean signal to noise ratio of the 
endogenous peaks determined during the validation and extrapolating these ratios to 
give the concentration that would lead to a signal to noise ratio of 3:1. In the case of 17β-
hydroxy-5β-androst-1-ene-3-one, the calculation was based on the 250 pg ml-1 calibrants 
since no endogenous peaks were present.  
 
** The limit of quantification is given as the endogenous concentration calculated during 
batch 1 of the validation. In the case of 17β-hydroxy-5β-androst-1-ene-3-one, the limit of 
quantification is given as the lowest calibrant that can be quantified with a % bias of 
<25.0%. Although these values are the formal limits of quantification, because this 
method uses a standard addition approach, the true limits of quantification may in some 
cases be much lower than those given above.  
 
 
Steroid 
 
Calculated Limit of 
Detection (pg ml-1)* 
 
 
Limit of Quantification 
(pg ml-1)** 
 
BAB-Androstanediol  
94.1 
 
449.3 (endogenous) 
ABA-Estranediol  10.9 178.7 (endogenous) 
Epinandrolone  19.8 81.7 (endogenous) 
19-Noretiocholanolone  32.4 82.7 (endogenous) 
 
17β-Hydroxy-5β-androst-1-ene-3-one 
 
160.7 
250 (not detected  
endogenously) 
Epiboldenone  10.5 55.9 (endogenous)  
ABA-Pregnanediol  12.2 1,168.5 (endogenous) 
Epioestradiol 14.8 475.1 (endogenous) 
 
 
3.4 Discussion 
 
The present study provides a convenient method of quantifying ‘endogenous’ urinary 
steroids of a wide range of structures using techniques that are available in most drug 
residue surveillance laboratories. The extractive dansylation of oestradiol away from the 
androgens/progestagens in particular is useful since it prevents the need for a second 
aliquot of urine and also enhanced sensitivity. The use of an enol-TBDMS derivatisation 
approach prior to the GC-MS/MS analysis of the androgens and progestagens was 
found to be useful for analyzing reduced steroids, since they tend to fragment more 
extensively when analysed as enol-TMS derivatives; hence limiting the sensitivity 
compared to the enol-TBDMS version (James Scarth, personal observation). 
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The methods presented above are, for some steroids, more sensitive than previous 
studies (discussed further in chapter 7), allowing the demonstration that all of the 
targeted analytes, with the exception of 17β-hydroxy-5β-androst-1-ene-3-one, were 
endogenous in the pool of bovine steer urine (Table 5). The fact that epioestradiol, ABA-
pregnanediol and BAB-androstanediol were detected endogenously is not surprising 
since oestradiol, testosterone and progesterone are generally regarded as ubiquitous 
among male and female mammals; being produced by intact animal’s gonads and in 
castrated animals through adrenal biosynthesis (Hadley and Levine, 2006). Somewhat 
lower in concentration were the nandrolone metabolites epinandrolone, ABA-estranediol 
and 19-noretiocholanolone (Table 5). Epinandrolone is known to be produced by 
pregnant bovine animals at the end of gestation (De Brabander et al. 1994) and, as 
discussed in chapter 1, by injured animals. However, in contrast to previous published 
studies (McEvoy et al. 1999), the current research has demonstrated that epinandrolone, 
19-noretiocholanolone and ABA-estranediol are also endogenous in uninjured castrated 
male animals, albeit at relatively low concentrations. Both boldenone and epiboldenone 
have been shown previously to be endogenous in certain sub-populations of animals (De 
Brabander et al. 2004), although it is not certain exactly what the source of these 1-
dehydro-steroids are and what conditions lead to their presence (Scarth et al. 2009). As 
discussed further in chapter 1, one theory is that they are produced by microbial 
transformation of other steroids present in faeces, which is why the EU guidelines 
require that sampling be performed without faecal contamination (European 
Commission, 2003). Results from the current study show that while epiboldenone itself 
was present at low concentrations in a pool of bovine steer urines, the reduced 
metabolite 17β-hydroxy-5β-androst-1-ene-3-one was not detectable above the limit of 
detection and may therefore be useful in detecting boldenone abuse (Table 5).  
 
Since it is known that the majority of endogenous steroids in the bovine are excreted 
predominantly as glucuronide conjugates (Scarth et al. 2009), the current method used 
selective glucuronide conjugate hydrolysis using recombinantly produced β-
glucuronidase enzyme to measure the concentrations of combined free and glucuronide 
versions of all steroids. This is an important point of clarification, since the use of 
alternative methods that hydrolyse all steroid conjugates present (therefore including 
sulphates) may in theory lead to higher determined concentrations than those reported 
herein. In the future, when applying any thresholds determined using this currently 
reported method, it will be necessary for laboratories to determine ‘free and glucuronide’ 
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concentrations in order to ensure that their results are applicable to the method used to 
set the thresholds. The methods above have since been applied to urine samples from a 
large population of untreated male and female animals, the results of which will be 
published separately in due course. 
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4.1 Drug metabolism in the equine 
 
An appreciation of the pathways of drug metabolism and the underlying enzymology is 
important in the veterinary industry in predicting the toxicology or pharmacology of new 
chemical entities. It is also important in the horseracing and food production industries in 
order to target the relevant metabolites for the detection of drugs of abuse. The majority 
of the published literature on metabolism in the equine derives from studies looking at 
the detection of drug abuse in horseracing, with a much smaller proportion originating 
from studies aimed at targeting molecular enzymology aspects for veterinary drug 
development purposes. However, horses are also considered food-producing animals in 
some countries, which impacts on therapeutic drug usage patterns (and hence 
metabolism research) due to legislations regarding the residues of veterinary drugs 
entering the food chain (EU Council Directive 96/23/EC). Much of the published equine 
drug metabolism literature is unavailable to the general scientific public because it is has 
largely been published in the proceedings of the International Conference of Racing 
Analysts and Veterinarians (ICRAV), which is not searchable on sites such as Scopus or 
Medline. The following chapter will serve to introduce the topic of equine drug 
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metabolism, before highlighting issues surrounding the detection of ‘designer’ steroids 
(with particular reference to detection of steroid abuse within horseracing). In order to put 
the following equine information into context, some comparisons of metabolism with the 
human, bovine and porcine will also be given. These species were chosen because they 
represent animals of particular interest within competitive sport and food production. 
 
 
4.1.1 The equidae family  
 
The term equine itself encompasses all species of animal within the equidae family. The 
major extant species within the equidae family fall into one genera (Equus). Most 
members of the equidae family are able to interbreed and produce viable offspring, 
although these are almost always sterile (Skelton, 2000). The horse (Equus caballus) is 
now virtually extinct naturally in the wild but survives in large numbers in human captivity 
and in some feral populations that have developed on several continents. Due to the 
selective breeding of horses by humans that has been occurring for thousands of years, 
distinct breeds have become apparent. For example Shire horses have been selected for 
their strength and ability to do work, while Thoroughbreds have been bred for their speed 
(Budiansky, 1998).   
 
The Thoroughbred is one of the oldest pedigrees with records spanning three centuries 
and is of particular importance in horseracing. A feature of this breed is the narrow 
genetic variation with ten founder females accounting for 72% of maternal lineages and 
one founder stallion being responsible for 95% of paternal lineages (Cunningham et al. 
2001). Genetic variability, measured as average heterozygosity, is significantly lower in 
Thoroughbred horses (H=0.353 +/- 0.065) than in Argentine Creole horses (H=0.585 +/- 
0.131) (Diaz et al. 2002). This narrow genetic stock of thoroughbreds may therefore be 
expected to lead to reduced polymorphism in many characters when compared to other 
breeds.  
                          
The differences that exist in overall morphology between horse breeds may also be 
relevant to aspects of drug metabolism. As an example, it has been reported that 
significant differences in the pH of Standardbred and Thoroughbred horse urine exist 
and that this could be expected to lead to the differential excretion of some drugs 
(Stanley et al. 1996). Thoroughbred urine showed a bimodal distribution with a major 
Review: equine steroid metabolism and detection 
167 of 331 
peak at pH 5.5 and a minor peak at pH 8.0 while Standardbreds had a single peak at pH 
8.0.  
 
Donkeys are closely related to the horse (a domestic breed of the species Equus asinus) 
and a notable difference between the two species is the increased ability of donkeys to 
survive large losses in body water (Lizarraga et al. 2004). Only a very small amount of 
qualitative literature is available for the donkey and comparisons are mainly based on 
pharmacokinetics of the parent drug. Although the clearance of some drugs such as 
caffeine show similar excretion profiles between the two species, donkeys generally 
have a much greater capacity for drug metabolism. The clearance of phenylbutazone for 
example has been shown to be between 5 and 15 times higher in donkeys than in 
horses (Lizarraga et al. 2004).   
 
Several gross physiological factors may lead to differences in drug metabolism between 
the equine, bovine, porcine and human. The diet of the four species is different; humans 
and porcine animals are typically omnivores, while equine and bovine species are 
herbivores (Kararli, 1995, Budiansky, 1998). Bovine animals are foregut fermenters and 
possess a large rumen, while equine animals are hindgut fermenters and have a more 
developed caecum with a rich flora of microorganisms that potentially contribute to the 
metabolism of a drug (Bailey et al. 2002). A particular feature of the equine caecal flora 
is that they are known to produce relatively large quantities of monoamines, which are 
absorbed into the bloodstream and have the potential to influence a number of 
physiological variables (Bailey et al. 2002 and Elliot et al. 2003).  The porcine caecum is 
reduced in size compared to that of the equine, while it is almost completely regressed in 
humans (Kararli, 1995). Another feature of the equine is the capacity of its spleen to 
sequester red blood cells in times of inactivity or, conversely, to expel red blood cells into 
the circulation during periods of stress or exercise. The equine’s huge spleen can alter 
the red blood cell content of blood by up to 50%, which may have evolved as an 
adaptation to exercise in this species (Stewart and McKenzie, 2002). The spleens of 
many other species, however, are relatively much smaller and have a significantly 
reduced capacity for altering blood volume. The potential for massive changes in blood 
volume in the equine depending on the exercise and/or excitation status of the animal 
has obvious implications for variations in the pharmacokinetics of drugs. 
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4.1.2 Methods used for studying drug metabolism in the equine 
 
Studies on drug metabolism in equine species have been confined to Equus caballus 
(horses) and Equus asinus (asses and domestic donkeys). Within these studies, there 
exists a large body of in-vivo and a very much smaller body of in-vitro drug metabolism 
literature. Unless specified otherwise, all studies reviewed from this point onwards were 
carried out using Equus caballus species. A specific breed will only be referred to when 
there exists a point of comparison with another breed or sub-species. 
 
A large proportion of the published data on drug metabolism in the horse relates to the 
detection of drug abuse. Although an understanding of enzymology would help in 
analysing data, it has is not been the primary aim of these studies, which therefore 
leaves many questions about the underlying biology unanswered.  
 
 
4.1.2.1 Analytical techniques for studying equine drug metabolism 
 
In general, unless an authentic commercial reference standard is available or is easily 
synthesized, the structures of equine metabolites in surveillance research studies are 
generally inferred from their analytical behaviour or through comparison with known 
metabolic information from other species. The analytical techniques used for the actual 
metabolite identification have evolved significantly over the last 50 years. Initially, thin 
layer chromatography-fluorescence detection (TLC-FL), often using radio-labelled drug 
as tracers or to provide quantitative data, were very popular techniques (Moss and 
Rylance, 1967). While TLC-FL based detection has now largely been superseded, a 
minority of laboratories still use some TLC-FL for screening or confirmation of specific 
substances. High-performance liquid-chromatography linked to ultraviolet detection 
(HPLC-UV) was very popular until the 1980s/1990s (Limbrey and Chapman, 1983), after 
which gas chromatography and then liquid-chromatography linked to mass spectrometry 
(GC- and LC-MS respectively) became the techniques of choice (McKinney 2009, Teale 
and Houghton, 2010, Scarth et al. 2010a). While immunoassay techniques can be very 
useful for drug screening, they are generally of less use when it comes to performing 
metabolism studies as they provide little information on the structure of the metabolites. 
Nuclear magnetic resonance (NMR) analysis has occasionally been used to definitively 
identify metabolites (Pearce and Lushnikova, 2006), but this typically requires extensive 
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purification of large sample volumes and thus takes a significant amount of time and 
money and is not always feasible. 
 
Although there has been a major shift from GC-MS to LC-MS in the past decade, GC-MS 
has remained an important tool because certain compounds, especially saturated steroid 
metabolites, suffer from poor ionisation properties under the atmospheric pressure 
ionisation conditions of LC-MS (McKinney et al. 2009, Teale and Houghton, 2010). The 
ability of many modern instruments to carry out MSn experiments makes them 
particularly useful for identifying metabolites. Especially feasible are triple quadrupole 
instruments useful since they allow a combination of full scan MS, selected reaction 
monitoring (SRM), product ion scanning and more generic neutral loss or precursor ion 
scans to be performed; each with their own benefits depending on the type of study 
involved. For both GC- and LC-MS, the availability of deuterated or other labelled 
analogues of the drug can significantly aid the metabolite identification process, both in 
terms of the ‘shift’ technique (Scarth et al. 2010b) and the observation of peak doublets if 
a mixture of labelled/unlabelled versions of the drug is administered (Samuels et al. 
1998). While selective derivatisation procedures prior to GC-MS analysis have been 
used as aid in the structural elucidation process for several decades, the application of 
derivatisation to LC-MS structural elucidation has been more recent. Also, the recent 
emergence of higher resolution LC equipment allowing the use of sub-2 m particle 
sizes and high flow rates means that metabolites with similar molecular masses and 
retention times can now be more easily resolved and that analytical run times are shorter 
(Plumb et al. 2009). 
 
Most recently, robust high-resolution-accurate-mass LC-MS (HR-LC-MS) systems 
operating at an increased level of resolution, typically ranging between 7,500 and 
100,000 full width at half maximum height (FWHM) depending on the type of mass 
analyser employed, and have started gaining popularity for sports drug surveillance 
screening and research (Virus et al. 2008, Scarth et al. 2010a). Because the data 
acquired are full scan analyses of intact [M+H]+ or [M-H]- species at very high resolution, 
the results can be analysed using statistical packages designed to pick out subtle 
differences between pre and post-administration samples. Some systems also allow in-
source or collision activated dissociation to be performed; with the result that the 
accurate mass assignments of the fragment ions can significantly aid the structural 
elucidation process. Further advantages of using HR-LC-MS include the ability to 
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retrospectively analyse data once new information comes to light and the extended 
analyte coverage through the use of full scan MS. 
 
In light of the fact that equine drug metabolism studies rarely utilize radiolabelled dosing 
(discussed further below), it is important to design sample preparation, extraction and 
analysis techniques that are not optimized too specifically on the ‘parent’ drug as 
metabolites often differ significantly in their behaviour.  For these reasons, the best 
designed equine studies typically involve the use of sequential or parallel sample 
preparation, extraction, and analysis steps in order to encompass e.g. the extremes of 
polarity, ionic nature, volatility, phase two conjugation, metabolite lability to temperature 
and pH (Wynne et al. 2004). A particular feature of equine urine, which impacts on the 
choice of sample preparation or extraction technique, is its wide range of pH, which is 
affected by factors such as diet and exercise (Woods et al. 1990). Also, equine plasma 
contains relatively high esterase activity, so it is important to consider whether any 
metabolites detected in the matrix are authentic or artefacts (Scarth et al. 2010a).  
 
A particularly important consideration regarding sample preparation relates to the 
hydrolysis of urine samples prior to extraction to cleave the phase two conjugates. While 
this is generally beneficial in the extraction and analysis of the drugs, it means that the 
mode of conjugation is often undetermined. This is not always the case, however, and 
selective hydrolytic procedures or LC-MS techniques have sometimes been able to 
determine the nature of a conjugate. The conjugation pathways for endogenous and 
exogenous steroids in the horse, for example, are particularly well characterised 
(Houghton, 1992). The particular method used for hydrolysing phase two conjugates 
prior to analysis is of critical importance in measuring the metabolite profile. For 
example, recombinantly produced β-glucuronidase from E. coli is relatively selective for 
hydrolysing glucuronides, whereas β-glucuronidase from Helix pomatia also contains aryl 
sulphatase and other enzymes leading to hydrolysis of some aromatic sulphates and 
various phase one reactions (Houghton et al. 1992). Simultaneous hydrolysis of 
glucuronide and sulphate conjugates is possible using strongly acidified methanol 
(methanolysis), although the harsh conditions may lead to losses or by-products (Gomes 
et al. 2009). At present, there are very few drug screening assays based on the analysis 
of intact phase two conjugates (Lampinen-Salomonsson et al. 2006, Grace et al. 2008). 
This may be partly due to a lack of reference standards for equine phase two 
metabolites, but also because they are not generally suitable for analysis by GC-MS. 
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However, the combination of LC-MS analysis with in vitro production of conjugated 
metabolites may now allow the development of intact phase two conjugate screening 
assays on a larger scale. This would be advantageous since it could in theory 
significantly reduce the amount of sample preparation required and, in the case of 
urinary steroid metabolites, mean that they could be detected efficiently using 
electrospray ionization. 
 
4.1.2.2 In vivo equine metabolism studies 
 
The most comprehensive in vivo metabolism studies involve the administration of a 
radiolabelled analogue of the drug in order to trace its fate with maximum certainty. This 
offers several benefits including; the ability to study the mass balance of the drug in 
different excreted products, the ability to focus the analysis on sample fractions 
containing increased levels of radioactivity and to ensure the suitability and high recovery 
of sample preparation and extraction techniques as an analytical aid (Seymour et al. 
1990). The drawbacks of radiolabelled studies are the cost of preparing the material, the 
ethical considerations regarding the administration of radioactivity, the requirements for 
specialized analytical equipment and the precautionary measures in handling and 
disposing of the samples (especially when dealing with large animals such as horses). In 
drug surveillance laboratories the number of radiolabelled in vivo equine metabolism 
studies is limited and reducing in frequency, whereas they appear to have been carried 
out during veterinary drug development as a convenient way to study the mass balance 
and pharmacokinetics. 
 
With regard to in vivo drug administration studies in drug surveillance research, the 
range of studied matrices generally mirrors the most suitable ones for routine testing. 
Equine urine has been the most extensively studied matrix to date; partly because of its 
applicability to post-race testing protocols, but also because it typically contains a much 
higher proportion of metabolites than plasma. Other matrices that have been studied 
include faeces (Popot et al. 2004, Popot et al. 2006), hair (Dunnett et al. 2005) and 
saliva (Horner, 1976). Although not typically containing as large a proportion of 
metabolites as urine or faeces, blood analysis is gaining importance due to its ease and 
speed of collection during training or pre-race, a general requirement for less sample 
purification compared to urine and a greater relevance of the observed parent drug 
concentrations to evaluation of their pharmacological effect (Kwok et al. 2010). There are 
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also regional differences, such that testing protocols in the USA place greater emphasis 
on blood analysis compared to some other parts of the world (Arthur, 2008). 
 
4.1.2.3 In vitro equine metabolism studies 
 
While in vivo metabolism studies are the mainstay of equine metabolism research, the 
use of in vitro techniques utilising ex vivo liver or lung preparation is gaining popularity 
(Scarth et al. 2010a). In vivo experiments have the advantage that the whole plethora of 
possible transformation can be considered and allows the most representative picture of 
the situation for real-life samples. However, in vivo experiments require animal 
experimentation and hence there are additional ethical considerations and significant 
resource requirements. Also, the identification of drug metabolites in urine is often 
complicated by the presence of interferences, the timescales of the experiments are 
relatively long, compounds without previously defined toxicological profiles such as 
‘designer’ drugs cannot be easily studied for ethical reasons and it is difficult to carry out 
mechanistic studies such as the identification of the enzymes responsible for 
metabolism. By comparison, in vitro methods do not require animal experimentation, 
although there can be ethical issues related to the supply of tissues, can be carried out 
quickly, produce a ‘cleaner’ extract for analysis, can be used to study ‘designer’ drugs 
(discussed further later in this chapter) and can be more easily tailored to study 
mechanistic aspects (Scarth et al. 2010a). Some of the disadvantages of using in vitro 
methods include the lack of an intact biological system and the inability to generate 
quantitative in vivo / in vitro correlation. It is therefore important to recognize these 
limitations as well as the advantages.  
 
In vitro studies are used in equine surveillance laboratories to complement the in vivo 
studies (Ho et al. 2005, Ho et al. 2007a and b, Kwok et al. 2006, Scarth et al. 2010a), but 
proportionally more in vitro studies have been conducted in the veterinary arena, where 
they are useful e.g. in determining possible routes of metabolism. Of the published 
equine drug surveillance studies, in vitro techniques have been used to study the 
biosynthetic pathways of C18 androgens in testicular tissue [Smith et al. 1987] and the 
B-ring unsaturated oestrogens in placental tissue [Marshall et al. 1989]. More recently, 
equine liver microsomes have been used to study the phase one metabolism of the 
anabolic-androgenic steroids clostebol acetate and mesterolone [Ho et al. 2007b], 
methenolone acetate [Ho et al. 2005], turinabol [Ho et al. 2007a], a range of designer 
Review: equine steroid metabolism and detection 
173 of 331 
steroids [Kwok et al. 2006] and the non-steroidal anti-inflammatory drug phenylbutazone 
[Stanley and Whitley 2006]. Most recently, two equine cytochrome P450 (CYP) enzyme 
isoforms, named CYP2D50 and CYP2C92, have for the first time been sequenced and 
their activity compared to human CYP2D and CYP2C isoforms (DiMaio Knych et al. 
2008, DiMaio Knych et al. 2009). 
 
In vitro technologies have to date been somewhat more widely applied in the human 
sports field (for example Levesque et al. 2005 and Gauthier et al. 2009). Several authors 
have also reported the scaling up of in vitro conditions to allow the production and 
purification of mg quantities of human phase one [Lehnmen et al. 1981, Vail et al. 2005] 
and phase two (Kuuranne et al. 2002, Kuuranne et al. 2003 Jäntti et al. 2007, Hintikka et 
al. 2008) drug metabolites, thus enabling characterisation using techniques such as 
NMR. These approaches often require the use of recombinantly expressed enzymes or 
tissue from animals that have been administered enzyme inducing chemicals. Since 
there are currently no recombinantly expressed equine drug metabolizing enzymes 
available and because there are ethical issues surrounding the administration of enzyme 
inducing chemicals to horses, these approaches are less viable in the horseracing 
industry. Other factors that have limited the use of in vitro technologies in equine drug 
surveillance include the availability of equine tissues and a limited knowledge of the 
application of in vitro techniques.  However, equine tissues are now becoming more 
readily available from specialist suppliers and there is increasing demand from many 
angles to reduce the use of animals in experimentation. The increased usage of HR-LC-
MS also provides a strong incentive to utilize in vitro methods for studying drug 
metabolism. The technique not only provides a powerful tool for the rapid interpretation 
of drug metabolism but is also increasingly used as a screening technique within drug 
control laboratories. Where only knowledge of the qualitative profile of metabolites is 
required it is relatively straight forward to insert the relevant masses and retention times 
into a detection database, in-vitro techniques are ideally suited to this application (Scarth 
et al. 2010a). 
 
In order to confirm the presence of a metabolite in the case of a positive drug finding it is 
necessary to compare the mass spectral and chromatographic performance of the 
analyte against a standard material. Currently in this situation, International Laboratory 
Accreditation Cooperation-G7 guidelines on the ‘Accreditation Requirements and 
Operating Criteria for Horseracing Laboratories’ [ILAC-G7, 2009] allow the use of in vivo 
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urine/plasma samples resulting from a drug administration as qualitative reference 
material. However, this is not ideal as it requires animal experimentation. In 2009, a new 
revision of the ILAC-G7 guidelines (ILAC-G7, 2009) stated for the first time (article 16.4) 
that in vitro incubations can now be used in place of in vivo post-administration samples. 
It is important to stress that under the ILAC-G7 guidelines, it is not necessary to produce 
large quantities of in vitro metabolite that can be isolated and subject to NMR. As with 
the existing in vivo post-administration paradigm, it is simply necessary to demonstrate 
that the analytical data are sufficient to fully justify the compound’s identity as a 
metabolite by demonstrating the presence of a diagnostic analyte spectrum in post-
administration samples but not in pre-dose samples or blanks. It is therefore envisaged 
that a major benefit of in-vitro methods will be to provide reference materials where no 
‘parent’ drug can be detected and for which no chemically synthesized metabolite 
reference standard is available. 
 
4.2 Metabolism of anabolic-androgenic steroids in the equine  
 
Because of their importance as ergogenic drugs of abuse within the horseracing industry 
and due to their involvement in equine reproduction, steroid metabolism has received 
more focus in the equine than any other class of compounds. Anabolic-androgenic 
steroids are banned under Federation Equestre Internationale (FEI, 2010) rules and also 
by horseracing authorities that are signatories to Article 6 of the International Agreement 
on Breeding, Racing and Wagering (IFHA, 2008). Most recently, the use of anabolic-
androgenic steroids (AASs) has also become controlled in the majority of US 
horseracing events (Teale and Houghton, 2010). 
 
In-vivo and in-vitro studies of both endogenous and exogenous steroid metabolism in the 
horse have been conducted and there is increasing interest within the veterinary field to 
understand the molecular biology of their action as well as measuring their 
concentrations in biological fluids. The presence and metabolism of endogenous AASs in 
meat producing animals, including the horse, has been reviewed in chapter 1 (and 
published in Scarth el al. 2009) and a review article addressing the metabolism of both 
endogenous and exogenous AASs in the horse has recently been produced (Teale and 
Houghton 2010). Also, a review of the analytical methodologies used to detect steroid 
abuse has also recently been published (McKinney 2009). Because these 
aforementioned articles already provide a thorough coverage of the field, the current 
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section of this review will serve to summarize the overall trends within the equine and to 
provide some further information on the enzymology of steroid metabolism within this 
species.  
 
All the major mammalian steroid biosynthetic pathways have been demonstrated to be 
present in the horse: equine follicular cDNAs from CYP11A1, 3-hydroxysteroid 
dehydrogenase/5-/4-isomerase (Boerboom and Sirois 2001) and 17-hydroxysteroid 
dehydrogenase have been cloned (Brown et al. 2004); equine steroid acute regulatory 
protein (STAR) and CYP17 mRNA have been detected in theca cells (Watson et al. 
2004); CYP17 has been immunolocalised in the mare corpus luteum (Rodger et al 
1998); equine CYP19 cDNA has been cloned (Seralini et al 2003) and also 
immunolocalised in testicular tissue (Almadhidi, 1995). The existence of many of the 
remaining steroidal CYPs and oxidoreductases is based on the detection of their 
metabolites in biological fluids (Makin, 1985).  
 
Again, in order to provide a frame of reference, the following section will compare some 
aspects of steroid metabolism in the equine to the porcine, bovine and human.  
 
A major species difference in steroid biosynthesis involves CYP17, which catalyses both 
the 17-hydroxylation and 17,20-lyase of pregnenolone and progesterone in two distinct 
steps (Mason, 2002). The 17-hydroxylation step is efficient for both pregnenolone and 
progesterone in all species but the 17,20 lyase is often selective for one particular 
substrate. In the equine and porcine, both 17-hydroxyprogesterone and 17-
hydroxypregnenolone can be substrates, but human and bovine activity is selective for 
17-hydroxypregnenolone. This leads to the human and bovine using predominantly the 
5-ene pathway and the equine and porcine both the 4-ene and 5-ene pathways for the 
biosynthesis of the androgens and oestrogens (Mason, 2002). Although these enzymatic 
preferences for different precursors exist, circulating 5-ene concentrations are generally 
high in human, bovine, porcine and equine species relative to those such as the cervine 
in which 4-ene steroids predominate (Wichman et al. 1984). Males and females of all 
four species are able to produce the oestrone and oestradiol, but the concentrations 
produced by intact male equine and porcine animals are far greater than those of the 
human or bovine (McKinnon and Voss, 1993). Intact male porcine animals also produce 
relatively large quantities of 16-androstene steroids (Hadley and Levine, 2006), while 
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pregnant equine animals secrete large amounts of the B-ring unsaturated steroids equilin 
and equilenin (McKinnon and Voss, 1993).  
 
Differences in the presence and phase 1 catabolism of endogenous AASs and their 
routes of excretion (urine vs faeces etc.) were discussed at length in chapter 1, so the 
details will not be repeated here. However, it is pertinent to note that that while 
3/3/5/5-reduction and 17-oxidation are important catabolic pathways in each 
species, equine animals also tend to secondarily reduce 17-keto groups to from a 
mixture of 17- and 17-hydroxy isomers and bovine animals predominantly reduce 17-
keto groups to from 17-hydroxy isomers. For synthetic AAS analogues, in which many 
of the classical oxidative and reductive routes of metabolism are hindered, multiple 
carbon skeleton hydroxylations are common and the only major differences between the 
species are the positions of hydroxylation. Phase two conjugations of AASs involve 
glucuronidation and sulphation in all four species, but there is a trend for sulphation to 
predominate in the equine and glucuronidation in the bovine and human. More data 
would be required before a trend in the porcine can be stated, but endogenous AAS data 
suggests that sulphation is prominent (Schwarzenberger et al. 1993). In the horse, there 
is also a preference for steroids with a 17β-hydroxy group to form sulphates and those 
with a 17α-hydroxy group to form glucuronides (Teale and Houghton et al. 2010). 
 
Table 1 summarizes the metabolism of individual AASs in the equine while Figure 1 
summarizes the major routes of anabolic-androgenic steroid catabolism in this species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Review: equine steroid metabolism and detection 
177 of 331 
 
 
 
 
 
Fig 1 – summary of some of the common pathways of AAS metabolism in the horse. See 
table 1 for a more extensive summary for individual steroids (including those with various 
substitutions not shown above). 
  
Table 1a – summary of the phase 1 and 2 metabolism of the androgenic-anabolic steroids studied in the horse. 
Steroid References Phase 1 metabolites Phase 2 metabolism Comments 
 
Boldenone 
 
 
Dumasia et al. 1983, 
Ho et al. 2004 
 
A range of metabolites result from 
modifications including oxidation and 
subsequent reduction at C17, reduction at Δ1 
and Δ4 and hydroxylation at C6 and C16. 
 
Boldenone predominantly as 
sulphate. Minor metabolites 
predominantly as 
glucuronides. 
 
Boldenone and 
boldenone sulphate 
endogenous in intact 
males at low levels. 
 
Clostebol 
 
 
Leung et al. 2005 
 
Major = 4-chloroandrost-4-ene-3α,17β-diol and 
4-chloroandrostane-3α,17β-diol. 
Minor = various metabolites resulting from 
reduction at C3 and Δ4, oxidation at C17 and 
hydroxylation at C6. 
 
The majority of metabolites 
were detected in the 
sulphate fraction. 
 
 
Danazol 
 
  
Tang et al. 2000 
 
Major = ethisterone,  
6-hydroxyethisterone and      
2-(hydroxymethyl)ethisterone. 
Minor metabolites include a number of other 
oxidised metabolites following isoxazole ring 
cleavage. 
 
Mixture of free, glucuronide 
and sulphate 
 
 
Cleavage of the 
isoxazole ring a 
major feature of 
danazol metabolism; 
something that is not 
observed for the 
pyrazole ring in 
stanozolol 
 
Desoxyvinyltestostero
ne analogues 
(designer steroid 
analogues)  
 
 
Kwok et al. 2006 
 
A mixture of metabolites resulting from the 
addition of a ketone or hydroxy at C2 and/or 
C3, reduction or shifting of the double bond 
within the A-ring and reduction and 
hydroxylation of the vinyl group  
 
Predominantly in the 
glucuronide fraction. 
 
A range of other 
analogues with 
various substitutions 
at position 17 were 
also studied in vitro, 
but not in vivo 
 
Ethylestrenol 
 
 
Gourdie et al. 1994, 
Kim et al. 1996. 
 
Major = reduction at C17. 
A range of minor metabolites result from 
modifications including reduction at C3 and 
hydroxylation at various sites, including 
C15/16. 
 
Ethylestrenol in the free 
fraction, with the other 
metabolites predominantly in 
the glucuronide fraction, but 
with some sulphation 
 
 
 
  
Table 1b – summary of the phase 1 and 2 metabolism of the androgenic-anabolic steroids studied in the horse. 
Steroid References Phase 1 metabolites Phase 2 metabolism Comments 
 
Fluoxymesterone 
 
 
Stanley el al. 1997a, 
Yamada et al. 2008a 
 
 
Major = 9α-fluoro-11β-hydroxy-17,17-
dimethyl-18-norandrosta-4-13-dien-3-
one. 
Minor = 17-epifluoxymesterone, 
16- and 20-hydroxyfluoxymesterone 
 
Predominantly in the free fraction 
for all metabolites, with a smaller 
proportion in the glucuronide 
fraction 
 
Loss of the 17-hydroxy group 
with subsequent migration of the 
C18 methyl group to the C17-
position is an interesting feature 
of fluoxymesterone metabolism. 
 
Furazabol 
 
Yamada et al. 2008b 
 
Major = 16α-hydroxyfurazabol.  
 
Data not available. 
 
 
Mestanolone 
 
 
Yamada et al. 2007 
 
Forms the A-ring reduced metabolites 
of methyltestosterone. 
 
Forms the A-ring reduced 
metabolites of 
methyltestosterone. 
 
Mestanolone a metabolite of 
methyltestosterone and 
oxymetholone. 
 
Mesterolone 
 
 
Ho et al. 2007b 
 
Major = 1α-methyl, 3,16-dihydroxy-
5α-androstan-17-one and 1α-methyl, 
3,18-dihydroxy-5α-androstan-17-one. 
Minor = a range of metabolites 
resulting from reduction at C3, 
epimerisation at C17 and 
hydroxylation at C16. 
 
Split between the glucuronide 
and sulphate fractions, with 17α-
hydroxy isomers predominantly 
as glucuronides and 17β-hydroxy 
isomers predominantly as 
sulphates. 
 
 
Methandienone 
 
 
Edlund et al. 1989, 
Hagedorn et al. 
1992, McKinney et 
al. 2001b, Kurosawa 
et al. 2006 
 
 
Major = 16-hydroxymethandieneone, 
Δ4-reduced + 6 and 16-hydroxylated 
as well as Δ4-reduced and 6,16-
dihydroxylated methandienone. Minor 
= a number of metabolites, including 
epimethandienone, and a range of A-
ring fully reduced metabolites (being 
the longest detected metabolites). 
 
16-hydroxymethandieneone 
predominantly as sulphate, 
epimethandienone predominantly 
as free and the remainder of 
metabolites split between the 
glucuronide and sulphate 
fractions. 
 
Some sulphate conjugates 
unstable in urine, leading to 
‘apparent’ unconjugated 
metabolites if storage conditions 
not adequate 
 
 
Methandriol 
 
 
Yamada et al. 
2008b, Kurosawa et 
al. 2006 
 
As the A-ring reduced metabolites of 
methyltestosterone 
 
A mixture of glucuronide and 
sulphate for parent methandriol. 
As methyltestosterone for the A-
ring reduced metabolites. 
 
  
Table 1c – summary of the phase 1 and 2 metabolism of the androgenic-anabolic steroids studied in the horse. 
Steroid References Phase 1 metabolites Phase 2 metabolism Comments
 
Methenolone 
 
 
Ho et al. 2005 
 
Mixture of epimethenolone, 17-keto-16-
hydroxymethenolone, 16-hydroxymethenolone and 
2,6-dihydroxy-methenolone (this metabolite was only 
observed in vitro) 
 
Metabolites split between both the 
glucuronide and sulphate 
fractions. 
 
 
Methyltestosterone 
 
 
Schoene et al. 1994, 
Stanley et al. 1997b, 
McKinney et al. 2007 
 
Hydroxylation at C6, C15, C16 and C20, 
epimerization at C17 as well as a range of 
metabolites resulting from A-ring reduction, including 
mestanolone 
 
Predominantly as sulphates. 
 
 
 
Nandrolone 
 
 
Houghton 1977, 
Houghton et al. 1984, 
Roig et al. 2007, 
Houghton et al. 2007 
 
 
Major = 5α-estrane-3β,17α-diol. 
Minor = a number of metabolites, including 
epinandrolone, norepiandrosterone, 5α-estrane-
3β,17β-diol and various C16-hydroxylated 
metabolites. 
 
5α-estrane-3β,17α-diol 
predominantly as glucuronide, 
while nandrolone predominantly as 
sulphate. Other metabolites split 
between both fractions. 
 
Some C18 androgens 
endogenous in intact 
males and pregnant 
females. Now thought 
to be predominantly 
analytical artefacts 
caused by degradation 
of 19-oic acids. 
 
Norethandrolone 
 
 
McKinney et al. 2001a 
 
 
Mixture of metabolites resulting from reduction of the 
A-ring and hydroxylation at C16, C20 + C21 (also 
forming a carboxylic acid at C21) 
 
Carboxylic acids in free fraction. 
The remainder of metabolites in 
either the sulphate, glucuronide or 
a mixture of both fractions. 
 
Norethandrolone also 
a metabolite of 
ethylestrenol 
 
Normethandrolone 
(nomethandrone) 
 
 
Fox et al. 2000 
 
Mixture of metabolites including, 
epinormethandrolone, 
A-ring reduced metabolites, 6- and 16-
hydroxynormethandrolone and A-ring reduced 16-
hydroxynormethandrolone 
 
C6- and C16-hydroxylated 
metabolites predominantly in the 
glucuronide fraction, with the 
remainder split between the 
glucuronide and sulphate fraction  
 
71% of the overall 
radioactive dose 
excreted in 
glucuronide fraction 
 
Oxymetholone 
 
Yamada et al. 2008c, 
Tang et al. 1998 
 
Mixture of mestanolone, C3-reduced mestanolone 
isomers, 2-hydroxymethyl-17α-methyl-5α-androstan-
3,17β-diol and 2,17α-di(hydroxymethyl)-5α-
androstan-3,17β-diol. 
 
Metabolites split between both the 
glucuronide and sulphate 
fractions. 
 
  
Table 1d – summary of the phase 1 and 2 metabolism of the androgenic-anabolic steroids studied in the horse 
Steroid References Phase 1 metabolites Phase 2 metabolism Comments 
 
6-Oxo (androst-4-
ene-3,6,17-trione) 
 
Leung et al. 2010 
 
An extensive array of metabolites resulting from 
reduction at C3, Δ4, C6, and C17.  
 
Some detected in both free and 
glucuronide fractions, while others 
in glucuronide only. Sulphation not 
assessed due to the acid lability of 
metabolites.  
 
 
Stanozolol 
 
 
Muck and Henion, 
1990, McKinney et 
al. 2004, Scarth et 
al. 2010b 
 
 
Major = 15-, 16α- and 16β-hydroxystanozolol. 
Minor = 16-ketostanozolol and 3’, 4α, 4β and 6α-
hydroxystanozolol. 
  
 
Stanozolol and 15-
hydroxystanozolol predominantly 
as glucuronide, while 16α- and 
16β-hydroxystanozolol 
predominantly as sulphates. 
 
16α- and 16β-
hydroxylation proposed 
to be mediated by an 
enzyme related to 
human CYP2C8s  
 
Testosterone 
 
 
Houghton and 
Dumasia 1979, 
Dumaisa and 
Houghton 1981 
 
Major = 5α-androstrane-3β,17α-diol. 
Minor = a number of metabolites, including 
epitestosterone, epiandrosterone, 5α-androstrane-
3β,17β-diol and various C16-hydroxylated 
metabolites 
 
5α-androstrane-3β,17α-diol 
predominantly as glucuronide, 
while testosterone predominantly 
as sulphate. Other metabolites 
split between both fractions 
 
Testosterone 
endogenous in intact 
males, geldings and 
females. 
 
 
Testosterone 
precursors (DHEA 
or androst-4-ene-
3,17-dione) 
 
Dehennin et al. 
2001 
 
Increased excretion of testosterone metabolites for 
both DHEA and androst-4-ene-3,17-dione 
administration. DHEA also increased levels of 
androst-5-ene-3,17-diols.  
 
Concentrations given as ‘total’ 
only, but is stated that DHEA 
sulphate ‘attained high levels after 
DHEA administration.’ 
 
 
 
Trenbolone 
 
 
Houghton et al. 
1992, Suann et al. 
2000 
 
Major = epitrenbolone.  
Minor = various 16-hydroxylated metabolites. 
 
Mixture of glucuronide and 
sulphate. 
 
A-ring metabolism 
inhibited by the 
extended A-B-C-ring 
conjugation. 
 
Turinabol 
 
 
Ho et al. 2007a 
Major = epiturinabol, 20-hydroxyturinabol, 6β,20-
dihydroxyturinabol and a range of A-ring reduced 
metabolites. 
Minor (in vitro only) = 6βhydroxy and 6β, 16-
dihydroxyturinabol. 
 
Excreted as a mixture of sulphated 
and free steroids 
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4.3 The detection of steroid abuse in horseracing 
 
4.3.1 Detection of the classical ‘synthetic’ and ‘endogenous’ steroids 
 
The range of analytical techniques used for detecting steroid abuse in equine sports was 
discussed in the introduction to this thesis, so this section will serve to discuss highlight 
issues that are relevant to specific AASs. 
 
In the majority of instances, detection of the abuse of classical ‘synthetic’ steroids in 
equine sports relies on a simple qualitative demonstration of their presence. Urine and 
plasma are the two most popular matrices used for testing and require somewhat 
different analytical approaches. Abuse of the majority of AASs in plasma can be detected 
by monitoring ‘parent’ steroid, whereas in urine it is typically necessary to monitor the 
deconjugated metabolites listed in table 1 as well (Teale and Houghton, 2010).  Steroids 
such as trenbolone containing a high degree of chemical conjugation are generally more 
suitable for LC-MS analysis, whereas highly saturated steroids such as methandriol are 
more suited to GC-MS analysis. Many laboratories therefore operate both LC-MS and 
GC-MS screens for steroids in order to obtain the highest degree of analyte coverage 
(McKinney, 2009).  
 
In contrast to the situation for many of the other food producing species, methods for 
detecting the abuse of the majority of ‘endogenous’ AASs in equine sports are already 
available: 
 
Since 19-nor-androgens have not been shown to be endogenous in the gelding or 
filly/mare, their presence at any concentration is considered evidence of nandrolone 
abuse (with the exception of the pregnant mare, which is known to produce 19-nor-
androgens during gestation). A threshold utilising a ratio of 5α-estrane-3β,17α-diol:estr-
5(10)-ene-3β,17α-diol of greater than 1:1 was previously used to indicative nandrolone 
abuse in male horses (Houghton et al. 1984) since nandrolone is considered 
endogenous in this sex. However, this biomarker ratio approach has recently been 
replaced with a 45 ng ml-1 threshold for the nandrolone metabolite 5α-estrane-3β,17α-
diol (IFHA, 2008). 
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Since 1-dehydro-androgens have not been shown to be endogenous in the gelding or 
filly/mare, their presence at any concentration is considered evidence of boldenone 
abuse. However, boldenone has recently been shown to be naturally occurring as a 
sulphate conjugate in the urine of intact males (Ho et al. 2004) and a urinary threshold of 
15 ng ml-1 boldenone has been introduced in order to regulate abuse (IFHA, 2008). 
 
In the gelding and filly/mare, urinary threshold concentrations for testosterone have been 
set at 20 and 55 ng ml-1 respectively in order to control the abuse of this steroid (IFHA, 
2008). There is no urinary testosterone threshold in the intact male due to the high and 
variable concentrations produced in this animal.  
 
Unlike urine, definitive data on the plasma concentrations of ‘endogenous’ steroids in 
large populations of animals across different geographical locations are not currently 
available, so there are no internationally accepted thresholds in this matrix (McKinney 
2009). However, analytical methods based on the detection of intact testosterone, 
nandrolone and boldenone esters in equine plasma have recently been developed by 
our laboratory; which now provides a means of detecting abuse of these preparations 
(Gray et al. 2010). In the future, it is anticipated that the detection of intact steroids esters 
in hair may further enhance detection periods for these compounds.  
 
4.3.2 The threat of ‘designer’ steroids 
 
Designer steroids first came to the public attention in 2003 when a syringe containing the 
novel steroid tetrahydrogestrinone (THG) was handed to doping officials, which resulted 
in the disqualification of several athletes after they were subsequently found to have 
used the steroid (Catlin et al. 2004). Designer steroids have chemical structures based 
on previously marketed products, but with minor modifications which make them 
undetectable by the majority of current targeted mass spectrometric procedures. In the 
case of THG for example, the drug’s structure is based upon gestrinone, but with the 17-
alkyl side chain fully saturated such that the relative molecular mass of THG is 4 u higher 
than gestrinone. Designer steroids are synthesized either to deliberately evade 
detection, or as appears more common, to enable them to be marketed freely on the 
Internet to customers in some countries because their structures do not fall within the 
scope of legal regulations that prevent the sale of defined steroidal products. Although 
THG was the first such steroid to reach public attention, it is now known that the steroid 
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turinabol (4-chloro,17β-hydroxy,17α-methyl-androsta-1,4-dien-3-one) was distributed 
amongst East German athletes in a state sponsored doping programme in order to 
evade detection procedures in place at the time (Ungerleider, 2001). It is now also 
known that the company that produced THG, namely the Bay Area Laboratory 
Cooperative), also supplied the designer steroids norbolethone (17β-hydroxy-13β,17α-
diethylgon-4-en-3-one) and desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-
ol) to athletes (Kicman, 2008, McKinney 2009). 
 
As with any AAS, if testing is based on blood or hair then detection of the ‘parent’ steroid 
may be appropriate. However, if detection is to be based on excreted matrices such as 
urine and faeces, knowledge of the metabolism is typically required in order to direct 
detection protocols toward the appropriate target analyte. With this in mind, several 
strategies have been proposed to detect the abuse of designer steroids in biological 
samples taken from humans and animals.  
 
One approach that has been proposed by several authors is based on predicting the 
pattern of fragmentation under EI-GC-MS or LC-MS/MS conditions (Thevis et al. 2005, 
Fragkaki et al. 2009). Using this approach, a variety of scan functions can be used to 
screen for the presence of common fragments or neutral losses from a range of possible 
steroid structures in biological samples. If these initial screening analyses produce a 
suspicious result, then this may trigger a more in depth analysis of the sample in order to 
determine the possible structure of any unknown components.  
 
Another approach is to use bioassay guided fractionation of samples, followed up by in 
depth analysis of any fractions that produce positive bioassay results. One such 
approach has been published by Peters et al. (2010) uses a yeast expressed androgen 
receptor assay to highlight sample fractions that produce androgenic pharmacological 
effects. If the bioassay produces a suspicious result, then this may trigger a more in 
depth analysis of the sample fraction in order to determine the possible structure of any 
unknown components. An alternative bioassay based on ELISA has been reported by 
Hungerford et al. (2005). This approach utilises an antibody that recognises steroids that 
contain a 17α-methyl,16β,17β-dihydroxy epitope, therefore theoretically producing a 
suspicious result for any 17α-methyl steroid that undergoes 16β-hydroxylation as part of 
it’s metabolism. Since 16β-hydroxylation is a major pathway of metabolism of such 
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steroids, especially in equine animals (Houghton, 1992), this again highlights a 
suspicious sample for further work to identify any unknown molecules. 
 
While the above approaches are based on the detection of designer steroids through 
screening for the presence of the steroid or metabolite itself, an alternative method that 
is currently being investigated is the use of endogenous ‘biomarkers’ (Scarth et al. 2006, 
Mooney et al. 2009). The theory of the biomarker approach is that regardless of 
structure, the majority of AASs are likely to produce their pharmacological actions 
through similar means such as through binding to the androgen receptor or antagonising 
the cortisol receptor. Therefore, as long as they produce similar pharmacological effects, 
designer steroids may be just as likely as classical steroids to induce a change in 
endogenous biomarker profile and hence for the suspicious sample to undergo further 
investigation. 
 
The above approaches are considered most suitable for identifying new designer 
steroids that regulatory authorities are not aware previously existed, such as THG. 
However, the extent of abuse of this type of designer steroid is hard to predict and it is 
anticipated that it would be limited to a small group of elite individuals who are able to 
obtain access to a small number of rogue chemists. The designer steroids that appear to 
be the most widely available are those marketed on the Internet. Although these steroids 
contain novel structures in order to enable them to be marketed freely on the Internet to 
customers in some countries (because their structures do not fall within the scope of 
legal regulations that prevent the sale of defined steroidal products), the regulatory 
authorities are able to maintain an awareness of their emergence through Internet 
searches. For these steroids, it is therefore possible to purchase materials that can then 
be used for analytical method development purposes.  
 
While it is theoretically possible to conduct in vivo metabolism studies using Internet 
available designer steroids, the fact that these compounds typically lack toxicological 
characterisation makes this approach difficult to justify on ethical grounds. Several other 
approaches have therefore been reported for producing metabolite information where 
reference standards of designer steroids are available. Peters et al. (2009) proposed an 
in silico approach to identifying the presence of designer steroids and/or their 
metabolites in samples using a range of possible transformations of existing steroid 
structures. Lootens et al. (2009) and Pozo et al. (2009) have recently developed a rodent 
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model transplanted with human hepatocytes. Using this approach, human type 
metabolism can be investigated without the need for experimenting on people. In the 
future, it may be possible to adapt this approach to utilise equine hepatocytes. However, 
this technique still requires the use of animal experimentation. Therefore, attractive 
alternatives that have shown excellent qualitative in vivo correlation are the use of 
different in vitro models, involving incubation of steroids with either ex vivo mammalian 
liver preparations (Ho et al. 2005, Ho et al. 2007a and 2007b, Leung et al. 2004) or 
surrogate invertebrate models (De Wasch et al. 2002, Verheyden et al. 2007); hence 
negating the requirement for mammalian in vivo experimentation.  
 
Several designer steroid studies have been carried out in the human. Levesque et al. 
(2005) and Gauthier et al. in (2009) used human hepatocytes to study the in vitro 
metabolism of THG and 17α-methyl-drostanolone respectively, while Rodchenkov et al. 
in (2006) studied the in vivo human metabolism of a number of capsulated products 
purported to contain different steroidal products. In the latter study, however, reference 
standards for the compounds in question were not available to confirm the structures of 
the steroids contained in the capsules obtained on the Internet.  
 
To date, no studies have reported the metabolism of designer steroids in the canine and 
only one study has been reported in the equine. In the equine study, Kwok et al. (2006) 
reported the in vivo and in vitro metabolism of desoxy-vinyltestosterone and some of its 
analogues. The objective of the remainder of part 2 of this thesis was therefore to further 
develop and assess the suitability of in vitro techniques for conducting equine drug 
metabolism studies (chapter 5) and to use the developed in vitro methods to study the 
metabolism of a novel ‘designer’ steroid in the equine (chapter 6). 
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Chapter 5: Assessment of the applicability of in vitro 
technologies to study drug metabolism in the equine  
 
______________________________________________________________________ 
After: 
 
Scarth, J., Spencer, H., Hudson, S., Gray, B., Teale, P. and Hillyer, L. The 
application of in vitro technologies to study the metabolism of the 
androgenic/anabolic steroid stanozolol in the equine. (2010). Steroids. 75, 57-
69. 
 
______________________________________________________________________ 
 
 
 
5.1 Introduction 
 
During the past decade, in vitro methods for studying drug metabolism have become 
widespread in the drug development industry (Yuan et al. 2002). In contrast, while a 
small number of authors have reported the use of in vitro studies in sports drug 
surveillance research, their application has to date not been widespread (see chapter 4 
for a more detailed discussion). Although there are many scientific advantages to the use 
of in vitro techniques, the reduced need for animal experimentation is a significant 
benefit to animal welfare. In the equine, in vitro techniques have been used to study the 
biosynthetic pathways of C18 androgens in testicular tissue (Smith et al. 1987) and the 
B-ring unsaturated oestrogens in placental tissue (Marshall et al. 1989). More recently, 
equine liver microsomes have been used to study the phase 1 metabolism of the 
androgenic-anabolic steroids clostebol acetate and mesterolone (Leung et al. 2004), 
methenolone acetate (Ho et al. 2005), turinabol (Ho et al. 2007), a range of designer 
steroids (Kwok et al. 2006) and the non-steroidal anti-inflammatory drug phenylbutazone 
(Stanley et al. 2006). In general, the in vitro studies reported to date have produced 
comparable qualitative metabolite profiles to those obtained in urine following in vivo 
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administrations, but some quantitative differences have been observed. Most recently, 
two equine cytochrome P450 (CYP) enzyme isoforms, named CYP2D50 and CYP2C92, 
have for the first time been sequenced and their activity compared to human CYP2C and 
D isoforms (DiMaio Knych et al. 2008 and 2009). While the equine and human isoforms 
shared some substrate specificity, there were significant differences in the enzyme 
kinetics and the range of metabolites produced in the different species. In vitro 
techniques have also been applied in the human sports field. For example, hepatocyte 
preparations have been used to study the phase 1 and 2 metabolism of the designer 
steroid tetrahydrogestrinone (THG) (Lévesque et al. 2009). The authors were able to 
isolate enough material to perform NMR analysis of some of the resulting metabolites. 
Although the majority of research has focussed on harvesting mammalian tissues since 
these are generally considered to be the most representative of the in vivo mammalian 
situation, invertebrate models such as those involving maggots and crustaceans have 
also shown promise (Verheyden et al. 2007, De Wasch et al. 2002). 
 
In the work reported in the current chapter, the use of equine liver microsomes, and for 
the first time liver and lung S9 tissue fractions, were used to study the metabolism of the 
androgenic/anabolic steroid stanozolol in the equine. The overall aim of these 
experiments was to assess the suitability of in vitro techniques for studying steroid 
metabolism in this species. The major objectives were a) to compare the in vitro phase 1 
metabolite profile observed here with urinary profiles previously reported in vivo in the 
equine, b) to further characterise some of the metabolites observed and c) to identify 
some of the enzymatic mechanisms that may be responsible for the metabolism. 
 
Stanozolol (17β-hydroxy,17α-methyl-5α-androstano[3,2-c]pyrazole - see Fig 1) is a 
synthetic testosterone derivative that first came to public attention following the positive 
drugs test of Ben Johnson at the 1988 Olympics. The main reason for selecting 
stanozolol in the current study was because significant data regarding it’s in vivo 
metabolism in the equine is available. 
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Fig 1 – structure of stanozolol with carbon numbering indicated. Arrows point to the sites 
of mono-hydroxylation produced in the equine liver microsomal fractions that could either 
be confirmed by reference standards or suggested (shown by a ?) based on pattern of 
fragmentation. See details in the text for a full description of these equine metabolites. 
 
Although the early studies in the 1980s and 1990s most often used GC-MS to study 
stanozolol metabolism, differences in the ease of derivatisation of the different hydroxy 
products made it difficult to be certain of the relative abundance of the different 
metabolites. For example, 3’-hydroxy-stanozolol derivatises to the TMS-ether relatively 
easily while the 16β-hydroxy-isomers do not (Poelmans et al. 2002). The adoption of LC-
MS in the 1990s and 2000s was a significant advantage as this technique does not 
require derivatisation of stanozolol and it is therefore easier to compare the relative 
abundance of the different hydroxy products (Poelmans et al. 2002, Van De Wiele, 
2000). In humans, the major metabolites of stanozolol following oral administration have 
been shown to be 3’-hydroxy-stanozolol, 4β-hydroxy-stanozolol and 16β-hydroxy-
stanozolol, but several di-hydroxy- and 17-epi- metabolites have also been detected 
(Schanzer et al. 1990, Masse et al. 1989). In cattle, the major metabolite of stanozolol is 
16β-hydroxy-stanozolol (Van De Wiele et al. Ferchaud et al. 1997, De Brabander et al. 
1998, Delahaut et al. 1998), but depending on the route of administration additional 
dihydroxy metabolites have also been detected (Ferchaud et al. 1997). An equine study 
using triple-quadrupole LC-MS/MS analysis of urinary extracts following an oral dose of 
stanozolol reported the detection of several mono-hydroxy stanozolol metabolites, but in 
most cases the stereochemistry could not be confirmed (Muck and Henion, 1990). A 
later equine study using ion trap LC-MS/MS analysis of urinary extracts following an 
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intra-muscular dose of stanozolol was able to confirm the presence of 16β-hydroxy-
stanozolol as a major phase 1 metabolite and postulate two further mono-hydroxy- 
metabolites as 15-hydroxy- and a 16α-hydroxy-stanozolol based on their pattern of mass 
spectral fragmentation (McKinney et al. 2004). Phase 2 metabolism of these metabolites 
was a mixture of sulfation and glucuronidation. Neither 3’-hydroxy-stanozolol, 4α/4β-
hydroxy-stanozolol or di-hydroxy-stanozolol isomers could be found. Most recently, a 
rigorous study of the mass spectrometric behaviour of stanozolol and several mono-
hydroxy-metabolites has been conducted using both a quadrupole-linear ion trap and a 
high-resolution/accurate-mass linear ion trap-orbitrap LC-MS/MS analyzer (Thevis et al. 
2005). 
 
5.2 Experimental 
 
5.2.1 Chemicals and reagents 
 
Deionized water was prepared using an SG Ultrachem TWF UV system (Barsbuttel, 
Germany). All organic solvents, acids and bases were analytical grade and were 
purchased from Fisher Scientific (Loughborough, UK). Trizma base and HCl, NADPH 
(variant N-1630), N-Methyl-n-(trimethylsilyl)-trifluoroacetamide, ethane thiol, ammonium 
iodide, β-glucuronidase from Helix pomatia (type HP-2), pancreatin (8xUSP – product 
P7545) and Stanozolol were obtained from Sigma-Aldrich (Dorset, UK). D3-stanozolol 
and 16β-hydroxy-stanozolol were supplied by Cerilliant (Texas, USA). 3’-hydroxy-
stanozolol was purchased from the National Measurement institute of Australia (Sydney, 
Australia). 4α- and 4β-hydroxy-stanozolol were gifts from the Institut für Biochemie, der 
Deutschen Sporthochschule Köln, (Köln, Germany) and 6α-hydroxy-stanozolol was 
purchased from the Australian Racing Forensic Laboratory (Kensington, Australia). C18, 
6 cc, 500  mg Sep-pak Vac solid phase extraction cartridges and a 100 mm x 2.1ID 3 µm 
Atlantis T3 column were supplied by Waters (Wexford, Ireland). Strata XC 3ml 60mg 
solid phase extraction cartridges were obtained from Phenomenex (Macclesfield, UK). 
Equine liver microsomes and S9 (both at 20 mg ml-1 protein and from a Quarter horse) 
were purchased from Xenotech Llc. (Lenexa, USA), while equine lung S9 (at 20 mg ml-1 
and from a thoroughbred horse) was prepared by Asterand (Royston, UK). The horses 
used were euthanized by ethically approved means for reasons not related to the current 
study. 
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5.2.2 In vitro experiments 
 
Incubations of stanozolol, D3-stanozolol, 6α-hydroxy-stanozolol or 16β-hydroxy-
stanozolol were performed with equine liver microsomes, liver S9 or lung S9. Reactions 
volumes were 0.33 ml and contained drug (25 μM), microsome or S9 (at 0.5 mg ml-1 
protein), NADPH (0.63 mM) and pH 7.4 TRIS buffer (50 mM). Samples were incubated 
in a water bath at 37oC for 2 hours and 50 μl aliquots were quenched at 0 and 120 mins 
by the addition of 75 μl of ice-cold acetonitrile. Control experiments with no added 
cofactor were also performed in order to check that metabolism was responsible for 
producing any metabolites observed.  
 
Stanozolol was also incubated with equine liver microsomes under the above conditions, 
but with the addition of a range of chemicals that are known to inhibit individual human 
cytochrome P450 isoforms (selectively in most cases) in order to try and provide some 
preliminary information on the enzymes that might be responsible for the metabolism of 
stanozolol in the equine. Chemical inhibitors were added in excess of their published 
human IC50 values in order to allow for any reduction in affinity that may occur between 
species and were; α-naphthoflavone (at 12 μM to inhibit CYP1A2), 8-methoxypsoralen 
(at 12 μM to inhibit CYP2A6), setraline (at 12 μM to inhibit CYP2B6), quercetin (at 12 μM 
to inhibit CYP2C8), sulfaphenazole (at 6 μM to inhibit CYP2C9), ticlopidine (at 12 μM to 
inhibit CYP2C19), quinidine (at 6 μM to inhibit CYP2D6), clomethiazole (at 12 μM to 
inhibit CYP2E1) and ketoconazole (at 0.6 μM to inhibit CYP3A4). Chemical inhibitors 
that resulted in inhibition of stanozolol metabolism in this initial screen were then subject 
to full IC50 analysis using a full range of inhibitor concentrations.  
 
For samples that were analysed by LC/MS/MS, the quenched aliquots were then 
centrifuged for 5 mins at 11,000 rpm, the supernatant transferred to a separate vial and 
blown down to dryness and reconstituted in 5 µl propan-2-ol followed by 95 µl of water, 
before being submitted to LC-MS analysis on the Thermo LTQ-Orbitrap or Sciex 5500 Q 
Trap. 
 
For samples that were analysed by GC-MS, the quenched aliquots were diluted to 2 ml 
with water and then added to 6 ml, 500 mg C18 solid phase extraction cartridges that 
had previously been primed with 5 ml methanol and 5 ml water. The cartridges were then 
washed with 5 ml water and 5 ml hexane before being dried under vacuum for 20 mins 
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and then eluted with 5 ml diethyl ether. Samples were then blown down to dryness, 
reconstituted in 30 μl of an enol-trimethylsilyl derivatising reagent (made by adding 60 μl 
of ethane thiol and 30 mg ammonium iodide to 10 ml N-Methyl-n-(trimethylsilyl)-
trifluoroacetamide) and heated at 800c for 2.5 hours before being transferred to tapered 
vials and submitted to GCMS analysis on the Agilent 7000A.  
 
5.2.3 In vivo experiments 
 
An oral dose of 140 mg Stanozolol (preparation Stromba) was administered to a 
thoroughbred gelding following an ethically approved protocol. Urine samples were 
collected from the animal and pooled over the following three time periods; 0-24, 24-28 
and 48-72-hours.  
 
Urine samples were prepared for analysis by mixing 2 ml of urine sample with 1 ml of 1 
M pH 4.7 acetate buffer, 100 μl of a β-glucuronidase from Helix pomatia solution (40,000 
units ml-1 in water) and 100 μl of a pancreatin solution (made by dissolving 1.25 g of 
Sigma product P7545 in 50 ml of 0.05 M pH 6.6 acetate buffer) and then hydrolysing 
overnight at 40oC. Samples were then extracted the following day by conditioning a 
Phenomenex Strata XC 3 ml 60 mg solid phase extraction cartridge with 3 ml methanol 
and 3 ml water, loading the samples, washing with 3 ml 0.1M pH 9.0 acetate buffer, 3 ml 
water, 3 ml 0.1 M HCl, 3 ml methanol, 3 ml diethyl ether and then eluting with 2 x 1 ml of 
ethyl acetate:propan-2-ol:ammonia: 80:17:3. Samples were then evaporated to dryness 
and reconstituted in 5 µl propan-2-ol followed by 95 µl of water before being submitted to 
LC-MS analysis on the Thermo LTQ-Orbitrap. 
 
 
5.2.4 Thermo LTQ-Orbitrap high-resolution/accurate mass LC-MS analyses 
 
Urine samples from the stanozolol in vivo administrations and tissue incubates from the 
in vitro incubations were analysed by a full scan, high resolution/accurate mass LC-MS 
screen. 
 
10 μl of sample was introduced onto a Thermo Accela autosampler/HPLC linked to a 
Thermo Discovery LTQ-Orbitrap. Chromatography was carried out using a Waters 100 
mm x 2.1 ID 3 µm Atlantis T3 column held at 40OC. Flow rate was 400 μl min-1 and 
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mobile phase A was 0.1% acetic acid with 300 µg l-1 uracil (external calibrant) and 
mobile phase B was 0.1% acetic acid in acetonitrile with 300 µg l-1 uracil (external 
calibrant). Mobile phase B was at 0% at 0 mins, rising to 10% at 1.2 mins, 35% at 2.0 
mins, 65% at 3.0 mins, 98% at 3.5 mins, held at 98% until 4.5 mins before being reduced 
back to 0% at 4.51 mins.  
 
Sample ionisation was carried out in the positive mode using the electrospray source at 
a capillary temperature of 200oC, a sheath gas flow of 30 units, an auxiliary gas flow of 
10 units and an ionspray voltage of 4.5 kV. Full scan centroid data over a range from 90 
to 650 u was then acquired by the LTQ Orbitrap using a resolution of 30,000 at FWHM. 
Data was acquired and processed using the Xcalibur version 2.0.7 software. 
 
5.2.5 Applied Biosystems Sciex 5500 Q Trap LC-MS/MS analyses 
 
Since the equine liver microsomal incubations produced the most concentrated and 
cleanest extracts, a selection of these samples were analysed using product ion 
scanning LC-MS/MS techniques in order to structurally elucidate some of the metabolites 
produced. In addition to the in vitro samples, 10 ng injections of all available reference 
standards were also performed in order to match chromatographic retention time and 
mass spectra to those observed in the samples. 
 
10 μl of sample was introduced into an Applied Biosystems Sciex 5500 Q Trap using a 
Waters Acquity autosampler/HPLC. Chromatography was carried out using a Waters 
100 mm x 2.1 ID 3 µm Atlantis T3 column held at 40OC and using an elongated HPLC 
gradient relative to the Orbitrap analyses in order to provide some addition separation of 
the metabolites. Flow rate was 400 μl min-1 and mobile phase A was 0.1% formic acid in 
water and mobile phase B was acetonitrile. Mobile phase B was at 2% at 0 mins, rising 
to 7% at 0.2 mins, 10% at 1.2 mins, 50% at 5.0 mins, 100% at 5.2 mins, held at 100% 
until 6.2 mins before being reduced back to 2% at 6.25 mins and then being held at 2% 
until 7.0 mins. 
 
Structural information regarding the metabolites was achieved using the ‘enhanced 
product ion scan (EPI)’ mode (uses collision induced dissociation of precursor ions in the 
collision cell followed by product ion scanning using the linear ion trap function). Sample 
ionisation was carried out in the positive mode using the Turbo Ionspray source at a 
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source temperature of 600oC. Ion spray voltage was 5500 V, gas one had a flow of 50 
units, gas two a flow of 50 units, the curtain gas had a flow of 10 units, the CAD gas 
setting was ‘low’, declustering potential was 120 V and entrance potential 10 V. Scan 
ranges were from 50 u up to 5 u above the chosen precursor ion. The Q1 resolution was 
‘unit’, the Q3 entry barrier was 8 V, the scan rate was 10,000 u s-1, the dynamic fill time 
setting on the linear ion trap was used and the step size was 0.12 u. Collision energies 
ranged between 45 and 65 eV, with exact details being given in the relevant results 
section. Data was acquired in profile mode and processed using the Analyst version 1.5 
software. 
 
5.2.6 Agilent 7000A GC-MS analyses 
 
A selection of extracts from the equine liver microsome incubations were analysed using 
EI-GC-MS in order to ascertain whether a 15-hydroxy-stanozolol metabolite had been 
produced, as previous in vivo studies in our laboratories (Phil Teale, personal 
communication) had suggested that GC-MS was able to identify this metabolite in 
samples resulting from an in vivo stanozolol administration.  
 
1 μl of sample was introduced into an Agilent 7683B injector held at 260oC in a pulsed 
splitless mode (at 1 psi with a 0.5 min pressure pulse at 25 psi). The split valve was 
opened at 1 min with a flow of 50 ml min-1. chromatography was carried out using an 
Agilent 7890A gas chromatograph with helium as the carrier gas (1.5 ml min-1) and a 3 
0m x 250 um x 0.25 um Thermo TR-50MS column initially held at 150oC for 1 min and 
then ramped by 15oC min-1 to 320oC before being held for 6 mins (total run-time 18.33 
mins). Mass spectrometry was carried out using an Agilent 7000A triple quadrupole 
mass spectrometer operated in the electron ionization (EI) mode. Source temperature 
was 230oC, electron energy was 70 eV, electron multiplier voltage was 500 V and the 
scan range was 50 to 700 u over 400 ms. Data was acquired and processed using the 
Agilent Masshunter version B.04.00 software. 
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5.3 Results and Discussion 
 
5.3.1 Comparison of in vivo urine and in vitro incubate results 
 
The results of the in vivo urine and in vitro tissue samples that were run by high 
resolution/accurate mass on the Orbitrap are shown in Fig 2. In the analysed in vivo 
post-dose urine samples, no stanozolol related compounds could be detected in the 24-
48 and 48-72 hour post-dose urine pools. In the 0-24 hour post-dose urine pool, only a 
small amount of stanozolol parent drug was observed (not shown). Significant instrument 
responses in the current study were, however, seen for ions relating to hydroxy and keto 
stanozolol metabolites. For m/z 345.2537 relating to hydroxy-stanozolol, four major 
peaks at 3.71, 3.84, 4.06 and 4.16 mins were observed. Additionally, a number of very 
much smaller chromatographically unresolved peaks appeared to be present for this m/z. 
The peak at 4.16 mins correlated in retention time with 16β-hydroxy-stanozolol, but the 
other peaks in the chromatogram could not be assigned stereochemistry based on their 
mono-isotopic masses alone. A peak with m/z 343.2380 relating to a keto-stanozolol 
metabolite was also observed in the 0-24 hour in vivo post-dose urine sample with a 
signal intensity approximately 10% of the largest hydroxy-metabolite response.  
 
In the equine liver microsome and S9 in vitro post-dose incubations, the same four major 
hydroxy-stanozolol and the one keto-stanozolol peaks were present as in the 0-24 hour 
in vivo post-dose urine sample. The relative intensities of the overall metabolite profiles 
were approximately three-fold higher in the liver microsome relative to S9 incubations, 
consistent with a more concentrated source of CYP mediated activity toward stanozolol 
being present in the microsomal fraction. The relative profile of the different metabolites 
between the microsomal and S9 fractions was similar, with the exception that the 
intensity of the peak relating to 16β-hydroxy-stanozolol varied between incubations when 
using microsomes (cause unknown). In the equine lung S9 incubations, the yield of 
metabolites was very much lower and only one of the hydroxy-stanozolol metabolites 
(peak at 4.05 mins) could be detected in this fraction. This is consistent with the 
reportedly lower level of certain drug metabolising enzyme activities in the lung of most 
species (Gibson and Skeet, 2001). 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2 – comparison of hydroxy-stanozolol (m/z 345.2537 at a mass tolerance of 10 ppm) chromatograms on the Orbitrap for; A) equine 
liver microsomes, B) equine liver S9 and C) equine lung S9 and D) equine in vivo post-administration urine sample (see text for details 
of sample origin). Note: a minor metabolite at 4.14 mins, assigned as a keto-stanozolol (m/z 343.25), was also observed in the liver 
microsome and in vivo administrations, but is not shown above (see later results from the 5500 Q trap that was able to assign a 
structure to this keto-metabolite). 
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The in vitro incubation conditions used in the current study were such that only phase 1 
enzymatic pathways were activated. This means that metabolites resulting from phase 2 
conjugations with moieties such as glucuronic or sulphuric acid would not be produced. 
However, in theory the relevant cofactors necessary for activating phase 2 metabolism 
could be added to the incubation and is therefore an area for future research. One result 
of this selective phase 1 enzyme pathway activation is that sulfates would not be formed 
in the 17 position of stanozolol or its metabolites. The significance of this lies in that the 
spontaneous decomposition of the 17-sulfates of stanozolol and its metabolites has been 
proposed as a mechanism for the formation of 17-epimers of some 17α-methylated 
steroids (Schanzer et al. 1992). Therefore, the absence of any additional hydroxy-
stanozolol peaks in the in vivo samples compared to the in vitro samples suggests that 
either the spontaneous decomposition of the 17-sulfates of stanozolol and its metabolites 
is not the mechanism by which 17-epimers are formed, or that none of the four major 
hydroxy-stanozolol metabolites observed in vivo take the form of 17-epimers. Since the 
evidence for the spontaneous decomposition of the 17-sulfates of 17α-methylated 
steroids being the pathway to form 17-epimers is strong, the view of the authors is that 
the latter of the two explanations is more likely. 
 
5.3.2 Structural characterisation of the equine metabolites produced in vitro 
 
The stereochemistry of the different metabolites produced in vitro was analysed in more 
detail on the Sciex 5500 Q Trap using product ion scanning experiments. The reason 
that the LTQ-Orbitrap was not used for this purpose was that the low-mass cut-off on the 
LTQ component of this instrument meant that many of the metabolically diagnostic low 
mass ions could not be observed. This situation could theoretically be circumvented by 
the use of a similar LTQ-Orbitrap that makes use of a higher-energy collision 
decomposition (HCD) chamber.  
 
The product ion spectra acquired at 55 eV for reference standards of stanozolol, D3-
stanozolol, 3’-hydroxy-stanozolol, 6-hydroxy-stanozolol, 4α-hydroxy-stanozolol, 4β-
hydroxy-stanozolol and 16β-hydroxy-stanozolol are shown in Fig 3. As reported 
previously (Muck and Henion, 1990, McKinney et al. 2004, Thevis et al. 2005), the LC-
MS/MS spectra of stanozolol and it’s analogues are highly complex. Considerable 
energy needs to be imparted into the molecules before they fragment, and once 
fragmentation is achieved the molecules typically fragment through a range of pathways 
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to a large number of different products. Fragmentation can either proceed through a 
charge-driven route leading to moieties retaining the protonated pyrazole structure or 
alternatively through charge-remote fragmentations leading to a range of moieties, 
including some that retain the D-ring portion of the molecule.  
  
 
Fig 3a – reference standard product ion spectrum (5.89 mins) on the 5500 Q trap at a collision energy of 55 eV for stanozolol (precursor 
ion m/z 329.25). 
  
 
Fig 3b – reference standard product ion spectrum (5.89 mins) on the 5500 Q trap at a collision energy of 55 eV for D3-stanozolol 
(precursor ion m/z 332.25). 
 
  
 
Fig 3c – reference standard product ion spectrum (4.98 mins) on the 5500 Q trap at a collision energy of 55 eV for 3’-hydroxy-stanozolol 
(precursor ion m/z 345.25). 
 
  
 
Fig 3d – reference standard product ion spectrum (4.91 mins) on the 5500 Q trap at a collision energy of 55 eV for 6α-hydroxy-
stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3e – reference standard product ion spectrum (4.91 mins) on the 5500 Q trap at a collision energy of 55 eV for 4α-hydroxy-
stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3f – reference standard product ion spectrum (5.25 mins) on the 5500 Q trap at a collision energy of 55 eV for 4β-hydroxy-stanozolol 
(precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3g – reference standard product ion spectrum (4.82 mins) on the 5500 Q trap at a collision energy of 55 eV for 16β-hydroxy-
stanozolol (precursor ion m/z 345.25). 
  
 
A            B 
 
Fig 4 – total ion chromatogram of A) a product ion scan at a collision energy of 55 eV of m/z 345.25 (hydroxy-stanozolol) and B) a 
product ion scan at a collision energy of 45 eV of m/z 343.25 (keto-stanozolol) ran on the 5500 Q Trap following a 25 μM incubation of 
stanozolol with equine liver microsomes. Metabolite peaks that could be confirmed alongside a reference standard are labelled, while 
metabolites that could be postulated based on pattern of fragmentation are labelled with a question mark (see text for details). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5a – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 15-hydroxy-stanozolol 
metabolite M1 (3.83 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5b – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 6α-hydroxy-stanozolol 
metabolite M2 (4.02 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5c – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 16α-hydroxy-stanozolol 
metabolite M3 (4.17 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5d – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for one of the unknown hydroxy-stanozolol 
metabolites M4 (4.34 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5e – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for one of the unknown hydroxy-stanozolol 
metabolites M5 (4.61 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5f – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 16β-hydroxy-stanozolol 
metabolite M6 (4.82 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5g – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 4α-hydroxy-stanozolol 
metabolite M7 (4.91 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5h – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 3’-hydroxy-stanozolol 
metabolite M8 (4.98 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5i – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 18-hydroxy-stanozolol 
metabolite M9 (5.07 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5j – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 18-hydroxy-stanozolol 
metabolite M9 (5.07 mins) obtained following incubation of D3-stanozolol (precursor ion m/z 348.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5k – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed 4β-hydroxy-stanozolol 
metabolite M10 (5.25 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5l – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed stanozolol N-
oxide/hydroxylamine metabolite M11 (6.13 mins) obtained following incubation of stanozolol (precursor ion m/z 345.25). 
 
  
 
 
    
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5m – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed keto-stanozolol metabolite 
M12 (4.86 mins) obtained following incubation of stanozolol (precursor ion m/z 343.25). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5n – product ion spectrum obtained on the 5500 Q Trap at a collision energy of 55 eV for the proposed keto-stanozolol metabolite 
M12 (4.86 mins) obtained following incubation of D3-stanozolol (precursor ion m/z 346.25). 
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A (at a collision energy of 55 eV) 
 
B (at a collision energy of 55 eV) 
 
C (at a collision energy of 55 eV) 
 
D (at a collision energy of 45 eV) 
 
Fig 6 – m/z 345.25 derived product ion scan chromatograms obtained on the 5500 Q 
Trap (following incubation of 25 uM stanozolol with equine liver microsomes) that aid the 
identification of metabolite peaks (see also the spectra in Fig 5). A; total ion 
chromatogram, B; extracted ion chromatogram of m/z 145, which distinguishes the 4α-
hydroxy-stanozolol peak at 4.01 minutes due to it’s increased m/z 145 (in common with 
the 4β-isomer at 5.25 minutes), C; extracted ion chromatogram of m/z 97, which 
distinguishes the 3’-hydroxy-stanozolol peak at 5.00 minutes due to it’s increased m/z 97 
(in common with the postulated stanozolol N-oxide or hydroxylamine peak at 6.13 
minutes) and D; extracted ion chromatogram of m/z 271, which distinguishes the 16β-
hydroxy-stanozolol peak at 4.82 minutes and suggests that the peak at 4.17 minutes is 
16α-hydroxy-stanozolol. 
 
  
 
 
 
 
 
 
 
 
Fig 7– m/z 361.25 derived product ion scan chromatograms relating to potential di-hydroxy-stanozolol metabolites obtained on the 5500 Q Trap 
at a collision energy of 55 eV following incubation with 25 uM of 6α-hydroxy-stanozolol. No peaks were seen following stanozolol or 16β-
hydroxy-stanozolol incubations.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A (M14)                 B (M15) 
 
Fig 8a – m/z 361.25 derived product ion spectra relating to potential di-hydroxy-stanozolol metabolites obtained on the 5500 Q Trap at a 
collision energy of 55 eV following incubation with 25 uM of 6α-hydroxy-stanozolol. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C (M15)                 D (M16) 
 
Fig 8b – m/z 361.25 derived product ion spectra relating to potential di-hydroxy-stanozolol metabolites obtained on the 5500 Q Trap at a 
collision energy of 55 eV following incubation with 25 uM of 6α-hydroxy-stanozolol. 
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Starting by analysing fragments of parent drug stanozolol (retention time 5.89 mins), 
diagnostic fragments are produced at m/z 81, resulting from charge retention in the 
pyrazole portion of the molecule, at m/z 311, resulting from the loss of water (derived 
from the hydroxy group attached to C17) and at m/z 297 (resulting from the neutral loss 
of 32). The fact that D3-stanozolol also loses 32 and forms a fragment with m/z 300 (and 
therefore retains the three deuterium atoms within the observed charged fragment) 
suggests that the loss of 32 relates to methanol and that the methyl group involved is 
derived from a site other than the deuterated C20 methyl group. The simplest 
explanation would be that the C18 methyl group and the hydroxy group attached to C17 
are lost as methanol in a concerted mechanism leading to the introduction of a double 
bond between C13 and C17 in the observed charged fragment. For 3’-hydroxy-
stanozolol (retention time 4.98 mins), the m/z of 81 that existed in the stanozolol spectra 
is incremented by 16 u to form m/z 97 due to the introduction of the 3’-hydroxy group into 
this pyrazole derived fragment. The product ion spectra of 6α-hydoxy-stanozolol 
(retention time 4.02 mins) does not produce any fragment ions that are indicative of the 
position of hydroxylation, but 4α- and 4β-hydroxy-stanozolol (retention times of 4.91 and 
5.25 mins respectively) show a very characteristic pattern of fragmentation. The spectra 
of these latter two metabolites are characterised by intense fragments at m/z 145 and 
the absence of m/z 81. As proposed by Thevis et al. (Thevis et al. 2005), this can be 
explained by a loss of water at C4 leading to the introduction of a double bond between 
position 4 and 5, with subsequent fission between carbons 6 and 7 and also between 9 
to 8 and 11 leading to a highly stable, conjugated structure. The product ion spectra of 
16β-hydroxy-stanozolol (retention time 4.82 mins) is similar to 6α-hydoxy-stanozolol, 
except that at lower collision energies it produces a fragment at m/z 271 (not observed 
with any of the other hydroxy-stanozolol metabolite reference standards), which is 
proposed to result from cleavage between carbons C13/C17 and C15/C16 depicted in 
Fig 3. 
 
For the equine microsomal incubations, total ion chromatograms resulting from the 
product ion scans of ions m/z 345.25 and 343.25, relating to potential hydroxy-stanozolol 
and keto-stanozolol metabolites respectively, are shown in Fig 4. From these 
chromatograms and the resulting spectra (Fig 5), it was possible to identify 11 hydroxy-
stanozolol (labelled M1 to M11) and one keto-stanozolol (labelled M12) metabolite. 
Hydroxy metabolites M4 and M5 did not produce any fragment ions that were considered 
to be indicative of their position of hydroxylation, but involvement of the pyrazole ring 
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was considered unlikely as both metabolites retained the m/z 81 fragment. Metabolites 
M2, M6, M7, M8 and M10 however, had chromatographic retention times and mass 
spectra that matched reference standards of 6α-, 16β-, 4α-, 3’- and 4β-hydroxy-
stanozolol respectively. Of these, metabolites M6, M7 and M8 were found to partially co-
elute under the conditions used here, but could be readily distinguished from each other 
based on mass spectral fragmentation as shown in Fig 6.  
 
Hydroxy metabolite M1 was the earliest eluting of the hydroxy-metabolites and was 
characterised by a small ion at m/z 287. Although this ion could not be definitively 
ascribed to a particular route of fragmentation, it was considered likely that if the 
metabolite were a 15-hydroxy-stanozolol (of unknown stereochemistry) then fission of 
the D-ring between carbons C13/C17 and C15/C16, analogous to that described for 16β-
hydroxy-stanozolol, would be the most likely explanation for the stability of this particular 
fragment (see Fig 5). This explanation is consistent with results obtained by McKinney et 
al. (2004) where they also proposed that the earliest eluting of their observed in vivo 
hydroxy-stanozolol metabolites to be a 15-hydroxy-stanozolol. The existence of a 15-
hydroxy metabolite of stanozolol in the equine was originally proposed in a previous in 
vivo study performed in our laboratories in the 1990s using electron ionisation GC-MS of 
trimethylsilylated stanozolol sample extracts following a stanozolol in vivo administration 
(Phil Teale – personal observation of previously unpublished data). The use of GC-MS in 
this previous study was highly informative as it was possible to assign the site of 
hydroxylation to either the 15- or 16- positions due to their different patterns of 
fragmentation. The purported 15-hydroxy-stanozolol produced a single intense fragment 
at m/z 231 resulting from a proposed cleavage between C14/C15 and C13/C17 and 
retention of the charge on the derivatised D-ring fragment of the molecule as shown in 
Fig 9. 16β-hydroxy-stanozolol on the other hand also contained a 218 m/z, resulting from 
a proposed cleavage between C15/C16 and C13/C17, again with retention of the charge 
on the derivatised D-ring fragment of the molecule. Trimethylsilylated extracts resulting 
from the in vitro incubation of stanozolol with equine liver microsomes were therefore 
analysed by GC-MS in the current study in order to try and detect the m/z 231 that had 
been shown by this previous study to be present following stanozolol administration. As 
shown in Fig 9, it was possible to identify a peak containing an intense m/z 231 in the 
post-dose in vitro samples. This proposed 15-hydroxy-stanozolol peak co-eluted with a 
peak whose retention time and spectra matched with that of a 4α-hydroxy-stanozolol 
reference standard, but the absence of the intense 231 m/z in either the reference 
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standard spectra or blank in vitro incubations provides support that this ion does relate to 
a potential 15-hydroxy-stanozolol-metabolite. Unfortunately, because of the inherent 
problems of analysing stanozolol by GC-MS (one of the reasons why the majority of the 
study was carried out by LC-MS), it was not possible to set the system up to reanalyse 
the samples using a different chromatographic method able to resolve the metabolite 
peaks. It was also not possible to identify any further compounds in other than the 
proposed 15-hydroxy- and 4α-hydroxy-stanozolol and parent stanozolol itself in the 
samples that were able to be run by GC-MS.  
 
 
A 
 
B 
 
C 
Fig 9 – Full scan EI spectra obtained on the Agilent 7000A for (A) stanozolol-bis-TMS 
reference standard (13.93 min), (B) 4α-hydroxy-stanozolol-tris-TMS reference standard (13.74 
min) and (C) co-eluting 4α- and ?15-hydroxy-stanozolol-tris-TMS spectrum obtained following 
an incubation of 25 uM stanozolol with equine liver microsomes (13.75 min – background 
subtracted). 
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As depicted in Fig 6, hydroxy-metabolite M3 contained an m/z 271 fragment when ran 
under low energy collision conditions. In vitro incubations of equine liver microsomes 
with D3-stanozolol instead of stanozolol (therefore forming deuterated version of the 
metabolites) support the suggestion that the m/z 271 fragment of 16β-hydroxy-stanozolol 
is produced through the route shown in Fig 5. If this is accepted, then since the spectra 
of M3 also contains the m/z 271, then the position of hydroxylation for this metabolite can 
only be on C16 or C20. However, if hydroxylation was in the C20 position then 
fragmentation would likely be very different to that observed and at least one of the 
deuterium atoms (known to be in the C20 position of D3-stanozolol) would also expect 
have been replaced with hydrogen during the process of metabolism. This line of 
evidence, coupled with the expected absence of 17-epimerisation under the in vitro 
conditions used, therefore lead to the suggestion that M3 is 16α-hydroxy-stanozolol. 
 
Hydroxy metabolite M9 fragments very differently to the other hydroxy-metabolites, 
producing an intense fragment at m/z 297. Incubations with D3-stanozolol instead of 
stanozolol caused the fragment for the analogous deuterated metabolite to be shifted to 
m/z 300, indicating that the C20 methyl group is retained within the charged molecule 
during this fragmentation. The mechanism that was considered most likely to lead to this 
stable, intense fragment was via the neutral loss of the hydroxy group at C17 
accompanied by a hydroxylated methyl group (as depicted in Fig 5). Three methyl 
groups exist within stanozolol that could be subject to hydroxylation. The C20 methyl 
group could not have been involved since the D3-stanozolol incubation experiment 
showed that this methyl group was not lost during fragmentation of this metabolite. The 
C19 methyl group was also not considered a likely candidate since none of the lower 
mass fragments that are known to retain the C19 carbon were seen to be altered. This 
process of deduction leads to the speculation that the hydroxylation may be in the C18 
position. This suggestion that is further supported by the observation that this would 
involve a neutral loss of the hydroxy group at C17 accompanied by a hydroxy-methyl 
group at C18, with the subsequent insertion of a stable double bond between carbons 
C13 and C17. 
 
Hydroxy metabolite M11 produced a small fragment at m/z 97 fragment (Fig 5 and 6).  
The presence of this m/z 97 fragment is in common with 3’-hydroxy-stanozolol and 
suggests that hydroxylation of this metabolite involves one of the nitrogens on the 
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pyrazole ring to form either an N-oxide or a hydroxylamine, a suggestion that is backed 
up by the significantly later retention time of this analyte relative to the other metabolites.  
 
Metabolite M12, a proposed keto metabolite due to its monitored M+H mass being 2 u 
down from a hydroxy-stanozolol, was found to produce diagnostic fragment ions at m/z 
257 and 313, for incubations with both stanozolol (from a precursor ion of m/z 343.25) 
and D3-stanozolol (from a precursor ion of m/z 346.25). This suggests that both neutral 
loses involved in these pathways of fragmentation included the C20 methyl group. Since 
the fragment at 313 involves the neutral loss of 30 u from the M+H ion of stanozolol (or 
33 from the M+H ion of D3-stanozolol), the proven inclusion of the C20 methyl group as 
part of this loss means that the other 15 u (or 18 in the case of D3-stanozolol) can only 
be reasonably attributed to a second methyl group from elsewhere in the molecule. The 
most likely methyl group was considered to be that of C18, since this would then involve 
a neutral loss of the two methyl groups at C17 and C18, with the subsequent insertion of 
a stable double bond between carbons C13 and C17. The fragment at m/z 257 was 
attributed to cleavage between carbons C14/C15 and C13/C17 as shown in Fig 5 and 
leads to the speculation that the added ketone group exist in either the 15 or 16 
positions. Support for this isomer taking 16-keto-stanozolol form was provided by 
incubations of equine liver microsomes with 16β-hydroxy-stanozolol instead of 
stanozolol. Since the hydroxy group for this alternative starting material was already 
known to be in the 16 position, then the observed keto-stanozolol-metabolite that was 
produced by the incubation was known to be in the 16-position. Since the keto-stanozolol 
metabolites produced by the incubations with both stanozolol and 16β-hydroxy-
stanozolol had effectively identical retention time and mass spectra (data not shown), 
then this is very strong evidence that this metabolite is 16-keto-stanozolol. 
 
Following the incubations of equine liver microsomes with stanozolol and 16β-hydroxy-
stanozolol, no di-hydroxy metabolites were detected on either the LTQ-Orbitrap or the 
5500 Q trap. However, as shown in Figs 7, when the starting material for incubation was 
change to 6α-hydroxy-stanozolol, four peaks with M+H masses of 361.25 (corresponding 
to di-hydroxy-stanozolol) were detected. Since the starting material for these 
experiments was 6α-hydroxy-stanozolol, it is already known that one of the two hydroxy 
positions is at C6. However, since there is the possibility that the α-hydroxy group at 
position 6 could theoretically have been oxidised to a ketone and then further reduced 
back to a hydroxy of either α or β configuration, it is not possible to assign the 
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stereochemistry of position 6 to these metabolites. Also, as Fig 8 shows, the spectra of 
these metabolites did not produce any fragment ions that could be used to locate the 
position of the second hydroxylation. All that can be said is that the pyrazole ring is not 
likely to be involved since fragments at m/z 81 are observed and is it unlikely to involve 
hydroxylation at position 4 since an enhanced peak at m/z 145 is not visible. Further 
work would need to be performed in order to confirm the locations of the second hydroxy 
group, but considering the propensity of the equine to hydroxylate steroids in the 16 
position, it could be speculated that one or all of these peaks could relate to 6,16-
hydroxy-stanozolol metabolites. 
 
5.3.3 In vitro enzyme inhibition studies 
 
The most definitive way to identify the enzyme isoforms responsible for the metabolism 
of a drug is to incubate the drug with individually expressed recombinantly produced 
versions of enzymes in order to see which ones are able to produce metabolite (James 
Scarth, personal observation). However, since no equine CYPs are commercially 
available as recombinantly expressed proteins, this is not currently a viable option. A 
second option regularly used by the drug development industry is to incubate drug and 
tissue in vitro along with chemical inhibitors that are known to selectively inhibit particular 
enzymes (Bjornsson et al. 2003). A reduced production of metabolite following 
incubation with a particular inhibitor suggests that the inhibited isoform is responsible for 
metabolism. Since a lot is known about the specificity of chemical inhibitors toward a 
range of different human CYPs and since it is a reasonable first step to identifying similar 
enzymes in other species, the chemical inhibitor approach was tested for the stanozolol 
in the equine. Considering the possibility that CYP isoforms in the horse may have an 
altered specificities or rates of reaction compared to the human, a positive result does 
not guarantee that a homologous enzyme exists and/or is involved in stanozolol 
metabolism in the horse. Neither does a negative result guarantee that an analogous 
enzyme does not exist and/or is not involved in metabolism. However, since the 
chemical inhibition route is the best option until recombinantly produced versions of 
equine CYPs are available, this approach was considered worthwhile as the clues it 
provides may guide future research. 
 
Following an initial screen of stanozolol with high concentrations of each of the chemical 
inhibitors (as described in the experimental section), the only chemicals that were found 
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to inhibit the metabolism of stanozolol were ketoconazole and quercetin (as measured by 
the production of 16α- and 16β-hydroxy-stanozolol since these appeared to be the major 
metabolites). More extensive analyses using these two inhibitors were then carried out in 
order to plot full IC50 profiles for the reactions. As detailed in Table 1, ketoconazole was 
a more potent inhibitor than quercetin. Also, the IC50 was lower for 16α-hydroxy- 
compared to 16β-hydroxy-stanozolol for both ketoconazole and quercetin. Quercetin was 
initially chosen as it is considered a relatively selective inhibitor of human CYP2C8 and 
ketoconazole because it is a known inhibitor of CYP3A4. However, complete selectivity 
toward a particular isoform is difficult to achieve and it is often necessary to analyze the 
overall pattern of inhibitors responses before drawing any conclusions. It is therefore 
pertinent to observe that in addition to being a CYP3A4 inhibitor, ketoconazole is also 
known to be a potent inhibitor of CYP2C8 (Bjornsson et al. 2003) The observation that 
both ketoconazole and quercetin were able to reduce the production of 16α-hydroxy- and 
16β-hydroxy-stanozolol by almost 100% at the high concentrations is strong evidence 
that an enzyme related to CYP2C8 is involved in the metabolism of stanozolol in the 
equine. This line of evidence is also consistent with the results of a study by Komuri et al. 
(1993) where the authors found that a purified equine CYP with a high degree of N-
terminal amino acid sequence homology to CYP2C isoforms was able to 16α-
hydroxylate the androgenic/anabolic steroid testosterone. The recent cloning of the 
CYP2C92 gene (DiMaio Knych et al. 2009) is also relevant since this proves the 
existence of at least one CYP2C enzyme isoform in the horse. 
 
Table 1 – determined IC50 values for the inhibition of 16α- and 16β-hydroxy-testosterone 
production from a 25 uM incubation of stanozolol with equine liver microsomes. 
 
 Determined IC50 (μM)
 Ketoconazole Quercetin
16α-hydroxy-
stanozolol 
 
 
 
0.06 (SE +/- 0.05) 
 
 
9.1 (SE +/- 5.5) 
16β-hydroxy-
stanozolol 
 
 
0.52 (SE +/- 0.37) 
 
19.3 (SE +/- 
28.7) 
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5.4 Conclusion 
 
In summary, the in vitro and in vivo phase 1 metabolism results reported herein compare 
well with the existing in vivo paradigm. Also, the flexibility offered by the in vitro 
techniques allowed experiments to be carried out with multiple starting materials, which 
significantly aided the identification of metabolite structures by GC- and LC-MS/MS and 
allowed a CYP isoform that may be important in equine steroid metabolism to be 
identified.  
 
In general, although such in vitro techniques do not serve as a replacement for in vivo 
studies in all situations, they do offer the following advantages: 
 
 The ability to reduce and refine the number of in vivo studies, 
therefore providing a significant benefit with respect to animal welfare.  
 To aid metabolite identification (since they generally produce a more 
concentrated, cleaner extract for analysis). 
 For fast reaction to potential new threats. 
 For studying the mechanisms of metabolism in more detail. 
 To biologically generate reference standards where no chemically 
synthesized metabolite standard is available. 
 For studying the fate of designer drugs that have no toxicological 
profiles. 
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Chapter 6: Metabolism of the ‘designer’ steroid 
estra-4,9-diene-3,17-dione in the equine and 
comparison to human and canine 
 
______________________________________________________________________ 
After: 
 
Scarth, J., Clarke, A., Teale, P. and Pearce, C. Comparative in vitro 
metabolism of the ‘designer’ steroid estra-4,9-diene-3,17-dione between the 
equine, canine and human: identification of target metabolites for use in sports 
doping control. (2010). Steroids, 75, 643-652. 
 
______________________________________________________________________ 
 
 
 
6.1 Introduction 
 
As discussed in chapter 4, the use of androgenic-anabolic steroids (AASs) in the majority 
of horseracing, greyhound racing and human sports are prohibited (Wada, 2009, 
Greyhound Board of Great Britain, 2009, International Federation of Horseracing 
Authorities, 2008). Effective doping control procedures are therefore required in order to 
control their prohibition. Targeted approaches such as gas and liquid chromatography 
linked to tandem mass spectrometry (GC and LC/MS/MS respectively) are the most 
commonly applied analytical methods (Biddle et al. 2009, Fragkaki et al. 2009, Pozo et 
al. 2009a). Using these techniques, the detection of the majority of marketed AAS 
products in human and animal sports is now possible (McKinney et al. 2009, Parr et al. 
2010).  
 
In 2003, however, the scandal surrounding the detection of the novel steroid 
tetrahydrogestrinone (THG) raised concerns about the possible use of such ‘designer’ 
steroids (Catlin et al. 2004). Designer steroids have chemical structures based on 
previously marketed products, but with minor modifications which make them 
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undetectable by the majority of current targeted mass spectrometric procedures (chapter 
4). In the case of THG for example, the drug’s structure is based upon gestrinone, but 
with the 17-alkyl side chain fully saturated such that the relative molecular mass of THG 
is 4 u higher than gestrinone (Catlin et al. 2004). Designer steroids are synthesized 
either to deliberately evade detection, or as appears more common, to enable them to be 
marketed freely on the Internet to customers in some countries because their structures 
do not fall within the scope of legal regulations that prevent the sale of defined steroidal 
products. An Internet search for ‘designer steroids’ quickly produces many hits for low-
cost formulations of steroids that can be ordered and delivered directly to a consumer’s 
home address. Since the majority of these compounds are available only on the Internet, 
their biological activity and the extent of their use is difficult to determine. One such 
steroid that currently (January 2010) features in a large number of marketed products 
and in Internet forums discussing its use by sportspersons (J. Scarth, personal 
observation) is estra-4,9-diene-3,17-dione. This compound is based on the structure of 
the known steroid trenbolone but differs in that the oxygen function at carbon 17 has 
been converted to a ketone and it is lacking the 11-12 double-bond (Fig 1). It is therefore 
not a pro-drug of trenbolone, but rather a structural analogue and hence its metabolism 
needs to be considered separately from trenbolone.  
 
A      B 
 
Fig 1 – structures of A; trenbolone (17β-hydroxy-estra-4,9,11-trien-3-one) and B; estra-
4,9-diene-3,17-dione (a structural analogue, not a pro-drug, of trenbolone). 
 
Effective control of steroids such as estra-4,9-diene-3,17-dione requires knowledge of 
their metabolism in order to be able to target the most abundant metabolites (Biddle et 
al. 2009, Houghton et al. 1979, Dumasia et al. 1983, Schänzer, 1996, Van Eenoo and 
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Delbeke, 2006, Poelmans et al. 2006). Because designer steroids do not have defined 
toxicological profiles, it is difficult to obtain ethical approval for in vivo administrations. In 
vivo experiments are also typically more costly than in vitro procedures. Therefore, 
attractive alternatives that have shown excellent qualitative in vivo correlation are the use 
of different in vitro models, involving incubation of steroids with either ex vivo mammalian 
liver preparations (Ho et al. 2005, Ho et al. 2007,Leung et al. 2004, Scarth et al. 2010a, 
Scarth et al. 2010b) or surrogate invertebrate models (De Wasch et al. 2002, Verheyden 
et al. 2007). Two recent equine publications from our laboratories for example have 
shown that for both steroidal (Scarth et al. 2010a) and non-steroidal (Scarth et al. 2010b) 
drugs, all major in vivo metabolites were also detected following in vitro incubation using 
either liver microsomes or S9 (as presented in chapter 5 using stanozolol as an 
example). It is important to point out, however, that while the qualitative profile of 
metabolites compares favourably between in vitro and in vivo, the quantitative profile of 
metabolites can vary between the two conditions. An alternative that has recently been 
developed is the use of rodent model transplanted with human hepatocytes (Lootens et 
al. 2009, Pozo et al. 2009b). Using this approach, human type metabolism can be 
investigated without the need for experimenting on people. In the future, it may be 
possible to adapt this approach to utilise equine hepatocytes. However, this technique 
still requires the use of animal experimentation.  
 
To date, no studies have reported the metabolism of designer steroids in the canine and 
only one study has been reported in the equine. In the equine study, Kwok et al. (2006) 
reported the in vivo and in vitro metabolism of desoxy-vinyltestosterone and some of its 
analogues. In contrast to the equine and canine, relatively more studies have been 
carried out in the human. Levesque et al. (2005) and Gauthier et al. in (2009) used 
human hepatocytes to study the in vitro metabolism of THG and 17α-methyl-
drostanolone respectively, while Rodchenkov et al. (2006) studied the in vivo human 
metabolism of a number of capsulated products purported to contain different steroidal 
products. In the latter study, however, reference standards for the compounds in 
question were not available to confirm the structures of the steroids contained in the 
capsules obtained on the Internet. Thevis et al. (2005a) reported the mass spectrometric 
behaviour of a range of different designer steroids, but this report was limited to the 
structures of the ‘parent’ steroids. Because of this limited number of studies, there still 
remains a large number of designer steroids are available on the Internet for which 
knowledge of metabolism is not available. 
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In addition to knowledge of the metabolism of a designer steroid, it would also be ideal to 
be able to retrospectively analyse sample testing data once a new steroid is discovered 
in order that it can be determined whether abuse of the product has occurred. Most of 
the existing targeted GC- or LC-MS/MS procedures do not allow for this retrospectivity 
(McKinney et al. 2009). Recently, however, full scan high-resolution accurate-mass LC-
MS (HR-LC-MS) has been applied to the study of the metabolism and detection of drugs 
in doping control (Scarth et al. 2010a, Virus et al. 2008, Thevis et al. 2005b). Because 
full scan data are acquired, previously tested samples can be retrospectively analysed 
once intelligence of a new designer steroid becomes available.  
 
In this study, the in vitro metabolism of estra-4,9-diene-3,17-dione is reported for the first 
time. This is also the first study comparing the metabolism of a designer steroid in the 
three major species subject to regular doping control; namely equine, canine and human. 
In order to allow the retrospective analysis of sample testing data, the use of a HR-LC-
MS Thermo LTQ-Orbitrap instrument was employed for metabolite identification of 
underivatised sample extracts. The full scan HR-LC-MS Orbitrap data was then 
complemented by several further experiments targeted at elucidating more detailed 
structural information for the most abundant metabolites. These included; HR-LC-MS/MS 
of the underivatised metabolites, functional group selective chemical derivatisation and 
full scan HR-LC-MS, enzyme inhibition experiments and electron ionisation (EI) GC-MS 
analysis of methoxyamine-trimethylsilyl (MO-TMS) derivatives. 
 
6.2 Experimental 
 
6.2.1 Chemicals and reagents 
 
Deionized water was prepared using an SG Ultrachem TWF UV system (Barsbuttel, 
Germany). Pyridine and all acids, bases and solvents were analytical grade and were 
purchased from Fisher Scientific (Loughborough, UK). Trizma base and HCl, N-Methyl-n-
(trimethylsilyl)-trifluoroacetamide, sodium borohydride, methoxyamine hydrochloride, 
NADPH and NAD were obtained from Sigma-Aldrich (Dorset, UK). A 100 mm x 2.0 ID 
2.5 µm HST Luna C18(2) column was obtained from Phenomenex (Macclesfield, UK). 
Equine liver S9 (at 20 mg ml-1 protein and from a female Quarter horse), canine liver S9 
(at 20 mg ml-1 and from a mixed male/female Beagle pool) and human liver S9 (at 20 mg 
ml-1 and from a mixed male/female pool) were purchased from Xenotech Llc. (Lenexa, 
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USA). Estra-4,9-diene-3,17-dione was supplied by Toronto Research Chemicals (North 
York, Canada). Finasteride was obtained from Merck Share and Dohme (Granville, 
Australia).  
 
6.2.2 Nuclear Magnetic Resonance (NMR) analysis of estra-4,9-diene-3,17-dione 
 
As a quality control measure, the estra-4,9-diene-3,17-dione reference standard used for 
the in vitro incubations was examined by NMR.  A sample of the standard (~3 mg) was 
dissolved in fully deuterated methanol (MeOH-d4) and the resulting solution (~0.5 ml) 
used for all NMR experiments analysed on a Bruker Avance DRX 500.  1H, 13C and 
DEPT-135 spectra were acquired using standard pulse sequences and demonstrated 
consistency with the proposed structure, as summarised below. 
 
1H spectrum (500 MHz): δ5.67 (1H, singlet) – consistent with H-4; δ1.04 (3H, s) – 
consistent with Me-18; δ2.95 (2H, multiplet), δ2.48 (7H, m), δ 2.10 (4H, m), δ 1.85 (1H, 
m), δ1.70 (1H, m), δ1.49 (1H, m) and δ1.37 (2H, m) – not individually assigned but with 
chemical shifts consistent with all other methine and methylene protons expected. 
 
13C spectrum (125 MHz; partially assigned using DEPT-135): δ222.5 (C-17); δ202.5 (C-
3); δ 160.4 and δ147.8 (C-5/C-10); δ127.2 (C-9); δ122.6 (C-4); δ52.6 and δ40.0 (C-8/C-
14); δ 48.9 (C-13); δ37.9, δ36.7, δ32.7, δ31.7, δ27.7, δ26.8, δ26.1 and δ 22.8 (C-1/C-
2/C-6/C-7/C-11/C-12/C-15/C-16); and δ13.5 (C-18). 
 
Standard injections of a steroid reference solution were also performed under the LC- 
and GC-MS conditions that were used for the identification of metabolites (see below). 
The outcome of these experiments is detailed in the results section where the 
significance of any impurities in relation to metabolite identification is discussed. 
 
6.2.3 In vitro incubations 
 
Incubations of estra-4,9-diene-3,17-dione were performed with equine, canine and 
human liver S9 (the post-mitochondrial spin tissue fraction). The S9 fraction was 
preferred over microsomes since it contains a wider range of drug metabolising enzymes 
(Gibson and Skeet, 2001). Also, S9 and microsome fractions are currently the only tissue 
preparations commercially available in the equine (liver slices were not available from 
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the horse and would have presented practical problems regarding obtaining fresh liver 
from each three species at the same time). Reactions volumes were 0.66 ml and 
contained drug (at 15 or 150 μM), liver S9 (at 1 mg ml-1 protein for all species and 
therefore providing as level basis as possible for which to compare metabolic activity 
between species), NADPH (0.63 mM), NAD (0.63 mM) and pH 7.4 TRIS buffer (50 mM). 
Samples were incubated in a water bath at 37oC for 2 hours and 150 μl aliquots were 
quenched at 0 and 120 mins by the addition of 300 μl of ice-cold acetonitrile. Control 
experiments with either no added cofactor or no S9 were also performed in order to 
check that metabolism was responsible for producing any metabolites observed.  
 
If required, it is possible to activate phase 2 metabolic pathways in liver S9 tissue. 
However, phase 2 metabolism was not activated in vitro since the current methods of 
choice for the analysis for steroids in sports drug surveillance generally use 
deconjugation followed by analysis of the ‘free’ drug using either GC- or LC-MS/MS 
(Biddle et al. 2009, Fragkaki et al. 2009, Pozo et al. 2009, McKinney et al. 2009). While 
the choice of whether to activate phase 2 metabolism or not may also have a small 
influence on the quantitative profile of phase 1 metabolites (due to a sequestering effect 
of the conjugating moiety), this effect is generally only small (J. Scarth, personal 
observation) and does not affect the qualitative profile of metabolites. 
 
6.2.4 Enzyme inhibition experiments 
 
Estra-4,9-diene-3,17-dione was also incubated under the above conditions, but in the 
presence of finasteride (at 50 μM). The rationale for adding finasteride is because it is a 
known inhibitor of the 5α-reductase type 2 (Vis and Schröder, 2009) and 5β-reductase 
(Drury et al. 2009) enzymes. Therefore, if incubation with this inhibitor causes a fall in the 
production of any mono-reduced metabolites, then this would be supporting evidence 
that reduction occurs at a site distinct from the 5-position.  
 
6.2.5 Preparation of samples for LC- or GC-MS analysis 
 
Sample were analysed by LC/MS either underivatised or following chemical modification 
to form methoxyamine derivatives of the ketone groups (as an aid to structural 
elucidation). In both cases, the quenched aliquots from the in vitro incubations were 
centrifuged for 5 mins at 11,000 rpm, the supernatant transferred to a separate vial and 
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blown down to dryness at 60oC. For the underivatised samples, these were simply 
reconstituted in 5 µl propan-2-ol followed by 95 µl of water and then submitted to LC-MS 
analysis on the Thermo LTQ-Orbitrap. For the derivatised samples, 50 μl of 
methoxyamine in pyridine (1 M) was added and the samples heated at 60oC for 30-mins. 
Samples were then blown down to dryness at 60 oC, reconstituted in 5 µl propan-2-ol 
followed by 95 µl of water and then submitted to LC-MS analysis on the Thermo LTQ-
Orbitrap. 
 
For samples that were analysed by GC-MS as their methoxyamine-trimethylsilyl (MO-
TMS) derivatives, the quenched aliquots from the in vitro incubations were centrifuged 
for 5 mins at 11,000 rpm, the supernatant transferred to a separate vial and blown down 
to dryness at 60oC. 50 μl of methoxyamine in pyridine (1 M) was added and the samples 
heated at 60oC for 30-mins. Samples were then blown down to dryness at 60 oC, 
reconstituted in 50 μl of N-Methyl-n-(trimethylsilyl)-trifluoroacetamide (MSTFA) and 
heated at 600C for 2-hours before being submitted to GC-MS analysis on the Varian 
1200L.  
 
6.2.6 Chemical reduction of estra-4,9-diene-3,17-dione 
 
Estra-4,9-diene-3,17-dione was reduced by mixing 0.5 mg of the steroid with 500 μl 
methanol, 100 μl water and 1 mg of sodium borohydride in a 3 ml glass vial suspended 
in a beaker containing ice. The mixture was then left to react for 30-minutes. 50 μl 
aliquots of the reaction mixture were removed to separate glass vials at 0, 10, 20 and 30 
minutes. To each aliquot was then immediately added 2 ml of 0.02 M HCl and 4 ml 
diethyl ether before samples were capped and rotary mixed for 10-minutes. The organic 
layer was then removed to a clean glass vial, blown down to dryness at 60 oC, 
reconstituted in 10 µl propan-2-ol followed by 190 µl of water and submitted for HR-LC-
MS analyses under the same conditions that were used for the analyses of the in vitro 
incubates. 
 
6.2.7 Thermo LTQ-Orbitrap HR-LC-MS and HR-LC-MS/MS analyses  
 
Initial metabolite identification was carried out using HR-LC-MS and then followed-up by 
HR-LC-MS/MS in order to obtain more detailed structural information regarding the 
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metabolites. All data was acquired and processed using the Xcalibur version 2.0.7 
software. 
 
For the full scan HR-LC-MS metabolite identification experiments, 10 μl of sample was 
introduced onto a Thermo Accela autosampler/HPLC linked to a Thermo Discovery LTQ-
Orbitrap. Chromatography was carried out using a Phenomenex 100 mm x 2.0 ID 2.5 µm 
HST Luna C18(2) column held at 35OC. Flow rate was 400 μl min-1 until 4.0 mins, at 
which time it was increased linearly to 500 μl min-1 at 4.20, before being held at this flow 
rate until 4.99 mins, reduced back to 400 μl min-1 by 5.00 mins and then held at this flow 
rate until the end of the run. Mobile phase A was 0.1% acetic acid with 300 µg l-1 uracil 
(external calibrant), mobile phase B was 0.1% acetic acid in methanol with 300 µg l-1 
uracil (external calibrant) and mobile phase C was 99:1 methanol:2 M pH 4 acetate 
buffer with 300 µg l-1 uracil (external calibrant). Mobile phase A was 90% at 0 mins, 
dropping to 40% at 1.0 mins and then 2% at 3.49 mins, before being held at 2% until 
4.99 mins when it was increased to 90% over 0.01 mins and held at 90% until 5.5 mins. 
Mobile phase B was 10% at 0 mins, rising to 60% at 1.0 mins, 98% at 3.49 mins, before 
dropping to 23% at 3.50 mins, held at 23% until 4.50 mins when it was increased to 98% 
over 0.01 mins, held at 98% until 4.99 mins, dropped to 10% over 0.01 mins and then 
held at 10% until 5.5 mins. Mobile phase C was 0% from 0 to 3.49 mins, before being 
increased to 75% over 0.01 mins at 3.49 mins, held at 75% until 4.50 mins, dropped 
back to 0% over 0.01 mins and then held at 0% until 5.50 mins. Sample ionisation was 
carried out in the positive mode using the electrospray source at a capillary temperature 
of 200oC, a sheath gas flow of 40 units, an auxiliary gas flow of 5 units and an 
electrospray voltage of 4.5 kV. Full scan centroid data over a range from 100 to 550 u 
was then acquired by the LTQ Orbitrap using a resolution of 30,000 at full width at half 
maximum height (FWHM).  
 
For the follow-up HR-MS/MS experiments, instrumental conditions were the same as the 
above, except that the chosen MS/MS precursor ions (see results section for details) 
were first isolated in the LTQ section of the instrument and then fragmented at a 
normalised collision energy of 35, before the resulting ions were supplied (via a C-trap) 
onto the Orbitrap itself for full scan centroid analysis at a resolution of 30,000 at FWHM.  
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6.2.8 Varian 1200L GC-MS analyses 
 
1 μl of sample was introduced into a Varian 1177 split-splitless injector held at 260oC. 
The injector split was initially closed, before being opened after 1.00 mins at a split ratio 
of to 50:1 for the remainder of the run-time. Chromatography was carried out using a 
Varian CP-3800 gas chromatograph with helium as the carrier gas (1.3 ml min-1). A 
Varian VF-5MS 30m x 250 um x 0.25 um column was initially held at 180oC for 1.00 
minutes and then ramped by 20oC min-1 to 250oC at 4.50 minutes, ramped by a further 
5.0oC min-1 to 310oC at 16.50 minutes and then held at 310oC until 30.00 minutes. 
 
Mass spectrometry was carried out using a Varian 1200L triple quadrupole mass 
spectrometer operated in the positive electron ionization (EI) mode. Full scan centroid 
data between 50 and 600 u was acquired. Transfer line temperature was 280oC, ion 
source temperature was 230oC, electron energy was 70 eV and the electron multiplier 
was used in extended dynamic range mode. Data were acquired and processed using 
the Varian Workstation version 6.9 software. 
 
6.3 Results and Discussion 
 
6.3.1 Comparison of the full scan high-resolution accurate-mass LC-MS data 
between equine, canine and human 
 
Underivatised compounds detected by HR-LC-MS were assigned as metabolites when a 
peak was observed at a mass tolerance of 5 ppm in an extracted ion chromatogram from 
the post-dose in vitro incubations that was not present in the pre-dose or control 
incubations. Investigated metabolic transformations were pre-defined and included single 
or multiple events (including combinations) of reduction, oxidation, hydroxylation, 
carboxylation, demethylation and dehydration. The total ion chromatograms were also 
inspected for the presence of any addition peaks that appeared in the post-dose 
samples. Using this strategy, 11 putative metabolites of estra-4,9-diene-3,17-dione were 
identified in the 150 μM estra-4,9-diene-3,17-dione incubations across the different 
species. The results from the 15 and 150 μM incubations produced comparable 
metabolite profiles in all species, but some of the more minor metabolites were only 
visible in the 150 μM incubations due to their low concentrations. Therefore, only the 
results from the 150 μM incubations will be discussed herein.  
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All eleven of the putative metabolites were detected in the equine incubations, with 
instrumental responses generally much higher than in the other species (Fig 2, 3 and 4 
and Table 1). Although the estra-4,9-diene-3,17-dione reference standard was shown by 
NMR to be relatively pure, the high sensitivity of the LTQ-Orbitrap allowed the detection 
of two small impurities corresponding to hydroxylated versions of the ‘parent’ steroid at 
m/z 287.1642 (peaks at 2.80 and 2.98 mins in Fig 2D). Peak intensities of these two 
impurities compared to that of the parent steroid in a drug standard solution (with relative 
abundances therefore not affected by enzymatic metabolism) were 0.5 and 0.1 % 
respectively. No further impurities were identified by either LC- or GC-MS. Because 
these impurity peaks did not increase in size between the pre- and post-dose 
incubations, they were not assigned as metabolites. However, when considering any 
potential reduced-hydroxy metabolites appearing in the post-dose samples in vitro, the 
possibility arises that one or more of these may have derived from the hydroxylated 
impurities rather than directly from the parent steroid. However, any such reduced-
hydroxy compounds detected may still have relevance for detection of estra-4,9-diene-
3,17-dione abuse since analysis by our laboratories of marketed capsules containing 
estra-4,9-diene-3,17-dione have demonstrated that these impurities are also present in 
these products (data not shown) and hence would also be expected to contribute to the 
metabolic profile in vivo. 
 
The major metabolite (M1) detected in all species, and therefore the most suitable 
candidate for screening of estra-4,9-diene-3,17-dione abuse, was a mono-reduced 
metabolite with m/z 273.1849. The remainder of the metabolites detected were much 
less abundant, with none reaching more than 20% of the instrumental response of M1 
(Fig 3 and 4). A second, later eluting, mono-reduced metabolite, M2, was also present in 
each species. M3 was unique to the equine and corresponded to a di-reduced metabolite 
with m/z 275.2006. M4 and M5 were assigned as hydroxy-metabolites at m/z 287.1642. 
M4 was common to all species, but M5 was unique to the equine. It is important to note 
that M5 was observed to elute between two large impurities with the same elemental 
composition (as discussed earlier). Therefore, the failure to observe a discernable peak 
for M5 in the canine and human experiments does not necessarily mean that no 
metabolite was present, only that it was not large enough to be distinguished (unlike the 
equine). M6 to M11 were assigned as mono-reduced-hydroxy-metabolites at m/z 
289.1798. M6, M8 and M10 were common to all species, but M7 and M11 were only 
detected in the equine. M9 was only detected in the equine and human. Since the inter-
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species profile of metabolites M6 and M10 compared well with the inter-species profile of 
the major reduced metabolite M1, it is possible that these two metabolites are the 
reduced versions of the two hydroxylated reference standard impurities discussed 
earlier. As will be discussed in the following section, M5 and M8 produced unique 
fragment ions on MS/MS, distinct from those of the hydroxylated impurity peaks, 
providing strong evidence that M8 is a true metabolite of estra-4,9-diene-3,17-dione 
rather than a metabolite of a hydroxylated impurity.   
  
Table 1 – summary of the HR-LC-MS results obtained on the LTQ-Orbitrap for the different metabolites identified from the equine, 
canine and human S9 incubations (following incubation at 150 uM steroid and 1 mg ml-1 protein), their proposed structures, theoretical 
mono-isotopic masses and retention times (see text for more details and results of experiments using auxiliary techniques that help 
confirm the structures).  
 
* M5 was observed to elute between two large impurities with the same elemental composition. Therefore, the failure to observe a discernable peak for M5 in the canine and 
human experiments does not necessarily mean that no metabolite was present, only that it was not large enough to be distinguished (unlike the equine). 
 
** The positions of hydroxylation in M6, M7, M9, M10 and M11 could not be established. The site of reduction in these compounds could not be confirmed, but is proposed to 
be in either position 3 or 17 for each due to their detection as mono-MO derivatives (Figure 5). 
 
Metabolite peak observed in an extracted ion chromatogram 
when using a mass tolerance of 5 ppm (proposed structures 
appear in brackets) 
Theoretical 
mass 
(M+H+) 
 
Retention 
time 
(mins) 
 
Peak 
height in 
equine S9 
 
Peak height 
in canine S9 
 
Peak height 
in human 
S9 
 
      
Estra-4,9-diene-3,17-dione (parent drug) 271.1693 3.37 N/A N/A N/A 
      
M1 (17-hydroxy-estra-4,9-dien-3-one) 273.1849 3.57 4.5 x 107 6.8 x 106 1.6 x 107 
M2 (17-hydroxy-estra-4,9-dien-3-one or  
3-hydroxy-estra-4,9-dien-17-one) 
273.1849 3.79 1.2 x 106 2.0 x 105 1.0 x 105 
M3 (estra-4,9-diene-3,17-diol) 275.2006 3.65 3.1 x 104 No peak No peak 
M4 (A-, B- or C-ring hydroxy-estra-4,9-diene-3,17-dione) 287.1642 2.69 1.2 x 106 1.3 x 106 3.3 x 106 
M5 (15 or 16-hydroxy-estra-4,9-diene-3,17-dione) 287.1642 2.85 8.0 x 105 No peak* No peak* 
M6 (reduced and hydroxylated estra-4,9-diene-3,17-dione)** 289.1798 2.65 9.1 x 105 3.1 x 104 6.0 x 105 
M7 (reduced and hydroxylated estra-4,9-diene-3,17-dione)** 289.1798 2.76 2.8 x 105 No peak No peak 
M8 (15 or 16, 17-dihydroxy-estra-4,9-dien-3-one) 289.1798 2.94 3.4 x 106 2.6 x 104 1.2 x 105 
M9 (reduced and hydroxylated estra-4,9-diene-3,17-dione)** 289.1798 3.05 5.0 x 105 No peak 3.0 x 104 
M10 (reduced and hydroxylated estra-4,9-diene-3,17-dione)** 289.1798 3.15 7.9 x 104 2.2 x 104 2.5 x 104 
M11 (reduced and hydroxylated estra-4,9-diene-3,17-dione)** 289.1798 3.22 8.0 x 104 No peak No peak 
      
 
 
  
 
 
 
 
 
 
 
 
                                    A                             B 
 
 
 
 
 
 
 
 
 
                                    C                D                 E 
Fig 2– extracted HR-LC-MS  ion chromatograms at a mass tolerance of 5 ppm following incubation of equine liver S9 with estra-4,9-
diene-3,17-dione (150 μM) for A; ‘parent’ estra-4,9-diene-3,17-dione, B; M1 and M2 (mono-reduced at m/z 273.1849), C; M3 (di-
reduced at m/z 275.2006), D; M4 and M5 (hydroxylated at m/z 287.1642), E; M6 to M11 (mono-reduced and hydroxylated at m/z 
289.1798). 
  
 
Fig 3 – relative HR-LC-MS responses of the major mono-reduced metabolite (M1 – m/z 273.1849) following the equine, canine and 
human liver S9 incubations (1 mg ml-1 protein for all species) with estra-4,9-diene-3,17-dione (150 μM). 
  
Fig 4 - relative HR-LC-MS responses of the minor metabolites following the equine, canine and human liver S9 incubations (1 mg ml-1 
protein for all species) with estra-4,9-diene-3,17-dione (150 μM). M2 - mono-reduced (m/z 273.1849), M3 - di-reduced (m/z 275.2006), 
M4 and M5 - hydroxylated (m/z 287.1642), M6 to M11 – mono-reduced and hydroxylated (m/z 289.1798). See also a note in legend to 
Table 1 regarding M5. 
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Further structural elucidation of each of the metabolites, including positional information 
on the sites of reduction and hydroxylation, could not be gained from underivatised HR-
LC-MS data alone. A more detailed consideration of the metabolite structures will be 
presented in the following section, where alternative analytical approaches were 
employed.  
 
In terms of overall trends between the species, reductive metabolism in the canine 
appeared to be less significant that the other two species, while reductive metabolism in 
the equine was especially active. The equine was also unique in producing the di-
reduced metabolite M3 and also relatively large quantities of hydroxy-metabolite M5 and 
hydroxy-reduced metabolite M8. 
 
6.3.2 Structural characterisation of the metabolites produced in vitro 
 
A deuterated estra-4,9-diene-3,17-dione reference standard or other analogous steroids 
with a 4,9-diene structure were not commercially available at the time that this study was 
carried out. The class of steroids with structures closest to estra-4,9-diene-3,17-dione 
that might therefore be useful in guiding possible metabolic pathways were the 4,9,11-
triene steroids trenbolone, altrenogest, gestrinone and THG. For each of these steroids, 
the presence of the extended conjugated double-bond system inhibits reductive 
metabolism of the A-ring in all species studied to date. Trenbolone, for example, is 
metabolised principally to its 17α-isomer in both the horse (Houghton, 1992) and in man 
(De Boer et al. 1991). The horse also produces several 16-hydroxy-metabolites 
(Houghton, 1992). Altrenogest is similar to trenbolone, except that it contains a 17-α-
alkyl subsistent and has been shown to directly conjugate to glucuronide or sulfate in the 
horse, with no phase 1 metabolises having been observed (Lampinen-Salomonsson et 
al. 2006). The metabolism of THG and gestrinone have been studied in the human and 
both proceed through hydroxylation at position 18, with hydroxylation at the position 16 
also having been proposed as a minor pathway for THG (Lévesque et al. 2005) Data 
regarding the metabolism of steroids with 4,9,11-triene structures in the canine are 
currently lacking. Considering the results of the aforementioned studies, it might 
therefore be expected that the A-ring reductive metabolism of estra-4,9-diene-3,17-dione 
might also be inhibited and that reduction at position 17 might instead be more 
significant.  
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Since the equine produced all eleven of the major metabolites observed by HR-LC-MS 
and at generally higher concentrations than the other species, the follow-up analytical 
approaches targeted at elucidating the structures of the different metabolites were 
conducted using equine incubations.  
 
  
 
                       A                           B                         C 
 
Fig 5 – extracted HR-LC-MS ion chromatograms at a mass tolerance of 5 ppm following incubation of equine liver S9 with estra-4,9-
diene-3,17-dione (150 μM) followed by ketone group derivatisation with methoxyamine (MO). A; ‘parent’ estra-4,9-diene-3,17-dione (bis-
MO derivative at m//z 329.2224), B; mono-reduced metabolite M1 (mono-MO derivative at m//z 302.2115) and C; mono-reduced-
hydroxy metabolites (mono-MO derivative at m//z 318.2064). Note that the resolution of the syn and anti MO isomers is apparent in C; 
something that was not observed in either A or B). 
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Fig 6a – HR-LC-MS/MS spectrum and proposed diagnostic ion fragmentation pathways for 
estra-4,9-diene-3,17-dione. 
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Fig 6b – HR-LC-MS/MS spectrum and proposed diagnostic ion fragmentation pathways for 
17z-hydroxy-estra-4,9-dien-3-one (M1) following incubation of estra-4,9-diene-3,17-dione with 
equine liver S9 (150 μM). ‘z’ indicates unknown stereochemistry. 
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Fig 6c – HR-LC-MS/MS spectrum and proposed diagnostic ion fragmentation pathways for z-
hydroxy-estra-4,9-diene-3,17-dione (M4), following incubation of estra-4,9-diene-3,17-dione 
with equine liver S9 (150 μM). ‘z’ indicates unknown stereochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
268 of 331 
 
 
 
 
 
Fig 6d – HR-LC-MS/MS spectrum and proposed diagnostic ion fragmentation pathways for 
15z/16z-hydroxy-estra-4,9-diene-3,17-dione (M5) following incubation of estra-4,9-diene-3,17-
dione with equine liver S9 (150 μM). ‘z’ indicates unknown stereochemistry. 
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Fig 6e – HR-LC-MS/MS spectrum and proposed diagnostic ion fragmentation pathways for 
15z/16z,17z-dihydroxy-estra-4,9-dien-3-one (M8)  following incubation of estra-4,9-diene-
3,17-dione with equine liver S9 (150 μM). ‘z’ indicates unknown stereochemistry. 
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  A 
 
  B 
 
  C 
Fig 7 – EI-GC-MS spectra and proposed diagnostic ion fragmentation pathways for A; estra-
4,9-diene-3,17-dione bis-MO, B; 17z-hydroxy-4,9-dien-3-one MO-TMS (M1) and C; 
15z/16z,17z-dihydroxy-4,9-dien-3-one MO-bis-TMS (M8) following incubation of estra-4,9-
diene-3,17-dione with equine liver S9 (150 μM). ‘z’ indicates unknown stereochemistry. 
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Steroids with an intact 3-keto,4-ene double-bond system ionise well in positive ion 
electrospray LC-MS due to resonance stabilisation, whereas reduction at the 3 or 5 
positions significantly reduces the ionisation efficiency (Higashi et al. 2005). The first clue 
as to the structure of the major mono-reduced metabolite M1 therefore came from the 
strength of the HR-LC-MS signal that was observed for this analyte. The strong signal 
M1 (Fig 2B) suggests that reduction of metabolite M1 occurs at a site distinct from 
positions 3 or 5, namely at either the 9 or 17 positions. Further support for the lack of 
reduction at position 5 came from the enzyme inhibition experiments with the 5α-
reductase type 2/5β-reductase inhibitor finasteride, which failed to inhibit the formation of 
metabolite M1 (data not shown). 
 
Evidence for the reduction of metabolite M1 being at one of positions 3 or 17, rather than 
position 9, came from the chemical derivatisation experiments with methoxyamine (MO). 
MO derivatives will only form with ketone groups, not hydroxyl functions, and can 
therefore be used to ascertain whether reduction occurs at a carbon-carbon double bond 
or on a ketone. As shown in Fig 5, metabolite M1 formed only a mono-MO derivative, 
suggesting that one of the ketone groups had been reduced.   
 
Another clue as to the structure of metabolite M1 was provided by the chemical reduction 
experiment of estra-4,9-diene-3,17-dione with sodium borohydride. Under methanolic-
aqueous conditions, sodium borohydride is known to lead to preferential reduction of the 
17-keto group in 3,17-diketo-4-ene steroids because the 3-keto function is protected to 
some extent through it’s chemical conjugation (Goncharova and Grinenko, 1976, Kohler 
et al. 2007). Hence, the observation that metabolite peak M1 had the same 
chromatographic retention time on HR-LC-MS as the major mono-reduced product 
(>95%) from the chemical reduction of estra-4,9-diene-3,17-dione with sodium 
borohydride is strong supporting evidence for the site of reduction of M1 being at position 
17 (data not shown).  
 
Final support for the proposition of reduction at position 17 in metabolite M1 came from 
the full-scan mass spectra obtained by HR-LC-MS/MS and EI-GC-MS. Any proposed 
HR-LC-MS/MS fragments discussed in the following section were found to be within 1 
ppm of their theoretical mono-isotopic masses, therefore giving increased confidence in 
the assignment of product ion structures. As shown in Fig 6A, ‘parent’ estra-4,9-diene-
3,17-dione (precursor ion m/z 271) was proposed to fragment under HR-LC-MS/MS 
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through cleavage at carbons 8-14 and 12-13, forming a highly stable conjugated product 
ion at m/z 175. Metabolite M1 (precursor ion 273) on the other hand (Fig 6B) was 
proposed to fragment through cleavage at carbons 8-14 and 11-12 to form a product at 
m/z 161 and through the further loss of two hydrogens to form an observed product ion 
at m/z 159. Under low resolution EI-GC-MS conditions, the bis-MO derivative of estra-
4,9-diene-3,17-dione (molecular ion m/z 328) produced a diagnostic fragment ion at m/z 
190 (Fig 7A), proposed to have formed through cleavage between carbons 8-14 and 11-
12. For metabolite M1, a molecular ion at m/z 373 was observed, consistent with an MO-
TMS derivative of a metabolite reduced at one of the keto-functions (Fig 7B). Support for 
the reduction occurring at position 17 came from the diagnostic fragment ions at m/z 129 
and 242, each proposed to be generated through cleavage between carbons 14-15 and 
13-17, but with the charge residing on the A/B/C-ring portion of the molecule for m/z 242 
and on the D-ring moiety in the case of m/z 129. Further support for the proposed 
fragment at m/z 242 taking this structure is provided by the published spectrum of 
trenbolone-MO-TMS, which produces an analogous fragment at m/z 240, which is two u 
down on that of M1 because of the introduction of trenbolone’s double bond at position 
11 (Marques et al. 2007).  
 
Although the aforementioned results provide very strong evidence for the reduction of 
metabolite M1 occurring at position 17, the stereochemistry of the resulting hydroxy 
function remains unconfirmed at the current time. However, since sodium borohydride is 
known to lead to the selective reduction of the 17 ketone group to the corresponding 
17β-hydoxy isomer (Goncharova and Grinenko, 1976, Kohler et al. 2007), the correlation 
of the chromatographic retention time of metabolite M1 with that of the major mono-
reduced product following sodium borohydride reduction of estra-4,9-diene-3,17-dione is 
highly suggestive of M1 taking the 17β-hydoxy form. While it is unknown whether 17α 
and 17β isomers of metabolite M1 would resolve under the chromatographic conditions 
reported herein, extensions of the LC gradient and/or the use of an alternative HSS-T3 
polar embedded column failed to resolve metabolite M1 peak into two peaks, therefore 
suggesting a single stereochemistry for this metabolite.  
 
It was not possible to postulate exact positional information on the site of reduction of the 
minor metabolites M2 and M3 because the analytical sensitivity did not allow for the 
acquisition of quality HR-LC-MS/MS or EI-GC-MS/MS spectra. However, the absence of 
an analytical signal for a bis-MO derivative of M2 under HR-LC-MS conditions suggests 
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that reduction occurred at one of either the 3 or 17 positions. Also, the absence of an 
analytical signal for a mono- or bis-MO derivative of di-reduced metabolite M3 under HR-
LC-MS conditions suggests that reduction occurred at both the 3 and 17 positions. 
 
Hydroxy-metabolites metabolites M4 and M5 were not visible under EI-GC-MS 
conditions; possibly because of limiting sensitivity. However, good quality HR-LC-MS/MS 
spectra were able to be obtained (Fig 6C and 6D respectively). It might be speculated 
that a likely site of hydroxylation for metabolite M4, which was common to all three 
species, might be at position 6, since metabolism in this position is prevalent for 
androgenic-anabolic steroids in all three species (Houghton, 1992, Williams et al. 2000). 
However, the exact position of hydroxylation of metabolite M4 could not be located 
because of the lack of any diagnostic fragments. All that can be said with any certainty is 
that the absence of any characteristic D-ring fragments for metabolite M4 (in contrast to 
that observed for metabolite M5) suggests that hydroxylation occurred somewhere on 
the A/B/C-rings. For metabolite M5 on the other hand, hydroxylation was proposed at 
either position 15 or 16 on the D-ring. Evidence for this proposal was gained through the 
observation that m/z 175 present in the ‘parent’ drug spectrum was also present in the 
spectrum of M5, therefore ruling out hydroxylation on the A/B/C-rings. Another diagnostic 
fragment that was observed for metabolite M5 and lead to the speculation of a 15/16 
hydroxy-metabolite was at m/z 214. This fragment is proposed to occur through cleavage 
between carbons 14-15 and 13-17 as shown in Fig 6D. The suggestion of a 15/16 
hydroxy-metabolite is consistent with previous published data in the equine, where D-
ring hydroxylations are particularly prevalent compared to other species (Houghton, 
1992), occurring at both carbons 15 and 16 (McKinney, 2009, Houghton and Dumasia, 
1979, Scarth et al. 2010a, Houghton, 1992). 
 
Mono-reduced-hydroxy-metabolites metabolites M6, M7, M9, M10 and M11 were not 
visible under EI-GC-MS or HR-LC-MS/MS conditions; again, possibly because of limiting 
sensitivity. However, good quality EI-GC-MS and HR-LC-MS/MS spectra were able to be 
obtained for metabolite M8 (Figs 6E and 7C respectively). Under HR-LC-MS/MS 
conditions, the same m/z 175 and 214 fragments that were observed in the spectrum of 
hydroxy-metabolite M5 were also present in the spectrum of M8, suggesting that 
metabolite M8 was the analogous 17 reduced version of this compound. Under EI-GC-
MS conditions, the same m/z 242 fragment that was observed in the spectrum of 
reduced metabolite M1 was also present in the spectrum of M8, suggesting that 
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metabolite M8 was the analogous 15/16-hydroxylated version of this compound (and 
therefore consistent with the HR-LC-MS/MS data). Lastly, the observation that all of the 
reduced-hydroxy-metabolites produced only a mono-MO derivative when derivatised and 
analysed by HR-LC-MS/MS is consistent with each of them bearing either a 3 or a 17-
reduced oxygen function (Fig 5). 
 
6.4 Conclusion 
 
In summary, the in vitro metabolism of estra-4,9-diene-3,17-dione has been reported for 
the first time. This is also the first study comparing the metabolism of a designer steroid 
in the three major species subject to sport’s doping control; namely equine, canine and 
human. The major metabolite detected in all species was proposed to be an isomer of 
17-hydroxy-estra-4,9-dien-3-one. Less significant metabolic pathways in all species 
included hydroxylation and reduction followed by hydroxylation. Reductive metabolism in 
the canine was less significant than in the other two species, while the equine was 
unique in producing a doubly-reduced metabolite proposed to be an isomer of estra-4,9-
diene-3,17-diol and also relatively large quantities of D-ring hydroxy and hydroxy-
reduced metabolites. These proposed metabolic pathways are summarised in Fig 8.  
 
In the future, chemical synthesis of the proposed metabolites, or alternatively the scaling 
up of the in vitro incubations in order to allow the acquisition of quality MS/MS and/or 
NMR spectra for the minor metabolites, may allow for more precise stereochemistry to 
be assigned to the metabolites. For the time being however, the currently reported data 
are sufficient to allow for the screening and confirmation of the observed metabolites in 
laboratories with the relevant analytical equipment (ILAC-G7, 2009).  
 
Estra-4,9-diene-3,17-dione is one of many designer steroids that are currently (2010) 
marketed for sale on the Internet. A next step would therefore be to apply the analytical 
approaches developed herein to a wider range of these steroids. 
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Fig 8 – proposed pathways of estra-4,9-diene-3,17-dione metabolism in equine, canine 
and human. 
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CHAPTER 7: GENERAL DISCUSSION  
7.1 Main accomplishments 
 
7.1.1 Positioning of the research 
 
7.1.1.1 Steroid abuse in food production and animal sports 
 
As discussed in the introduction, steroids have been used to boost the mass and quality 
of animal carcasses in food production for economic reasons (Heitzman, 1975, Lone, 
1997, Kay, 2010). The majority of these steroids are anabolic-androgenic steroids 
(AASs) such as nandrolone, boldenone, stanozolol and testosterone. However, in some 
species oestrogens and progestagens may also produce anabolic effects. Although there 
a number of steroid preparations authorised for use in countries such as the USA, the 
use of growth promoters is banned within the EU (EU Council Directive 96/22/EC).  
 
In addition to their use in food production, steroids may also be used in competitive 
human and animal sports in order to improve performance. The range of steroids used 
for this purpose is generally limited to the AASs. Because of their potential to affect 
performance, the use of AASs in the majority of horseracing, greyhound racing and 
human sports is prohibited (IFHA, 2008, GBGB, 2009, FEI, 2010, WADA, 2009a). 
Protection of the welfare of individual competitors is another reason for prohibiting these 
substances; an aspect that takes increased importance in animal sports where trainers 
decide on the animal’s behalf what substances are administered. 
 
In order to enforce the ban on hormone use in food production, EU Council Directive 
96/23/EC (and EU Commission Decision 2002/657/EC) lays down the requirements for 
residue testing. Enforcement of the ban on steroid use in competitive sports is not 
regulated in law in the same way as in food production, but guidelines regarding the 
analytical methods that must be followed by individual laboratories when confirming 
cases of steroid abuse have been produced by both the animal (AORC, 2003, ILAC-G7, 
2009) and human authorities (WADA, 2009b).  
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As discussed in the introduction, the types of steroid used in food production and 
competitive sports fall into three broad classes: 
 
‘Exogenous’ steroids are known marketed ‘classical’ steroids, such as stanozolol. These 
contain synthetic structures that are thought not to occur naturally. Detection of this class 
of steroids is relatively straightforward since a purely qualitative demonstration of the 
presence of these synthetic steroids is all that is required in order to determine abuse. 
 
‘Endogenous’ steroids are also known marketed steroids, such as testosterone, but 
contain structures that are known to exist naturally. Detection of the abuse of 
‘endogenous’ steroids is more complicated because they are, by definition, ‘natural’ to 
some extent and so a simple qualitative demonstration of their presence is insufficient to 
indicate abuse (chapter 1). However, the classification of a steroid as ‘endogenous’ is a 
grey area and there are some steroids that may be considered ‘semi’-endogenous. 
 
‘Designer’ steroids are previously unmarketed steroids that contain synthetic structures 
that are thought not to occur naturally. Designer steroids have chemical structures based 
on previously marketed products, but with minor modifications which make them 
undetectable by the majority of targeted mass spectrometric procedures (chapter 4).  
 
Detection of the abuse of ‘classical’ synthetic steroids such as stanozolol in veterinary 
species is nowadays relatively straightforward. However, detection of the abuse of 
‘endogenous’ (naturally occurring) and ‘designer’ (containing novel structures) steroids is 
more complicated. Within the horseracing industry, analytical methods are already 
available to detect the abuse of the majority of endogenous AASs. However, the same is 
not true for the majority of endogenous steroids in other food producing animals. 
‘Designer’ steroids could in theory be abused in both horseracing and food production, 
but at present the majority of work on designer steroids has been commissioned by 
sports regulatory authorities.  
 
The range of analytical methods used for the detection of steroid abuse in food 
production and animal sports was discussed in detail in the introduction and in chapters 
1 and 4. The following section summarises the application of such methods to the 
detection of endogenous and designer steroids. It also explains the context and reasons 
for using the approaches adopted in the experimental chapters of this thesis. 
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7.1.1.2 The detection of endogenous steroid abuse in food production 
 
The majority of approaches attempting to detect the abuse of endogenous steroids in 
food production are based on the direct measurement of steroids and/or their 
metabolites. The methods used can broadly be separated into qualitative ‘marker 
metabolite’ and quantitative ‘threshold concentration’ approaches. The idea of the 
marker metabolite method is to identify a compound that is uniquely detected following 
the administration of a steroid, but which is not found in untreated animals. For example, 
Le Bizec et al 2006 and Destrez et al. 2009 have proposed the use of boldenone 
sulphate as a qualitative marker metabolite to demonstrate the abuse of boldenone in 
cattle. Alternatively, the idea of using a threshold comprises the determination of a 
concentration above which it is considered statistically unlikely that a result could be 
produced ‘naturally.’ Of course, it is important that the concentrations derived from 
population studies are relevant to the concentrations observed following administration. If 
they are too high then they may be above those produced following steroid 
administration and will be useless. An example of the threshold approach derives from 
the existing EU guidelines for the detection of testosterone in bovine plasma (as 
proposed by Heitzman 1994). Both the marker metabolite and concentration threshold 
approaches have their limitations. In each case, analyses of large populations of animals 
are required in order to validate the approach. The use of marker metabolites and 
concentration thresholds for the detection of endogenous steroids was discussed in 
more detail in chapter 1. 
 
As an alternative to the direct measurement of endogenous steroids in biological 
matrices, a range of assays based on detecting the biological effects of steroids have 
been developed. These assays can be broadly split into the areas of ‘biosensors’ and 
‘biomarkers’. Biosensors utilise biological techniques to detect the presence of steroidal 
activity in a sample ex vivo (outside of the body), whereas biomarker techniques aim to 
monitor activity through perturbation of ‘normal’ in vivo physiological parameters.  
 
Biosensors show a great deal of promise for detecting steroid abuse; especially where 
designer steroids are concerned (chapter 4). However, their use is likely to be restricted 
to screening rather than confirmation since the structure of the steroid is typically not 
identified unequivocally. Also, they are less useful for discerning the abuse of 
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endogenous steroids since, by definition, these compounds are natural and some 
biological activity is therefore always present.  
 
In certain respects, biosensors have been applied to residue surveillance for years in the 
form of immunoassays (Mooney et al. 2009a). Beyond the established field of 
immunoassay, several biologically based measurement technologies have recently been 
developed and are commonly classified as ‘biosensor’ technologies. Two such 
techniques are surface plasmon resonance (SPR) and potentiometric detection, where 
antibody-antigen binding can be measured quickly and assay times therefore reduced.  
For example, an SPR based immunobiosensor has recently been developed to detect 
the abuse of steroids through a reduced sex hormone-binding globulin binding capacity 
in bovine plasma (Mooney et al. 2009b). A further application in the biosensor field 
utilises knowledge of the endogenous biological receptor responsible for the 
pharmacological effect of the drug (i.e. Peters et al. 2010). The principle of this approach 
is that all drugs sharing a common method of action should be detectable through 
measuring the response of a recombinantly produced version of the relevant receptor. 
Some examples of the different receptor assays were given in chapter 1. 
 
The rapidly advancing applications of ‘omics’ related technologies, which allow the 
simultaneous analysis of a large number of components within a biological system, have 
huge potential to transform the way drug residue surveillance detection is performed. 
The idea behind applying the ‘omics’ approaches is not to detect the presence of a drug 
directly, but instead to be able to detect it’s cumulative biological effect (biomarker) within 
the animal through either targeted (pre-defined profiling) or untargeted (global profiling) 
approaches. One of the key advantages of the biomarker approach is that no matter 
what method of doping is used, then changes in the mRNA (transcriptomics), protein 
(proteomics) or metabolite (metabolomics) profiles should be detectable for drugs with 
common pharmacology. The definition of a ‘normal’ versus ‘suspect’ biomarker profile 
depends on whether ‘latitudinal’ or longitudinal’ comparisons are applied – both of which 
are currently being investigated (Scarth et al. 2006). Latitudinal comparisons rely on 
analysing large populations of individual subjects and defining a ‘normal’ range, a value 
outside of which is considered suspect. Longitudinal measurements on the other hand, 
could use a change in an animal’s own unique biomarker profile over time to indicate 
whether external perturbation had occurred. Whether biomarker approaches are suitable 
as confirmatory techniques or just as screening tools remains to be determined. 
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However, further studies are clearly warranted in order to investigate their great 
potential. Some examples of the different types of biomarker approaches were given in 
chapter 1. 
 
A further alterative technique for detecting the use of endogenous steroids is based on 
gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS). GC-C-
IRMS relies on detecting differences in the relative 12C and 13C composition of steroids 
between the natural and synthetic states. Synthetic steroids are typically synthesized 
from a single C3 plant (often soy), while the natural diet of the bovine is usually a mixture 
of both C3 and C4 plants (Balizs et al. 2005). The terms C3 and C4 refer to the type of 
metabolic pathway used by the plant in synthesising organic compounds during 
photosynthesis, utilising either 3 or 4 carbon-chain metabolites respectively. The 
significance of this lies in the fact that the two types of pathway display differing degrees 
of discrimination against 13C and thus result in different 13C to 12C ratios. C4 plants have 
lower discrimination against 13C than C3 plants, resulting in higher 13C to 12C ratios in C4 
plant material (Balizs et al. 2005). Since steroids produced within the body will derive 
carbon from both C3 and C4 plant material of dietary sources, the resulting 13C to 12C 
ratio will be lower after exogenous steroid administration (mainly C3 plant material 
derived) relative to the endogenous state.  
 
Geographical location has been cited as an important factor determining the degree of 
discrimination provided by GC-C-IRMS; mainly because of differences in feeding 
practices. In the UK for example, animals are typically fed a much higher base of C3 
plants than in Europe, leading to a lower difference in the δ13C values between 
administered steroids and the ERC (Mason et al. 1998). However, as studies by Buisson 
et al. 2005 and Hebestreit et al. 2006 have shown (chapter 1), δ13C values in animals fed 
a C3 diet may still be sufficiently different following administration of testosterone to allow 
detection of the abuse of this steroid.  
 
The GC-C-IRMS method requires substantial sample preparation prior to analysis 
including hydrolysis, solid phase extraction, liquid-liquid extraction and HPLC 
fractionation steps, as the influence of matrix interferences need to be minimised. 
Suitable derivatisation of the extracts followed by separation using gas chromatography 
further purifies the extract before introduction into a furnace. The furnace then combusts 
the introduced sample, which is analysed alongside a reference gas by mass 
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spectrometry in order to determine the relative proportions of 13C and 12C (Prevost et al. 
2004). The laborious nature of the sample preparation technique currently makes the 
technique unsuitable for use as a screening tool (Piper et al. 2010), but it has already 
found use as a confirmatory technique for testosterone abuse in human sports (Saudan 
et al. 2006). The executive summary of the ISOSTER project GRD1-2001-40085 in 2006 
(ISOSTER, 2006) showed that the GC-C-IRMS method for detecting testosterone abuse 
in bovine urine was successfully validated in several European laboratories. The use of 
GC-C-IRMS for the detection of endogenous steroids was discussed in more detail in 
chapter 1. 
 
The majority of injectable steroid preparations contains steroids in esterified forms. The 
direct detection of steroid esters in matrices from an animal may, therefore, be indicative 
of steroid abuse. Depending on the matrix in question, contamination issues also need to 
be considered carefully in order to eliminate environmental contact as a possible cause 
of false non-compliant results. The detection of intact steroid esters in hair has attracted 
the most attention in literature for this purpose and has already found use in some 
European laboratories as a confirmatory technique for detecting natural steroid abuse 
(see for example Marcos et al. 2004, Nielen et al. 2006, Boyer et al. 2007, Anielski, 
2008, Stolker et al. 2009 and Duffy et al. 2010). Until recently, the detection of intact 
steroid esters in plasma was hampered by their typically low concentrations in this matrix 
relative to analytical limits of detection (LOD) (Kim et al. 2000, Hooijerink et al. 1994). 
However, effective analytical methods based on the detection of intact testosterone, 
nandrolone and boldenone esters below 10 pg ml-1 in equine plasma have recently been 
developed (Gray et al. 2010). The use of steroid esters for the detection of endogenous 
steroids was discussed in more detail in chapter 1. 
 
The above discussions suggested that some techniques may be suitable for both 
screening and confirmation whereas others may only be suitable for one of these uses. 
The choice of which technique to use in each situation is dictated by a number of 
practical, political and economic factors, which are likely to vary in different parts of the 
world. This subject is taken up further in the future perspectives section of this 
discussion, but there is currently no consensus on what is the most appropriate 
approach. The literature review reported in chapter 1 suggested that the use of threshold 
concentrations may be suitable for detection in the UK. The experiments reported in 
chapters 2 and 3 were therefore designed to validate thresholds for detecting some 
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important endogenous steroids in the porcine and bovine since these are two particularly 
important food producing species in the UK.  
 
7.1.1.3 The detection of designer steroid abuse in animal sports 
 
As with any AAS, if testing is based on blood or hair then detection of the ‘parent’ steroid 
may be appropriate. However, if detection is to be based on excreted matrices such as 
urine and faeces, knowledge of the metabolism is typically required in order to direct 
detection protocols toward the appropriate target analyte. With this in mind, several 
strategies have been proposed to detect the abuse of known or unknown designer 
steroids in biological samples taken from humans and animals.  
 
One approach that has been proposed by several authors is based on predicting the 
pattern of fragmentation under EI-GC-MS or LC-MS/MS conditions (Thevis et al. 2005a, 
Fragkaki et al. 2009). Using this approach, a variety of scan functions can be used to 
screen for the presence of common fragments or neutral losses from a range of possible 
steroid structures in biological samples. If these initial screening analyses produce a 
suspicious result, then this may trigger a more in depth analysis of the sample in order to 
determine the possible structure of any unknown component.  
 
Another approach is to use bioassay guided fractionation of samples, followed up by in 
depth analysis of any fractions that produce positive bioassay results. One such 
approach has been published by Peters et al. (2010) and uses a yeast expressed 
androgen receptor assay to highlight sample fractions that produce androgenic 
pharmacological effects. If the bioassay produces a suspicious result, then this may 
trigger a more in depth analysis. An alternative bioassay based on ELISA has been 
reported by Hungerford et al. (2005). This approach utilises an antibody that recognises 
steroids that contain a 17α-methyl,16β,17β-dihydroxy epitope, therefore theoretically 
producing a suspicious result for any 17α-methyl steroid that undergoes 16β-
hydroxylation as part of it’s metabolism. Since 16β-hydroxylation is a major pathway of 
phase 1 metabolism of such steroids, especially in equine animals (Houghton, 1992), 
this again highlights a suspicious sample for further work to identify any unknown 
molecules. 
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While the above approaches are based on the detection of designer steroids through 
screening for the presence of the steroid or metabolite itself, an alternative method that 
is currently being investigated is the use of endogenous ‘biomarkers’ (Scarth et al. 2006, 
Mooney et al. 2009a). The theory of the biomarker approach states that regardless of 
structure, the majority of AASs are likely to produce their pharmacological actions 
through similar means such as through binding to the androgen receptor or antagonising 
the cortisol receptor. Therefore, as long as they produce similar pharmacological effects, 
designer steroids may just as likely as classical steroids induce a change in endogenous 
biomarker profile. 
 
Each of the above methods (mass spectrometric fragmentation prediction, bioassays or 
biomarkers) are considered most suitable for identifying new designer steroids that 
regulatory authorities are not aware previously existed, such as tetrahydrogestrinone 
(THG). However, the extent of abuse of this type of designer steroid is hard to predict 
and it is anticipated that it would be limited to a small group of elite individuals who are 
able to obtain access to a small number of rogue chemists. The designer steroids that 
appear to be the most widely available are those marketed on the Internet. Although 
these steroids contain novel structures in order to enable them to be marketed freely on 
the Internet to customers in some countries (because their structures do not fall within 
the scope of legal regulations that prevent the sale of defined steroidal products), the 
regulatory authorities are able to maintain an awareness of their emergence through 
Internet searches. For these steroids, it is therefore possible to purchase materials that 
can then be used for analytical method development purposes.  
 
While it is theoretically possible to conduct in vivo metabolism studies using Internet 
available designer steroids, the fact that these compounds typically lack toxicological 
characterisation makes this approach difficult to justify on ethical grounds. Several other 
approaches have therefore been reported for producing metabolite information where 
reference standards of designer steroids are available. Peters et al. (2009) proposed an 
in silico (computer modelling) approach to identify the presence of designer steroids 
and/or their metabolites in samples using a range of possible transformations of existing 
steroid structures. Lootens et al. (2009) and Pozo et al. (2009) have recently developed 
a rodent model transplanted with human hepatocytes. Using this approach, human type 
metabolism can be investigated without the need for experimenting on people. In the 
future, it may be possible to adapt this approach to utilise equine hepatocytes. However, 
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this technique still requires the use of animal experimentation. Attractive alternatives that 
have shown excellent qualitative in vivo correlation are the use of different in vitro 
models, involving incubation of steroids with either ex vivo mammalian liver preparations 
(Ho et al. 2005, Ho et al. 2007a and 2007b, Leung et al. 2004) or surrogate invertebrate 
models (De Wasch et al. 2002, Verheyden et al. 2007), which negate the requirement for 
mammalian in vivo experimentation. To date, several designer steroid metabolism 
studies have been carried out in the human. Levesque et al. (2005) and Gauthier et al. in 
(2009) used human hepatocytes to study the in vitro metabolism of THG and 17α-
methyl-drostanolone respectively, while Rodchenkov et al. in (2006) studied the in vivo 
human metabolism of a number of capsulated products purported to contain different 
steroidal products. To date, however, no studies have reported the metabolism of 
designer steroids in the canine and only one study has been reported in the equine 
(Kwok et al. 2006).  
 
In this context, the objective of part 2 of this thesis was to review the equine steroid 
metabolism literature (chapter 4), to assess the suitability of in vitro techniques for 
conducting equine steroid metabolism studies (chapter 5) and to use the developed in 
vitro methods to study the equine metabolism of a novel ‘designer’ steroid (chapter 6).  
 
7.1.2 Main research findings 
 
Because endogenous and designer steroids cannot be easily detected using existing 
protocols, the work described in this thesis focussed on the development of analytical 
methodologies for the detection of their abuse in food production and animal sports 
respectively. However, rather than focussing purely on the specific areas of expertise 
developed in the author’s own laboratory, a major facet of these works was consultation 
and collaboration with experts in other organisations around the world in order to develop 
the most ‘rounded’ approaches possible (summarised in the literature reviews in 
chapters 1 and 4). The following sections (7.1.2.1 and 7.1.2.2) summarise the main 
findings of the research presented in this thesis. 
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7.1.2.1 The detection of endogenous steroid abuse in food production using 
threshold concentrations 
 
The following points summarise the main findings in part 1 of this thesis: 
 
 In chapter 1, a review on the presence, metabolism and detection of 
endogenous anabolic-androgenic steroids in mammalian food producing 
animals was presented. This was the first comprehensive review of the topic to 
be published and was invaluable in guiding the research in the remainder of 
part 1 of this thesis. From this review, the concentration threshold approach 
was considered suitable for the detection of endogenous steroid abuse in the 
UK. However, it is not necessarily advocated as a unilateral international 
approach because of differences in farming practices, animal populations, 
laboratory facilities and possible patterns of drug abuse, etc. 
 
 In chapter 2, an analytical biomarker approach for the detection of nandrolone 
abuse in the porcine was developed and validated. The method was based on 
the quantification of the nandrolone metabolite 19-noretiocholanolone in the 
unconjugated (free) fraction of urine using GC-MS/MS. The method was then 
applied to large populations of untreated UK animals in order to establish 
threshold concentrations for regulating nandrolone abuse. At a false non-
compliance rate of 1 in 10,000 of the normal population, the suggested 
confirmatory thresholds (7,502 pg ml-1 for boars and 19,200 pg ml-1 in gilts) are 
able to detect the abuse of nandrolone for several weeks following 
administration of this steroid. Alternative concentration thresholds were also 
presented at lower non-compliance rates to serve for use in screening assays 
prior to confirmation by other techniques should this be required. 
 
 In chapter 3, an analytical biomarker approach for the detection of nandrolone, 
boldenone, testosterone, progesterone and oestradiol was developed and 
validated. Using a single aliquot of urine, metabolite markers of the AASs and 
progestagens were extracted for GC-MS/MS analysis, while oestrogens were 
removed into a separate fraction using an extractive derivatisation with dansyl 
chloride and analysed using LC-MS/MS. The methods have since been applied 
to urine samples from a large population of untreated male and female animals 
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in order to produce data for establishing screening and confirmatory 
concentration thresholds, the results of which will be published separately. 
 
7.1.2.2 The detection of designer steroid abuse in animal sports using in vitro 
models 
 
The following points summarise the main findings in part 2 of this thesis: 
 
 In chapter 4, a review on the metabolism and detection of endogenous 
anabolic-androgenic steroids in the equine was presented. This review 
highlighted that detection of the abuse of designer steroids is challenging and at 
present few data are available in the equine. From this review, the development 
of an in vitro model was chosen for assessing the metabolism of Internet 
available designer steroids so that information regarding the metabolites 
produced can be inserted into routine screening methods. However, this is not 
necessarily advocated as a unilateral international approach since it is only 
suitable for steroids in which a source of reference material can be found. 
 
 In chapter 5, the suitability of using in vitro techniques in place of animal 
administrations for conducting qualitative metabolism experiments was 
assessed using stanozolol in the equine as an example. Using high 
resolution/accurate mass full scan analysis on an Orbitrap LC-MS system, 
equine liver microsome and S9 in vitro fractions were found to generate all the 
major phase-1 metabolites observed following in vivo administrations. Along 
with other studies conducted by the author correlating the in vitro and in vivo 
metabolites from a wide range of non-steroidal drugs in the equine (Scarth et al. 
2010), this chapter suggested that in vitro techniques could serve as a viable 
alternative to identify suitable target metabolites when in vivo administrations 
are not possible.  
 
 In chapter 6, the in vitro methods developed in chapter 5 were used to study the 
metabolism of a novel designer steroid, namely estra-4,9-diene-3,17-dione, in 
the equine. The study was also conducted with canine and human tissue, which 
was the first time that the metabolism of a designer steroid in the three major 
species subject to sport’s doping control was compared. The information 
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regarding the equine target metabolites have since been included in the routine 
screening methods used at the author’s laboratory in order to detect any 
potential abuse of this steroid. 
 
7.2 Contribution to scientific knowledge 
 
The following sections (7.2.1 and 7.2.2) summarise in more detail the range of different 
contributions that the research in this thesis makes to scientific knowledge. 
 
7.2.1 Endogenous steroids in food producing animals 
 
In part 1, chapter 1, the extensive literature regarding the presence and metabolism of 
endogenous AASs in food producing animals and the methods used to detect their 
abuse was reviewed. The wide variation of the natural and post-steroid administration 
metabolite profiles for the different compounds was highlighted in this chapter. It also 
reiterated the challenging nature of ‘proving’ the abuse of endogenous steroids, which 
revolves around the fact that a simple qualititative demonstration of the presence of 
these steroids is typically insufficient. Importantly, it was also evident that that the more 
sensitive analytical methods become, the more steroids are discovered to be 
endogenous at low concentrations (Table 1). Nandrolone, for example, was once thought 
to be solely exogenous, but is now known to occur naturally in a number of animal 
species. A wide range of different approaches for their detection have, therefore, been 
proposed by authors, including threshold, marker metabolite and biomarker approaches, 
the detection of exogenous steroid esters in plasma/hair and the use of GC-C-IRMS. 
During the preparation of this chapter and prior to the start of the analytical phase of this 
thesis, many international colleagues inside and outside of Europe were consulted for 
their opinions so that the author could make an informed decision on how to best tackle 
the challenges. It was obvious from these experiences that there is no single correct 
answer on how best to tackle the potential abuse of endogenous steroids. Much of the 
decision making process involves consideration of political, economic and other practical 
factors rather than just scientific ideals. In this respect, the use of the concentration 
threshold approach was considered most applicable at the current time to detect steroid 
abuse within the UK. The remainder of part 1 of this thesis, therefore, set out to develop 
analytical methods prior to applying them to large animal populations in order to produce 
data from which to derive possible thresholds.   
 293 of 331 
Table 1 – summary of the endogenous occurrence of androgenic-anabolic steroids in mammalian meat-producing animal species.  
NMP = National Monitoring Programme, therefore not controlled with respect to steroid abuse. 
 
 
Steroid  
 
Details of endogenous presence in different species 
 
 
Bovine 
 
Ovine Porcine Equine Cervine Caprine 
 
 
Testosterone  
 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in males 
and females at varying 
concentrations 
 
Ubiquitous in males and 
females at varying 
concentrations 
 
Ubiquitous in males 
and females at 
varying 
concentrations 
 
Ubiquitous in males 
and females at varying 
concentrations 
 
 
 
 
Nandrolone and 
related 19-nor 
androgens 
 
 
Epinandrolone detectable 
during pregnancy. Most 
other studies find no 
nandrolone or related 
metabolites in males, but 
some find trace amounts in 
male and female urine i.e. 
following casualty 
(Kennedy et al. 2009) 
 
Epinandrolone detectable 
during pregnancy. Two 
reports published on the 
endogenous presence of 
urinary nandrolone, 
epinandrolone and 19-
norandrostenedione in 
male + female UK and 
Austrian populations 
 
 
Nandrolone and 19-
norandrostenedione 
detected in urine and 
some other matrices of 
animals of all sexes 
(including intersex 
animals) at different 
concentrations 
 
Detected in urine of 
pregnant mares and at 
high concentrations in 
stallions (probably as a 
byproduct of the high 
concentration of 
aromatisation in the 
testes) but not in 
geldings or fillies 
 
Urinary 
epinandrolone 
detected in a 
pregnant red deer, 
but no other animals 
studied.  One of 35 
urines from an 
Australian NMP 
contained 
epinandrolone but 
not nandrolone  
 
Epinandrolone, but not 
nandrolone, detected 
in urine during 
pregnancy, while 
neither analyte 
detected in non-
pregnant females. 
Studies on 
endogenous 
concentrations in 
males is lacking  
 
 
 
 
Boldenone and 
related 1-dehydro 
androgens 
 
 
Boldenone and related 
compounds have been 
detected in urine and 
faeces, possibly secondary 
to their formation by gut 
bacteria. Some phase 1 + 2 
metabolites only detected 
after boldenone admin. 
Boldenone precursors also 
detected in wood crates 
from calves housing 
 
Insufficient data to draw 
any conclusions, although 
2 of 961 urines from an 
Australian NMP 
contained low 
concentrations of 
epiboldenone 
 
 
Boldenone detected in 
urine and some other 
matrices of boars, 
cryptorchids, gilts and 
barrows at different 
concentrations, but not 
above the LOD in sows 
or an intersex animal 
 
Boldenone detected at 
low concentrations in the 
urine of stallions, but not 
geldings or fillies 
 
Insufficient data to 
draw any 
conclusions, 
although zero of 35 
urines from an 
Australian NMP 
contained boldenone 
or epiboldenone 
 
 
Insufficient data to 
draw any conclusions 
Chapter 7 
 
294 of 331 
In chapter 2, an analytical biomarker approach for the detection of nandrolone abuse in 
the porcine was developed and validated. The method was based on the quantification 
of the nandrolone metabolite 19-noretiocholanolone in the unconjugated (free) fraction of 
urine using analysis by GC-MS/MS. This analyte was selected because it has been 
shown to be a major metabolite following nandrolone administration, but not in untreated 
animals (Roig et al. 2007, Ventura et al. 2008) (see proposed pathways in Figure 1).  
 
Figure 1 – diagram depicting some of the possible metabolic pathways leading to the 
presence of 19-noretiocholanolone in porcine urine.  
 
The LOD (13.2 pg ml-1) was significantly lower than previously reported porcine 
methods, the most sensitive of which was 100 pg ml-1 (Roig et al. 2007). This increase in 
sensitivity was achieved through the use of an extensive sample clean-up (providing a 
reduced matrix background), the application of a PTV injector (allowing a large 
proportion of the sample to be injected) and analysis by GC-MS/MS (providing enhanced 
selectivity). When applied to a population of untreated animals, 19-noretiocholanolone 
distributions in boars and gilts were bimodal, with a small number of concentrations in 
each sex around the 1,000 pg ml-1 region and the majority of concentrations closer to the 
lower end of the calibration range. This was the first study to demonstrate that 19-
noretiocholanolone is endogenous in the porcine and hence would require a 
concentration threshold rather than a qualitative marker metabolite approach as 
proposed previously (Roig et al. 2007, Ventura et al. 2008). The detection of low 
concentrations of 19-noretiocholanolone in porcine urine is, perhaps, not surprising since 
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it might be expected that a small amount of the proposed nandrolone carboxylic acid 
precursor might be converted into nandrolone metabolites in vivo. Indeed, the analogous 
situation is observed in the equine, where very low concentrations of the major equine 
nandrolone metabolite 5α-estrane-3β,17α-diol can be detected in the urine of stallions 
(Teale and Houghton, 2010). 
 
Statistical analysis of the population data was carried out in order to suggest screening 
and confirmatory thresholds for this steroid in the urine of boars and gilts. Because of the 
non-normal distribution of the data, it was necessary to use a non-parametric method of 
statistical analysis and the Chebyshev inequality was considered the most suitable as it 
makes minimal assumptions about the population distribution and produces conservative 
thresholds relative to methods based on normally distributed data (Roy Macarthur, 
personal communication). At a false non-compliance rate of 1 in 10,000 of the normal 
population, the suggested confirmatory thresholds are 7,502 pg ml-1 for boars and 
19,200 pg ml-1 in gilts. To put these thresholds into context, in a recent study 
administering 2 mg/kg nandrolone laurate via intra-muscular injection to six boars aged 
8-10 weeks, the mean free fraction 19-noretiocholanolone concentration at the last time-
point of the study (15 days following administration) was 28,400 pg/mL, with a range of 
9,600 to 53,600 pg/mL (Ventura et al. 2008). The suggested thresholds should therefore 
be able to detect the abuse of nandrolone for a significant time period in most treated 
animals and lead to rates of both low false compliance and non-compliance. The 
validation of these thresholds is significant as there are currently no other published 
methods available for the detection of nandrolone abuse in the porcine. Thresholds for 
screening may be set at a lower probability, but there then needs to be a secondary 
mechanism for confirmation if the confirmatory threshold is not also breeched. Typically, 
this may include follow-up analyses using gas chromatography carbon isotope mass 
spectrometry (GC-C-IRMS) (Prévost et al. 2004), detection of an intact steroid ester 
(Boyer et al. 2007) or an on-farm inspection (Jack Kay, personal communication). In an 
ideal world, a confirmatory threshold would also be suitable as a screening threshold, but 
this requires that the threshold is able to produce both low rates of false compliance and 
non-compliance; an ideal that is seldom achieved.  
 
In chapter 3, an analytical biomarker approach for the detection of nandrolone, 
boldenone, testosterone, progesterone and oestradiol in the bovine was developed and 
validated. Using a single aliquot of urine, metabolite markers of the AASs and 
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progestagens were extracted for GC-MS/MS analysis, while epioestradiol was removed 
into a separate fraction using an extractive derivatisation with dansyl chloride and 
analysed using LC-MS/MS. The high sensitivity of this method was achieved through the 
use of an extensive sample clean-up (providing a reduced matrix background), the 
application of a PTV injector for GC-MS/MS (allowing a large proportion of the sample to 
be injected) and the separation of epioestradiol into a separate derivatised fraction for 
LC-MS/MS (enhancing sensitivity in the positive electrospray mode through the addition 
of the high proton affinity dansyl moiety). Using a standard addition calibration line 
approach in pooled bovine urine, the method was linear between the endogenous 
concentrations and those augmented with 3,000 pg ml-1. The determined LODs were in 
several instances lower than those published previously using mass spectrometric based 
methods (with the exception of 5α-pregnane-3β,20α-diol, for which no data was available 
for comparison) (Table 2). 
 
Table 2 – determined LODs using the current method in comparison to those reported 
previously (to the best of the author’s knowledge).   
 
 
Steroid 
Current 
LOD 
(pg ml -1) 
 
Lowest previously reported mass 
spectrometric based LOD/CCα (pg ml -1) 
5β-androstane-3α,17β-diol 94.1 LOD = 500 (Biddle et al. 2003) 
5α-estrane-3β,17α-diol 10.9 
LOD = 500 (Biddle et al. 2003). Pinel et al. 
2010 reported 5α-estrane-3β,17α-diol 
excretion profiles, but no LOD/CCα. 
Epinandrolone 19.8 CCα = 30 (Pinel et al. 2008) 
19-Noretiocholanolone 32.4 CCα = 20 (Pinel et al. 2008) 
17β-Hydroxy-5β- 
androst-1-ene-3-one 
 
160.7 
 
LOD = 50 (Le Bizec et al. 2006) 
Epiboldenone 10.5 LOD = 10 (Arts et al. 1996 using high resolution MS) 
5α-pregnane-3β,20α-diol 12.2 N/A – no published LOD/CCα 
Epioestradiol 14.8 CCα = 40 (Pinel et al. 2008) 
 
With the exception of the boldenone metabolite 17β-hydroxy-5β-androst-1-en-3-one, all 
metabolites were shown to be endogenous at some concentration in pooled urine from 
untreated steers. The observation that testosterone, progesterone and oestradiol 
metabolites were detected is not surprising since the testosterone, progesterone and 
oestradiol are known to be endogenous in this species (Scarth et al. 2009). In contrast, 
the fact that epiboldenone and the nandrolone metabolites 5α-estrane-3β,17α-diol, 
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epinandrolone and 19-noretiocholanolone were detected in the pooled UK steer urine is 
perhaps more significant. Epiboldenone has previously been shown to be endogenous in 
animal populations in other countries (De Brabander et al. 2004) and epinandrolone 
been detected in the urine of injured male cattle and pregnant females (Kennedy et al. 
2009). However, the results from this thesis suggest that certain nandrolone metabolites 
are also endogenous at low concentrations in uninjured steers. Possible traces of 17β-
hydroxy-5β-androst-1-en-3-one have been reported previously in the urine of untreated 
bovine animals (Le Bizec et al. 2006), but it’s identity as an endogenous compound has 
yet to be confirmed unambiguously. The analytical methods presented herein have since 
been applied to urine samples from a large population of untreated male and female 
animals in order to produce data for establishing screening and confirmatory 
concentration thresholds, the results of which will be published separately in due course. 
 
The adoption of the threshold concentration approaches for detecting steroid abuse in 
veterinary species as proposed in part 1 of this thesis is currently being considered by 
the relevant UK regulatory authorities. While it is anticipated that these thresholds may 
find use as either screening and/or confirmatory techniques, they may only form part of a 
wider portfolio of techniques that are applied in different situations. These may also 
include marker metabolites, ‘omics’ biomarker approaches, GC-C-IRMS, detection of 
intact steroid esters in plasma/hair and on farm visits. This subject is taken up further in 
the future perspectives section of this discussion. 
 
7.2.2 Designer steroids in animal sports 
 
In part 2, chapter 4, the metabolism of AASs in the equine and the methods used to 
detect their abuse was reviewed. The trends within the equine metabolism data were 
also compared to those of the human, porcine and bovine, highlighting some interesting 
differences between these different species. This chapter exemplifies the need for 
performing metabolism studies in order that urinary based detection methods are 
targeted toward the most appropriate marker metabolites. Figure 2 summarises the 
major pathways of AAS metabolism in the horse.  
 
One of the biggest perceived current threats in terms of AAS use in animal sports is the 
possible abuse of designer steroids, particularly those readily available for purchase from 
Internet sites. The remainder of part 2 therefore set out to develop in vitro methods for 
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studying the metabolism of Internet available designer steroids in order to identify marker 
metabolites for inclusion in drug screening procedures. An in vitro rather than in vivo 
approach was necessary because of the ethical constraints of administering previously 
untested substances to healthy animals.  
 
 
Figure 2 – summary of some of the common pathways of AAS metabolism in the horse.  
 
In chapter 5, equine liver/lung microsomes and S9 tissue fractions were used to study 
the in vitro metabolism of the AAS stanozolol. The results were also correlated with 
those obtained following an in vivo administration of the steroid. The major aim of this 
study was to assess the feasibility of using in vitro techniques in place of animal 
administrations for conducting qualitative metabolism experiments. Using high 
resolution/accurate mass full scan analysis on an Orbitrap LC-MS system, equine liver 
microsome and S9 in vitro fractions were found to generate all the major phase 1 
metabolites observed following in vivo administrations. The results also correlated well 
with previously published data regarding the metabolism of stanozolol, which proposed 
that 16α-, 16β- and 15-hydroxystanozolol were the major equine phase 1 metabolites 
(Muck and Henion 1990, McKinney et al. 2004). Additionally, analysis of the liver 
microsomal incubates using a shallower LC gradient combined with various MS/MS 
functions on a Sciex 5500 Q trap instrument allowed the identification of a number of 
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phase 1 metabolites previously unreported in the equine or any other species. Figure 3 
summarises the range of different hydroxystanozolol isomers that were identified. 
Comparison between liver and lung S9 metabolism showed that the liver was the major 
site of metabolic activity in the equine. Furthermore, using chemical enzyme inhibitors 
that are known to be selective for particular isoforms in other species suggested that an 
enzyme related to CYP2C8 may be responsible the production of 16-hydroxy-stanozolol 
metabolites in the equine. This suggestion is also consistent with the results of a study 
by Komuri et al. (Komuri et al. 1993) where the authors found that a purified equine CYP 
with a high degree of N-terminal amino acid sequence homology to CYP2C isoforms was 
able to 16α-hydroxylate the androgenic/anabolic steroid testosterone. Along with other 
studies conducted by the author correlating the in vitro/in vivo metabolism of a wider 
range of non-steroidal drugs in the equine (Scarth et al. 2010), this chapter suggested 
that in vitro techniques could serve as a viable alternative to identifying suitable target 
metabolites when in vivo administrations are not possible.  
 
 
 
Figure 3 – structure of stanozolol with carbon numbering indicated. Arrows point to the 
sites of mono-hydroxylation produced in the equine liver microsomal fractions that could 
either be confirmed by reference standards or suggested (shown by a ?) based on 
pattern of fragmentation. 
 
In chapter 6, the in vitro methods developed in chapter 5 were used to study the 
metabolism of a novel designer steroid, namely estra-4,9-diene-3,17-dione, in the 
equine. The study was also conducted with canine and human tissue, which was the first 
time that the metabolism of a designer steroid in the canine was studied and was also 
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the first time that the metabolism of a designer steroid in all three major species subject 
to sport’s doping control was compared. The in vitro metabolism of several designer 
steroids has been reported previously using human tissues (Levesque et al. 2005, 
Kuuranne et al. 2008, Gauthier et al. 2009), but only one previous study in the equine 
has been published (Kwok et al. 2006). The methods presented in chapter 6 extended 
those used in the previous equine study by employing the use of the liver S9 fraction in 
order to increase the range of enzymes involved. Also, in order to permit the 
retrospective analysis of sample testing data, the use of high resolution/accurate mass 
full scan analysis on an Orbitrap LC-MS system was employed for metabolite 
identification of underivatised sample extracts. The full scan Orbitrap data were 
complemented by several further experiments targeted at elucidating more detailed 
structural information for the most abundant metabolites. These included; MS/MS of the 
underivatised metabolites, functional group selective chemical derivatisation followed by 
full scan LC-MS, enzyme inhibition experiments and full scan electron ionisation GC-MS 
analysis of methoxyamine-trimethylsilyl derivatives.  
 
The major metabolite detected in all species, and therefore the most suitable candidate 
for screening of estra-4,9-diene-3,17-dione abuse, was proposed to be an isomer of 17-
hydroxy-estra-4,9-diene-3-one. Less significant metabolic pathways in all species 
included hydroxylation and reduction followed by hydroxylation. Reductive metabolism in 
the canine was less significant than in the other two species, while the equine was 
unique in producing a di-reduced metabolite (proposed to be an isomer of estra-4,9-
diene-3,17-diol) and also relatively large quantities of D-ring hydroxy and hydroxy-
reduced metabolites.  
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Figure 4 – proposed pathways of estra-4,9-diene-3,17-dione metabolism in equine, 
canine and human. 
 
The proposed metabolism of estra-4,9-diene-3,17-dione is summarised in Figure 4. 
These pathways are consistent with those of the 4,9,11-triene analogues (as opposed to 
4,9-diene) trenbolone, altrenogest and THG. For each of these steroids, the presence of 
the extended conjugated double-bond system inhibits reductive metabolism. Trenbolone, 
for example, is metabolised principally to its 17α-isomer in both the horse (Houghton, 
1992) and in man (De Boer et al. 1991). The horse also produces several 16-hydroxy-
metabolites (Houghton, 1992). Altrenogest is similar to trenbolone, except that it contains 
a 17-α-alkyl subsistent and has been shown to directly conjugate to glucuronide or 
sulfate in the horse, with no phase 1 metabolises having been observed (Lampinen-
Salomonsson et al. 2006). The metabolism of THG and gestrinone have been studied in 
the human and both proceed through hydroxylation at position 18, with hydroxylation at 
the position 16 also having been proposed as a minor pathway for THG (Levesque et al. 
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2005). Data regarding the metabolism of steroids with 4,9,11-triene structures in the 
canine are currently lacking. 
 
The information regarding the equine target metabolites of the designer steroid estra-4,9-
diene-3,17-dione that was reported in part 2 of this thesis has since been included in the 
routine drug screening methods used at the author’s laboratory in order to detect any 
potential abuse of this steroid.  
 
7.3 Future perspectives 
 
While the author has attempted to tackle a number of analytical challenges in the current 
thesis, the work has its limitations and a number of unanswered questions and areas for 
future research inevitably remain. The following section serves to highlight some areas of 
research that may follow on from these studies.  
 
7.3.1 The detection of endogenous steroid abuse in food production  
 
With regard to the porcine results reported in chapter 2, the observation of only very low 
concentrations of 19-nortiocholanolnoe in the urine of untreated animals is difficult to 
reconcile if nandrolone itself is truly endogenous in this species. As proposed in chapters 
1 and 2, this situation could be explained if the routinely detected nandrolone is in fact 
predominantly an analytical artefact from the degradation of a testosterone-19-carboxylic 
acid (as demonstrated in the equine by Houghton et al. 2007). If this is the case, then the 
presence of a small amount of endogenous 19-noretiocholanolone in urine (as observed 
herein) may be expected if a small proportion of the testosterone-19-carboxylic acid is 
degraded to nandrolone in the body and subject to metabolism in the liver. Further 
experiments may therefore be justified in order to confirm this hypothesis. Also, the 
reasons for the existence of a bimodal distribution of 19-noretiocholanolone 
concentrations in the urine of boars and gilts are currently unknown. Further experiments 
to probe the cause of the varying concentration of this analyte may therefore be 
warranted in order to establish the underlying physiology and determine the function, if 
any, of the secreted 19-norandrogens.  
 
The bovine methods developed in chapter 3 have since been applied to urine samples 
from a large population of untreated male and female animals. The data produced will be 
General Discussion 
303 of 331 
used in a similar way to that from the porcine studies in proposing screening and 
confirmatory concentration thresholds. The results of these studies will be published 
separately in due course, but are also likely to pose a number of questions and therefore 
areas for future research. As described earlier, epiboldenone and the nandrolone 
metabolites 5α-estrane-3β,17α-diol, epinandrolone and 19-noretiocholanolone were 
found to be endogenous in the pooled steer urine used for the current study. Although a 
number of theories have been put forward regarding the origin of 1-dehydrosteroids in 
the bovine (chapter 1), further work would be required in order to clarify the origin of 
epiboldenone in the urine from UK bovine animals. Further work would also be required 
in order to determine the origin of the nandrolone metabolites in these populations, since 
nandrolone metabolites have only been detected endogenously in injured males or 
pregnant females to date (Kennedy et al. 2009). 
 
For both the porcine and bovine results reported in this thesis, there were limitations with 
regard to the demographic of the animal populations used. For example, they were 
limited to certain age ranges, geographical location (UK), sexes (no castrated porcine 
animals or uncastrated bovine animals were available), disease and pregnancy states as 
well as concomitant medications such as those relating to immunocastration or oestrous 
synchronisation. Furthermore, there are also several other animal species in the UK that 
are considered meat producing species. Cervine, equine and caprine species were not 
considered here for economic reasons (only a finite resource was available). However, 
ovine populations were studied and the results from these studies in relation to 
nandrolone and boldenone detection will be reported separately in due course. In 
addition to the aforementioned limitations, the range of steroids considered in each 
species was not exhaustive. For example, while the bovine studies focussed on 
androgens, oestrogens and progestagens, they did not consider corticosteroids. Also, 
the porcine studies focussed solely on detecting nandrolone abuse. Further studies 
concerning a wider range of steroid/species combinations may therefore be warranted. 
Also, the current studies were limited to urine as the target matrix. While this was 
considered suitable for testing on-farm and at slaughter within the UK, it may not be 
applicable elsewhere in the world and would not be suitable for testing imported meat 
products. Since the beginning of the current study, increases in analytical sensitivity in 
various laboratories have meant that further compounds have also been identified as 
endogenous. For example, it is now suspected that prednisolone (Arioli et al. 2010, 
Bredehöft et al. 2010) and thiouracil (Vanden Bussche et al. 2010) may occur ‘naturally’ 
Chapter 7 
 
304 of 331 
in some species; possibly through biosynthesis within bodily tissues or through bacterial 
conversion in the gut/excreta. However, further work is required in order to clarify the 
precise origin of these compounds. 
 
As mentioned earlier, the adoption of threshold concentration approaches for detecting 
steroid abuse in veterinary species is currently being considered by the relevant UK 
regulatory authorities. This process will involve lengthy discussion with parties 
possessing the relevant practical, political, economic and legal knowledge. A major 
consideration is whether the concentration thresholds carry enough legal weight for use 
as formal confirmatory methods or if they will instead be restricted as screening tests. If 
thresholds are used for either purpose then the degree of statistical confidence required 
at each stage will need to be agreed. A false non-compliance rate of 1 in 10,000 was 
proposed in the current thesis for use in confirmation since this is already deemed to 
give acceptable confidence in the analogous area of horseracing doping control (chapter 
4 and Houghton and Crone, 2000). If used for screening, then a lower false non-
compliance rate of 1 in 1,000 was proposed in order to reduce the number of false 
compliance results, but still produce only a relatively low number of false non-compliant 
results requiring follow-up analyses. However, the relevant regulatory authorities would 
need to agree the statistical confidence required at each stage in order to strike the 
appropriate balance between false compliant and false non-compliant results. If 
threshold concentrations are not used for formal confirmation (or at least not on their 
own), viable alternatives may include marker metabolite, ‘omics’ biomarker approaches, 
GC-C-IRMS, detection of intact steroid esters in plasma/hair and on-farm visits. With the 
exception of on-farm visits, however, these alternative confirmatory approaches may 
also require more research and discussion before they can be used in the UK.  
 
7.3.2 The detection of designer steroid abuse in animal sports 
 
The structures of the in vitro synthesised metabolites of estra-4,9-diene-3,17-dione 
proposed in chapter 5 are, at present, only putative. In the future, chemical synthesis of 
the proposed metabolites, or alternatively the scaling up of the in vitro incubations in 
order to allow the acquisition of quality MS/MS or NMR spectra for the minor metabolites, 
may allow for more precise stereochemistry to be assigned to the metabolites. Also, 
estra-4,9-diene-3,17-dione is one of many designer steroids that are currently (2010) 
marketed for sale on the Internet. Further efforts are therefore underway in our 
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laboratory (and other laboratories around the world) to use these in vitro techniques to 
study the metabolism of a wider range of designer steroids in human, equine and canine 
species. As discussed earlier in chapter 5, the degree of in vivo / in vitro qualitative 
correlation with regard to drug metabolism has in general been found to be good. 
However, if any tested samples from humans or animals are found in the future to 
contain evidence for the presence of designer steroid metabolites, these results may 
further assist in determining the true extent of correlation and help further refine the 
techniques.  
 
One limitation of the in vitro approach used in this thesis is that it can only be applied to 
Internet available designer steroids since these are the only types of designer steroid for 
which materials can be purchased for use in experimentation. For compounds which 
may initially be unknown to regulatory authorities, such as THG, the problem of not 
knowing their existence is significant as it implies that the in vitro approach is not viable. 
For these steroids, further evaluation of the alternative research methods described in 
section 7.1.1.3 may, therefore, be warranted in order to ensure that these compounds do 
not go ‘undetected.’ One significant recent development with respect to the detection of 
all designer steroids is the increasing adoption of full scan HR-LC-MS (chapters 4, 5 and 
6). Using this technique, data can theoretically be retrospectively analysed once 
information about the existence of a new steroid is found. If aliquots of the original 
sample matrix are stored for long periods of time, it may even be feasible to retest the 
sample in order to confirm the presence of any suspicious retrospective findings. 
 
The in vitro method used for the equine designer steroid metabolism studies in this 
thesis utilised liver S9 fractions from Quarter horse. However, the majority of horses 
racing in the UK are of the Thoroughbred breed. In the future, it may therefore be useful 
to produce liver material from this breed to see if this improves the in vivo / in vitro 
correlation. In this respect, it would also be interesting to extend the range of tissues 
used for this purpose to include those such as kidney, intestine and faeces. Recent 
research has also focused on extending the in vitro methods to allow the production of 
phase 2 steroid metabolites in order that they can be used for method development and 
for use as reference standards (Taylor et al. 2010). While the current thesis focussed on 
applying in vitro methods to study the metabolism of designer steroids, there are also 
other classes of designer drugs for which these approaches may be applicable. For 
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example, Hudson et al. (2010) have recently reported the finding of a number of designer 
cannabinoid compounds in ‘herbal high’ products sold in the UK.  
 
In addition to abuse in sports, it is also possible that designer steroids may be used as 
growth promoting agents in food production. In vitro techniques could also be useful for 
studying metabolism in these animals if they are deemed to be a threat to the consumer. 
 
7.3.3 Beyond endogenous and designer steroids 
 
Whilst endogenous and designer steroids are two of the most challenging classes of 
growth promoters for detection purposes in food production and horseracing, new 
chemical entities are constantly being developed by pharmaceutical companies. In this 
respect, it is pertinent to note that a range of other anabolic agents are currently being 
tested for their clinical efficacy, including non-steroidal selective androgen receptor 
modulators (SARMs), myostatin inhibitors, growth hormone secretagogues (in addition to 
the existing problem of recombinant growth hormone itself) and a range of possible 
macromolecule based therapies including ‘gene’ therapy. While the approaches 
described in this thesis may be applicable to some of these new challenges, they will no 
doubt be ineffective against others. Appropriate solutions to these forthcoming 
challenges may therefore require a whole new range of approaches from a fresh crop of 
enthusiastic young scientists!  
 
Of course, the above considerations are all dependent on the different hormone bans 
remaining in place. It is possible, in theory at least, that one or more of the bans could be 
overturned on political or scientific grounds. This would no doubt mean that the 
requirements for residue testing would change significantly. However, the bans remain in 
place for the foreseeable future (and so therefore do the efforts of the doping chemists). 
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SUMMARY 
 
Despite many years spent trying to develop approaches for the control of steroid abuse 
in food production and competitive sports, numerous obstacles still remain and research 
efforts therefore continue. When the appropriate sample collection and analytical 
procedures are employed, detection of the abuse of ‘classical’ synthetic steroids such as 
stanozolol in veterinary species is nowadays relatively straightforward. However, 
detection of the abuse of ‘endogenous’ (naturally occurring) and ‘designer’ (containing 
novel structures) steroids is not straightforward and many analytical challenges remain to 
be tackled. 
 
Within the horseracing industry, analytical methods are already available to detect the 
abuse of the majority of endogenous anabolic-androgenic steroids (AAS). However, the 
same is not true for the majority of endogenous steroids in other food producing animals. 
‘Designer’ steroids could in theory be abused in both horseracing and food production, 
but at present the majority of work on designer steroids has been commissioned by 
sports regulatory authorities. One reason that this class of compounds has received 
more attention in sports doping control is because of the proven use of designer steroids 
such as THG by a number of athletes. Another factor may relate to the fact that human 
and animal sports typically involve single individuals looking to gain marginal advantages 
for significant financial and/or sociological gain, whereas food production involves large 
herds of animals with smaller financial return relative to the risk. These differences in 
return relative to risk could, therefore, be considered to make the abuse of ‘exotic’ 
treatments such as designer steroids more likely in competitive sports compared to food 
production. In light of the aforementioned discussion, the aim of this thesis was to 
develop novel analytical approaches for the detection of ‘endogenous’ steroid abuse in 
food-production (part 1) and of ‘designer’ steroid abuse in animal sports (part 2). The 
primary focus of this work related to AASs such as nandrolone, boldenone, testosterone 
and their synthetic ’designer’ analogues. However, the important natural steroids 
oestradiol and progesterone were also considered in relation to the detection of their 
abuse in the bovine (chapter 3) because it is not just AASs that may be abused in food 
production (unlike in competitive sports).  
 
In part 1, chapter 1, the extensive literature regarding the presence and metabolism of 
endogenous AASs in food producing animals and the methods used to detect their 
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abuse was reviewed. The wide variation of the natural and post steroid administration 
metabolite profiles for the different compounds was highlighted in this chapter. It also 
reiterated the challenging nature of ‘proving’ the abuse of endogenous steroids, which 
revolves around the fact that a simple qualititative demonstration of the presence of 
these steroids is typically insufficient. Importantly, it was also evident that the more 
sensitive analytical methods become, the more steroids are discovered to be 
endogenous at low concentrations. Nandrolone, for example, was once thought to be 
solely exogenous, but is now know to occur naturally in a number of animal species. A 
wide range of different approaches to detection have therefore been proposed by 
authors, including threshold and biomarker approaches, the detection of exogenous 
steroid esters in plasma/hair and the use of GC-C-IRMS. During the preparation of this 
chapter and prior to the start of the analytical phase of this thesis, many international 
colleagues inside and outside of Europe were consulted for their opinions so that the 
author could make an informed decision on how to best tackle the challenges. It was 
obvious from these experiences that there is no single correct answer on how best to 
tackle the potential abuse of endogenous steroids. Much of the decision making process 
involves consideration of political, economic and other practical factors rather than just 
scientific ideals. In this respect, the use of the concentration threshold approach was 
considered most applicable at the current time to detection of abuse within the UK. The 
remainder of part 1 of this thesis therefore set out to develop analytical methods prior to 
applying them to large animal populations in order to produce data from which to derive 
possible thresholds.  
 
In chapter 2, an analytical biomarker approach for the detection of nandrolone abuse in 
the porcine was developed and validated. The method was based on the quantification 
of the nandrolone metabolite 19-noretiocholanolone in the unconjugated (free) fraction of 
urine using analysis by GC-MS/MS. The lower and upper limits of quantification of the 
assay were 25 and 3,000 pg ml-1 respectively. The limit of detection was calculated as 
13.2 pg ml-1, which is significantly lower than previously reported methods. When applied 
to a population of untreated animals, 19-noretiocholanolone distributions in boars and gilt 
were bimodal, with a small number of concentrations in each sex at around the 1,000 pg 
ml-1 region and the majority of concentrations closer to the lower end of the calibration 
range. This was the first study to demonstrate that 19-noretiocholanolone is endogenous 
in the porcine and hence would benefit from a threshold approach. Statistical analysis of 
the data using a statistical method based on the Chebyshev inequality was carried out in 
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order to suggest screening and confirmatory thresholds for this steroid in the urine of 
boars and gilts. The adoption of particular thresholds, however, will be at the discretion 
of the individual regulating authorities. At a false non-compliance rate of 1 in 10,000 of 
the normal population (a standard number adopted within the horseracing industry and 
therefore extended to the food production area), the suggested confirmatory thresholds 
(7,502 pg ml-1 for boars and 19,200 pg ml-1 in gilts) are able to detect the abuse of 
nandrolone for several weeks following administration of this steroid. 
 
In chapter 3, an analytical biomarker approach for the detection of nandrolone, 
boldenone, testosterone, progesterone and oestradiol was developed and validated. 
Using a single aliquot of urine, metabolite markers of the AASs and progestagens were 
extracted for analysis by GC-MS/MS analysis, while oestrogens were removed into a 
separate fraction using an extractive derivatisation with dansyl chloride and analysed 
using LC-MS/MS. Using a standard addition calibration line approach in pooled bovine 
urine, the method was found to be more sensitive for some steroids compared to 
previously published methods. Limits of detection for the different analytes ranged from 
10.5 to 160.7 pg ml-1, and the method was linear between the endogenous 
concentrations and those augmented with 3,000 pg ml-1. With the possible exception of 
the boldenone metabolite 17β-hydroxy-5β-androst-1-en-3-one, all metabolites were 
shown to be endogenous at some concentration in both male and female bovine urine 
samples. The methods have since been applied to urine samples from a large population 
of untreated male and female animals in order to produce data for establishing screening 
and confirmatory concentration thresholds, the results of which will be published 
separately in due course. 
 
In part 2, chapter 4, the metabolism of AASs in the equine and the methods used to 
detect their abuse was reviewed. The trends within the equine metabolism data were 
also compared to those of the human, porcine and bovine, highlighting some interesting 
differences between the species. This chapter exemplifies the need for performing 
metabolism studies in order that urinary based detection methods are targeted toward 
the most appropriate marker metabolites. One of the biggest perceived current threats in 
terms of AAS use in animal sports is the possible abuse of designer steroids, particularly 
those readily available for purchase from Internet sites. The remainder of part 2 therefore 
set out to develop in vitro methods for studying the metabolism of Internet available 
designer steroids in order to identify marker metabolites for inclusion in drug screening 
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procedures. An in vitro rather than in vivo approach was necessary because of the 
ethical constraints of administering previously untested substances to healthy animals.   
 
In chapter 5, equine liver/lung microsomes and S9 tissue fractions were used to study 
the metabolism of the AAS stanozolol and the results correlated with those following in 
vivo administration of the steroid. The major aim of this study was to assess the 
feasibility of using in vitro techniques in place of animal administrations for conducting 
qualitative metabolism experiments. Using high resolution/accurate mass full scan 
analysis on an Orbitrap LC-MS system, equine liver microsome and S9 in vitro fractions 
were found to generate all the major phase-1 metabolites observed following in vivo 
administrations. Additionally, analysis of the liver microsomal incubates using a 
shallower LC gradient combined with various MS/MS functions on a Sciex 5500 Q trap 
instrument allowed the identification of a number of phase 1 metabolites previously 
unreported in the equine or any other species. Comparison between liver and lung S9 
metabolism showed that the liver was the major site of metabolic activity in the equine. 
Furthermore, using chemical enzyme inhibitors that are known to be selective for 
particular isoforms in other species suggested that an enzyme related to CYP2C8 may 
be responsible the production of 16-hydroxy-stanozolol metabolites in the equine. Along 
with other studies conducted by the author correlating the in vitro and in vivo metabolites 
from a wide range of drugs in the equine, this chapter suggested that in vitro techniques 
could serve as a viable alternative to identifying suitable target metabolites when in vivo 
administrations are not possible.  
 
In chapter 6, the in vitro methods developed in chapter 5 were used to study the 
metabolism of a novel designer steroid, namely estra-4,9-diene-3,17-dione, in the 
equine. The study was also conducted with canine and human tissue, which was the first 
time that the metabolism of a designer steroid in the three major species subject to 
sport’s doping control was compared. In order to permit the retrospective analysis of 
sample testing data, the use of high resolution/accurate mass full scan analysis on an 
Orbitrap LC-MS system was employed for metabolite identification of underivatised 
sample extracts. The full scan Orbitrap data was complemented by several further 
experiments targeted at elucidating more detailed structural information for the most 
abundant metabolites. These included; MS/MS of the underivatised metabolites, 
functional group selective chemical derivatisation followed by full scan LC-MS, enzyme 
inhibition experiments and full scan electron ionisation GC-MS analysis of 
Summary 
319 of 331 
methoxyamine-trimethylsilyl derivatives. The major metabolite detected in all species 
and, therefore, the most suitable candidate for screening of estra-4,9-diene-3,17-dione 
abuse was proposed to be an isomer of 17-hydroxy-estra-4,9-diene-3-one. Less 
significant metabolic pathways in all species included hydroxylation and reduction 
followed by hydroxylation. Reductive metabolism in the canine was less significant than 
in the other two species, while the equine was unique in producing a di-reduced 
metabolite (proposed to be an isomer of estra-4,9-diene-3,17-diol) and also relatively 
large quantities of D-ring hydroxy and hydroxy-reduced metabolites. The information 
regarding the equine target metabolites of estra-4,9-diene-3,17-dione has since been 
included in the routine drug screening methods used at the author’s laboratory in order to 
detect any potential abuse of this steroid.  
 
In conclusion, the work conducted in this thesis provides food residue and animal sports 
drug surveillance laboratories with some new analytical approaches to use in the fight 
against endogenous and designer steroid abuse in veterinary species. Work is ongoing 
in the author’s laboratory (and in collaboration with other researchers around the world) 
to try and build on these approaches and to further enhance their applicability.  
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SAMENVATTING 
Ondanks de jarenlange ontwikkelingen in de controle op steroïd misbruik in de 
voedselproductie en de competitie sport, blijven er nog vele obstakels over en dienen de 
onderzoeksinspanningen verder gezet. Wanneer de geschikte monstername en juiste 
analytische procedures worden gebruikt, is de detectie van “klassieke” synthetische 
steroïden zoals stanozolol in (nuts)dieren vandaag de dag vrij rechtlijnig. De detectie van 
het misbruik van “endogene” (natuurlijk voorkomende) en “designer” steroïden (steroïden 
met nieuwe structuren) is echter nog niet zo eenduidig en er blijven op dit punt nog 
verschillende analytische uitdagingen. 
 
Binnen de wereld van het paardenrennen zijn reeds analytische methodes beschikbaar 
om het misbruik van de meeste endogene anabole-androgene steroïden (AAS) te 
detecteren. Dit is echter niet het geval voor de meeste endogene steroïden bij 
nutsdieren. “Designer” steroïden kunnen in theorie zowel worden misbruikt in 
paardenrennen als voedselproductie. Het meeste onderzoek op het gebied van 
“designer” steroïden gebeurt op dit ogenblik eerder in opdracht van de regelgevende 
instanties op sportgebied. In het licht van deze vaststellingen bestond het doel van deze 
thesis erin om nieuwe analytische benaderingen te ontwikkelen voor de detectie van het 
misbruik van “endogene” steroïden in de voedselproductie en van  “designer” steroïd 
misbruik in de sport. Dit werk concentreert zich in eerste instantie op AAS’s zoals 
nandrolone, boldenone, testosteron, stanozolol, trenbolone en hun analogen. Omdat niet 
alleen AASs kunnen worden misbruikt in voedselproductie (in tegenstelling met 
competitie sport) werden de belangrijke natuurlijke steroïden oestradiol en progesteron 
echter ook beschouwd in relatie tot het opsporen van hun misbruik bij het rund. 
 
In hoofdstuk 1, wordt een overzicht gegeven van de uitvoerige literatuur die voorhanden 
is met betrekking tot de aanwezigheid en het metabolisme van endogene AAS’s bij 
nutsdieren en van de methodes voor het opsporen van hun misbruik. De nadruk werd 
hierbij gelegd op het brede bereik aan metabole profielen van verschillende natuurlijke 
en exogeen toegediende steroïden . Een belangrijk leiddraad daarbij is het feit dat het 
kwalitatieve aantonen van de aanwezigheid van deze steroïden -op zich- onvoldoende is 
om het misbruik van endogene steroïden te bewijzen. Naarmate immers de analytische 
methodes gevoeliger werden, werd de endogene oorsprong van verschillende steroïden 
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bij lagere concentraties aangetoond. Nandrolone, bijvoorbeeld, werd vroeger als 
uitsluitend exogene component bestempeld. Nu is echter geweten dat dit steroïd 
natuurlijk voorkomt in een aantal species. Daarom wordt in de literatuur een brede 
waaier van verschillende benaderingen voor de detectie van hun misbruik voorgesteld: 
“drempelwaarde” en “biomerker” benaderingen, de detectie van exogene steroïd esters 
in plasma/haar en het gebruik van GC-C-IRMS. Voor de start van de analytische fase 
van deze thesis werden verschillende internationale collega’s, binnen en buiten Europa 
geconsulteerd ter voorbereiding van dit onderzoek. De auteur probeerde, aan de hand 
van hun opinies, een gefundeerde beslissing te nemen hoe deze uitdaging best kon 
worden aangepakt. Vanuit deze ervaring werd besloten dat het probleem van het 
potentieel misbruik van endogene steroïden niet op één enkele maar op verschillende 
manieren diende aangepakt te worden. Bij een groot deel van het beslissingsproces 
waren immers naast wetenschappelijke, ook politieke, economische en andere 
praktische overwegingen betrokken. Het gebruik van een concentratiedrempel 
benadering wordt, vandaag de dag beschouwd als meest toepasbaar om het misbruik 
binnen het Verenigd Koninkrijk te bestrijden. In het vervolg van deze thesis werden 
daarom eerst analytische methodes ontwikkeld, alvorens deze toe te passen op grote 
dierpopulaties. Uit deze gegevens kunnen mogelijke drempelwaarden worden afgeleid. 
 
In hoofdstuk 2 werd een analytische biomerker benadering voor de detectie van 
nandrolone misbruik bij het varken ontwikkeld en gevalideerd. De methode baseerde 
zich op de kwantificatie van het nandrolone metaboliet 19-noretiocholanolone in de 
ongeconjugeerde (vrije) fractie van urine door analyse met GC-MS/MS. De laagste en 
hoogste limieten van kwantificatie van deze bepaling waren respectievelijk 25 and 3,000 
pg ml-1. De detectielimiet werd berekend als 13.2 pg ml-1, en is gevoelig lager dan bij 
vroeger gepubliceerde methodes. Wanneer deze methode werd toegepast op een 
populatie onbehandelde dieren, bleken de 19-noretiocholanolone distributies in beren en 
jonge zeugen (gelten) bimodiaal. Een klein aantal concentraties bij elke sexe bevinden 
zich rond de 1,000 pg ml-1, terwijl de meerderheid van de concentraties dicht bij het 
laagste deel van het calibratie bereik lag. Dit was de eerste studie die aantoonde dat 19-
noretiocholanolone endogeen is bij het varken en dat een “drempelwaarde” aanpak dus 
noodzakelijk is. Statistische analyse van de gegevens met een statistische methode 
gebaseerd op de Chebyshev ongelijkheid werd uitgevoerd om screenings- en 
confirmatie drempelwaarden voor te stellen voor dit steroïd in de urine van beren en 
jonge zeugen. Het gebruiken van deze bijzondere screening drempelwaarden wordt 
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overgelaten aan de individuele regelgevende autoriteiten. Met de voorgestelde 
drempelwaarden voor confirmatie (7,502 pg ml-1 voor beren en 19,200 pg ml-1 voor jonge 
zeugen) kan het misbruik van nandrolone worden gedetecteerd gedurende verschillende 
weken na de toediening van dit steroïd met een vals niet-conforme verhouding van 1 op 
10,000 van de normale populatie (een standaardwaarde aangenomen binnen de 
paardenrennen en daarom uitgebreid naar de voedselproducerende sector). 
 
In hoofdstuk 3, werd een analytische biomerker benadering voor de detectie van 
nandrolone, boldenone, testosteron, progesteron en oestradiol ontwikkeld en 
gevalideerd. Gebruik makend van een enkel monster urine werden de metaboliet 
merkers van de AAS’s en de progestagenen geëxtraheerd voor analyse met GC-MS/MS. 
De oestrogenen werden uit dezelfde portie geëxtraheerd en na derivatisatie met 
dansylchloride tot een afzonderlijke fractie en geanalyseerd met LC-MS/MS. Door 
gebruik te maken van een standaardadditie calibratiecurve in een mengsel van 
runderurines, werden detectielimieten bereikt die varieerden tussen 10.5 tot 160.7 pg ml-
1. De methode was lineair tussen de endogene concentraties en deze waaraan 3,000 pg 
ml-1 werd toegevoegd. Met mogelijke uitzondering van het boldenone metaboliet 17β-
hydroxy-5β-androst-1-en-3-one, werd aangetoond dat alle metabolieten endogeneen 
waren bij bepaalde  concentraties en dit in urinestalen van zowel mannelijke als 
vrouwelijke dieren. De methodes werden nadien toegepast op urine monsters van een 
grote populatie onbehandelde mannelijke en vrouwelijke dieren. Dit liet toe concentratie 
drempelwaarden voor screening en confirmatie vast te leggen. Deze resultaten zullen 
ten gepaste tijde worden gepubliceerd. 
 
In hoofdstuk 4, wordt een overzicht gegeven van het metabolisme van de AAS’s bij het 
paard en van de methodes die worden gebruikt om hun misbruik op te sporen. De 
gegevens over het metabolisme bij het paard werden ook vergeleken met deze bij de 
mens, het varken en het rund. Daarbij vielen enkele belangrijke verschillen op tussen de 
verschillende species. Dit hoofdstuk benadrukt de noodzaak aan metabolisatie studies 
zodat de detectiemethodes zich kunnen toespitsen zijn op de meest geschikte 
merkermetabolieten (bij analyse van urine). Een van de belangrijkste recente gevaren bij 
gebruik van AAS in de sportwereld is het mogelijk misbruik van “designer” steroïden (in 
het bijzonder deze vlot verkrijgbaar via het Internet). In het laatste deel van dit hoofdstuk 
worden daarom in vitro testen opgezet om het metabolisme van, via het Internet 
beschikbare, “designer” steroïden te bestuderen. Op die manier kunnen merker 
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metabolieten worden geïdentificeerd die dan in de screening procedures kunnen worden 
inge-bouwd. Een in vitro in plaats van een in vivo benadering was noodzakelijk omwille 
van de ethische beperkingen voor het toedienen van deze “ongeteste” producten aan 
gezonde dieren.  
 
In hoofdstuk 5, werden lever/long microsomen van het paard en S9 weefsel fracties 
gebruikt om het metabolisme van het AAS stanozolol te bestuderen. De resultaten 
werden gecorreleerd met deze uit volgend uit de in vivo toediening van het steroïd om de 
haalbaarheid van in vitro technieken in plaats van dierproeven te beoordelen. Door 
gebruik te maken van hoge resolutie/accurate massa “full scan” analyse op een Orbitrap 
LC-MS systeem, werd gevonden dat paarde-lever microsomen en S9 in vitro fracties 
dezelfde belangrijke fase I metabolieten genereren als bij in vivo toediening. Aanvullend 
werden lever microsomale incubaten geanalyseerd met een langere LC gradient, 
gecombineerd met verschillende MS/MS functies op een Sciex 5500 Q trap instrument. 
Dit liet de identificatie van een aantal nieuwe fase I metabolieten, nog niet beschreven bij 
het paard en andere species, toe. Vergelijking tussen lever en long S9 metabolisme 
toonde aan dat de lever de belangrijkste plaats was van metabole activiteit bij het paard. 
Er werd verder gebruik te maken van chemische enzyme inhibitoren, bekend voor hun 
selectiviteit voor particuliere isovormen in andere species. Daaruit volgde dat een 
enzyme, gerelateerd aan CYP2C8, verantwoordelijk kan zijn voor de vorming van 16-
hydroxy-stanozolol metabolieten bij het paard. Ook in andere experimenten uitgevoerd 
door de auteur, werden in vitro en in vivo metabolieten van een brede waaier 
geneesmiddelen voor het paard vergeleken. Daaruit kon worden besloten dat in vitro 
technieken kunnen dienen als een geschikt alternatief om geschikte target metabolieten 
te identificeren wanneer in vivo toedieningen onmogelijk zijn. 
 
In hoofdstuk 6, werden de in vitro methodes, ontwikkeld in hoofdstuk 5 gebruikt om het 
metabolisme van een nieuw “designer” steroïd, estra-4,9-diene-3,17-dione, bij het paard 
te bestuderen. De studie werd ook uitgevoerd met weefsel afkomstig van honden en 
mensen. Het was de eerste maal dat het metabolisme van een “designer steroïd” in de 
drie belangrijkste species voor de controle op sportdoping werd vergeleken. Om de 
retrospectieve analyse van de data van monsters toe te laten en zo de metabolieten in 
niet gederivatiseerde monsters te identificeren, werd gebruik gemaakt van hoge 
resolutie/accurate massa full scan analysis op een Orbitrap LC-MS system. De full scan 
Orbitrap data werden aangevuld met verschillende verdere experimenten om meer 
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gedetailleerde structurele informatie te bekomen van de meest voorkomende 
metabolieten. De gebruikte technieken waren: MS/MS van de ongederivatiseerd 
metabolieten, selectieve chemische derivatisatie van functionele groepen gevolgd door 
‘full scan’ LC-MS, enzyme inhibitie experimenten en ‘full scan’ electronimpact ionisatie 
GC-MS analyse van methoxyamine-trimethylsilyl derivaten. Het belangrijkste 
gedetecteerde metaboliet in alle species is een isomeer van 17-hydroxy-estra-4,9-diene-
3-one. Deze molecule is dan ook de meest geschikte kandidaat voor screening op het 
misbruik van estra-4,9-diene-3,17-dione. Minder significante metabo-lische wegen in alle 
species zijn hydroxylatie en reductie gevolgd door hydroxylatie. Het reductive 
metabolisme bij de hond was minder uitgesproken dan bij de twee andere species, 
terwijl het paard uniek was in het produceren van een di-gereduceerd metaboliet (een 
isomeer van estra-4,9-diene-3,17-diol) en ook relatief grote hoeveelheden van D-ring 
hydroxy- en hydroxy-gereduceerde metabolieten. De informatie betreffende “target” 
metabolieten van estra-4,9-diene-3,17-dione bij het paard is sinds dit onderzoek gebruikt 
in de routine drug screening van het laboratorium van de auteur om potentieel misbruik 
van dit steroïd te detecteren.  
 
Als conclusie kan worden gesteld dat het onderzoek vervat in deze thesis de controle 
laboratoria op het gebied van residuen in voeding en sportdoping (bij dieren) voorziet 
van enkele nieuwe analytische benaderingen die kunnen worden gebruikt in de strijd 
tegen endogeen en “designer” steroïd misbruik bij nutsdieren. In het laboratorium van de 
auteur wordt -in samenwerking met andere wetenschappers van alle nationaliteiten- 
gewerkt om deze nieuwe benaderingen uit te testen en uit te bouwen om zo hun 
toepasbaarheid verder te verhogen.  
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